<?xml version="1.0" encoding="Windows-31J"?>
<ArticleSet xmlns="http://www.openarchives.org/OAI/2.0/">
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0912-3814</Issn>
      <Volume>41</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Direct and Element‐Mediated Edaphic Effects Shape Resource‐Conservative Leaf Trait Variation Across Serpentine and Limestone Soils</ArticleTitle>
    <FirstPage LZero="delete">e70124</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Ueyama</LastName>
        <Affiliation>Department of Biology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emi</FirstName>
        <LastName>Kusatake</LastName>
        <Affiliation>Department of Biology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makiko</FirstName>
        <LastName>Mimura</LastName>
        <Affiliation>Department of Biology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Edaphically extreme substrates, such as serpentine and limestone, impose strong physiological constraints on plants and are frequently associated with resource-conservative leaf traits and narrow plant endemism. However, it remains unclear how edaphic selection shapes leaf traits and whether these shifts are driven primarily by direct soil-imposed constraints or indirectly by changes in leaf elemental composition. Here, we examined soil&#8211;leaf elemental relationships, leaf functional traits, and CSR strategies (Competitive, Stress-tolerant, and Ruderal strategy) using piecewise structural equation modeling across 16 populations of five closely related Epimedium taxa distributed on serpentine, limestone, and other substrates in western Japan. Despite marked differences in soil and leaf elemental composition between serpentine and limestone sites, populations on both substrates converged toward resource-conservative leaf traits, including lower specific leaf area (SLA) and a shift toward thicker leaves and higher leaf dry matter content (LDMC), even after accounting for species identity. Piecewise structural equation modeling revealed two pathways consistent with the proposed hypotheses: A strong direct association between soil elemental composition and leaf trait variation and a weaker indirect association involving leaf elemental composition. Together, our results suggest that edaphic mosaics are linked to convergent resource-conservative phenotypes through two partly overlapping pathways across serpentine and limestone soils: strong direct associations with leaf functional traits and weaker associations involving leaf elemental composition.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CSR scheme</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">edaphic stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">leaf economics spectrum</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stress tolerance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">trait convergence</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2052-0492</Issn>
      <Volume>14</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sequence and timing of organ donation discussions in brain-dead donors: a subanalysis of the J-RESPECT study</ArticleTitle>
    <FirstPage LZero="delete">76</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mineji</FirstName>
        <LastName>Hayakawa</LastName>
        <Affiliation>Department of Emergency Medicine, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Yokobori</LastName>
        <Affiliation>Department of Emergency Medicine, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Division of Emergency and Critical Care Medicine, Niigata University Graduate School of Medical and Dental Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Atsumi</LastName>
        <Affiliation>Department of Emergency and Disaster Medicine, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Tasaki</LastName>
        <Affiliation>Acute and Critical Care Center, Nagasaki University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Tsurukiri</LastName>
        <Affiliation>Emergency and Critical Care Medicine, Tokyo Medical University Hachioji Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mariko</FirstName>
        <LastName>Hayamizu</LastName>
        <Affiliation>Department of Emergency Medicine, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shimon</FirstName>
        <LastName>Murahashi</LastName>
        <Affiliation>Acute and Critical Care Center, Nagasaki University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Munehiro</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Japanese Red Cross Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Hyogo Emergency Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukari</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Emergency Medicine, Nagoya Ekisaikai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Narumiya</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Japanese Red Cross Kyoto Daini Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Mizutani</LastName>
        <Affiliation>Department of Emergency Medicine, Hamamatsu Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Miyajima</LastName>
        <Affiliation>Emergency and Critical Care Center, Nagaoka Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Shimazaki</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Kansai Medical University Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Institute of Medicine, University of Tsukuba Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nozomu</FirstName>
        <LastName>Shima</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Deuchi</LastName>
        <Affiliation>Division of Emergency and Critical Care Medicine, Niigata University Graduate School of Medical and Dental Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitomi</FirstName>
        <LastName>Nakayasu</LastName>
        <Affiliation>Emergency and Critical Care Medicine, Seirei Hamamatsu General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Department of Emergency Medicine, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Faculty of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>J-RESPECT study group</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background The optimal timing of organ donation discussions in patients with catastrophic brain injury remains unclear. In Japan, national guidance recommends providing information after recognition of a state compatible with brain death; however, real-world practice has not been well characterized. This study aimed to evaluate the sequence of organ donation option presentation relative to clinical determination of a brain death-compatible state and to assess option presentation timing.&lt;br&gt;
Methods We conducted a multicenter retrospective cohort study using data from the J-RESPECT study, including adult brain-dead donors from 16 institutions in Japan between 2010 and 2023. Donors were classified as brain death-first (option presented after clinical determination of a brain death-compatible state) or option-first (option presented before such determination). Mixed-effects logistic and linear regression models with random intercepts for institution were used to examine factors associated with presentation sequence and timing.&lt;br&gt;
Results Among 190 donors, 76 (40%) were classified as brain death-first and 114 (60%) as option-first. In mixed-effects logistic regression, age was the only independent factor associated with presentation sequence (adjusted OR 1.03 per year, 95% CI 1.00&#8211;1.07), while substantial between-institution variability was observed (intraclass correlation coefficient&#8201;=&#8201;0.32). Institutional timing policy was not significantly associated with presentation sequence. The median interval from admission to option presentation was 5 days in the brain death-first group and 2 days in the option-first group (p&#8201;&lt;&#8201;0.001).&lt;br&gt;
Conclusions Substantial inter-institutional variability exists in the sequence and timing of organ donation discussions in Japan. Further studies are needed to determine optimal approaches to organ donation communication and timing in clinical practice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Brain death</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Communication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Decision-making</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">End-of-life care</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Intensive care</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Organ donation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2075-4418</Issn>
      <Volume>16</Volume>
      <Issue>20</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Association Between Urine pH and Kidney Outcomes in Patients with Biopsy-Proven Kidney Disease</ArticleTitle>
    <FirstPage LZero="delete">3418</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naruhiko</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nakanoh</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Lower urine pH has been associated with reduced kidney function and increased risk of kidney disease, but its prognostic and pathological significance in biopsy-proven kidney disease remains unclear. Medullary cast formation has been shown to predict adverse renal outcomes beyond cortical interstitial fibrosis and tubular atrophy (IFTA), although its clinical determinants are not fully understood. We examined the associations of urine pH with kidney outcomes and medullary cast formation in patients undergoing native kidney biopsy. Methods: Among 1167 adults who underwent native kidney biopsy between 2011 and 2024, 503 patients with evaluable medullary tissue were included. Urine pH was analyzed in relation to clinical and histological variables and kidney outcomes. The primary outcome was a &#8805;40% decline in estimated glomerular filtration rate (eGFR) or initiation of renal replacement therapy. Results: Mean baseline eGFR was 60.7 ± 26.2 mL/min/1.73 m2 and urine pH was 6.15 ± 0.84. During a median follow-up of 2.11 years, 113 patients (22.5%) reached the outcome. Lower urine pH was associated with higher risk of kidney outcomes. In multivariable Cox models, urine pH remained independently associated with outcomes (hazard ratio per 1-unit increase, 0.69; 95% CI, 0.52&#8211;0.92). Addition of urine pH modestly improved discrimination (C-index 0.642 to 0.654; likelihood ratio test, p = 0.009). Lower urine pH was associated with greater medullary cast formation in unadjusted analysis. Conclusions: Lower urine pH was independently associated with adverse kidney outcomes and with greater medullary cast formation, suggesting that urine pH may reflect intratubular pathological changes associated with CKD progression.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">urine pH</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">kidney outcomes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">medullary casts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">global glomerulosclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">interstitial fibrosis and tubular atrophy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0919-8172</Issn>
      <Volume>33</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oncological Outcomes and Safety Profiles of Adjuvant Nivolumab in Muscle‐Invasive Urothelial Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">e70664</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Departmentof Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Iwatani</LastName>
        <Affiliation>Departmentof Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomofumi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Yamanoi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuma</FirstName>
        <LastName>Tsuboi</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Murao</LastName>
        <Affiliation>Department of Urology, Hiroshima City Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Nakada</LastName>
        <Affiliation>Department of Urology, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Urology, Shimane University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Departmentof Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Departmentof Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Urology, Shimane University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives&lt;br&gt;
Perioperative immunotherapy has become the standard of care in patients with high-risk muscle-invasive urothelial carcinoma (MIUC). This study aimed to clarify oncological outcomes and safety profiles of adjuvant nivolumab therapy in MIUC, focusing on upper tract urothelial carcinoma (UTUC).&lt;br&gt;
Methods&lt;br&gt;
This multicenter study comprised 97 patients undergoing removal of primary tumors, followed by adjuvant nivolumab therapy with a potential follow-up period &#8805;&#8201;12&#8201;months. Patients were divided according to the primary tumor location: bladder cancer (BC), n&#8201;=&#8201;66 (68%); UTUC, n&#8201;=&#8201;31 (32%). Multivariable Cox regression analyses were applied to identify prognostic factors for disease-free survival (DFS).&lt;br&gt;
Results&lt;br&gt;
Before surgery, 38% of patients had an estimated glomerular filtration rate (eGFR)&#8201;&lt;&#8201;50&#8201;mL/min/1.73m2, but this proportion increased to 57% at nivolumab initiation with 19% of UTUC having eGFR&#8201;&lt;&#8201;30. The overall DFS at 6&#8201;months was 61.5%. DFS did not differ significantly between BC and UTUC (p&#8201;=&#8201;0.83). On multivariable analyses, a higher absolute eosinophil count was significantly associated with worse DFS (HR 2.24; 95% CI, 1.24&#8211;4.03, p&#8201;=&#8201;0.007), while primary tumor location was not. Immune-related adverse events (irAEs) of adrenal insufficiency and hypophysitis occurred in 8% and 4% of patients, respectively, with grade &#8805;&#8201;3 occurring at 3.3&#8211;18.3&#8201;months.&lt;br&gt;
Conclusions&lt;br&gt;
Adjuvant nivolumab therapy may provide comparable oncological outcomes between BC and UTUC. Baseline eosinophil count was an independent prognosticator for DFS. The incidences of adrenal insufficiency and hypophysitis appeared higher in our real-world data. Clinicians should recognize these irAEs due to nonspecific symptoms and considerable variability in time of onset.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">adjuvant nivolumab </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">eosinophil</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypophysitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value"> upper tract urothelial carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">urothelial carcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>31</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Differential impact of host-related factors on survival outcomes between IO+IO and IO+TKI in metastatic renal cell carcinoma: a multicenter retrospective study</ArticleTitle>
    <FirstPage LZero="delete">1658</FirstPage>
    <LastPage>1667</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lan</FirstName>
        <LastName>Inoki</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Urology, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuhisa</FirstName>
        <LastName>Nukaya</LastName>
        <Affiliation>Department of Urology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Maenosono</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Morinaka</LastName>
        <Affiliation>Department of Urology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumasa</FirstName>
        <LastName>Komura</LastName>
        <Affiliation>Department of Urology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Urology, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruo</FirstName>
        <LastName>Inamoto</LastName>
        <Affiliation>Department of Urology, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito</FirstName>
        <LastName>Azuma</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutoshi</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Immune checkpoint inhibitor (ICI)-based combination therapies, including immune checkpoint inhibitor plus immune checkpoint inhibitor (IO&#8201;+&#8201;IO) and immune checkpoint inhibitor plus tyrosine kinase inhibitor (IO&#8201;+&#8201;TKI) regimens, have significantly improved outcomes in metastatic renal cell carcinoma (mRCC). However, the prognostic impact of host-related factors in patients receiving these therapies remains unclear.&lt;br&gt;
Methods We retrospectively analyzed 493 patients with mRCC treated with IO+IO (n&#8201;=&#8201;205) or IO+TKI (n&#8201;=&#8201;288) as first-line therapy. Survival outcomes and treatment responses were evaluated according to host-related factors using Cox proportional hazards models.&lt;br&gt;
Results In the IO+IO cohort, multiple host-related factors were independently associated with worse overall survival, including BMI&#8201;&lt;&#8201;25 kg/m2 (HR 2.280, p&#8201;=&#8201;0.007), dyslipidemia (HR 2.079, p&#8201;=&#8201;0.019), PPI use (HR 1.605, p&#8201;=&#8201;0.039), and opioid use (HR 2.919, p&#8201;=&#8201;0.008). In contrast, in the IO+TKI cohort, only IMDC poor risk (HR 4.169, p&#8201;&lt;&#8201;0.001) and opioid use (HR 3.328, p&#8201;&lt;&#8201;0.001) were significantly associated with overall survival. Host-related factors showed limited associations with objective response and disease control rates in both cohorts.&lt;br&gt;
Conclusion The prognostic impact of host-related factors differs according to treatment regimen in mRCC. These findings suggest that host immune and metabolic conditions play a more prominent role in immune-driven IO+IO therapy, whereas tumor-related factors may predominate in IO+TKI therapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Metastatic renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Host-related factors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prognosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Combination therapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>公益社団法人日本都市計画学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0916-0647</Issn>
      <Volume>61</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>CIDパイロットプロジェクトとSpecial Rate型BIDおよび寄付金型BIDの比較分析 -オーストラリア・ニューサウスウェールズ州を対象として-</ArticleTitle>
    <FirstPage LZero="delete">895</FirstPage>
    <LastPage>902</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Kitano</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>日本のエリアマネジメント負担金制度は、合意形成に要する高い同意要件が原因で停滞している。本研究は、オーストラリア・ニューサウスウェールズ州における三類型のBID（Business　Improvement District）を調査し、日本のエリアマネジメント活動の改善に資する提案を行うことを目的とする。調査の結果、制度は都市規模に応じて活用されていることが明らかとなった。地方都市では行政が主な権限を要する「Special Rate型BID」が展開されている一方、都市部では民間側が主な権限を要する「CIDパイロットプロジェクト」や「寄付金型BID」が展開されている。これらの知見に基づき、本論文は、地域の組織能力の成熟度に合わせて行政主導から民間主体へと体制を移行させる「段階的移行モデル」を提案する。柔軟かつ都市規模に適した制度選択を可能にすることは、導入障壁を下げ、日本の都市におけるエリアマネジメント活動を活性化させる上で不可欠である。</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">BID</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">エリアマネジメント (Area Based Management)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">地域再生エリアマネジメント負担金制度 (Japanese BID System)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">地方都市 (Regional Cities)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Special Rate</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Radiogenomic Analysis of Contrast-Enhanced MRI for Predicting Pathogenic BRCA Variants in Ovarian Cancer</ArticleTitle>
    <FirstPage LZero="delete">317</FirstPage>
    <LastPage>325</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hayato</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Radiological Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanako</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Tada</LastName>
        <Affiliation>Okayama Diagnostic Imaging Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Nagao</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Iguchi</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/71341</ArticleId>
    </ArticleIdList>
    <Abstract>This study evaluated the feasibility of predicting pathogenic BRCA1/2 variants in ovarian cancer using radiogenomic analysis of contrast-enhanced MRI. Twenty six patients were analyzed, including 14 with pathogenic BRCA1/2 variants and 12 without. Contrast enhanced MRI was used to generate two dimensional (2D) and three dimensional (3D) tumor segmentations. Radiomic features extracted with PyRadiomics were reduced using least absolute shrinkage and selection operator (LASSO) regression, yielding two selected features. Linear discriminant analysis (LDA) models were trained on 18 patients and tested on 8, with performance assessed using sensitivity, specificity, accuracy, and the area under the receiver operating characteristic (ROC) curve. The DeLong test compared AUCs between segmentation methods. Automated machine learning (AutoML) was performed with a training set of 20 patients and a test set of 6, with multiple performance metrics calculated. LDA achieved approximately 60% accuracy in both 2D and 3D test datasets. AUCs were 0.80 (3D) and 0.77 (2D), with no significant difference (p=0.85). AutoML identified CatBoost_BAG_L2_FULL as the optimal model, achieving accuracy above 80%. MRI-based radiogenomic analysis demonstrated moderate classification performance for identifying pathogenic BRCA1/2 variants in ovarian cancer. These preliminary findings suggest a potential role for noninvasive prediction, warranting further validation in larger cohorts.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ovarian cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">BRCA1/2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiogenomics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MRI</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dynamics of Serum Amyloid A Levels in the Blood, Brain and Liver in a Mouse Model of Focal Cerebral Ischemia</ArticleTitle>
    <FirstPage LZero="delete">309</FirstPage>
    <LastPage>316</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Egashira</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oncology and Infectious Disease Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Irie</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ushio</LastName>
        <Affiliation>Department of Emergency and Disaster Medical Pharmacy, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Manabe</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayuko</FirstName>
        <LastName>Masaki</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Mukai</LastName>
        <Affiliation>Department of Microbiology Laboratory, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Emergency and Critical Care Medicine, Fukuoka University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Hosokawa</LastName>
        <Affiliation>Department of Immunological and Molecular Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomomitsu</FirstName>
        <LastName>Satho</LastName>
        <Affiliation>Department of Microbiology Laboratory, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazunori</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Mishima</LastName>
        <Affiliation>Department of Physiology and Pharmacology, Faculty of Pharmaceutical Sciences, Fukuoka University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/71340</ArticleId>
    </ArticleIdList>
    <Abstract>This study examined the dynamics of serum amyloid A (SAA) levels in the blood, brain, and liver over time using a mouse model of focal cerebral ischemia induced by occlusion of the middle cerebral artery (MCA) for 4 h followed by reperfusion. Blood SAA concentrations increased transiently after cerebral infarction, coinciding with changes in brain and liver SAA gene expression and protein levels. SAA concentrations in the brain, liver, and blood increased at similar time points after cerebral infarction, suggesting that SAA may serve as an important indicator of the associated pathological condition.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">stroke</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cerebral ischemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">serum amyloid A</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">temporal dynamics</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>High Accuracy of Pelvic Tilt Measurement Using Three-Dimensional Planning Software: A Validation Study Using Dry Bone Models</ArticleTitle>
    <FirstPage LZero="delete">289</FirstPage>
    <LastPage>298</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Komuta</LastName>
        <Affiliation>Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Division of Comprehensive Musculoskeletal Medicine, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Homma</LastName>
        <Affiliation>Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhisa</FirstName>
        <LastName>Funayama</LastName>
        <Affiliation>Division of Legal Medicine, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Hirano</LastName>
        <Affiliation>Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoji</FirstName>
        <LastName>Horigome</LastName>
        <Affiliation>Division of Comprehensive Musculoskeletal Medicine, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Izumi</FirstName>
        <LastName>Minato</LastName>
        <Affiliation>Department of Orthopedic Surgery, Niigata Rinko Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Division of Orthopedic Surgery, Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/71338</ArticleId>
    </ArticleIdList>
    <Abstract>The “CR Alignment” function was recently introduced in ZedHip&#174;, the hip joint module of ZedView&#174;, to evaluate pelvic tilt in non-supine positions via two-dimensional (2D)&#8210;3D matching using radiographs. However, its ccuracy has not been validated. This study therefore evaluated the accuracy of pelvic tilt measurements using the CR Alignment function in dry pelvic bone specimens. Two cadaveric pelvic bone models were placed in nine orientations (anterior/posterior tilt and left/right rotation). Both radiographic and CT images were acquired in each position. In Study 1, pelvic tilt measured directly from CT images was defined as the “true value.” Three observers used the CR Alignment function to calculate pelvic tilt on radiographs, and measurement errors were determined relative to the true values. In Study 2, measurement errors were compared between matched (same position) and mismatched (different position) imaging. In Study 1, the mean measurement error was 1.28±0.64°. Intra- and interobserver intraclass correlation coefficients were 0.996-0.998 and 0.997, respectively. In Study 2, the mean errors were 1.20±0.88° (matched) and 1.32±1.03° (mismatched). This software exhibited high accuracy and reproducibility in 2D&#8210;3D matching of pelvic tilt, with lower variability under matched acquisition, demonstrating its utility for pre- and postoperative assessment in joint arthroplasty.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">total hip arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pelvic tilt</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">three-dimensional planning software</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">two-dimensional and threedimensional matching</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiographic analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Artificial Intelligence-Assisted Peroral Cholangioscopy for the Diagnosis and Management of Biliary Strictures: Current Evidence and Future Directions</ArticleTitle>
    <FirstPage LZero="delete">271</FirstPage>
    <LastPage>277</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Review</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/71336</ArticleId>
    </ArticleIdList>
    <Abstract>Peroral cholangioscopy (POCS) enables direct intraductal visualization and targeted biopsies for indeterminate biliary strictures. However, its diagnostic performance remains operator-dependent and is limited by sampling error. As artificial intelligence (AI) has rapidly advanced in gastrointestinal endoscopy, AI-assisted cholangioscopy has progressed from proof-of-concept image classification to multicenter validation, feature detection, and real-time application. Recent studies using digital single-operator cholangioscopy have reported diagnostic accuracy comparable to that of experts in differentiating malignant from benign strictures, and feature-based approaches can automatically detect tumor vessels and other key visual characteristics. Beyond classification, generative models may enhance mucosal and margin visualization through virtual chromoendoscopy, potentially improving lesion-margin assessment. Furthermore, new models compatible with multiple systems are emerging to address device heterogeneity, which is a key barrier to routine practice. This review summarizes the current evidence on AI-assisted POCS, discusses practical considerations for clinical translation, and highlights future directions, including real-time integration and multimodal decision support.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">peroral cholangioscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">biliary stricture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">deep learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">virtual chromoendoscopy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japanese Society of Toxicology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0388-1350</Issn>
      <Volume>51</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Integration of QSAR modeling and in vitro validation for identification of food-derived Nrf2 activators against arsenic-induced toxicity</ArticleTitle>
    <FirstPage LZero="delete">533</FirstPage>
    <LastPage>547</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ngo Thanh</FirstName>
        <LastName>Huong</LastName>
        <Affiliation>Laboratory of Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Kodama</LastName>
        <Affiliation>Laboratory of Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Laboratory of Toxicology, Division of Pharmaceutical Sciences, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Arsenic exposure is a major public health concern due to its toxicity and carcinogenicity, largely mediated by oxidative stress, and activation of the Nrf2 signaling pathway is considered a promising strategy to mitigate such damage. In this study, a quantitative structure&#8211;activity relationship (QSAR) model was developed to identify potential Nrf2 activators from food-derived compounds. Machine learning algorithms, including Random Forest (RF), Support Vector Machine (SVM), Linear Discriminant Analysis (LDA), and a stacking model, were developed and optimized. The optimized RF, SVM, and LDA models were subsequently integrated into a stacking framework, which was selected as the final predictive model for virtual screening based on its robust and balanced predictive performance. The stacking model achieved the highest accuracy during five-fold cross-validation (0.77) and demonstrated competitive performance on the independent test set (0.742 ± 0.040), with balanced precision, sensitivity, and F-measure. Consequently, the stacking model was selected as the final model for virtual screening. A total of 70,926 compounds retrieved from a food-derived database were filtered based on physicochemical criteria, and QSAR-based virtual screening predicted 920 compounds as potential activators of the Nrf2 signaling pathway, from which 5,7-Dimethylchrysin (FooDB ID: FDB015537) and Demethylvestitol (FooDB ID: FDB012218) were selected for experimental validation. In vitro assays using HepG2 cells demonstrated that 5,7-Dimethylchrysin significantly enhanced cell viability against sodium arsenite (150 μM)-induced cytotoxicity, with an effective concentration (EC50) of 0.54 μM, whereas Demethylvestitol exhibited only limited protective effects. Furthermore, luciferase reporter assays confirmed that 5,7-Dimethylchrysin activated antioxidant response element (ARE)-driven transcription in a concentration-dependent manner, producing a 1.5 to 2.4-fold increase at concentrations ranging from 0.78 to 6.25 μM. Overall, these findings highlight the effectiveness of integrating QSAR modeling with experimental validation to identify food-derived compounds with protective potential against arsenic-induced toxicity, with 5,7-Dimethylchrysin emerging as a promising candidate for further investigation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Arsenic toxicity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nrf2 activator</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">QSAR modeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Food-derived compounds</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">In vitro</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2075-1729</Issn>
      <Volume>16</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Purification, Structural Characterization, and Genomic Insights of an Anti-MRSA Peptide from Mangrove-Derived Brevibacillus sp. A34</ArticleTitle>
    <FirstPage LZero="delete">1697</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Thanyamai</FirstName>
        <LastName>Thongin</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Namfa</FirstName>
        <LastName>Sermkaew</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Apichart</FirstName>
        <LastName>Atipairin</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sucheewin</FirstName>
        <LastName>Krobthong</LastName>
        <Affiliation>Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry, Faculty of Science, Chulalongkorn University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chanat</FirstName>
        <LastName>Aonbangkhen</LastName>
        <Affiliation>Center of Excellence in Natural Products Chemistry (CENP), Department of Chemistry, Faculty of Science, Chulalongkorn University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Infectious Diseases, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama 700-8558, Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nuttapon</FirstName>
        <LastName>Songnaka</LastName>
        <Affiliation>School of Pharmacy, Walailak University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The widespread prevalence of methicillin-resistant Staphylococcus aureus (MRSA) in community and healthcare settings has driven the urgent search for novel antibacterial agents. Mangrove sediments are an underexplored source of antimicrobial-producing bacteria. This study characterized an antimicrobial fraction and the genome of the mangrove-derived isolate Brevibacillus sp. A34. The active fraction was purified via ammonium sulfate precipitation, cation-exchange chromatography, and reversed-phase chromatography. De novo MS/MS analysis assigned the octapeptide LLLLLLAH (905.19 Da), designated as A34 AMP, which was further confirmed by chemical synthesis. This active peptide inhibited all four tested S. aureus strains, including three MRSA strains, with a minimum inhibitory concentration (MIC) of 62 &#181;g/mL. At 2× and 4× MIC, A34 AMP exhibited a concentration-dependent bactericidal effect within 20 h. Increased SYTOX Green uptake and morphological alterations supported a membrane permeabilization mechanism, and antimicrobial activity was retained following thermal, pH, protease, and surfactant treatments. Genome mining identified 23 putative biosynthetic gene clusters, including an 11-module nonribosomal peptide synthetase (NRPS) cluster linked to A34 AMP through three-dimensional adenylation-domain modeling. Collectively, these findings highlight A34 AMP from Brevibacillus sp. A34 as a promising bioactive anti-staphylococcal peptide scaffold.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Brevibacillus sp.</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antimicrobial peptide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">AMP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mangrove</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anti-MRSA</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2227-9032</Issn>
      <Volume>14</Volume>
      <Issue>20</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cross-Cultural Adaptation and Initial Psychometric Evaluation of the Japanese Version of the Chronic Kidney Disease Self-Efficacy Scale (CKDSE-J)</ArticleTitle>
    <FirstPage LZero="delete">3393</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tingting</FirstName>
        <LastName>Geng</LastName>
        <Affiliation>Doctor’s Program, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kajiwara</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Morimoto</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Self-efficacy is an important determinant of self-care among adults with chronic kidney disease (CKD). The Chronic Kidney Disease Self-Efficacy Scale (CKD-SE) is a disease-specific measure, but its use has not been reported in Japan. This study translated and culturally adapted the CKD-SE into Japanese and conducted an initial psychometric evaluation. Methods: A cross-sectional survey was conducted among Japanese adults with CKD stages G3a&#8211;G5 not receiving dialysis. Structural validity and internal consistency were evaluated in 227 participants, and construct validity was evaluated in 222. Structural validity was examined using confirmatory factor analysis (CFA) and exploratory structural equation modeling (ESEM). Results: The original 25-item four-factor CFA showed a poor fit, and ESEM yielded an improper solution involving Item 19. Sequential evaluation resulted in a 23-item structure. The 23-item CFA showed mixed fit, whereas Target ESEM showed improved overall fit (CFI = 0.935, TLI = 0.902, RMSEA = 0.060, SRMR = 0.033). However, several autonomy items showed weak target loadings and cross-loadings. Proposed subscale scores correlated positively with self-care behavior (r = 0.27&#8211;0.46), and McDonald’s omega ranged from 0.84 to 0.90. Conclusions: The 23-item CKDSE-J showed improved overall model fit under Target ESEM, but the structural definition of autonomy remained uncertain. Because the structure was refined and evaluated in the same sample, independent replication and further psychometric evaluation are needed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chronic kidney disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">self-efficacy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">self-care</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cultural adaptation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psychometric evaluation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">exploratory structural equation modeling</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>IEEE</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tourism Demand Forecasting Using Machine Learning with Cross-Model Feature Ranking</ArticleTitle>
    <FirstPage LZero="delete">11689307</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yomei</FirstName>
        <LastName>Hendra</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Migita</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norikazu</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study proposes a machine learning (ML) framework for forecasting tourist visits to a destination, leveraging feature ranking consistency across heterogeneous models. The proposed framework uses a unified stepwise feature selection pipeline to systematically determine a subset of given features that reduces prediction error of an ML model. The transferability of feature rankings is demonstrated through experiments using ML models including Random Forest, XGBoost, LightGBM, and Support Vector Regression (SVR), and a dataset related to tourist visits to West Sumatra, Indonesia. Experimental results show that i) SVR using top four features in the feature ranking based on SHAP achieves the highest accuracy and ii) application of the feature ranking based on XGBoost improves performance stability across other models, reducing error fluctuations. These findings reveal that an optimized feature subset combined with cross-model ranking transfer can outperform more complex ensembles, highlighting the importance of ranking robustness in tourism forecasting. The proposed framework provides a methodological foundation for building interpretable and dataefficient decision support systems for tourism management and policy planning.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">tourism forecasting</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">support vector regression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">XGBoost</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">feature ranking</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0959-8049</Issn>
      <Volume>248</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Molecular characteristics and clinical outcomes of ERBB2-activating mutation-positive non-small cell lung cancer: A Japanese nationwide real-world cohort</ArticleTitle>
    <FirstPage LZero="delete">117443</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiji</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naofumi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Takada</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Erb-b2 receptor tyrosine kinase 2 (ERBB2)-activating mutations are well-documented oncogenic drivers in non-small cell lung cancer (NSCLC), occurring in approximately 1&#8211;4% of cases. These alterations include a heterogeneous spectrum of variant subtypes; however, the clinicogenomic characteristics and clinical significance of the individual variants have yet to be elucidated.&lt;br&gt;
Methods: We searched the nationwide Center for Cancer Genomics and Advanced Therapeutics database, which integrates comprehensive genome profiling data generated in routine clinical practice across Japan, to investigate the molecular landscape and clinical outcomes of patients with ERBB2-mutated NSCLC.&lt;br&gt;
Results: A total of 319 patients with ERBB2-activating mutations were included in this retrospective analysis. Although 74% of the patients harbored canonical tyrosine kinase domain (TKD) in-frame insertions, 26% carried noncanonical variants, including TKD missense (8%), transmembrane/juxtamembrane domain (10%), and extracellular domain (ECD) mutations (8%). Co-occurring oncogenic driver alterations were identified in only 18 cases (5.6%) and were largely restricted to noncanonical variants, whereas no co-occurring driver alterations were detected among patients with TKD in-frame mutations. Noncanonical variants―TKD missense and ECD mutations in particular―were associated with an increased tumor mutational burden. Among 288 patients with available survival data, 78 (27%) received trastuzumab deruxtecan (T-DXd) during their clinical course. After excluding patients who had started treatment with T-DXd before undergoing comprehensive genome profiling testing, time-dependent T-DXd exposure was associated with a reduced risk of death (adjusted hazard ratio, 0.63; 95% confidence interval, 0.39&#8211;1.01; P&#8239;=&#8239;0.057).&lt;br&gt;
Conclusions: ERBB2-mutated NSCLC exhibited substantial molecular heterogeneity, with canonical TKD in-frame insertions characterized by a low frequency of co-occurring oncogenic driver alterations. Among patients harboring ERBB2-activating mutations, exposure to T-DXd was associated with improved overall survival.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ERBB2 mutation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Variant subtype</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Comprehensive genomic profiling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trastuzumab-deruxtecan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Non-small cell lung cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0169-5002</Issn>
      <Volume>218</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>ULK1, a novel therapeutic target to delay drug tolerance to EGFR&#8211;TKIs in an EGFR-mutant non-small cell lung cancer model</ArticleTitle>
    <FirstPage LZero="delete">109516</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kammei</FirstName>
        <LastName>Rai</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiro</FirstName>
        <LastName>Kuribayashi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Nishi</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naofumi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Ochi</LastName>
        <Affiliation>Department of General Internal Medicine 4, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The presence of drug-tolerant persister (DTP) cells reduces the effectiveness of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in EGFR-mutated non-small cell lung cancer (NSCLC). Although autophagy is a potential target for eliminating DTP cells, clinical trials targeting autophagy in EGFR-mutant NSCLC have been unsuccessful―likely because most trials have utilized chloroquine, non-specifically inhibiting autophagy targeting lysosomes with dose limitations. This study focused on unc-51-like autophagy activating kinase 1 (ULK1), a more specific target for autophagy inhibition, to assess whether ULK1 inhibition delays the emergence of tolerance to EGFR-tyrosine kinase inhibitors in EGFR-mutant NSCLC cells.&lt;br&gt;
Methods: DTP cells were generated by treating EGFR-mutant NSCLC cell lines with osimertinib. Autophagy status and ULK1 expression were evaluated using immunofluorescence, western blotting, and quantitative real-time PCR. The effects of both pharmacological and genetic inhibition of ULK1 were examined in vitro and in vivo.&lt;br&gt;
Results: ULK1 and LC3-II, markers of autophagy, were upregulated in DTP cells. Inhibition of ULK1, either pharmacologically or genetically, suppressed autophagy, prevented the formation of DTP cells, and enhanced the antitumor activity of osimertinib in both in vitro and in vivo models. Furthermore, upregulation of ULK1 expression through serum starvation conferred tolerance to osimertinib, reinforcing ULK1′s role in drug tolerance. Notably, ULK1 inhibition showed modest efficacy even after cells transitioned to the DTP or acquired resistance states.&lt;br&gt;
Conclusion: ULK1 plays a critical role in mediating drug tolerance in EGFR-mutant NSCLC. Targeting ULK1 represents a promising therapeutic approach to enhance the efficacy of EGFR-TKIs and to delay the development of drug tolerance.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ULK1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Autophagy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EGFR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TKI</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Osimertinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Non-small cell lung cancer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1718-7729</Issn>
      <Volume>33</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Limited Immune-Mediated Efficacy of Anti-PD-L1/VEGF in EGFR-TKI-Na&#239;ve Egfr-Mutant Lung Cancer with Non-Inflamed Tumor Microenvironment</ArticleTitle>
    <FirstPage LZero="delete">315</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Atsuko</FirstName>
        <LastName>Hirabae</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiro</FirstName>
        <LastName>Kuribayashi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachi</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takamasa</FirstName>
        <LastName>Nakasuka</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Nishii</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisao</FirstName>
        <LastName>Higo</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kammei</FirstName>
        <LastName>Rai</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masamichi</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Product Research Department, Kamakura Research Laboratories, Chugai Pharmaceutical Co., Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Kiura</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Immune checkpoint inhibitors (ICIs) show limited efficacy in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma due to its non-inflamed tumor microenvironment (TME). While quadruple therapy combining chemotherapy, anti-programmed death-ligand 1 (PD-L1), and anti-vascular endothelial growth factor (VEGF) antibodies has shown inconsistent results in EGFR-tyrosine kinase inhibitor (TKI)-pretreated patients, whether anti-VEGF therapy can modulate the intrinsic non-inflamed TME remains unknown. We employed an EGFR-TKI-na&#239;ve syngeneic Egfr-mutant mouse model and evaluated effects of anti-VEGF, anti-PD-L1, carboplatin, and paclitaxel as monotherapies and combinations, with TME analysis via immunohistochemistry (IHC), flow cytometry, and RNA sequencing. Anti-PD-L1 showed no antitumor effect, and adding anti-VEGF failed to convert the TME to an inflamed status. Although paclitaxel―but not carboplatin―combined with low-dose anti-VEGF inhibited tumor growth, adding anti-PD-L1 provided no benefit, indicating the anti-VEGF-A antibody evaluated here has a limited role in sensitizing tumors to anti-PD-L1 regardless of chemotherapy. CD8+ T-cell depletion did not attenuate the effect of paclitaxel plus low-dose anti-VEGF, and IHC and RNA sequencing revealed increased natural killer cell infiltration, suggesting a CD8+ T-cell-independent, innate immune mechanism. These findings provide preclinical evidence that the evaluated anti-VEGF has limited immunomodulatory activity in EGFR-TKI-na&#239;ve Egfr-mutant tumors with a non-inflamed TME, and suggest immunotherapeutic strategies beyond CD8+ T-cell-mediated immunity warrant investigation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">EGFR mutation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-small cell lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">syngeneic mouse model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antitumor immunity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-inflamed tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">VEGF</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PD-L1</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1759-7706</Issn>
      <Volume>17</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Interstitial Lung Disease in Patients With Unresectable Stage III NSCLC Treated With Chemoradiotherapy Followed by Durvalumab in Japan: Analysis From the Multicenter Prospective AYAME Study</ArticleTitle>
    <FirstPage LZero="delete">e70299</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nobuyuki</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Internal Medicine III, Wakayama Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotsugu</FirstName>
        <LastName>Kenmotsu</LastName>
        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Burak</FirstName>
        <LastName>Akdemir</LastName>
        <Affiliation>Oncology Medical, AstraZeneca K.K</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Uematsu</LastName>
        <Affiliation>Oncology Medical, AstraZeneca K.K</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Evidence and Observational Research, Medical, AstraZeneca K.K</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Koto</LastName>
        <Affiliation>Evidence and Observational Research, Medical, AstraZeneca K.K</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Evidence and Observational Research, Medical, AstraZeneca K.K</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Iwao</LastName>
        <Affiliation>Oncology Medical, AstraZeneca K.K</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Oncology Medical, AstraZeneca K.K</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Department of Thoracic Surgery, International University of Health and Welfare Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Gemma</LastName>
        <Affiliation>Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Mitsudomi</LastName>
        <Affiliation>Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Pulmonary Medicine, Nippon Medical School Musashi Kosugi Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Interstitial lung disease (ILD) is a concerning adverse event associated with immune checkpoint inhibitors, including durvalumab. This analysis of the multicenter AYAME study assessed the longterm safety of durvalumab, focusing on ILD.&lt;br&gt;
Methods: AYAME enrolled patients prescribed durvalumab for unresectable stage III non-small cell lung cancer (NSCLC) after chemoradiotherapy (CRT) from July 2019 to December 2020 in Japan. Patients received durvalumab for &#8804;&#8201;12&#8201;months and were prospectively followed for 3&#8201;years. Incidence, severity, and management of ILD were examined. Multivariable logistic regression analysis was conducted to investigate the association of patient characteristics with grade &#8805;&#8201;2 ILD occurrence.&lt;br&gt;
Results: Of 511 patients in the safety analysis population, ILD occurred in 383 patients (75.0%) from durvalumab initiation to subsequent treatment start; median time to occurrence was 44.0&#8201;days. ILD led to permanent durvalumab discontinuation in 121/383 patients (31.6%), dose interruption in 111/383 (29.0%), and corticosteroid intervention in 168/383 (43.9%). Grade &#8805;&#8201;2 ILD occurrence was higher in patients with volume of lung parenchyma that received 20&#8201;Gy (V20) &#8805;&#8201;25% versus &lt;&#8201;25% (60.3% vs. 29.4%; adjusted odds ratio 2.20, 95% confidence interval 1.08&#8211;4.48), 5&#8201;Gy (V5)&#8201;&#8805;&#8201;median (37.85%) versus &lt; median (51.5% vs. 27.2%; 1.79, 1.07&#8211;3.00), and grade 1 ILD before durvalumab administration versus no ILD (50.0% vs. 37.6%; 2.11, 1.07&#8211;4.17).&lt;br&gt;
Conclusions: This study of durvalumab for NSCLC after CRT in a real-world setting indicated factors associated with grade &#8805;&#8201;2 ILD and provided valuable insights into ILD management strategies. These findings may contribute to establishing effective approaches to minimize ILD risk in practice.&lt;br&gt;
Trial Registration: UMIN000037090/NCT03995875</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemoradiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">durvalumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">interstitial</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lung diseases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-small- cell lung</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1556-0864</Issn>
      <Volume>21</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Long-Term Safety and Effectiveness of Durvalumab in Unresectable Stage III NSCLC in Japan: A Multicenter Prospective Study (AYAME)</ArticleTitle>
    <FirstPage LZero="delete">160</FirstPage>
    <LastPage>173</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hirotsugu</FirstName>
        <LastName>Kenmotsu</LastName>
        <Affiliation>Division of Thoracic Oncology, Shizuoka Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Respiratory Medicine, Nippon Medical School, Musashi Kosugi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Uematsu</LastName>
        <Affiliation>Oncology Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Burak</FirstName>
        <LastName>Akdemir</LastName>
        <Affiliation>Oncology Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Fukui</LastName>
        <Affiliation>Evidence and Observational Research, Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Koto</LastName>
        <Affiliation>Evidence and Observational Research, Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Evidence and Observational Research, Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Iwao</LastName>
        <Affiliation>Oncology Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Oncology Medical, AstraZeneca K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Department of Thoracic Surgery, International University of Health and Welfare Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Gemma</LastName>
        <Affiliation>Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Mitsudomi</LastName>
        <Affiliation>Division of Thoracic Surgery, Department of Surgery, Kindai University Faculty of Medicine and Faculty of Medicine &amp; Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyuki</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Internal Medicine III, Wakayama Medical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Based on the PACIFIC trial results, durvalumab after chemoradiotherapy (CRT) is the standard of care for unresectable stage III NSCLC. However, few large-scale studies have prospectively evaluated its long-term effectiveness and safety, including subsequent treatment.&lt;br&gt;
Methods: This multicenter, noninterventional study (AYAME) enrolled patients who were prescribed durvalumab for unresectable stage III NSCLC after CRT (July 2019&#8211;December 2020; 52 sites; Japan). Patients received durvalumab for a maximum of 12 months and were prospectively followed up for 3 years, including the post-durvalumab treatment period. Primary end points were real-world progression-free survival (rwPFS), the incidence of interstitial lung disease (ILD), and adverse events of special interest (AESIs).&lt;br&gt;
Results: Of the 529 enrolled patients, 512 received durvalumab and 511 comprised the safety analysis population. The median time to onset of the first presentation or occurrence of ILD was 45.0 days. ILD of any grade occurred in 387 patients (75.7%) over the 3-year study period: grade 3, 57 (11.2%); grade 4, none (0.0%); and grade 5, 9 (1.8%). The most common AESIs of any grade during durvalumab treatment were thyroid dysfunction (12.5%), hepatic dysfunction (7.2%), and colitis (2.0%). No durvalumab treatment-related ILD or AESIs occurred during the post-treatment period. The median [95% confidence interval] rwPFS was 23.2 [18.2, 27.2] months in the effectiveness analysis population (n = 495). rwPFS rates were 62.5%, 54.6%, 49.4%, and 40.4% at 12, 18, 24, and 36 months, respectively.&lt;br&gt;
Conclusions: This first and largest prospective, observational study demonstrated the long-term safety and effectiveness of durvalumab for unresectable stage III NSCLC after CRT in a real-world clinical setting.&lt;br&gt;
Clinical Trial Registration: UMIN000037090 and NCT03995875</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Durvalumab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chemoradiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interstitial lung disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Real-world evidence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Unresectable stage III NSCLC</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0047-6374</Issn>
      <Volume>234</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The eukaryotic host&#8211;microbe&#8211;phage&#8211;nutrition interplay determines the bacterial effectors of supplemental lysine’s health benefits: An experimental cellular senescence model of digestive conditions in older adults</ArticleTitle>
    <FirstPage LZero="delete">112260</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Darab</FirstName>
        <LastName>Ghadimi</LastName>
        <Affiliation>Department of Microbiology and Biotechnology, Max Rubner-Institut</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sophia</FirstName>
        <LastName>Bl&#246;mer</LastName>
        <Affiliation>Faculty of Medicine, Christian-Albrechts-University of Kiel</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aysel &#350;AH&#304;N</FirstName>
        <LastName>KAYA</LastName>
        <Affiliation>Department of Nutrition and Dietetics, Faculty of Health Sciences, Antalya Bilim University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sandra</FirstName>
        <LastName>Kr&#252;ger</LastName>
        <Affiliation>Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Christoph</FirstName>
        <LastName>R&#246;cken</LastName>
        <Affiliation>Institute of Pathology, Kiel University, University Hospital, Schleswig-Holstein</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heiner</FirstName>
        <LastName>Sch&#228;fer</LastName>
        <Affiliation>Laboratory of Molecular Gastroenterology &amp; Hepatology, Christian-Albrechts-University &amp; UKSH Campus Kiel</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Geraldine</FirstName>
        <LastName>de Heer</LastName>
        <Affiliation>University Center for Nutritional Medicine, University Medical Centre Hamburg-Eppendorf</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dominik</FirstName>
        <LastName>Jarczak</LastName>
        <Affiliation>University Center for Nutritional Medicine, University Medical Centre Hamburg-Eppendorf</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Bacteriology, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigenobu</FirstName>
        <LastName>Matsuzaki</LastName>
        <Affiliation>Department of Medical Laboratory Science, Faculty of Health Sciences, Kochi Gakuen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wilhelm</FirstName>
        <LastName>Bockelmann</LastName>
        <Affiliation>Department of Microbiology and Biotechnology, Max Rubner-Institut</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recently, the consumption of various forms of the nutritive amino acid lysine (e.g., nutraceuticals and dietary supplements) has increased, particularly among the elderly, as it cannot be synthesized by the human body and plays a crucial role in several cellular physiological processes, including intestinal calcium and iron absorption, proteinogenesis, and fatty acid metabolism. However, the biochemical and immunological events that occur within the eukaryotic host-microbe-phage-nutrition interaction, especially when high amounts of lysine are consumed in nutraceutical or dietary supplement form by the elderly due to age-related requirements, as well as the impact on gut bacteria-derived metabolites, have not yet been fully studied. We hypothesized that (1) within an infectious-inflamed digestive milieu, the metabolism of excess extracellular lysine differs between young and senescent digestive cells, and (2) phages within the milieu exhibit alterations in host-microbe cometabolite signal profiles. To address this, we examined how gut microbes and phages, key regulators of eukaryotic host physiology, influence the immunometabolism of excess lysine. By combining two models of young and senescent digestive cells, the pathogenic P. aeruginosa PAO1, the Pseudomonas phage KPP22, and the anti-inflammatory bacterium Intestinimonas butyriciproducens, and simulating the pathogenesis of the interactive process of excessive lysine ingestion, we developed a five-way screening approach to explore key cell readouts, including viability, integrity, and function of the epithelial barrier, as well as cellular immunometabolic responses to exogenous lysine supplementation in cultures under infectious inflammation. Our findings are consistent with the possibility that host&#8211;microbe&#8211;microbe interactions involving lysine utilization and cross-feeding may influence the effects of lysine supplementation. These effects, whether beneficial or detrimental, can depend on the bacterial community, including the presence of pathogenic or potentially beneficial bacteria, interactions with intestinal phages, and the physiological conditions and metabolic requirements of the host and individual microbial taxa.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Inflammaging</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lysine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Host cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Phages</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Syntrophy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cell senescence</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ako</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironari</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gastroenterology, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Kinugasa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Hirai</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Terasawa</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Tsutsumi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Horiguchi</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Bioinformatics Analysis Center, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of Virology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoyuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, with limited therapeutic options and poor clinical outcomes. Although PDAC has traditionally been thought to arise from ductal epithelial cells, recent studies using genetically engineered mouse models have demonstrated that acinar cells can also serve as a cell of origin, giving rise to tumors with distinct biological properties. Here, we investigated whether such lineage-specific differences are preserved in human PDAC. RNA sequencing was performed on resected specimens from 40 treatment-na&#239;ve patients with PDAC, and tumors were classified into Acinar- and Ductal-subtypes using lineage-specific gene expression signatures derived from mouse models. This classification strategy was further applied to human PDAC cell lines, followed by in vitro drug sensitivity assays. Patients with Acinar-subtype tumors had significantly longer overall survival than those with Ductal-subtype tumors (median, 54.0 vs. 26.5&#8201;months; p&#8201;&lt;&#8201;0.01), and multivariate analysis identified the ductal cell-derived tumor signature as an independent predictor of poor prognosis (HR, 3.74 [95% CI, 1.41&#8211;9.97]; p&#8201;=&#8201;0.01). Among patients who developed postoperative recurrence, Acinar-subtype tumors were associated with more durable disease control (&#8805;&#8201;10&#8201;months) following gemcitabine-based chemotherapy than Ductal-subtype tumors (63.6% vs. 16.7%; p&#8201;=&#8201;0.02). Consistently, pancreatic cancer cell lines classified as Acinar-subtype showed greater sensitivity to gemcitabine (p&#8201;&lt;&#8201;0.01) and paclitaxel (p&#8201;&lt;&#8201;0.05). These findings extend the clinical relevance of cell-of-origin signatures beyond prognostic stratification, highlighting the potential of cell-of-origin-based classification for treatment stratification and precision medicine in PDAC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">acinar cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ductal cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pancreatic ductal adenocarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">precision medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transcriptomic classification</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>IEEE</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Multi-Objective Optimization for Decision Support for Supply Warehouse Location Under Earthquake Disaster Conditions ― A Case Study in Okayama City, Japan ―</ArticleTitle>
    <FirstPage LZero="delete">684</FirstPage>
    <LastPage>689</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Kuroda</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaki</FirstName>
        <LastName>Kawamoto</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In this study, we consider a Nankai Trough earthquake scenario and examine the optimal location of a new emergency supply warehouse to strengthen the emergency supply chain. Conventional facility location studies have primarily emphasized accessibility to demand points. In contrast, this study also incorporates safety based on disaster risk. We formulate an extended p-median model as a multi-objective optimization problem that simultaneously considers accessibility and safety as two evaluation criteria. Multiple scalarization methods are applied to obtain solutions under different preference settings. Numerical experiments using real-world data reveal a clear trade-off between accessibility and safety. The results also show that differences in scalarization methods affect the characteristics of the obtained solutions. Furthermore, by comparing our results with the previous study, we show that the proposed approach can flexibly derive a wide range of solutions, from distance-oriented to safety-oriented configurations. These findings provide useful insights for proposing resilient supply locations in disaster preparedness planning.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">facility location problem</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p-median problem</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multi-objective optimization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">decision support</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">disaster management</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2475-0328</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Geriatric Nutritional Risk Index Predicts Short‐ and Long‐Term Outcomes in the Oldest‐Old With Colorectal Cancer: A Multi‐Institutional Analysis of 225 Nonagenarians</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Toshima</LastName>
        <Affiliation>Department of Surgery, Kagawa Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuminori</FirstName>
        <LastName>Teraishi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoe</FirstName>
        <LastName>Takanaga</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Inada</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Ohtani</LastName>
        <Affiliation>Department of Surgery, Saiseikai Okayama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Surgery, Okayama Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoto</FirstName>
        <LastName>Hori</LastName>
        <Affiliation>Department of Surgery, Tottori Municipal Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Shigemitsu</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sumiharu</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Surgery, Okayama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsushi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Surgery, Kobe Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Okano</LastName>
        <Affiliation>Department of Surgery, Onomichi City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuji</FirstName>
        <LastName>Nobuhisa</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumitaka</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Umeoka</LastName>
        <Affiliation>Department of Surgery, Matsuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>The Setouchi Colorectal Neoplasm Registration Study Group</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aim: Surgical outcomes for colorectal cancer (CRC) in nonagenarians remain uncertain due to frailty, comorbidities, and malnutrition. The Geriatric Nutritional Risk Index (GNRI) is associated with surgical outcomes in older patients with CRC, but its prognostic value in nonagenarians is unclear. This study evaluated the GNRI's predictive value for short- and long-term surgical outcomes in this population.&lt;br&gt;
Methods: We retrospectively analyzed 225 nonagenarians undergoing surgical resection of CRC at 15 institutions between 2011 and 2022. Patients were stratified by GNRI-high/low status using two cutoffs: 98 (Cohort 1) and 86 (Cohort 2). Outcomes included postoperative complications, length of hospital stay, and overall survival (OS). Stabilized inverse-probability-of-treatment weighting (IPTW) was used to adjust for measured confounding.&lt;br&gt;
Results: The median age was 92&#8201;years (female, 64.9%; colon cancer, 79.6%). GNRI-high patients had higher body mass index and albumin levels. Complication rates did not differ between the groups. After adjustment, GNRI-high patients in Cohort 1 had a shorter expected hospital stay (ratio 0.70, 95% CI 0.51&#8211;0.96; p&#8201;=&#8201;0.025) but no significant OS difference. In Cohort 2, GNRI-high patients had better OS (p&#8201;&lt;&#8201;0.01), confirmed by adjusted Cox models (HR 0.54, 95% CI 0.35&#8211;0.82; p&#8201;&lt;&#8201;0.01).&lt;br&gt;
Conclusions: Preoperative GNRI was associated with hospital stay and OS in nonagenarians undergoing CRC surgery, although the OS association was significant only with the cohort-derived cutoff of 86, which requires external validation, and not with the literature-based cutoff of 98. The GNRI is a simple tool to stratify surgical risk and optimize perioperative nutritional status in this vulnerable population.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">geriatric nutritional risk index</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oldest-old patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">overall survival</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">surgical outcome</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1664-2392</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy in Japanese adults with growth hormone deficiency receiving weekly somapacitan or daily growth hormone: results from phase 3 REAL 1 trial</ArticleTitle>
    <FirstPage LZero="delete">1534891</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michael H&#248;jby</FirstName>
        <LastName>Rasmussen</LastName>
        <Affiliation>Clinical Drug Development, Novo Nordisk A/S</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Endo</LastName>
        <Affiliation>Medical Affairs Department, Novo Nordisk Pharma Ltd.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Claus</FirstName>
        <LastName>Sv&#230;rke</LastName>
        <Affiliation>Clinical Drug Development, Novo Nordisk A/S</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeyuki</FirstName>
        <LastName>Tahara</LastName>
        <Affiliation>Department of Neurological Surgery, Nippon Medical School, Musashikosugi Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gudmundur</FirstName>
        <LastName>Johannsson</LastName>
        <Affiliation>Department of Internal Medicine and Clinical Nutrition, Institute of Medicine at Sahlgrenska Academy, University of Gothenburg and Department of Endocrinology, Diabetology, and Metabolism, Sahlgrenska University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Somapacitan is a long-acting growth hormone (GH) derivative approved for once-weekly treatment of adult GH deficiency (AGHD). This study aimed to evaluate the efficacy and safety of somapacitan and daily GH in Japanese individuals with AGHD.&lt;br&gt;
Methods: This subgroup study included the 34-week main period of the multinational, randomized, parallel-group, phase 3 trial, REAL 1 (NCT02229851). Participants received once-weekly somapacitan or daily GH (Norditropin&#174;), both administered subcutaneously. Investigators and trial sites were blinded. A total of 36 Japanese GH-na&#239;ve individuals with AGHD were allocated to somapacitan or daily GH (excluding the placebo group of the global trial). Endpoints included change in truncal fat percentage to week 34 measured using dual-energy x-ray absorptiometry, as well as other body composition measures. Insulin-like growth factor I standard deviation score values were used for dose titration.&lt;br&gt;
Results: In total, 36 Japanese individuals were included (18 and 18 in the somapacitan and daily GH group, respectively). 35 completed the main period (34 weeks). Mean (SD) change from baseline to week 34 in truncal fat percentage was -2.23 (2.50) %-points in the somapacitan group and -2.12 (4.21) %-points in the daily GH group. Other body composition measures also improved in both groups, including reduced visceral fat and increased lean body mass. Somapacitan was well tolerated, with a safety profile similar to daily GH.&lt;br&gt;
Conclusions: In Japanese treatment-na&#239;ve individuals with AGHD, once-weekly somapacitan demonstrated similar efficacy and safety to daily GH after 34 weeks of treatment. Somapacitan provides an effective alternative to daily GH in AGHD.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">growth hormone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adult growth hormone deficiency</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">long-acting growth hormone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">somapacitan</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japan</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1012-2443</Issn>
      <Volume>94</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>An XAI-based meta-parameter tuning for time-series forecasting</ArticleTitle>
    <FirstPage LZero="delete">1</FirstPage>
    <LastPage>18</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shimon</FirstName>
        <LastName>Sumita</LastName>
        <Affiliation>Osaka University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Iida</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuhiro</FirstName>
        <LastName>Tsuchiya</LastName>
        <Affiliation>Osaka University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>How can we efficiently determine meta-parameter values for deep learning-based time-series forecasting given a time-series dataset? This paper introduces Xtune, an efficient and novel meta-parameter tuning method for deep learning-based time-series forecasting, leveraging explainable AI techniques. In particular, this study focuses on optimizing the window size for time-series forecasting. Xtune determines the optimal meta-parameter value for these methods and can also be applied to tune the window size for anomaly detection methods that utilize deep learning-based time-series forecasting. Extensive experiments on real-world datasets and forecasting methods demonstrate that Xtune efficiently identifies the optimal meta-parameter value and consistently outperforms the existing methods in terms of execution speed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Parameter optimization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">XAI</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Deep learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Time-series forecasting</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Anomaly detection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1432-0851</Issn>
      <Volume>74</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Novel combination therapy for platinum-eligible patients with locally advanced or metastatic urothelial carcinoma: a systematic review and network meta-analysis</ArticleTitle>
    <FirstPage LZero="delete">76</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsushi</FirstName>
        <LastName>Kawada</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ekaterina</FirstName>
        <LastName>Laukhtina</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pawel</FirstName>
        <LastName>Rajwa</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fahad</FirstName>
        <LastName>Quhal</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Benjamin</FirstName>
        <LastName>Pradere</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wataru</FirstName>
        <LastName>Fukuokaya</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Iwatani</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Renate</FirstName>
        <LastName>Pichler</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center Innsbruck (CCCI), Medical University of Innsbruck</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jeremy Yuen-Chun</FirstName>
        <LastName>Teoh</LastName>
        <Affiliation>S.H. Ho Urology Centre, Department of Surgery, The Chinese University of Hong Kong</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marco</FirstName>
        <LastName>Moschini</LastName>
        <Affiliation>Department of Urology, San Raffaele Hospital and Scientific Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wojciech</FirstName>
        <LastName>Krajewski</LastName>
        <Affiliation>Department of Minimally Invasive and Robotic Urology, Wroc&#322;aw Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Miki</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shahrokh F.</FirstName>
        <LastName>Shariat</LastName>
        <Affiliation>Department of Urology, Comprehensive Cancer Center, Medical University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Urology, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>European Association of Urology&#8211;Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU)</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Recent phase 3 randomized controlled trials (RCTs) demonstrate the promising impact of immune checkpoint inhibitor (ICI)-based combination therapies on locally advanced or metastatic urothelial carcinoma (UC). However, comparative data on the efficacy and toxicity of different ICI-based combinations are lacking. This study aims to compare the efficacy of first-line ICI-based combination therapies for locally advanced or metastatic UC using phase 3 RCT data. In November 2023, three databases were searched for RCTs evaluating oncological outcomes in patients with locally advanced or metastatic UC who were treated with first-line ICI-based combination therapies. Network meta-analysis (NMA) was conducted to compare outcomes, including overall survival (OS), progression-free survival (PFS), objective response rates (ORRs), complete response rates (CRRs), and treatment-related adverse events (TRAEs). Subgroup analyses were based on PD-L1 status and cisplatin eligibility. The NMA included five RCTs. Enfortumab vedotin (EV) + pembrolizumab ranked the highest for improving OS (100%), PFS (100%), ORR (96%), and CRR (96%), followed by nivolumab + chemotherapy. EV + pembrolizumab combination superiority held across PD-L1 status and cisplatin eligibility. In patients who are cisplatin-eligible, EV + pembrolizumab significantly improved OS (HR: 0.68, 95%CI 0.47&#8211;0.99) and PFS (HR: 0.67, 95%CI 0.49&#8211;0.92) compared to nivolumab + chemotherapy. Durvalumab + tremelimumab was the safest combination for severe TRAEs, and EV + pembrolizumab ranked second. Our analyses support EV + pembrolizumab combination as a first-line treatment for locally advanced or metastatic UC. Thus, EV + pembrolizumab may become a guideline-changing standard treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Enfortumab vedotin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Urothelial carcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2210-6014</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Relationship Between Heated Tobacco Products and Placental Abruption: A Prospective Cohort Study Using Online Questionnaire</ArticleTitle>
    <FirstPage LZero="delete">30</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hikaru</FirstName>
        <LastName>Ooba</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jota</FirstName>
        <LastName>Maki</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tabuchi</LastName>
        <Affiliation>Division of Epidemiology, School of Public Health, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Placental abruption (PA) is a critical obstetric complication, with maternal smoking recognized as a key risk factor. Despite the increased use of heated tobacco products (HTPs), the impact of HTPs remains unclear. This study investigated whether pregnant women using HTPs are at a higher risk of PA than non-users.&lt;br&gt;
Methods: We analyzed data from “the Japan COVID-19 and Society Internet Survey,” a prospective, self-reported online survey cohort. Questionnaires were randomly distributed between July 28, 2021, and August 30, 2021. Pregnant respondents in 2021 were invited to complete an additional survey from February 14, 2022, to February 28, 2022. We set the outcome as the absolute risk difference (aRD) and relative risk ratio (rRR) of PA incidence due to smoking HTPs in the first trimester of pregnancy. The sample size included 12 836 participants. We calculated outcomes using a generalized linear model (GLM) and inverse probability of treatment weighting (IPTW). We also performed a Bayesian approach and multiple-bias analysis for sensitivity analysis.&lt;br&gt;
Results: We found the robust aRD of 0.07 (95% confidence interval (CI): 0.06, 0.09) and the rRR of 11.3 (95% CI: 7.5, 17.0). Multiple bias analyses showed that unmeasurable confounders would need to have at least an rRR&#8201;=&#8201;14 relationship with both exposure and outcome to disprove the observed association. There has not been post hoc analysis or secondary use of data.&lt;br&gt;
Conclusion: Early pregnancy use of HTPs is associated with an increased risk of PA.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Placental abruption</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heated tobacco products</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pregnancy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tobacco use</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2076-2607</Issn>
      <Volume>14</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Virotherapy for Spinal and Spinal Cord Tumors: Current Evidence and Future Perspectives</ArticleTitle>
    <FirstPage LZero="delete">2110</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Uotani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Takatori</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutaka</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenzaburo</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Shinohara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tazawa</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Tumors of the spine and spinal cord, including primary and metastatic vertebral tumors, intramedullary gliomas, and refractory intradural lesions, are challenging to treat because curative local therapy is limited by the eloquent, nonregenerating neural tissue surrounding them. Oncolytic virotherapy may offer a rational alternative by combining tumor-selective oncolysis with the induction of systemic antitumor immunity, while sparing normal neural cells. This review summarizes the current field of oncolytic viruses, including adenovirus, herpes simplex virus, reovirus, and others, in the context of spinal and spinal cord tumors. Clinical data in the spine remain scarce; however, the rationale is based on histological evidence from sarcomas and other tumors, extensive glioma experience, including diffuse intrinsic pontine glioma, and preclinical activity in nerve sheath and meningioma models. We discuss the telomerase-specific oncolytic adenovirus OBP-301 and its derivatives, whose hTERT-driven replication provides histology-agnostic tumor selectivity, while sparing the telomerase-silent spinal cord. This telomerase dependence, however, limits activity against tumors that maintain telomeres through the alternative lengthening of telomeres (ALT) pathway, such as many osteosarcomas and some spinal cord astrocytomas. We also discuss delivery and safety within the confined spinal canal, combination strategies, and future directions, such as extracellular vesicle-mediated delivery and biomarker-guided patient selection. Although clinical translation to the spine will require dedicated preclinical and early-phase studies, virotherapy represents a promising, mechanistically grounded modality for these therapeutically challenging tumors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oncolytic virotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spinal cord tumor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spinal metastasis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oncolytic adenovirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OBP-301</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hTERT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">telomerase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">glioma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">blood&#8211;spinal cord barrier</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer immunotherapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0032-0781</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Disrupted FLOWERING LOCUS C alleles from weedy radish enhance the florigenic potential of rootstocks for graft-mediated floral induction in Brassicaceae</ArticleTitle>
    <FirstPage LZero="delete">pcag119</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ko</FirstName>
        <LastName>Motoki</LastName>
        <Affiliation>Graduate School of Environmental, Life and Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Graduate School of Environmental, Life and Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazusa</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Graduate School of Environmental, Life and Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Kinoshita</LastName>
        <Affiliation>Graduate School of Agriculture, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Kashima</LastName>
        <Affiliation>Faculty of Science, Department of Biomolecular Science, Toho University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Ushijima</LastName>
        <Affiliation>Graduate School of Environmental, Life and Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tanjuro</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Graduate School of Environmental, Life and Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichiro</FirstName>
        <LastName>Yasuba</LastName>
        <Affiliation>Graduate School of Environmental, Life and Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Munetaka</FirstName>
        <LastName>Hosokawa</LastName>
        <Affiliation>Faculty of Agriculture, Kindai University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Graft-mediated floral induction is a classical yet promising breeding technique that accelerates seed production and shortens generation time in crops. However, its application remains limited to a few species because floral induction is often unstable. Even among florally induced rootstocks, grafted scions can differ in their flowering response depending on rootstock genotype, but the genetic basis of this variation remains unclear. Here, using a Brassicaceae grafting model, we investigated two early-bolting radish (Raphanus sativus) accessions differing in their ability to induce flowering. We focused on a significant difference in FLOWERING LOCUS T (FT) expression between these accessions and identified two quantitative trait loci (QTLs) associated with FT levels. Transcriptomic and genomic analyses revealed that both QTLs harbored previously unreported disrupted alleles of FLOWERING LOCUS C (FLC) homologs, key floral repressors involved in vernalization, which showed reduced expression and produced defective transcripts. Grafting experiments demonstrated that these disrupted FLC alleles enhanced floral induction, with RsFLC1 having a major effect. Our results indicate that the FT expression threshold required for graft-mediated floral induction is higher than that for rootstock flowering itself and that this threshold is reached when FLC-mediated repression is substantially reduced. These alleles were inferred to have originated from weedy radish (Raphanus raphanistrum), likely contributing to early flowering in disturbed environments. This study suggests that exploring genetic variations in FT expression is an effective strategy to develop highly florigenic rootstocks, thereby broadening the application of graft-mediated floral induction in crop breeding.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Brassica oleracea</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FLOWERING LOCUS C</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FLOWERING LOCUS T</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">graft-mediated floral induction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vernalization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">weedy radish (Raphanus raphanistrum)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0008-6215</Issn>
      <Volume>338</Volume>
      <Issue>16</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2003</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Stereoselectivity in deoxygenation of 5-hydroxy-5-phosphinyl-hexofuranoses (α-hydroxyphosphonates)</ArticleTitle>
    <FirstPage LZero="delete">1641</FirstPage>
    <LastPage>1650</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Hanaya</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken-ichi</FirstName>
        <LastName>Sugiyama</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Heizan</FirstName>
        <LastName>Kawamoto</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The addition of dimethyl phosphonate to six different hexofuranos-5-uloses in the presence of DBU, followed by esterification with methoxalyl chloride and then radical reduction, afforded 5-deoxy-5-dimethoxyphosphinyl-d- and l-hexofuranoses. The stereoselectivity of the deoxygenation and possible transition-state models are discussed.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Phospho sugar</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Deoxygenation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">α-Hydroxyphosphonate</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2198-3844</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>SPRED2 Negatively Regulates CD8+ T Cell-Mediated Antitumor Immunity in Breast Cancer</ArticleTitle>
    <FirstPage LZero="delete">e77909</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Miao</FirstName>
        <LastName>Tian</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teizo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kun</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chunning</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tong</FirstName>
        <LastName>Gao</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Advanced International and Information Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Fujisawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiaki</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Pathology and Experimental Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Activation of the RAS/RAF/ERK pathway is crucial for adaptive immunity. Here, we provide evidence that Sprouty-related EVH1 domain containing 2 (SPRED2), an endogenous inhibitor of this pathway, negatively regulates CD8+ T cell-mediated antitumor immunity in breast cancer. In EO771 and 4T1 mouse models, Spred2−/− mice exhibit reduced tumor growth, with lower endpoint lung metastatic burden in the 4T1 model, accompanied by increased T-cell infiltration and activation. Spred2−/− T cells show enhanced cytokine expression, proliferation,survival, in vitro cytotoxicity, and memory-like phenotypes, particularly among CD8+ T cells. Adoptive transfer of Spred2−/− CD8+ T cells into tumor-bearing wild-type hosts similarly reduces endpoint lung metastatic burden. MEK inhibition with U0126 attenuates increased interferon-gamma and granzyme B expression in Spred2−/− CD8+ T cells. Transcriptomic analyses reveal an inverse correlation between SPRED2 expression and antitumor CD8+ T cell states in both humans and mice. In tumor-infiltrating T cells from patients with breast cancer, SPRED2low T cells show enriched effector and cytotoxicity programs and are associated with “immune-hot” tumors, whereas survival associations vary with CD8+ T cell context. Collectively, these findings suggest that SPRED2 functions as a cell-intrinsic negative regulator of CD8+ T-cell activation and highlight its potential as a therapeutic target to enhance T cell&#8211;based cancer immunotherapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">breast cancer </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD8+ T cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">MAPK/ERK</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor microenvironment</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japan Medical Association</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2433-3298</Issn>
      <Volume>8</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Unraveling Causality: Innovations in Epidemiologic Methods</ArticleTitle>
    <FirstPage LZero="delete">323</FirstPage>
    <LastPage>337</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Etsuji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>For several decades, the counterfactual model and the sufficient cause model have shaped our understanding of causation in biomedical science and, more recently, the link between these two models has enabled us to obtain a deeper understanding of causality. In this article, I provide a brief overview of these fundamental causal models using a simple example. The counterfactual model focuses on one particular cause or intervention and gives an account of the various effects of that cause. By contrast, the sufficient cause model considers sets of actions, events, or states of nature which together inevitably bring about the outcome under consideration. In other words, the counterfactual framework addresses the question “what if?” while the sufficient cause framework addresses the question “why does it happen?” Although these two models are distinct and address different causal questions, they are closely related and used to elucidate the same cause-effect relationships. Importantly, the sufficient cause model makes clear that causation is a multifactorial phenomenon, and it is a “finer” model than the counterfactual model; an individual is of one and only one response type in the counterfactual framework, whereas an individual may be at risk of none, one, or several sufficient causes. Understanding the link between the two causal models can provide greater insight into causality and can facilitate the use of each model in appropriate contexts, highlighting their respective strengths. I will briefly present three topics of interest from our research: the relationship between the concepts of confounding and of covariate balance; distinctions between attributable fractions and etiologic fractions; and the identification of operating mediation and mechanism. It is important to scrutinize observed associations in a complementary manner, using both the counterfactual model and the sufficient cause model, employing both inductive and deductive reasoning. This holistic approach will better help us to unravel causality.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">attributable fraction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">causal inference</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">confounding</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">counterfactual model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">covariate balance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">etiologic fraction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mediation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sufficient cause model</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2311-5521</Issn>
      <Volume>11</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>First-Order Wall-Slip-Induced Departure from Inverse-Cubic Scaling of Levitation-Pressure RMS in a Push&#8211;Pull Levitation Stage</ArticleTitle>
    <FirstPage LZero="delete">218</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Eisuke</FirstName>
        <LastName>Umesaki</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junji</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshinori</FirstName>
        <LastName>Kouchi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study clarifies how rarefaction-induced wall slip in a thin gas film affects the established inverse-cubic scaling law for the spatial nonuniformity of levitation pressure in a push&#8211;pull levitation stage. The levitation force in this stage is generated by the combined action of blowing and suction. The continuum-based stress description is retained, and only the wall boundary condition is changed from the no-slip condition to a first-order slip condition. Three-dimensional incompressible unsteady Stokes simulations in a thin-gap unit-cell model are combined with a lubrication-theory scaling analysis. The effects of levitation height, blowing-velocity distribution, port-radius ratio, and computational-domain width are examined systematically. The results show that wall slip has only a minor influence at relatively large levitation heights. As the levitation height decreases, however, rarefaction-induced slip increases the flow-rate conductance. Consequently, the intensity of the spatial variation in levitation pressure is systematically reduced below that predicted by the no-slip inverse-cubic scaling law. This departure is well described by a correction relation derived from the lubrication approximation and remains robust against changes in the prescribed blowing-velocity distribution and geometric conditions. These findings provide an incompressible baseline for predicting levitation-pressure nonuniformity within the nominal gap-based Knudsen-number range examined here.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">push&#8211;pull levitation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">wall slip</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rarefaction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lubrication approximation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pressure RMS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thin gas film</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Knudsen number</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>18</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Salivary miR-324-5p Is Associated with Periodontal Inflamed Surface Area in People Living with HIV Receiving Antiretroviral Therapy: A Case&#8211;Control Study</ArticleTitle>
    <FirstPage LZero="delete">8117</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mohammad</FirstName>
        <LastName>Nurhamim</LastName>
        <Affiliation>Department of Preventive Dentistry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Yokoi</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ekuni</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Periodontitis is a common inflammatory disease that affects the tooth-supporting tissues. Salivary microRNA (miRNA) expression in extracellular vesicles (EVs) can reflect periodontal status. Both the prevalence and severity of periodontitis are higher in people with human immunodeficiency virus (PWH). This study aimed to identify miRNA in salivary EVs associated with periodontitis in PWH receiving antiretroviral therapy (ART). The case group comprised PWH with periodontitis undergoing ART, while the control group included individuals with periodontitis but without HIV infection. The study was conducted in two phases. In the first phase, a specific miRNA was identified in the case group using next-generation sequencing analysis, resulting in the selection of hsa-miR-324-5p as a candidate marker of periodontitis. In the second phase, the association between miRNA expression of hsa-miR-324-5p and periodontal status in the case group was evaluated using real-time-quantitative PCR (RT-qPCR). RT-qPCR analysis demonstrated that hsa-miR-324-5p expression was significantly associated with periodontal inflamed surface area (PISA). Bioinformatic analysis identified 10 potential hub genes for hsa-miR-324-5p that are involved in protein kinase binding and are associated with the adherens junction pathway, that may be contributing to the pathogenesis of periodontitis. Salivary hsa-miR-324-5p derived from EVs may be associated with the severity of periodontitis among PWH receiving ART.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">miR-324-5p</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">saliva</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">marker</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HIV</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value"> extracellular vesicles</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inflammation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-3751</Issn>
      <Volume>604</Volume>
      <Issue>18</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Integrative simulation analysis of myocardial ischaemia&#8211;reperfusion injury</ArticleTitle>
    <FirstPage LZero="delete">7640</FirstPage>
    <LastPage>7662</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takao</FirstName>
        <LastName>Shimayoshi</LastName>
        <Affiliation>Center for Artificial Intelligence and Mathematical Data Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Department of Physiology and Biophysics, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Integrative and Systems Physiology, Faculty of Medical Sciences, University of Fukui</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cardiac ischaemia, reduced coronary blood flow, causes significant damages to the heart, and paradoxically reperfusion, restored flow after ischaemia, often results in more severe injury. Although the mechanisms underlying cardiac ischaemia&#8211;reperfusion injury have been intensively investigated, effective therapeutic strategies applicable during reperfusion to mitigate this damage have not been established yet. To obtain more insights into the mechanisms underlying ischaemia&#8211;reperfusion injury, and to explore effective methods to relieve reperfusion injury, we developed a comprehensive mathematical model of ventricular myocyte, implementing excitation&#8211;contraction (E&#8211;C) coupling, cytosolic and mitochondrial pH regulation, pH dependence of major components of E&#8211;C coupling and cellular energy metabolism, including mitochondrial oxidative phosphorylation. The mathematical model successfully reproduced experimentally observed findings on cardiac ischaemia&#8211;reperfusion injury, such as intracellular and extracellular acidosis, cytosolic Na+ overload, cytosolic Ca2+ overload, mitochondrial dysfunction, action potential shortening and contraction failure. It was found that the reperfusion-induced exacerbation of Na+i, Ca2+i overloads was mainly caused by insufficient production of NADH, which is used in mitochondrial oxidative phosphorylation to synthesize ATP for Na+/K+ pump and sarcoplasmic/endoplasmic reticulum Ca2+ pump (SERCA) to expel accumulated cytosolic Na+ and Ca2+, respectively. It was suggested that the preservation of mitochondrial NADH production, attenuation of ATP consumption via SERCA or contraction for a short period or activation of the Na+/K+ pump during reperfusion mitigates reperfusion injury.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">computational modelling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">heart</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ischaemia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mitochondria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reperfusion</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>BMJ</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2044-6055</Issn>
      <Volume>16</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Study protocol for a phase II clinical trial evaluating the safety and efficacy of favipiravir injection combined with oseltamivir in influenza treatment</ArticleTitle>
    <FirstPage LZero="delete">e106715</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sayaka</FirstName>
        <LastName>Hikida</LastName>
        <Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Nomoto</LastName>
        <Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukari</FirstName>
        <LastName>Uemura</LastName>
        <Affiliation>Laboratory of Biostatistics, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadaki</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Izumikawa</LastName>
        <Affiliation>Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Ohge</LastName>
        <Affiliation>Project Research Center for Nosocomial Infectious Diseases, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Yamato</LastName>
        <Affiliation>Infectious Diseases Center, Rinku General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Infectious Diseases, International University of Health and Welfare Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Hase</LastName>
        <Affiliation>Department of Infectious Diseases, Japanese Red Cross Narita Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuji</FirstName>
        <LastName>Aoyagi</LastName>
        <Affiliation>Department of Clinical Microbiology and Infection, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Nukui</LastName>
        <Affiliation>Department of Infection Control &amp; Laboratory Medicine, Kyoto Prefectural University of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuko</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>First Department of Internal Medicine, Division of Infectious, Respiratory, and Digestive Medicine, University of the Ryukyus Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshio</FirstName>
        <LastName>Takesue</LastName>
        <Affiliation>Chita Peninsula General Medical Organization, Rinku Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kota</FirstName>
        <LastName>Sawada</LastName>
        <Affiliation>Laboratory of Biostatistics, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Laboratory of Biostatistics, Department of Data Science, Center for Clinical Sciences, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Department of Infectious Disease Pathology, National Institute of Infectious Diseases, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Namiko</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kozue</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Miyazaki</LastName>
        <Affiliation>Center for Clinical Sciences, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Morino</LastName>
        <Affiliation>Center for Clinical Sciences, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Tokita</LastName>
        <Affiliation>Center for Clinical Sciences, Japan Institute for Health Security</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Ohmagari</LastName>
        <Affiliation>Disease Control and Prevention Center, National Center for Global Health and Medicine, Japan Institute for Health Security</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction Older adults are at an increased risk of influenza-related hospitalisation and mortality due to a combination of risk factors. Severe influenza and excess mortality in this population remain major public health concerns, underscoring the need for novel treatment strategies.&lt;br&gt;
Methods and analysis This multicentre, investigator-initiated, randomised, double-blind clinical trial evaluated the efficacy and safety of the investigational drug favipiravir injection (T-705IV) in combination with oseltamivir phosphate, compared with oseltamivir monotherapy in hospitalised patients with influenza aged &#8805;65 years. Both T-705IV and oseltamivir phosphate will be administered for 5&#8201;days. The primary endpoint is time from randomisation to recovery within 15 days. Recovery is defined as either actual hospital discharge or sustained clinical status permitting discharge for 3 consecutive days. Clinical status will be assessed using a 7-point ordinal scale based on hospitalisation status and oxygen requirement. The primary analysis employs a Bayesian Cox proportional hazards model with a non-informative prior to estimate the posterior probability that the HR exceeds 1.0. The secondary endpoints include the distribution of 7-point scale scores over a 29-day period; rates of clinical worsening at days 15 and 29; duration of fever; all-cause mortality; intensive care unit admission within 29 days; pneumonia complication rate at 15 days; and changes in viral titre and viral RNA load on days 1, 2, 3 and 7. Safety will be assessed through the collection of adverse events (AEs) up to day 29. Pharmacokinetic evaluation will include measurement of plasma favipiravir concentrations on day 3. The planned sample size is 80 patients (40 per group).&lt;br&gt;
Ethics and dissemination Written informed consent will be obtained from all participants. This study was approved by the Center Hospital of the National Center for Global Health and Medicine Institutional Review Board (approval number: NCGM-I-022-24a) and registered in the Japan Registry of Clinical Trials. Study findings will be disseminated through peer-reviewed publications and/or presentations at academic conferences.&lt;br&gt;
Trial registration number jRCT2031240586,</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>The Korean Geriatrics Society</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2508-4798</Issn>
      <Volume>30</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Variation in the Association between Frailty and Disability over 10 Years: A Cohort Study</ArticleTitle>
    <FirstPage LZero="delete">143</FirstPage>
    <LastPage>150</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Akikazu</FirstName>
        <LastName>Hagiyama</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soshi</FirstName>
        <LastName>Takao</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Although frailty is associated with disability, its long-term persistence and changes over time remain unclear. This study aimed to investigate the long-term association between frailty and the incidence of disability over a 10-year follow-up period, evaluating how this association changed over time. Methods: This cohort study was conducted in Okayama City, Japan. Community-dwelling older adults aged &#8805;65 years were included. Frailty was assessed using the Kihon Checklist, and disability was defined as a new certification for long-term care insurance. The association between frailty and disability was examined across five time periods (years 1&#8211;2, 3&#8211;4, 5&#8211;6, 7&#8211;8, and 9&#8211;10) using a marginal structural model with inverse probability of treatment weighting and inverse probability of censoring weighting. Results: The final analysis included 45,291 participants, with 17.3% classified as frail. The adjusted odds ratios (ORs) for the association between frailty and the incidence of disability gradually decreased over time but remained throughout the 10-year follow-up period. The adjusted ORs and 95% confidence intervals were 2.90 (2.55&#8211;3.29) for years 1&#8211;2, 2.40 (2.09&#8211;2.75) for years 3&#8211;4, 2.03 (1.76&#8211;2.34) for years 5&#8211;6, 1.75 (1.52&#8211;2.01) for years 7&#8211;8, and 1.58 (1.38&#8211;1.82) for years 9&#8211;10. Conclusion: Frailty was consistently associated with the incidence of disability over a 10-year follow-up period, with a stronger association in the earlier years and a gradual decline over time.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Frailty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Persons with disabilities</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Aged</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Longitudinal studies</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>AIP Publishing</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-9606</Issn>
      <Volume>165</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Scaled-charge ion force field optimized for individual ion partial molar volumes in water</ArticleTitle>
    <FirstPage LZero="delete">104508</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Aoi</FirstName>
        <LastName>Taira</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Katsuto</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kanon</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonari</FirstName>
        <LastName>Sumi</LastName>
        <Affiliation>Graduate School of Engineering, Muroran Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichiro</FirstName>
        <LastName>Koga</LastName>
        <Affiliation>Department of Chemistry, Faculty of Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We present an ion partial molar volume force field for common monovalent and divalent ionic species, including Li+, Na+, K+, Cs+, Mg2+, Ca2+, F−, Cl−, Br−, I−, OH−, and H3O+. When combined with the TIP4P/2005 water model, the force field enables quantitative investigations of ion-specific effects in both bulk and interfacial properties. The iPMV force field is developed based on a single guiding principle: the ion&#8211;water interaction parameters are optimized such that the experimental partial molar volume of each individual ion at infinite dilution―determined via the ultrasonic vibrational potential method―is reproduced by construction. An exception is made for the hydronium ion, for which we also provide an alternative interface-optimized model. The force field employs a charge scaling factor of 0.75 and adopts the Lorentz&#8211;Berthelot combining rules for cross-Lennard-Jones interactions, with specific modifications for divalent cations. A distinctive feature of the iPMV force field is that, despite its straightforward design, a single set of ion parameters consistently reproduces a wide range of experimental properties―from volumetric and interfacial properties to salting-out/in effects and transport coefficients. This robust performance suggests a fundamental correlation between the partial molar volumes of individual ions and the broader physical properties of aqueous electrolyte solutions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>3050-5976</Issn>
      <Volume>2</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Older patients with LBCL show comparable outcomes to younger patients and product-specific profiles in CAR-T therapy</ArticleTitle>
    <FirstPage LZero="delete">100037</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Hematology, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Arai</LastName>
        <Affiliation>Department of Hematology, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Department of Hematology, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Kaji</LastName>
        <Affiliation>Department of Hematology, Toranomon Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Minakata</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Jichi Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kitawaki</LastName>
        <Affiliation>Department of Hematology, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Hematology and Oncology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsu</FirstName>
        <LastName>Shimoyama</LastName>
        <Affiliation>Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>Department of Hematology, Hyogo Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Makita</LastName>
        <Affiliation>Department of Hematology, National Cancer Center Hospital, Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Hematology, Toranomon Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emiko</FirstName>
        <LastName>Sakaida</LastName>
        <Affiliation>Department of Hematology, Chiba University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Hematology, Osaka Metropolitan University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiyo</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Division of Transfusion Medicine, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Umezawa</LastName>
        <Affiliation>Department of Hematology, Institute of Science Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haryoon</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Atsuta</LastName>
        <Affiliation>Japanese Data Center for Hematopoietic Cell Transplantation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Anti-CD19 chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a key treatment option for patients with relapsed or refractory large B-cell lymphoma (LBCL). However, data on its effectiveness and safety in older populations remain limited, particularly in real-world clinical practice. Moreover, comparative outcomes among different CAR-T products across age groups have not yet been fully characterized. We conducted a nationwide retrospective cohort study using data from the Japanese Society for Transplantation and Cellular Therapy. A total of 908 patients who received CAR-T therapy between January 2019 and September 2024 were included. Patients were categorized as younger (aged &lt;65 years) or older (aged &#8805;65 years). Subgroup analyses were performed by CAR-T product (tisagenlecleucel [tisa-cel], lisocabtagene maraleucel [liso-cel], and axicabtagene ciloleucel [axi-cel]). In univariate analysis, 1-year overall survival (OS) and progression-free survival (PFS) were comparable between younger and older patients (OS, 69.4% vs 65.7% [P = .40]; PFS, 47.9% vs 54.1% [P = .17]). In multivariate analysis, age &#8805;65 years showed no significant association with OS (hazard ratio, 0.88; 95% confidence interval, 0.65-1.21; P = .44). The incidence of immune effector cell&#8211;associated neurotoxicity syndrome was significantly higher in older patients (12.7% vs 7.0%; P = .005). Compared with tisa-cel, axi-cel and liso-cel were associated with superior PFS, predominantly in younger patients. Among older patients, axi-cel was associated with higher nonrelapse mortality rate than tisa-cel. CAR-T therapy is feasible and effective for older patients with LBCL. These findings support age-adapted treatment strategies that consider both the efficacy and toxicity of each product.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1520-541X</Issn>
      <Volume>28</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sexual Dimorphism in Vertebral Number: Developmental Implications Inferred From Vertebral and Body Proportions</ArticleTitle>
    <FirstPage LZero="delete">e70062</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazunori</FirstName>
        <LastName>Yamahira</LastName>
        <Affiliation>Tropical Biosphere Research Center, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">V. K.</FirstName>
        <LastName>Anoop</LastName>
        <Affiliation>Tropical Biosphere Research Center, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rajeev</FirstName>
        <LastName>Raghavan</LastName>
        <Affiliation>Department of Fisheries Resource Management, Kerala University of Fisheries and Ocean Studies</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Ushimado Marine Institute, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Ansai</LastName>
        <Affiliation>Ushimado Marine Institute, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Segmentation is a fundamental feature of vertebrate body plans, and variation in vertebral number contributes substantially to morphological diversity. Although sexual dimorphism in vertebral number has been documented in several vertebrate lineages, its developmental basis remains poorly understood. Here, we report pronounced sexual dimorphism in vertebral number in the western Indian endemic ricefish Oryzias setnai, distributed across ~1800&#8201;km. Radiographic analyses of individuals collected throughout its range revealed that vertebral number increased with latitude in both sexes, while males consistently possessed more vertebrae than females irrespective of geographic origin. Size-adjusted analyses showed that this dimorphism is associated with sex differences in head size and position-dependent variation in vertebral length. However, positional allometric analyses demonstrated that both the magnitude and direction of these sex differences vary markedly during growth. In particular, among smaller individuals, posterior vertebrae were relatively shorter in males than in females, suggesting reduced somite length in the posterior body axis of male embryos and potentially reflecting sex-specific differences in the dynamics of somitogenesis. Given that this variation arises between males and females within a single species sharing an essentially identical genetic background, O. setnai provides a rare empirical system not only for linking early developmental processes to intraspecific sexual variation in vertebrate body plans but also as a powerful model to investigate the developmental basis of body plan variation across species.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">axial patterning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">developmental mechanisms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">latitude</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oryzias</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">segmentation interval</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vertebral length</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>日本健康教育学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1340-2560</Issn>
      <Volume>34</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>中・高・大学生の健診結果活用の促進要因―ヘルスリテラシースキルフレームワークを用いた検討―</ArticleTitle>
    <FirstPage LZero="delete">118</FirstPage>
    <LastPage>129</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hitomi</FirstName>
        <LastName>ONISHI</LastName>
        <Affiliation>The Joint Graduate School (Ph.D. Program) in Science of School Education, Hyogo University of Teacher Education</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuki</FirstName>
        <LastName>NISHIOKA</LastName>
        <Affiliation>Faculty of Psychology and Collaboration, Kyoto Women’s University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiko</FirstName>
        <LastName>ITO</LastName>
        <Affiliation>Graduate School of Education, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>目的：学校健康診断結果活用（以下，活用）と関連要因及び相互の関連性をヘルスリテラシースキルフレームワークを用いて明らかにすることを目的とした．&lt;br&gt;
方法：中学生493名，高校生360名，大学1年生297名を対象に無記名自記式質問紙調査を行った．調査内容は活用と，健康への関心，ヘルスリテラシー（以下，HL），健診結果に対する認識，健診結果の読解力（以下，読解力），意思決定バランスとした．これらの関連性を示す仮説モデルを校種，性別の多母集団同時パス解析で検証した．&lt;br&gt;
結果：仮説モデルに4つのパスを追加した修正モデルで，校種，性別いずれにおいても配置不変モデルで良好な適合度を得た．健診結果に対する認識から読解力，読解力から意思決定バランス，意思決定バランスから活用，健康への関心から読解力，意思決定バランス，活用へのパス及び，HLから活用へのパスは全ての校種において有意であった．健康への関心と結果に対する認識からHL，HLから読解力，意思決定バランスへのパスは中・高校生のみで有意であった．&lt;br&gt;
結論：中・高・大学生の健診結果活用を促すためには，健診結果を分かりやすくすること，健診結果の読解力及び意思決定バランスの向上，すなわち恩恵の認識の向上と，負担の認識の軽減が有効であり，その際に対象者の健康への関心とHLの程度を考慮する必要性が示唆された．</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">読みやすさ (readability)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">読解力 (reading comprehension)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">意思決定バランス (decision balance)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">健康への関心 (health interest)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ヘルスリテラシー (health literacy)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Pharmaceutical Society of Japan</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-6158</Issn>
      <Volume>49</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effect of Deuterated Drugs on Safety: Insights from Pharmacovigilance Data Analysis</ArticleTitle>
    <FirstPage LZero="delete">983</FirstPage>
    <LastPage>988</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Department of Neuropsychiatry, Okayama Psychiatric Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Nawa</LastName>
        <Affiliation>Department of Pharmacy, Faculty of Pharmacy, Shujitsu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Asai</LastName>
        <Affiliation>Department of Pharmacy, Faculty of Pharmacy, Shujitsu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Niimura</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Goda</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Ishizawa</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Huntington’s disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive, and psychiatric symptoms. Tetrabenazine (TBZ), a vesicular monoamine transporter 2 inhibitor, is commonly used to manage chorea; however, it may exhibit fluctuating plasma levels and elicit frequent adverse events. In this study, we aimed to clarify the effects of TBZ deuteration on its safety profile. We compared the safety profiles of TBZ and deutetrabenazine (DTBZ) in real-world clinical practice using disproportionality analysis and the large-scale pharmacovigilance database, VigiBase―the WHO’s global database of adverse drug reactions. Adverse event signals were assessed using the information component (IC). Seriousness was classified according to clinical outcome, and time to onset (TTO) was analyzed for selected events. TBZ showed signals for disorientation, dystonia, and sleep disorders (IC025 &gt; 0), whereas DTBZ did not. Serious adverse events were reported in 54.7% of TBZ cases and 37.9% of DTBZ cases. The TTO of sleep disorder was also evaluated; however, the number of cases with available TTO information was limited. DTBZ showed fewer adverse event signals and a lower proportion of serious adverse events than TBZ. These findings suggest potential differences in the safety profiles of the two drugs, which may influence tolerability in the treatment of HD.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">deuterated drug</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">VigiBase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">heavy drug</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">safety advantage</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pharmacovigilance analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0941-4355</Issn>
      <Volume>34</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Machine learning approaches to predict early cardiac immune-related adverse events in patients receiving immune checkpoint inhibitors</ArticleTitle>
    <FirstPage LZero="delete">809</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Michael</FirstName>
        <LastName>Sayer</LastName>
        <Affiliation>School of Pharmacy &amp; Pharmaceutical Sciences, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peter D.</FirstName>
        <LastName>Chang</LastName>
        <Affiliation>School of Medicine, Pathology &amp; Laboratory Medicine, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reina</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misako</FirstName>
        <LastName>Nagasaka</LastName>
        <Affiliation>Division of Hematology and Oncology, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ali A.</FirstName>
        <LastName>Naqvi</LastName>
        <Affiliation>Mary &amp; Steve Wen Cardiovascular Division, Department of Medicine, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Pranav M.</FirstName>
        <LastName>Patel</LastName>
        <Affiliation>Mary &amp; Steve Wen Cardiovascular Division, Department of Medicine, University of California</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya F.</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>School of Pharmacy &amp; Pharmaceutical Sciences, University of California</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Immune checkpoint inhibitor (ICI)&#8211;induced cardiac immune-related adverse events (cardiac irAEs) are rare yet serious complications. Clinical assessment tools to identify at-risk patients would allow for more effective prevention strategies, thus improving clinical outcomes. We constructed various machine learning (ML) models to predict these events among patients receiving ICI therapy.&lt;br&gt;
Methods A cohort of patients receiving ICI therapy from 2010 to 2023 was identified from the TriNetX database. Cardiac irAEs were defined as the occurrence of relevant diagnosis codes within 90 days of ICI initiation, with corresponding hospital visits. We created ML models to predict these events, including elastic net logistic regression and multiple tree-based approaches (gradient boosted trees and random forest). We evaluated model performance with different performance measures and utilized assigned risk scores to stratify risk of cardiac irAEs into low, medium, and high-risk tiers.&lt;br&gt;
Results We identified 61,117 patients receiving ICI therapy, with nearly 2% of patients experiencing cardiac irAEs. Model performance on testing data was comparable with all approaches (AUC&#8201;=&#8201;0.71&#8211;0.72, balanced accuracy&#8201;=&#8201;65&#8211;66%). Each model emphasized distinct features to make classifications, as observed with feature importance and SHAP values. Comparing cardiac irAE rates among assigned risk strata, patients identified as high risk were significantly more likely to experience cardiac irAEs compared to lower tiers.&lt;br&gt;
Conclusion Our preliminary exploration of ML methods demonstrated the potential for risk assessment tools to predict rare cardiac irAEs in patients receiving ICI therapy. Follow-up studies can implement time series approaches to harness longitudinal data that incorporates real-time labs, new diagnoses, and new therapy, to refine predictions further.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Immune checkpoint inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Immune-related adverse events</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Myocarditis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pericarditis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Risk assessment tools</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>SAGE Publications</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-1253</Issn>
      <Volume>16</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Seizures associated with clozapine augmentation by other antipsychotics: a pharmacovigilance&#8211;pharmacodynamic analysis using VigiBase</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Hatano</LastName>
        <Affiliation>Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Department of Pharmacy, Asahikawa Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takenao</FirstName>
        <LastName>Koseki</LastName>
        <Affiliation>Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rina</FirstName>
        <LastName>Horii</LastName>
        <Affiliation>Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nozomi</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeo</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Psychiatry, Fujita Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenshi</FirstName>
        <LastName>Takechi</LastName>
        <Affiliation>Department of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Esumi</LastName>
        <Affiliation>The Faculty of Pharmaceutical Sciences, Kobe Gakuin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Pharmacotherapeutics and Informatics, Fujita Health University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Clozapine is associated with a high risk of central nervous system abnormalities. However, seizure risk related to interactions between clozapine and other antipsychotics remains poorly characterized, and the pharmacological mechanisms underlying these seizures are unclear.
Objectives: We aimed to evaluate safety signals for seizures associated with clozapine augmentation by other antipsychotics and analyze the relationship between these signals and neurotransmitter receptor occupancy profiles.&lt;br&gt;
Design: A pharmacovigilance&#8211;pharmacodynamic analysis using a spontaneous reporting system.&lt;br&gt;
Methods: This pharmacovigilance study used VigiBase, an adverse drug reaction database maintained by the World Health Organization. Drug&#8211;drug interactions (DDIs) between clozapine and other antipsychotics were assessed using the Ω shrinkage measure model. The association between DDI signals and neurotransmitter receptor occupancy was evaluated using linear regression. Robustness was tested using four frequency statistical models: additive, multiplicative, combination risk ratio, and chi-square statistic models.
Results: Of 38,758,077 reports in VigiBase between 1990 and 2024, 230,371 involved clozapine. Among antipsychotics classified under ATC code N05A, DDIs with clozapine were detected for amisulpride, chlorpromazine, haloperidol, lurasidone, olanzapine, penfluridol, risperidone, sulpiride, zotepine, and zuclopenthixol. A significant association between dopamine D4 receptor occupancy and the point estimates of signal values was observed in the Ω shrinkage measure model (β&#8201;=&#8201;0.295, 95% confidence interval: 0.119&#8211;0.471, p&#8201;=&#8201;0.002) and replicated across all frequency statistical models.&lt;br&gt;
Conclusions: These findings suggest a potential role of dopamine D4 receptor occupancy in seizures associated with clozapine augmentation by other antipsychotics. Further large-scale epidemiological studies are needed to validate these findings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2475-0328</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Biological Resectability in Colorectal Liver Metastases: A Nomogram‐Based Continuous Risk Model to Define Borderline Disease</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuzo</FirstName>
        <LastName>Umeda</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Fuji</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Surgery, Okayama Saiseikai General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Koujima</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Tenwakai Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Satoh</LastName>
        <Affiliation>Department of Surgery, Hiroshima Citizens Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Resectability in colorectal liver metastases (CRLM) is traditionally defined by technical feasibility; however, a biologically based definition of borderline resectable disease has not been established. We evaluated the prognostic impact of KRAS mutation and developed a model for biological risk stratification.&lt;br&gt;
Methods: This multi-institutional retrospective study included 584 patients undergoing initial hepatectomy for CRLM. The impact of KRAS mutation was assessed according to primary tumor sidedness and tumor burden score (TBS). A nomogram predicting overall survival (OS) was constructed using independent prognostic factors and compared with established clinical risk scores.&lt;br&gt;
Results: KRAS mutation was identified in 36.8% of patients and was associated with worse OS (median survival: 47.3 vs. 70.6&#8201;months, p&#8201;=&#8201;0.0006) and recurrence-free survival. This adverse impact was observed in left-sided tumors but not in right-sided tumors. TBS stratified prognosis in KRAS wild-type but not in mutant cases, suggesting that tumor biology may outweigh morphology. A nomogram incorporating KRAS status, TBS, CA19-9, primary nodal status, and extrahepatic disease demonstrated improved discriminatory ability compared with conventional models and stratified recurrence patterns, including extrahepatic recurrence.&lt;br&gt;
Conclusions: The prognostic impact of KRAS mutation depends on tumor sidedness and is independent of tumor morphology. Our nomogram provides a continuous biological risk assessment and may facilitate biological risk stratification and support future refinement of the concept of biologically borderline resectable CRLM.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">biology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">borderline resectable</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">colorectal liver metastases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genetic profile</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">KRAS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">morphology</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1462-5814</Issn>
      <Volume>2026</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Phenotypic Characterization of Porphyromonas gulae Fimbria Mutants</ArticleTitle>
    <FirstPage LZero="delete">1926696</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Inaba</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Ohara</LastName>
        <Affiliation>Department of Oral Microbiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Graduate School of Dentistry, The University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiyo</FirstName>
        <LastName>Matsumoto-Nakano</LastName>
        <Affiliation>Department of Pediatric Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Porphyromonas gulae has been established as a pathogen in animal periodontal disease and expresses several virulence factors, including fimbriae, lipopolysaccharide, and proteases. P. gulae fimbriae are classified into three genotypes (A, B, and C) based on the fimbrillin (fimA) gene encoding a fimbrial subunit protein. We previously reported that P. gulae organisms with type C fimbriae were clearly more virulent as compared to those with other fimbria types, though the basic function of this is not fully understood. Here, we investigated the function of fimbriae using fimA-deficient mutants. In the present study, bacterial fimbriae were related to biofilm tenacity, whereas biofilm formation was not. Also, P. gulae fimbriae are involved in bacterial adhesion and entry into gingival epithelial cells. The role of P. gulae fimbriae in bacterial pathogenicity was then determined using fimA-deficient mutants with a silkworm infection model. Additionally, P. gulae infection can induce inflammatory responses in gingival epithelial cells and also inhibit cell migration and proliferation. In contrast, a P. gulae fimA-deficient mutant did not cause several of those cellular responses. Together, the results show that fimbriae contribute to the pathogenicity of P. gulae by affecting bacterial functions and host cell interactions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">biofilm</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell invasion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell migration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fimbriae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Porphyromonas gulae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">silkworm larvae</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2590-1230</Issn>
      <Volume>32</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prediction of tool-path and cycle time errors of CNC machining using a transformer-based deep learning model</ArticleTitle>
    <FirstPage LZero="delete">112872</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Tech, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zongze</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Graduate School of Advanced Science and Engineering, Hiroshima University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The prediction of tool-path and cycle time errors of computer numerical control (CNC) machining is important in manufacturing field. In this study, these errors are considered as sequential data corresponding to the lines of G-code, i.e., the error prediction is a sequence-to-sequence task, and a Transformer-based deep learning model was constructed to predict the tool-path and cycle time errors simultaneously, taking the positional increments and feed rate as the input. The training datasets were created by running a randomly generated G-code on a real CNC machine tool and subsequently tracking the actual errors, where the motion and feed rate are stochastically defined. The model is validated by conducting the error prediction on six sets of G-code. In addition, the comparison with a Bi-LSTM-based deep learning model is conducted. The results show that the prediction accuracy of the Transformer model can achieve the mean prediction accuracies of ±1 μm and ±1 ms in tool-path and cycle time error predictions, respectively. Furthermore, the Transformer model has a smaller prediction uncertainty than the Bi-LSTM model. Compared with conventional methods only analyzing tool-path errors or cycle-time errors, the utilized model has an advantage in its ability to simultaneously predict tool-path errors and cycle time errors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CNC machining</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tool-path error</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cycle time error</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Deep learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Transformer</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Fuji Technology Press Ltd.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1883-8022</Issn>
      <Volume>20</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-Time Estimation of Temperature Field and Thermal Displacement in Machine Tool Linear Motion Systems Using Servo Data</ArticleTitle>
    <FirstPage LZero="delete">466</FirstPage>
    <LastPage>477</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryoji</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>YASDA PRECISION TOOLS K.K.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhito</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Heat generated in machine tools during operation causes thermal deformation and deteriorates machining accuracy. To suppress thermal deformation and the resulting displacement, strategies such as reducing heat generation, cooling machine elements that generate heat, and compensating for thermal displacement are generally adopted. However, existing methods for estimating and compensating for thermal deformation and displacement can only be adopted in limited situations. In particular, there are few reports on real-time estimation methods that take into account moving parts and actual machine operating conditions. For high-accuracy machining, it is important to understand the temperature field and the associated displacement. In this study, real-time estimation of the temperature field and displacement is carried out on a test apparatus equipped with a ball screw drive system and a linear guideway system. In the estimation process, heat generation values are first calculated from servo data corresponding to the machine operation. Using these calculated values, the temperature field is then derived through the finite volume method. Finally, the thermal displacement is obtained from the temperature field using a simplified estimation method. The results are validated by comparison with experimental data and with results from commercial finite element method software, demonstrating the effectiveness and real-time performance of the proposed approach.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">machine tool</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">finite volume method</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">temperature field</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thermal displacement</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">real-time estimation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0953-8194</Issn>
      <Volume>38</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Marine flatworms as windows into the evolution of bilaterian neuropeptide signalling</ArticleTitle>
    <FirstPage LZero="delete">e70259</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Ushimado Marine Institute, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayuko</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Ushimado Marine Institute, Faculty of Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xavier</FirstName>
        <LastName>Bailly</LastName>
        <Affiliation>Multicellular Marine Models Team, CNRS &#8211; Sorbonne University &#8211; Station Biologique de Roscoff</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotaka</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Biology, Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Ushimado Marine Institute, Faculty of Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The evolutionary origin(s) of neuropeptide signalling is still largely unknown. It has been hypothesised that signal transmission via neuropeptides played a crucial role in the regulation of nervous systems in the bilaterian ancestor. Identification, expression and functional analyses of neuropeptides and their receptors across different taxonomic groups are important for better understanding the origin(s) of bilaterian neuropeptide signalling. An example is flatworms belonging to the Platyhelminthes (spiralian protostomes) and Xenacoelomorpha (sister to all Bilateria or sister to Ambulacraria). Despite their simple morphology (i.e., a body plan lacking a coelom and circulatory system), they often possess brain-like central nervous systems and a number of bilaterian-conserved neuropeptides. This feature makes them useful models for analyses of neuropeptides and their links to nervous systems. Although previous studies have revealed orthologous relationships between vertebrate neuropeptides and those found in both marine Platyhelminthes and Xenacoelomorpha, our work suggests possible ancestral functions of vasopressin/oxytocin (VP/OT) peptides (platytocin) in these groups.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Neuropeptide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nervous system evolution</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Platyhelminthes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Xenacoelomorpha</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0009-2541</Issn>
      <Volume>713</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tungsten(VI) speciation in aqueous fluids at high pressures and high temperatures: in-situ Raman spectroscopy supported by DFT calculations</ArticleTitle>
    <FirstPage LZero="delete">123411</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Earth Science, Graduate School of Science, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michihiko</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Earth Science, Graduate School of Science, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Kagi</LastName>
        <Affiliation>Geochemical Research Center, Graduate School of Science, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Tungsten (W) is mobile in magmatic&#8211;hydrothermal and deep subduction zone fluids, and its stable isotopes offer potential as tracers of fluid-rock interactions. We investigated W behavior in aqueous fluids using in-situ Raman spectroscopy on slightly acidic to alkaline Na2WO4 solutions (10−3&#8211;10−1 M W) and WO3&#8211;H2O/D2O ± NaCl systems up to 1.4 GPa and &#8764;800 °C, with the band assignments supported by density functional theory (DFT) calculations. Raman spectra showed that the ν1 mode of WO42− persisted to the highest P&#8211;T conditions in alkaline fluids, while additional high-frequency bands near 950 or 973 cm−1 appeared at elevated T in the studied fluids. Their relative intensities depended on T, pH, and NaCl content; the 973 cm−1 band was only observed above 650 °C in Na-free fluids. Substitution of H2O with D2O did not significantly affect the band frequencies. Based on analogous molybdenum experiments, previous in-situ studies, and thermodynamic models, these high-T bands are assigned to mononuclear species rather than polynuclear species, consistent with the stepwise formation of hydrogentungstate anion, HWO4−, and then neutral tungstic acid, H2WO4, as T increases. DFT vibrational frequency calculations for HWO4−, H2WO4, and their D-substituted species support this interpretation, suggesting tetrahedral HWO4− and higher-coordinated H2WO4 as plausible species. The present study clarifies Raman band assignments for HWO4− and paratungstate A (W7O246−) to address previous ambiguities in the literature, and confirms that polynuclear species play a negligible role in high-T ore-forming fluids. The tetrahedral HWO4− appears to be a predominant transport species in NaCl-bearing metamorphic fluids and may govern stable W isotope fractionation during deep fluid-rock interactions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Tungsten</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Aqueous speciation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hydrothermal fluids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Subduction zone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Diamond anvil cell</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Raman spectroscopy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DFT calculations</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2198-4034</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of a preoperative accuracy prediction model using machine learning for implant placement in static-guided surgery: retrospective observational study</ArticleTitle>
    <FirstPage LZero="delete">44</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Mino</LastName>
        <Affiliation>Department of Removable Prosthodontics and Occlusion, School of Dentistry, Osaka Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yurina</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Semiconductor, Computer Science and Applied Mathematics, Graduate School of Science and Technology, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken’ichi</FirstName>
        <LastName>Morooka</LastName>
        <Affiliation>Division of Biomedical Engineering, Faculty of Advanced Science and Technology, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Tokumoto</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, School of Medicine, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Shimizu Dental Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Kurosaki</LastName>
        <Affiliation>Department of Removable Prosthodontics and Occlusion, School of Dentistry, Osaka Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Kimura-Ono</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromitsu</FirstName>
        <LastName>Kishimoto</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, School of Medicine, Hyogo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuo</FirstName>
        <LastName>Kuboki</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Maekawa</LastName>
        <Affiliation>Department of Removable Prosthodontics and Occlusion, School of Dentistry, Osaka Dental University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose This study aimed to develop a machine learning model capable of preoperatively predicting three-dimensional implant placement errors at the implant apex in static-guided surgery and to identify the clinical features associated with placement accuracy.&lt;br&gt;
Methods Clinical data partially derived from a previous observational study were analyzed. In total, 181 patients and 480 implants placed using fully static-guided surgery were included in this study. The outcome variable was defined as three-dimensional implant placement error at the implant apex relative to the preoperative simulation, dichotomized as less than 0.5 mm or &#8805;&#8201;0.5 mm. Twenty-one clinical and radiographic factors previously suggested to influence the placement accuracy were used as explanatory variables. The feature importance was evaluated using three gradient boosting decision tree models. Furthermore, a stacking model combining multiple classifiers was constructed, and the classification performance was assessed using ten-fold cross-validation.&lt;br&gt;
Results The feature importance analysis identified 12 features associated with implant placement errors. The stacking model demonstrated superior classification performance compared to individual classifiers. The true positive rate was 0.73, false negative rate was 0.27, false positive rate was 0.14, and true negative rate was 0.86.&lt;br&gt;
Conclusions The proposed stacking model correctly classified 86% of cases with implant placement error less than 0.5 mm and 73% of cases with implant placement error of &#8805;&#8201;0.5 mm. These findings suggest that the proposed model may support the preoperative evaluation of implant placement accuracy in static-guided surgeries.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Implant placement</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Accuracy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgical guide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Prediction algorithms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Decision trees</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Support vector machine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sensitivity and specificity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2075-4418</Issn>
      <Volume>16</Volume>
      <Issue>17</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Granular Swollen Epithelial Cells in Native Kidney Biopsies: Prevalence, Clinicopathological Associations and Kidney Outcomes</ArticleTitle>
    <FirstPage LZero="delete">2822</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naruhiko</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Nakanoh</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Granular swollen epithelial cells (GSECs) have been described primarily in mitochondrial cytopathies, in which they are regarded as a characteristic pathological finding that may aid in the diagnosis of mitochondrial dysfunction; however, their prevalence and clinical significance in native kidney disease remain unclear. We aimed to evaluate the prevalence, clinicopathological associations, and prognostic significance of GSECs in native kidney biopsy specimens. Methods: Among 1165 adults who underwent native kidney biopsy between 2011 and 2024, 501 patients with evaluable medullary tissue were included in this retrospective cohort study. GSECs were defined as enlarged tubular epithelial cells with conspicuous granular cytoplasm in medullary tubules, and cases were classified as GSEC-positive when at least one unequivocal GSEC was identified. Clinical and histopathological characteristics were compared between groups, and kidney outcomes were evaluated using Cox proportional hazards models. Results: The mean baseline eGFR was 60.8 ± 26.3 mL/min/1.73 m2, and the median urinary protein excretion was 1.1 g/gCr. During a median follow-up of 2.3 years, 112 patients (22.3%) reached the composite kidney outcome. GSECs were identified in 18% of native kidney biopsy specimens containing evaluable medullary tissue, and were observed across a broad spectrum of kidney diseases. GSEC positivity was associated with older age and underlying pathological diagnoses but was not associated with baseline kidney function or proteinuria. Kaplan&#8211;Meier and multivariable Cox analyses revealed no significant association between GSECs and kidney prognosis. Conclusions: GSECs are not specific to kidney allografts and are observed in a subset of diverse native kidney diseases. Although associated with certain clinical characteristics, no independent association between GSECs and kidney outcomes was observed in this cohort. These findings suggest that GSECs may reflect disease-dependent biological responses to tubular epithelial stress, potentially related to metabolic or mitochondrial alterations, rather than a marker of progressive kidney injury.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">granular swollen epithelial cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">native kidney biopsy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">kidney outcomes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">renal medulla</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mitochondria</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2212-8778</Issn>
      <Volume>112</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Adaptive oligodendrogenesis regulates blood-hypothalamus barrier permeability, hypothalamic glucose sensing and systemic glucose homeostasis in male mice</ArticleTitle>
    <FirstPage LZero="delete">102428</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sophie</FirstName>
        <LastName>Buller</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emily O.</FirstName>
        <LastName>Staricoff</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Christine</FirstName>
        <LastName>Riches</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Anthony</FirstName>
        <LastName>Tsang</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Giada</FirstName>
        <LastName>Giavara</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masa</FirstName>
        <LastName>Josipovic</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Ikemura</LastName>
        <Affiliation>Department of Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gabriel</FirstName>
        <LastName>Opoku</LastName>
        <Affiliation>Department of Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikumi</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Hirohata</LastName>
        <Affiliation>Department of Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saskia</FirstName>
        <LastName>Stenzel</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stuart G.</FirstName>
        <LastName>Nayar</LastName>
        <Affiliation>Wolfson Institute for Biomedical Research, University College London</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Marta</FirstName>
        <LastName>Ramos Vega</LastName>
        <Affiliation>GUBRA</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jacob</FirstName>
        <LastName>Hecksher-S&#248;rensen</LastName>
        <Affiliation>GUBRA</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sebastian</FirstName>
        <LastName>Timmler</LastName>
        <Affiliation>Cambridge Stem Cell Institute, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Georgina K.C.</FirstName>
        <LastName>Dowsett</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Brian Y.H.</FirstName>
        <LastName>Lam</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Giles S.H.</FirstName>
        <LastName>Yeo</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimberly M.</FirstName>
        <LastName>Alonge</LastName>
        <Affiliation>Diabetes Institute, University of Washington</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Huiliang</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Wolfson Institute for Biomedical Research, University College London</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">William D.</FirstName>
        <LastName>Richardson</LastName>
        <Affiliation>Wolfson Institute for Biomedical Research, University College London</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mark L.</FirstName>
        <LastName>Evans</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Clemence</FirstName>
        <LastName>Blouet</LastName>
        <Affiliation>Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective: Brain glucose sensing is critical for survival during hypoglycaemia, yet how glucose-sensing neurons access circulating glucose concentrations to maintain glucose homeostasis remains poorly understood. Here we tested the hypothesis that adult oligodendrogenesis in the median eminence (ME) is responsive to changes in blood glucose levels and contributes to hypothalamic glucose sensing through regulation of the blood-hypothalamus barrier.&lt;br&gt;
Methods: We used glycemic challenges and hypoinsulinaemic clamp studies to identify the effect of systemic changes in glycaemia on hypothalamic oligodendrocyte lineage cells. We used conditional knockout mouse models to dissect the respective contributions of adult oligodendrogenesis and new myelin formation to glucose homeostasis in adult male mice. Analyses combined immunofluorescence, serial electron microscopy, whole-brain tissue clearing, and transcriptomic analyses.&lt;br&gt;
Results: We found that adult oligodendrogenesis in the median eminence (ME) is modulated by changes in circulating glucose levels and rapidly upregulated by hypoglycaemia. Genetic blockade of new oligodendrocyte production in adult male mice impairs the regulation of glucose homeostasis, the integrity of the ME blood-hypothalamus barrier, and hypothalamic glucose sensing. Unexpectedly, functional integrity of adult-formed myelin is not required for the maintenance of glucose homeostasis. Instead, we show that blockade of adult oligodendrogenesis disrupts hypothalamic expression of A disintegrin and metallopeptidase with thrombospondin motifs 4 (ADAMTS4), a metallopeptidase whose brain expression is restricted to the oligodendrocyte lineage and whose ME expression requires ongoing adult oligodendrogenesis. We show that ADAMTS4 regulates hypothalamic perineuronal net deposition, vascular permeability and glucose sensing. Finally, we show that ME ADAMTS4 expression is regulated by changes in peripheral glycaemia and is dysregulated in diabetes, providing a mechanism by which ME oligodendrocytes contribute to the regulation of glucose homeostasis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Oligodendrogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Median eminence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Blood-hypothalamus barrier</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ADAMTS4</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Glucose sensing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hypoglycaemia</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2950-1334</Issn>
      <Volume>14</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical phenotypes and the risk factors of mild pulmonary hypertension</ArticleTitle>
    <FirstPage LZero="delete">100628</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Taya</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Ejiri</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Akagi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitake</FirstName>
        <LastName>Fukuda</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misaki</FirstName>
        <LastName>Kanezawa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Takaya</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: The definition of pulmonary hypertension (PH) was revised as mean pulmonary arterial pressure (mPAP) &gt;20&#8239;mmHg from &#8805;25&#8239;mmHg in the recent PH guidelines; however, the characteristics of PH patients with mPAP 21&#8211;24 mmHg have not been well described.&lt;br&gt;
Methods: A total of 1080 individuals who underwent right heart catheterization (2018&#8211;2022) was categorized into 3 groups by mPAP: no PH with mPAP &#8804;20&#8239;mmHg, mild PH with mPAP 21&#8211;24 mmHg, and conventional PH with mPAP &#8805;25&#8239;mmHg. We assessed PH subtypes of hemodynamic and clinical classification and compared survival outcomes (all-cause mortality, heart failure hospitalization, lung transplant) using Cox models.&lt;br&gt;
Results: Of them, 391 patients (36.2%) were diagnosed as PH including mild PH (n = 137) and conventional PH (n = 254). Phenotypically, mild PH was predominantly characterized by pre-capillary hemodynamics and Group 2 clinical classification. Mild PH is associated with an intermediate prognosis: outcomes are more favorable than in conventional PH but inferior to no PH (HR 1.74 [95% CI 1.15&#8211;2.61]). While the two PH phenotypes appear to share comorbidity-related factors, hemodynamic parameters were associated with survival outcomes not in mild PH but in conventional PH.&lt;br&gt;
Conclusions: The observation that mild PH constitutes approximately one-third of overall PH cases carries substantial clinical weight. The newly identified mild PH cohort was characterized mainly by pre-capillary and Group 2 subtypes. While mild PH is associated with an intermediate prognosis, comorbidities appear to be the primary determinant of outcomes in this group, unlike in conventional PH where hemodynamics play a larger role.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">mild pulmonary hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">prognosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">risk factor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>31</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Event-free survival and recurrence patterns after curative resection for locally advanced head and neck squamous cell carcinoma: single-institution real-world outcomes prior to the introduction of perioperative immunotherapy</ArticleTitle>
    <FirstPage LZero="delete">1890</FirstPage>
    <LastPage>1900</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuma</FirstName>
        <LastName>Makino</LastName>
        <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Naoi</LastName>
        <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuto</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Noda</LastName>
        <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Fujimoto</LastName>
        <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mizuo</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Otolaryngology - Head and Neck Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Perioperative immune checkpoint inhibitors have improved outcomes for resectable locally advanced head and neck squamous cell carcinoma (HNSCC). However, real-world surgical outcome data based on contemporary endpoints remain limited.&lt;br&gt;
Methods We retrospectively analyzed 233 patients who underwent curative-intent surgery for locally advanced HNSCC. Event-free survival (EFS) and overall survival (OS) were evaluated. Unresectable recurrence-free survival (URFS) was explored as an additional endpoint to capture post-recurrence treatment feasibility. Prognostic factors were assessed using Cox proportional hazards models.&lt;br&gt;
Results The median follow-up duration was 18.2 months. The 1-year EFS and OS rates were 67.1% and 89.4%, respectively. pN2 or higher disease, venous invasion, and perineural invasion were identified as independent adverse prognostic factors. Recurrence occurred in 34.8% of patients; among these, disease control at the last follow-up was achieved in 61.7% following curative-intent salvage treatment. Salvage surgery was associated with significantly improved post-recurrence survival (p&#8201;&lt;&#8201;0.001).&lt;br&gt;
Conclusions This study provides real-world surgical outcome data for resectable locally advanced HNSCC prior to the introduction of perioperative immunotherapy. Recurrence remains a major clinical challenge, with heterogeneous post-recurrence outcomes influenced by treatment feasibility. These findings may help inform interpretation of treatment outcomes and clinical decision-making in the evolving era of perioperative immunotherapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Head and neck squamous cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Event-free survival</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Recurrence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Salvage surgery</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1873-9601</Issn>
      <Volume>20</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Species‐specific roles of cellular communication network proteins in cartilage development: A comparative study using in vitro chondrogenic models</ArticleTitle>
    <FirstPage LZero="delete">e70089</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zhangzheng</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Anatomy, Histology and Embryology Faculty of Medicine, University of Debrecen</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Judit</FirstName>
        <LastName>V&#225;g&#243;</LastName>
        <Affiliation>Department of Anatomy, Histology and Embryology Faculty of Medicine, University of Debrecen</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Roland</FirstName>
        <LastName>Tak&#225;cs</LastName>
        <Affiliation>Department of Anatomy, Histology and Embryology Faculty of Medicine, University of Debrecen</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Szil&#225;rd</FirstName>
        <LastName>P&#243;liska</LastName>
        <Affiliation>Genomic Medicine and Bioinformatics Core Facility Department of Biochemistry and Molecular Biology Faculty of Medicine, University of Debrecen</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ee Hyun</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Department of Biomedical Materials Science Graduate School of JABA, Wonkwang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eun‐Jung</FirstName>
        <LastName>Jin</LastName>
        <Affiliation>Department of Biomedical Materials Science Graduate School of JABA, Wonkwang University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Biochemistry and Molecular Dentistry, Okayama University, Faculty of Medicine, Dentistry and Pharmaceutical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Celina G</FirstName>
        <LastName>Kleer</LastName>
        <Affiliation>Department of Pathology, University of Michigan Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Bernard</FirstName>
        <LastName>Perbal</LastName>
        <Affiliation>International CCN Society</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Csaba</FirstName>
        <LastName>Matta</LastName>
        <Affiliation>Department of Anatomy, Histology and Embryology Faculty of Medicine, University of Debrecen</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cellular communication network (CCN) proteins are key matricellular regulators of cartilage development, yet their species-specific roles and network-level context remain unclear. This study integrated bulk RNA sequencing from chicken and mouse embryonic limb bud micromass cultures and human mesenchymal stem cell chondrogenesis with co-expression, protein&#8211;protein interaction, and ortholog analyses to construct CCN-centered regulatory networks across models. CCN1 and CCN2 emerged as dominant, conserved hubs enriched in collagen-containing extracellular matrix, cartilage development, and growth factor signaling modules, whereas CCN3&#8211;CCN6 showed lower context-dependent expression and connectivity. Functional and ortholog analyses revealed moderate pathway conservation, with high conservation of IGF, EGFR, and HIF-1 signaling, but reduced overlap in hypoxia and mechanosensing/Hippo categories, indicating species-specific tuning of environmental sensing. A focused ortholog screen identified multifunctional conserved hubs, including COL2A1, TGFBR1, SMAD3, RUNX2, HIF1A, IGF1, SPP1, and CD44. Single-cell RNA-seq meta-analysis of human iPSC-derived chondrogenesis and embryonic limb datasets showed CCN1/2 expression and homologous network activity peaking in mesenchymal and early chondrocyte populations, consistent with model-dependent persistence into hypertrophic and ossification stages in vivo. Overall, this work defines a conserved CCN1/2-centered axis integrating extracellular matrix formation with growth factor and mechanical cues, providing a framework for model selection and CCN-targeted cartilage regeneration strategies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cartilage regeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CCN</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chondrogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoarthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">regulatory network</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transcriptomics</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2165-0497</Issn>
      <Volume>14</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Combinations of long terminal repeat and tax protein substitutions influence bovine leukemia virus transmission through altered viral productivity</ArticleTitle>
    <FirstPage LZero="delete">e0086926</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hironobu</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>School of Veterinary Medicine, Azabu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reiichiro</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Graduate School of Medicine and Veterinary Medicine, University of Miyazaki</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jumpei</FirstName>
        <LastName>Uchiyama</LastName>
        <Affiliation>Department of Infectious Diseases, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Sogawa</LastName>
        <Affiliation>School of Life and EnvironmentaScience, Azabu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroho</FirstName>
        <LastName>Ishida</LastName>
        <Affiliation>School of Veterinary Medicine, Azabu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Nagai</LastName>
        <Affiliation>School of Veterinary Medicine, Azabu University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Bovine leukemia virus (BLV) infection imposes a substantial economic burden on the global cattle industry. Although proviral load (PVL) in blood influences transmission, the effects of viral genetic variations, including the high viral production-associated long terminal repeat (LTR) substitution at nucleotide position 175 (LTR175), on herd-level dynamics remain unclear. This study investigated the effects of specific substitutions on the regulation of viral productivity and transmission. Longitudinal monitoring of a single farm (herd size: 50&#8211;68 cows; 438 samples collected) over a 7-year period revealed that viral strains carrying cytosine at LTR175 (LTR175C) significantly increased in frequency, becoming dominant over wild-type strains carrying thymidine. In contrast, amino acid substitutions in the Tax protein at positions 69 (Tax69) and 73 (Tax73) modified viral transactivation independent of LTR175. Structural modeling via AlphaFold2 predicted that Tax69 and Tax73 mutations alter protein properties, suggesting modulation of transactivation activity. Consistent with this prediction, in vitro assays confirmed that the substitutions modified viral production by regulating transactivation independent of LTR175. Moreover, high viral-productivity haplotypes containing LTR175C and Tax73Q (glutamine at amino acid residue 73) exhibited a transmission advantage within the herd, even when host PVL levels were not significantly elevated. These findings suggest that cellular-level viral productivity is one of the key determinants of transmission fitness. Overall, this study revealed a regulatory interaction between the LTR and Tax protein that optimizes viral spread and highlights the need for control strategies that account for viral genetic substitutions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bovine leukemia virus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">substitution</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">transmission</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">haplotype</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">molecular clone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">proviral load</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">reverse genetics</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0918-9440</Issn>
      <Volume>139</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Knockout of a single aquaporin, OsPIP2;4, decreases root water permeability in rice</ArticleTitle>
    <FirstPage LZero="delete">255</FirstPage>
    <LastPage>265</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Aya</FirstName>
        <LastName>Onishi</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Division of Applied Biology, Faculty of Textile Science and Technology, Shinshu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Ishitsuka</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shizuka</FirstName>
        <LastName>Sasano</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Division of Applied Biology, Faculty of Textile Science and Technology, Shinshu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yunosuke</FirstName>
        <LastName>Mito</LastName>
        <Affiliation>Division of Applied Biology, Faculty of Textile Science and Technology, Shinshu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeko</FirstName>
        <LastName>Utsugi</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Institute of Crop Science, NARO</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Majid</FirstName>
        <LastName>Mahdieh</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Katsuhara</LastName>
        <Affiliation>Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aquaporins (AQPs) are membrane proteins that facilitate water transport and are present in nearly all bacterial, animal, and plant cells. In plants, AQPs are classified into four or more subfamilies, with plasma membrane intrinsic proteins (PIPs) playing a key role in root water uptake and cellular water regulation. Previous studies have demonstrated that PIPs contribute to root hydraulic conductivity (Lpr) in various plant species. In this study, we examined the specific role of OsPIP2;4, one of the PIP-type aquaporins among 11 rice (Oryza sativa) PIP2s, in regulating Lpr. Transgenic rice plants, including OsPIP2;4-knockout (KO) and overexpressing (Ox) lines, were used for this investigation. Two independent KO lines, generated via the CRISPR-Cas9 system and T-DNA insertion mutagenesis, respectively, showed significantly lower Lpr compared to wild-type rice plants. The decrease in Lpr in the T-DNA KO line was associated with reduced OsPIP2;4 transcript levels, measured by real-time PCR, and lower OsPIP2;4 protein levels, as shown by immunohistochemical analysis. Conversely, no notable increase in Lpr was observed in the Ox lines. These results suggest that OsPIP2;4 is expressed in appropriate tissues in rice roots and is a key factor influencing Lpr. This research represents a significant step toward further understanding the physiological functions of OsPIP2;4 in rice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">PIP aquaporin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rice</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Root hydraulic conductivity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Root pressure chamber</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>一般社団法人 電気学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0385-4221</Issn>
      <Volume>146</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>多様な電力消費形態を考慮したスマートグリッド運用の最適化</ArticleTitle>
    <FirstPage LZero="delete">864</FirstPage>
    <LastPage>876</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takaki</FirstName>
        <LastName>Kawamoto</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuriko</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>School of Creative Science and Engineering, Waseda University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hasuike</LastName>
        <Affiliation>School of Creative Science and Engineering, Waseda University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>　This study examines an optimal operation model for a smart grid composed of multiple microgrids to promote renewable energy use in Japan. In Japan, about 70% of electricity is still supplied by fossil fuel power, while renewables account for only 18% despite a 36&#8211;38% target for 2030. Using demand and photovoltaic data from Setagaya Ward, we construct a system model with factory/office and residential microgrids and formulate a mathematical optimization model that considers power interchange, batteries and heat storage. Numerical experiments based on several case studies show the effectiveness of smart grid operation designed according to the proposed model in promoting renewable energy utilization and reducing total generation cost. In particular, the results show that increasing photovoltaic capacity, increasing the number of microgrids, and considering heat demand are all effective measures. However, these benefits depend on the season. Future work should extend the system model to account for seasonal variability and associated investment costs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">スマートグリッド (smart grid)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">マイクログリッド (microgrid)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">再生可能エネルギー (renewable energy)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">電力融通 (power interchange)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>岡山大学大学院教育学研究科</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1883-2423</Issn>
      <Volume>192</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>聴覚障害学生支援のための初学者向け大学ノートテイカー共同養成研修の効果・課題・あり方 ―多様な人的リソースを活用した養成研修モデルの検討―</ArticleTitle>
    <FirstPage LZero="delete">37</FirstPage>
    <LastPage>51</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>SHIMONAKAMURA</LastName>
        <Affiliation>Faculty of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroko</FirstName>
        <LastName>INOUE</LastName>
        <Affiliation>Child Consultation Center, Kumamoto city</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>TAKAGI</LastName>
        <Affiliation>Student Accessibility Support Room, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>SOEJIMA</LastName>
        <Affiliation>Student Accessibility Support Room, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>FUJISE</LastName>
        <Affiliation>Kumamoto Prefecture Mental Health Welfare Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/bgeou/71143</ArticleId>
    </ArticleIdList>
    <Abstract>　本研究は，多様な人的リソースを活用した聴覚障害学生支援のための初学者向けノートテイカー共同養成研修の効果と課題を明らかにし，今後の共同養成研修のあり方について検討することを目的とした。共同養成研修の効果として，【他大学との交流の有効性】，【研修順序の有効性】，【研修内容の充実】などが見られ，今後の研修の生かし方として，【研鑽や活動拡大】，【支援・研修の充実】などが挙げられており，研修の有効性が明らかになった。一方で，共同養成研修の課題として，交流プログラムの満足度が相対的に最も低く，【時間不足】が背景にあると考えられた。これらのことを踏まえて，共同養成研修のあり方として，学生・教職員が交流する十分な時間の確保や，各講義時間の増加のために，動画を視聴するオンデマンド形式を基本として，交流や演習などを対面，またはリアルタイムオンラインで実施するなどの研修方法が考えられる。</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">聴覚障害</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">障害学生</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">情報保障</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ノートテイク</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">共同養成</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0924-8579</Issn>
      <Volume>67</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Clinical characteristics and therapeutic dilemmas in nocardiosis: Insights from a case series</ArticleTitle>
    <FirstPage LZero="delete">107906</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Miyahara</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuma</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyoshi</FirstName>
        <LastName>Gotoh</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakura</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Iio</LastName>
        <Affiliation>Microbiology Division, Clinical Laboratory, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: Nocardiosis often requires prolonged antimicrobial therapy, and trimethoprim&#8211;sulfamethoxazole (TMP&#8211;SMX) is considered the cornerstone of treatment. However, TMP&#8211;SMX&#8211;related adverse events frequently complicate long-term therapy, and real-world data regarding treatment continuity and outcomes remain limited.&lt;br.&gt;
Methods: We conducted a retrospective observational study of patients with Nocardia species isolated from clinical specimens at a tertiary-care academic hospital in Japan between January 2015 and April 2025. Clinical characteristics, antimicrobial therapy, adverse events, and outcomes were reviewed.&lt;br&gt;
Results: Eleven cases were enrolled, with a median age of 65 years. The cohort comprised seven patients with severe nocardiosis (disseminated disease, brain abscess, and pneumonia in transplant recipients) and four patients with mild nocardiosis (cutaneous infection and pneumonia). Nine patients received TMP&#8211;SMX as part of the initial regimen, of whom seven required modification of therapy within 1 day to 3 months because of adverse events. Following modification of TMP&#8211;SMX, patients were treated with alternative regimens, including fluoroquinolone―and minocycline-based therapies, as well as β-lactam&#8211;containing combinations. Importantly, no cases of treatment failure or death were observed, and no relapses were identified during the available follow-up period, even among patients with those clinically complex diseases.&lt;br&gt;
Conclusions: Although TMP&#8211;SMX is the first-line therapy for nocardiosis, the majority of our patients did not tolerate the drug. Nevertheless, favorable outcomes were observed with alternative regimens, even in patients with clinically complex disease, suggesting that alternative regimens may be reasonable options when TMP&#8211;SMX is not tolerated.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Nocardiosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Treatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trimethoprim&#8211;sulfamethoxazole</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Alternative therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Dose modification</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>17</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Assessment of the Association of Periodontitis and Diabetes Mellitus with Alzheimer’s Disease in a Mouse Model</ArticleTitle>
    <FirstPage LZero="delete">7542</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Momoko</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kota</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Department of Preventive Dentistry, Division of Dentistry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mohammad</FirstName>
        <LastName>Nurhamim</LastName>
        <Affiliation>Department of Preventive Dentistry, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yixuan</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Preventive Dentistry, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Fukuhara</LastName>
        <Affiliation>Department of Preventive Dentistry, Dental School, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Uchida-Fukuhara</LastName>
        <Affiliation>Laboratory of Biological Anthropology, Research Center for Integrative Evolutionary Science, The Graduate University for Advanced Studies, SOKENDAI</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Md Monirul</FirstName>
        <LastName>Islam</LastName>
        <Affiliation>Centre for Policy Studies, University College Cork</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Oral Health Sciences, Faculty of Health Care Sciences, Takarazuka University of Medical and Health Care</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Neuropathology, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ekuni</LastName>
        <Affiliation>Department of Preventive Dentistry, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The purpose of the present study was to investigate how periodontitis and diabetes mellitus (DM) are associated with Alzheimer’s disease (AD) through microRNA (miRNA) using AD model mice. The experimental period was 8 weeks. Twenty-four male knock-in mice (B6-AppNL-G-F/NL-G-F/J) were divided into four groups: control group fed a normal diet (C), DM group fed a high-fat/sucrose diet (DM), periodontitis (P) group, and DM + periodontitis (DM+P) group. Memory performance was compared using the Y-maze test. Next-generation sequencing was performed on brain samples, and fold changes in miRNA expression were calculated by comparing the DM+P and C groups. Integrated miRNA&#8211;mRNA analysis identified putative miRNA-targeted mRNAs, and protein expression of the top candidate gene was assessed. Memory function in the DM+P group was significantly lower than in the C group. Among the seven mRNAs identified by the integrated analysis, Neurod1 showed the greatest decrease in expression, and it was predicted to be regulated by miR-693-3p. Neurod1 protein expression in the hippocampus was significantly lower in the DM+P group than the C group. Our results suggest that the combined exposure to periodontitis and DM was associated with AD-like pathological changes and identified the miR-693-3p/Neurod1 pair as a candidate regulatory axis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Alzheimer’s disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diabetes mellitus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">microRNA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mRNA</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0172-0643</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Fenestration Re-creation for Early Fontan Deterioration: Long-Term Hemodynamic and Clinical Outcomes</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Thi Hai Yen</FirstName>
        <LastName>Tran</LastName>
        <Affiliation>Department of Pediatrics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Kurita</LastName>
        <Affiliation>Department of Pediatrics, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maiko</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Pediatrics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Pediatrics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Shigemitsu</LastName>
        <Affiliation>Department of Pediatrics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Kawamoto</LastName>
        <Affiliation>Department of Pediatrics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayuko</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Pediatrics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Department of Pediatrics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Department of Pediatric anesthesiology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Kasahara</LastName>
        <Affiliation>Department of Cardiovascular Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Baba</LastName>
        <Affiliation>Department of Pediatrics, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Spontaneous closure of a Fontan fenestration may precipitate early hemodynamic deterioration in vulnerable patients. In such situations, fenestration re-creation may be considered as a rescue strategy when medical therapy is insufficient. However, the long-term hemodynamic consequences of this intervention remain poorly defined. We retrospectively reviewed 62 patients who underwent the Fontan procedure between January 2011 and December 2020 and subsequently experienced spontaneous fenestration closure. Patients were divided into two groups according to management strategy: those who underwent fenestration re-creation (Group 1, n&#8201;=&#8201;19) and those managed without re-creation (Group 2, n&#8201;=&#8201;43). Longitudinal hemodynamic data were analyzed using linear mixed models over a median follow-up of 10.2 years. Fenestration closed spontaneously at a median of 12 days (IQR 2.5&#8211;26.5) and initial re-creation was performed at the median of 42 days (IQR 11&#8211;213) postoperatively. Early and mide-term hemodynamic trends were broadly similar between groups, however, clear divergence emerged in the late follow-up. fenestration re-created patients demonstrated persistently higher central venous pressure and pulmonary vascular resistance, lower systemic vascular resistance, progressive increases in cardiac index, and declining oxygen saturation. Survival in this group remained above 80% during the mid-term follow-up but declined substantially in the late phase compared with patients without re-creation (52% vs. 85%, p&#8201;=&#8201;0.043). This was accompanied by higher incidences of protein-losing enteropathy/plastic bronchitis, thromboembolism, and severe cyanosis. Fenestration re-creation may provide temporary hemodynamic stabilization in early Fontan deterioration; however, its benefits appear to diminish in the late phase. These findings highlight the need for hemodynamically tailored management strategies and alternative therapeutic options for patients with deteriorating Fontan circulation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Fontan operation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Spontaneous fenestration closure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fenestration recreation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Longitudinal hemodynamic changes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume>31</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy of bepotastine compared with hydroxyzine in preventing rituximab-induced infusion-related reactions in non-hodgkin lymphoma patients: a phase II, double-blind, multicenter, and randomized trial</ArticleTitle>
    <FirstPage LZero="delete">979</FirstPage>
    <LastPage>988</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Kitahiro</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironobu</FirstName>
        <LastName>Minami</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimikazu</FirstName>
        <LastName>Yakushijin</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiji</FirstName>
        <LastName>Kurata</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rina</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miki</FirstName>
        <LastName>Saeki</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Okazoe-Hirakawa</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Iida</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Murase</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isamu</FirstName>
        <LastName>Harima</LastName>
        <Affiliation>Division of Medical Oncology/Hematology, Department of Medicine, Kobe University Hospital and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kotaro</FirstName>
        <LastName>Itohara</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Omura</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of Hematology and Oncology, Kita-Harima Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetomo</FirstName>
        <LastName>Takakura</LastName>
        <Affiliation>Department of Hematology and Oncology, Kita-Harima Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Kitao</LastName>
        <Affiliation>Department of Hematology and Oncology, Kita-Harima Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masako</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Pharmacy, Kita-Harima Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Manabu</FirstName>
        <LastName>Shimoyama</LastName>
        <Affiliation>Department of Hematology and Oncology, Kohnan Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Okuno</LastName>
        <Affiliation>Department of Pharmacy, Kohnan Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background This study evaluated the efficacy of hydroxyzine and bepotastine, first- and second-generation H1 receptor antagonists (H1RA), as pretreatments to prevent infusion-related reactions (IRRs) during the initial rituximab infusion in patients with non-Hodgkin lymphoma.&lt;br&gt;
Methods In this double-blind, multicenter, randomized phase II study, 40 patients received hydroxyzine or bepotastine with acetaminophen 30 min before rituximab infusion. Primary endpoint was incidence of&#8201;&#8805;&#8201;grade 2 IRRs based on the National Cancer Institute Common Terminology Criteria for Adverse Events. Secondary endpoints included IRRs severity, time to IRR onset, and H1RA-induced drowsiness.&lt;br&gt;
Results Incidence of&#8201;&#8805;&#8201;grade 2 IRRs was 52.4% and 31.6% for the hydroxyzine (n&#8201;=&#8201;21) and bepotastine (n&#8201;=&#8201;19) groups, respectively (P&#8201;=&#8201;0.184). Distribution of initial and maximum IRR grades in the two groups was not statistically significant (P&#8201;=&#8201;0.846 and 0.555). Median time (range) to IRR onset in the two groups was 67 (12&#8211;112) and 62 (10&#8211;119) min, respectively (P&#8201;=&#8201;0.981). Median visual analog scale score (range and 75th percentile) for drowsiness was 37 (0&#8211;100, 46) and 12 (0&#8211;100, 29) mm in the two groups, respectively (P&#8201;=&#8201;0.138). Incidence of&#8201;&#8805;&#8201;grade 2 IRRs in the absence of bone marrow infiltration was 43.8% and 14.3% in the two groups, respectively (P&#8201;=&#8201;0.118), and no group differences were observed with bone marrow infiltration.&lt;br&gt;
Conclusions Bepotastine did not show significant superiority over hydroxyzine in preventing rituximab-induced IRRs due to the small sample size. Nevertheless, this exploratory study provides insight for further confirmatory studies.&lt;br&gt;
Trial registration number and date of registration jRCTs051220169; February 14, 2023.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Rituximab</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infusion-related reactions</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Non-Hodgkin lymphoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bepotastine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hydroxyzine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Drowsiness</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2059-1381</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Potential effects of intradialytic exercise therapy on physical performance in hemodialysis patients based on the intervention period: a systematic review and meta-analysis</ArticleTitle>
    <FirstPage LZero="delete">19</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Internal Medicine, Teikyo University Hospital Mizonokuchi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Kojima Kidney and Dialysis Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromasa</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Nishimoto</LastName>
        <Affiliation>Department of Nephrology, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Hishikawa</LastName>
        <Affiliation>Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Tonomura</LastName>
        <Affiliation>Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Sofue</LastName>
        <Affiliation>Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Nephrology, Hyogo Prefectural Nishinomiya Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Saitoh</LastName>
        <Affiliation>Department of Physical Therapy, Faculty of Health Science, Juntendo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiei</FirstName>
        <LastName>Narita</LastName>
        <Affiliation>Niigata Institute for Health and Sports Medicine, Niigata Sports Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Yamagata</LastName>
        <Affiliation>Department of Nephrology, Institute of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Hoshino</LastName>
        <Affiliation>Division of Preventive and Sports Nephrology, Graduate School of Comprehensive Human Sciences, Tokyo Women’s Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroo</FirstName>
        <LastName>Kawarazaki</LastName>
        <Affiliation>Department of Internal Medicine, Teikyo University Hospital Mizonokuchi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Sakurada</LastName>
        <Affiliation>Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Intradialytic exercise during hemodialysis (HD) improves physical function and shows high adherence. In Japan, the 2018 guideline by the Japanese Society of Renal Rehabilitation supports intradialytic exercise, but medical insurance only covers the first 90 days. As new studies have emerged since the guideline was published, we conducted a systematic review and meta-analysis to evaluate the impact and optimal duration of exercise interventions beyond 12 weeks.&lt;br&gt;
Methods We followed a preregistered protocol (PROSPERO CRD42025642273) and PRISMA-P guidelines. Randomized controlled trials of adult patients undergoing HD performing structured exercise were identified via MEDLINE database (PubMed, March 2017&#8211;November 2024) and ICHUSHI-Web database. Two independent reviewers screened studies, extracted data, and assessed risk of bias using Cochrane RoB 2.0. Outcomes included peak oxygen uptake (VO2peak), maximal oxygen uptake (VO2max), 6 min walk distance, timed up and go (TUG) test, handgrip strength, sit-to-stand (STS) performance, and biochemical measures (hemoglobin, standard weekly urea Kt/V [std Kt/V]). Pooled mean differences (MD) with 95% confidence intervals (CI) were calculated using a mixed-effects model (Hartung&#8211;Knapp&#8211;Sidik&#8211;Jonkman method).&lt;br&gt;
Results A total of 71 studies, including 43 newly identified studies, were included. Risk of bias was moderate-to-high. Interventions&#8201;&gt;&#8201;12 weeks significantly improved 6 min walking distance (MD 52.4 m [95% CI 35.4&#8211;69.3], p&#8201;&lt;&#8201;0.01), VO2peak (MD 3.5 mL/kg/min [95% CI 1.96&#8211;5.04], p&#8201;&lt;&#8201;0.01), VO2max (MD 5.29 mL/kg/min [95% CI 2.36&#8211;8.22], p&#8201;&lt;&#8201;0.01), hemoglobin (MD 0.94 g/dL [95% CI 0.09&#8211;1.78], p&#8201;=&#8201;0.03), and std Kt/V (MD 0.16 [95% CI 0.12&#8211;0.20], p&#8201;&lt;&#8201;0.01). TUG (MD −1.68 s [95% CI −2.96 to −0.41], p&#8201;=&#8201;0.02), handgrip strength (MD 4.08 kg [95% CI 1.95&#8211;6.22], p&#8201;&lt;&#8201;0.01), and STS performance (MD −2.75 s [95% CI −4.45 to −1.05], p&#8201;&lt;&#8201;0.01) significantly improved in the integrated results of undefined study periods, with nonsignificant trends in studies of&#8201;&gt;&#8201;12 weeks of exercise.&lt;br&gt;
Conclusions Our findings suggest that exercise interventions lasting more than 12 weeks can enhance physical performance. Nevertheless, the applicability of these results to older patients remains uncertain, as most evidence is derived from middle-aged cohorts.&lt;br&gt;
Trial registration Registered in the PROSPERO database (CRD42025642273).</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Intradialytic exercise</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Physical performance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exercise period</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Short physical performance battery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Handgrip strength</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Systematic review</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Meta-analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2059-1381</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Duration-stratified effects of exercise therapy on health-related quality of life in hemodialysis patients: a systematic review and meta-analysis</ArticleTitle>
    <FirstPage LZero="delete">13</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Internal Medicine, Teikyo University Hospital Mizonokuchi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigeki</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Kojima Kidney and Dialysis Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromasa</FirstName>
        <LastName>Miyake</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Nishimoto</LastName>
        <Affiliation>Department of Nephrology, Nara Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Hishikawa</LastName>
        <Affiliation>Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Tonomura</LastName>
        <Affiliation>Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadashi</FirstName>
        <LastName>Sofue</LastName>
        <Affiliation>Department of Cardiorenal and Cerebrovascular Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiko</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Nephrology, Hyogo Prefectural Nishinomiya Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakazu</FirstName>
        <LastName>Saitoh</LastName>
        <Affiliation>Department of Physical Therapy, Faculty of Health Science, Juntendo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiei</FirstName>
        <LastName>Narita</LastName>
        <Affiliation>Niigata Institute for Health and Sports Medicine, Niigata Sports Association</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Yamagata</LastName>
        <Affiliation>Department of Nephrology, Institute of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junichi</FirstName>
        <LastName>Hoshino</LastName>
        <Affiliation>Department of Nephrology, Tokyo Women’s Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroo</FirstName>
        <LastName>Kawarazaki</LastName>
        <Affiliation>Department of Internal Medicine, Teikyo University Hospital Mizonokuchi</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Sakurada</LastName>
        <Affiliation>Division of Nephrology and Hypertension, Department of Internal Medicine, St. Marianna University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Patients on maintenance hemodialysis (HD) have reduced health-related quality of life (HRQoL). Structured exercise therapy is recommended, but domain-specific effects and the influence of intervention duration remain uncertain. This study evaluated the impact of structured exercise therapy on multiple HRQoL domains, including fatigue and depression, stratified by intervention duration.&lt;br&gt;
Methods: We conducted a systematic review and meta-analysis, searching MEDLINE (PubMed) through November 2024. The protocol was registered in PROSPERO (CRD42025642273). We included trials comparing structured exercise with non-exercise controls in adult HD patients. Primary outcomes were Short Form (SF)-36 Physical and Mental Component Summaries (PCS, MCS), fatigue, pain, general health, and depression (Beck Depression Inventory). Data were synthesized using random-effects models, stratified by intervention duration (&#8804;&#8201;3 versus&#8201;&gt;&#8201;3 months). Risk of bias was assessed using the Cochrane RoB 2 tool.&lt;br&gt;
Results: We identified 94 randomized controlled trials (5228 participants); 22 reported HRQoL outcomes and were meta-analyzed. Exercise significantly improved fatigue (mean difference [MD]&#8201;+&#8201;7.27, 95% confidence interval [CI] 4.75&#8211;9.80) and reduced depressive symptoms in&#8201;&gt;&#8201;3-month trials (MD&#8201;−7.62, 95% CI&#8201;−8.34 to&#8201;−6.90); no&#8201;&#8804;&#8201;3-month depression data were available. In overall analyses, general health (MD&#8201;+&#8201;11.59, 95% CI 6.98&#8211;16.21) and PCS (MD&#8201;+&#8201;5.83, 95% CI 0.71&#8211;10.94) improved, whereas MCS (MD&#8201;+&#8201;7.60, 95% CI&#8201;−3.75 to 18.94) and pain (MD&#8201;+&#8201;2.19, 95% CI&#8201;−4.41 to 8.79) showed no clear benefit. Short-term interventions (&#8804;&#8201;3 months) yielded significant improvements in pain and general health. In longer-term interventions (&gt;&#8201;3 months), general health estimates were similar in magnitude but statistically nonsignificant, and pain effects were also nonsignificant with substantial heterogeneity. Fatigue improved in both duration strata.&lt;br&gt;
Conclusions: Structured exercise therapy appears to improve fatigue in patients on maintenance HD and may provide additional gains in PCS and general health with interventions longer than 3 months. Improvements in depressive symptoms were observed from limited evidence, and duration-specific effects remain uncertain because no trials assessed depression at&#8201;&#8804;&#8201;3 months. Effects on pain and MCS remain uncertain owing to substantial heterogeneity. Larger long-term trials are needed to clarify the sustainability of HRQoL benefits beyond 3 months.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hemodialysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exercise therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Intradialytic exercise</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Health-related quality of life</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fatigue</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Depression</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Randomized controlled trials</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Meta-analysis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2096-241X</Issn>
      <Volume>10</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Microcontroller-Integrated Multichannel Time Detector for Paper-Based Analytical Devices ― Applications to Viscosity Measurements in Saliva Analysis and Protease-Activity Assays</ArticleTitle>
    <FirstPage LZero="delete">527</FirstPage>
    <LastPage>535</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Jianchao</FirstName>
        <LastName>Ren</LastName>
        <Affiliation>Department of Chemistry, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaewta</FirstName>
        <LastName>Danchana</LastName>
        <Affiliation>Department of Chemistry, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kaneta</LastName>
        <Affiliation>Department of Chemistry, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We designed and developed a microcontroller-integrated multichannel time detection system that uses a microfluidic paper-based analytical device (&#181;PAD) to measure liquid viscosity. This detection system is equipped with ten detectors to enhance the throughput of the measurements. The &#181;PAD utilizes capillary action to determine viscosity based on the flow time of a liquid sample. A conductivity detection system begins counting the flow time when a sample is introduced and stops the count when the sample reaches the detection electrode. Sodium chloride (NaCl) was pre-deposited in the detection channel of the &#181;PAD to enhance the conductivity of non-conductive samples, and Grade 1 CHR chromatography paper was selected as the optimal vehicle for substrates after comparing various channel widths, paper types, and channel lengths. The device demonstrated a linear correlation between flow time and viscosity for bovine serum albumin (BSA) and glucose solutions, which validates the theoretical model. The time readout measured protease activity when gelatin was used as a substrate and revealed an activity order of bromelain&#8201;&gt;&#8201;papain&#8201;&gt;&#8201;trypsin. The practical applicability of this system was further confirmed by testing real saliva samples, which demonstrated that the viscosity of saliva decreases rapidly after collection. Moreover, the results indicate that saliva viscosity was increased during extended durations of exercise. Overall, this &#181;PAD system provides a simple, low-cost, and portable solution for viscosity measurement, with potential applications in clinical diagnostics and field measurements.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Paper-based analytical device</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Time detector</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multichannel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Viscosity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Enzyme assay</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Saliva</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1356-9597</Issn>
      <Volume>31</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Transforming Life Science Through Chromosome‐Level Genome Assemblies</ArticleTitle>
    <FirstPage LZero="delete">e70145</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tetsuo</FirstName>
        <LastName>Kon</LastName>
        <Affiliation>Department of Neurosciences and Developmental Biology, University of Vienna</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosuke</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Graduate School of Engineering, Tokyo University of Agriculture and Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yi‐Jyun</FirstName>
        <LastName>Luo</LastName>
        <Affiliation>Biodiversity Research Center, Academia Sinica</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Johannes Nicolaus</FirstName>
        <LastName>Wibisana</LastName>
        <Affiliation>Genomics and Regulatory Systems Unit, Okinawa Institute of Science and Technology Graduate University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kouhei</FirstName>
        <LastName>Toga</LastName>
        <Affiliation>Laboratory of BioDX, PtBio Co‐Creation Research Center, Genome Editing Innovation Center, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Narumi</FirstName>
        <LastName>Uno</LastName>
        <Affiliation>Laboratory of Bioengineering, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Monden</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayuko</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Ushimado Marine Institute, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Advances in long-read sequencing and Hi&#8211;C scaffolding have made chromosome-level genome assembly increasingly accessible to individual laboratories, shifting genome research from large consortium-led projects toward investigator-driven studies across diverse taxa. This transition allows researchers to select organisms based on biological questions rather than the prior availability of genomic resources. In this review, we summarize the core experimental and computational steps for generating, evaluating, and annotating chromosome-level assemblies, and examine how they have advanced research in non-model organisms and genetically complex systems. Representative case studies illustrate four major contributions: resolving structural variation and lineage-specific genome architecture, linking genome organization to phenotypic innovation and plasticity, reconstructing deep chromosome evolution and macrosynteny, and distinguishing homologous and homoeologous chromosomes in polyploid genomes. These examples show that chromosome-level assemblies provide more than complete reference sequences. They establish a continuous genomic coordinate system through which genes, regulatory elements, transposable element insertions, sequence variants, and cellular states can be interpreted within broader chromosomal, population, and evolutionary contexts. We describe this integrative perspective as “glocal biology.” Future progress will require pangenomic, population-scale, and haplotype-resolved resources integrated with multi-omics and functional analyses. Collectively, chromosome-level genomics is reshaping life science by embedding molecular functions within chromosomal and evolutionary contexts.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chromosome-level genome assembly</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genome evolution</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hi&#8211;C scaffolding</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">long-read sequencing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">non-model animals</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2699-9307</Issn>
      <Volume>6</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>NUAK2 Inhibition Enhances Macromolecular Drug Delivery in a 3D Fibrotic Model of the Pancreatic Tumor Microenvironment</ArticleTitle>
    <FirstPage LZero="delete">e202500237</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Misaki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyoshi Y.</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayu</FirstName>
        <LastName>Ohira</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruko</FirstName>
        <LastName>Ohta‐Okano</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reika</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Seno</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saaya</FirstName>
        <LastName>Yara</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakura</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daichi</FirstName>
        <LastName>Shibata</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Materials Processing Graduate School of Engineering, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Toyooka</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Osada</LastName>
        <Affiliation>Department of Molecular Imaging and Theranostics Institute for Quantum Medical Science, National Institutes for Quantum Sciences and Technology (QST)  </Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Horacio</FirstName>
        <LastName>Cabral</LastName>
        <Affiliation>Department of Bioengineering Graduate School of Engineering, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Masamune</LastName>
        <Affiliation>Division of Gastroenterology Graduate School of Medicine, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsunobu R.</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Department of Pharmaceutical Biomedicine Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Pancreatic ductal adenocarcinoma (PDAC) features a fibrotic tumor microenvironment that impedes drug delivery and significantly limits the successful clinical application of nanomedicines. Targeting signaling in pancreatic stellate cells (PSCs), which drive fibrosis via excessive secretion of extracellular matrix proteins such as collagen I, may be useful in overcoming this fibrotic barrier. The AMPK-related kinases NUAK1/2 have recently gained interest as promoters of fibrosis, but whether they play a profibrotic role in PSCs remains unknown. Here, patient PSCs are used to assess NUAK1/2 involvement in the PDAC fibrotic barrier. Leveraging a 3D cell culture model of PDAC fibrosis, the effect of targeting NUAK1/2 on the permeability of macromolecular dextrans of various sizes, as well as physiologically relevant macromolecules, albumin and IgG, and clinical nanomedicines, Doxil and Abraxane, is investigated. NUAK1/2 inhibition is shown to diminish collagen I to enhance macromolecular permeability, via a mechanism independent of established pathways involving transforming growth factor-β (TGFβ) and yes-associated protein (YAP). Through isoform-specific knockdown, predominant NUAK2 involvement is demonstrated. Mechanistically, actin stress fiber regulation by NUAK2 is shown to be important. Altogether, these results show in&#8201;vitro that NUAK2 promotes fibrotic signaling in PSCs and may be targeted to enhance macromolecular drug delivery in PDAC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">fibrosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nanomedicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">NUAK kinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor microenvironment</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>公益社団法人 日本放射線技術学会</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0369-4305</Issn>
      <Volume>82</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>ベイズ推定を用いたラジオクロミックフィルムのADC値&#8211;線量変換法</ArticleTitle>
    <FirstPage LZero="delete">26-1707</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Tanimoto</LastName>
        <Affiliation>Department of Radiology, NHO Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Sugimoto</LastName>
        <Affiliation>Department of Radiological Technology, Faculty of Health Science and Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahide</FirstName>
        <LastName>Tamori</LastName>
        <Affiliation>Department of Radiology, NHO Kure Medical Center and Chugoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Yatsuki</LastName>
        <Affiliation>Department of Radiology, NHO Kure Medical Center and Chugoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Radiology, NHO Kure Medical Center and Chugoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuma</FirstName>
        <LastName>Sugahara</LastName>
        <Affiliation>Department of Radiology, NHO Kure Medical Center and Chugoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Oita</LastName>
        <Affiliation>Faculty of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>【目的】ラジオクロミックフィルムは高い空間分解能を有することから，患者別IMRT品質保証（IMRT QA）に広く利用されている．一方，ピクセル値を線量へ変換するためのキャリブレーションには，複数の既知線量で照射したフィルムが必要であり，作業負担が大きいことから，施設によってはフィルムロット変更時などに限定して実施される場合がある．本研究では，過去のキャリブレーションデータセットと対象フィルムの未照射時ピクセル値を用いてキャリブレーション曲線を推定するベイズ推定モデルを構築し，キャリブレーション作業の効率化を目的としてその有用性を検証した．【方法】TomoHDを用いて取得した93組のキャリブレーションデータセットを解析対象とした．線量および照射からスキャンまでの経過時間を説明変数とする二次多項式回帰モデルを構築した．モデルはスキャナの読み取り方向（縦方向・横方向）ごとに作成し，対象フィルムの未照射時ピクセル値を切片項として推定した．ベイズ推定にはStanを用い，トレースプロットおよびRhat統計量により収束性を評価した．更にモデル性能の評価には，異なるロットのEBT4フィルム10枚を用いて予測ピクセル値と実測値を比較するとともに，線量誤差を評価した．【結果】すべてのモデルでRhatは1.01未満を示し，良好な収束性が確認された．検証用フィルムでは，ピクセル値の誤差は3.6%未満，決定係数（R2）は0.99以上であった．また，線量誤差は24&#8201;cGyで平均2.7&#8201;cGy（SD 1.3），868.2&#8201;cGyで平均37.5&#8201;cGy（SD 12.8）であり，最大線量誤差は710.6&#8201;cGyにおいて66.6&#8201;cGyであった．【結語】本手法は，過去のキャリブレーションデータセットと対象フィルムの未照射時ピクセル値を用いてキャリブレーション曲線を推定できる可能性を示した．また，ラジオクロミックフィルムのキャリブレーション作業の効率化に寄与する可能性が示唆された．今後は患者別IMRT QAに適用し，線量分布評価への影響を検証する必要がある．</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">radiation therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">quality assurance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">patient-specific IMRT QA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiochromic film</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bayesian inference</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>AIP Publishing</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-9606</Issn>
      <Volume>165</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>High-resolution analysis of the S1&#8211;S0 transition of magnesium phthalocyanine: Rotational structure and electronic angular momentum</ArticleTitle>
    <FirstPage LZero="delete">074308</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsunari</FirstName>
        <LastName>Enomoto</LastName>
        <Affiliation>Department of Physics, University of Toyama</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kana</FirstName>
        <LastName>Iwakuni</LastName>
        <Affiliation>Institute for Laser Science, University of Electro-Communications</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Kuma</LastName>
        <Affiliation>Department of Physics, Rikkyo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi M. T.</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Institute for Laser Science, University of Electro-Communications</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We report a high-resolution spectroscopic analysis of the S1&#8211;S0 transition of magnesium phthalocyanine (MgPc), obtained by probing buffer-gas-cooled molecules with a narrow-linewidth laser. The observed spectrum exhibits a characteristic three-peak pattern, which is well reproduced by modeling MgPc as an oblate symmetric top with D4h symmetry. A key result of this work is that the spectrum is strongly influenced by electronic Coriolis coupling, which is associated with electronic angular momentum. The electronic Coriolis constant is determined to be &#8764;2, indicating an effective orbital angular momentum of about 2 in the excited S1 state, originating from the π-conjugated ring excitation. This provides a direct spectroscopic signature of electronic angular momentum in a large polyatomic molecule. The presence of nonzero electronic orbital angular momentum is qualitatively consistent with the perimeter model of phthalocyanines. The value lies within the range inferred from previous magnetic circular dichroism (MCD) studies. Compared with the previous MCD estimate, the present analysis provides a more state-specific and narrower constraint, demonstrating that high-resolution spectroscopy enables direct access to electronic and magnetic properties beyond conventional structural characterization.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society of Clinical Oncology (ASCO)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0732-183X</Issn>
      <Volume>43</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2&#8211;Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial</ArticleTitle>
    <FirstPage LZero="delete">1302</FirstPage>
    <LastPage>1313</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshinari</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Breast Surgery and Oncology, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shigehira</FirstName>
        <LastName>Saji</LastName>
        <Affiliation>Department of Medical Oncology, Fukushima Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimi</FirstName>
        <LastName>Takano</LastName>
        <Affiliation>Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of General Internal Medicine, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michiko</FirstName>
        <LastName>Tsuneizumi</LastName>
        <Affiliation>Department of Breast Surgery, Shizuoka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiyo</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Department of Breast Oncology, Aichi Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Breast Surgery, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junji</FirstName>
        <LastName>Tsurutani</LastName>
        <Affiliation>Advanced Cancer Translational Research Institute, Showa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuguo</FirstName>
        <LastName>Iwatani</LastName>
        <Affiliation>Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Kitada</LastName>
        <Affiliation>Department of Breast Disease Center, Asahikawa Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Tada</LastName>
        <Affiliation>Department of Surgery, Division of Breast and Endocrine Surgery, Tohoku University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Breast Surgery, Seirei Hamamatsu General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Higuchi</LastName>
        <Affiliation>Department of Breast Unit, Japanese Red Cross Saitama Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Iwasa</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Breast Medical Oncology, Gunma Prefectural Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Koizumi</LastName>
        <Affiliation>Department of Surgery 1, Division of Breast Surgery, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Medical HQs, Eisai Co, Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Medical HQs, Eisai Co, Ltd</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Biomedical Statistics and Bioinformatics, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norikazu</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Department of Breast Surgery, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC.&lt;br&gt;
Methods In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.gov identifier: NCT03264547/UMIN000027938), patients were randomly assigned (1:1) to receive eribulin 1.4 mg/m2 once daily on days 1 and 8 (eribulin group) or a taxane (docetaxel 75 mg/m2 once on day 1 or paclitaxel 80 mg/m2 once daily on days 1, 8, and 15; taxane group) intravenously in a 21-day cycle, each with HP on day 1. The primary end point was progression-free survival (PFS; intention-to-treat population). Secondary end points included objective response rate, overall survival (OS), patient-reported quality of life (QoL), and safety. Noninferiority was tested using the stratified Cox proportional hazards model to estimate hazard ratios (HRs) for PFS events, with a noninferiority HR margin of 1.33.&lt;br&gt;
Results Between August 2017 and June 2021, 446 patients (median age, 56.0 years) were enrolled. The median PFS was 14.0 and 12.9 months in the eribulin group (n = 224) and taxane group (n = 222 [docetaxel/paclitaxel, n = 186/36]), respectively (HR, 0.95 [95% CI, 0.76 to 1.19]), which confirmed the noninferiority of the study regimen. The median OS was 65.3 months in the taxane group but has not been reached in the eribulin group. Median time to QoL deterioration was numerically longer with eribulin than with taxane. Adverse event (AE) rates were similar, despite the longer duration of eribulin use. Infusion reaction, skin-related AEs, diarrhea, and edema were more common with taxane, whereas neutropenia was more common with eribulin.&lt;br&gt;
Conclusion The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>AME Publishing Company</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2304-3865</Issn>
      <Volume>13</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Primary angiosarcoma of the breast: a literature review</ArticleTitle>
    <FirstPage LZero="delete">68</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yidan</FirstName>
        <LastName>Zhu</LastName>
        <Affiliation>Department of Breast Surgery, Liaoning Cancer Hospital &amp; Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Nakamoto</LastName>
        <Affiliation>Department of General Thoracic Surgery and Breast and Endocrinological Surgery, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsukioki</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Iwatani</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuguo</FirstName>
        <LastName>Iwatani</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xinfeng</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Breast Surgery, Liaoning Cancer Hospital &amp; Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maki</FirstName>
        <LastName>Tanioka</LastName>
        <Affiliation>Department of Clinical AI Human Resources Development Program, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background and Objective: Primary angiosarcoma of the breast (PBA) is an extremely rare and heterogeneous disease. PBA is difficult to diagnose and has a poor prognosis. In order to better understand the disease and provide evidence-based treatment for PBA patients, a review of the published literature in the English language was conducted.&lt;br&gt;
Methods: A literature review in agreement with the PRISMA protocol was conducted. Medline and Cochrane databases were searched for English articles on PBA patients in September 2023 with a predetermined strategy. The articles were categorized and assessed based on hierarchical levels of scientific evidence.&lt;br&gt;
Key Content and Findings: A total of 255 articles were identified, among these 137 publications which included 1,888 patients met the criteria for inclusion in the final analysis. No prospective, randomized trials exclusive to PBA have been recognized. This article provides an overview of the most current and comprehensive evidence concerning the epidemiology, etiology, genomic features, clinical presentations, diagnosis, treatment, and prognosis of PBA.&lt;br&gt;
Conclusions: Despite the fact that current evidence is largely derived from retrospective studies, database analyses, and case reports, we utilized this information to tackle important clinical questions concerning optimal patient management practices for PBA. Complete surgical excision continues to be the mainstay treatment for PBA. However, the effectiveness of adjuvant therapies is still unclear. This narrative review highlights the urgent need for more rigorously designed research to enhance the management and treatment strategies for PBA.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Primary angiosarcoma of the breast (PBA)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">complete surgical excision</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hierarchal levels of scientific evidence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">literature review</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Amyloid-forming property of the N-terminal 1−70 residues of human apolipoprotein A-IV</ArticleTitle>
    <FirstPage LZero="delete">13203</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Norihiro</FirstName>
        <LastName>Namba</LastName>
        <Affiliation>Laboratory of Biophysical Chemistry, Kyoto Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tokiko</FirstName>
        <LastName>Danjo</LastName>
        <Affiliation>Laboratory of Biophysical Chemistry, Kyoto Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>Laboratory of Biophysical Chemistry, Kyoto Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Laboratory of Biophysical Chemistry, Kyoto Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ohgita</LastName>
        <Affiliation>Center for Instrumental Analysis, Kyoto Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshinori</FirstName>
        <LastName>Shimanouchi</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Laboratory of Biophysical Chemistry, Kyoto Pharmaceutical University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Apolipoprotein A-IV (apoA-IV), the largest member of the exchangeable apolipoprotein family, is a common constituent of amyloid deposits in renal and cardiac amyloidosis. In this study, we characterized the aggregation propensity of the apoA-IV N-terminal fragment to form amyloid fibrils using a variety of biophysical techniques. Thioflavin T fluorescence assay, circular dichroism measurement, and microscopic observations revealed that the N-terminal 1−70 amino acid fragment of apoA-IV readily forms amyloid fibrils by a transition from a random coil to a β-sheet-rich structure. Sequence-based analysis indicated that residues 7−16 and 38−42 are the major aggregation-prone segments within the N-terminal 1−70 residues of apoA-IV. Consistent with this, deletion of these residues strongly inhibited the β-transition and fibril formation of apoA-IV 1−70. Kinetic and thermodynamic analyses of fibril formation by the apoA-IV 1−70 fragment demonstrated that primary nucleation is the dominant step in fibril formation, for which the activation energy barrier is entirely entropic. In addition, we found that the presence of heparin, a representative glycosaminoglycan, accelerated fibril formation kinetics and enhanced the yield of apoA-IV 1−70 fibrils, and the positively charged residues K58-K59 play a critical role in heparin interaction. Overall, our results suggest that the strong amyloid-forming propensity of the N-terminal fragment of apoA-IV may play a key role in amyloid deposition associated with apoA-IV amyloidosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Apolipoprotein A-IV</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Aggregation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Amyloid fibril</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heparin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0911-6028</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Performance of generative artificial intelligence in oral and maxillofacial radiology based on the board-certification examination of Japan</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kawazu</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miki</FirstName>
        <LastName>Hisatomi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamiko</FirstName>
        <LastName>Fujikura</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Shibanuma</LastName>
        <Affiliation>Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuri</FirstName>
        <LastName>Namba</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Suzuka</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Division of Dentistry, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Saori</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Preliminary Examination Room, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihide</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Yanagi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objective To evaluate the performance and potential utility of generative artificial intelligence (AI) in oral and maxillofacial radiology using the board-certification examination administered by the Japanese Society for Oral and Maxillofacial Radiology (JSOMR).&lt;br&gt;
Methods The responses generated by ChatGPT for multiple-choice questions from the board-certification examination of the JSOMR over the three-year period from 2020 to 2022 were assessed. The questions were manually entered individually as prompts for GPT-3.5, GPT-4, and GPT-5, which are the models available from ChatGPT. The accuracy was calculated according to examination year, question format, and level of taxonomy.&lt;br&gt;
Results GPT-3.5 achieved an accuracy of 40.3% for the three years (42.9%, 42.0%, and 36.0% for 2020, 2021, and 2022, respectively), that of GPT-4 was 67.8% (67.3%, 74.0%, and 62.0%, respectively), and that of GPT-5 was 76.5% (79.6%, 78.0%, and 72.0%, respectively). GPT-5’s results exceeded the passing score for each year with the accuracy significantly outperformed that of GPT-3.5 and GPT-4. Regarding performance according to the question format, GPT-5 performed significantly superior to the earlier models, especially on two-answer questions.&lt;br&gt;
Conclusions On the board-certification examination of the JSOMR, the performance of GPT-5 was significantly superior to that of GPT-3.5 and GPT-4. This suggests that, given the rapid development of generative AI, GPT-5 has reached a level of text-based knowledge equivalent to that assessed in the board-certification examination of the JSOMR.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Generative artificial intelligence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ChatGPT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Large language model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Radiology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Education</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>S. Karger AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2296-9403</Issn>
      <Volume>10</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy and Safety of Three Janus Kinase Inhibitors in Ulcerative Colitis Patients over and under 65 Years of Age: A Real-World Comparative Analysis</ArticleTitle>
    <FirstPage LZero="delete">180</FirstPage>
    <LastPage>186</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Akiyama</LastName>
        <Affiliation>Department of Gastroenterology, Institute of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaoru</FirstName>
        <LastName>Yokoyama</LastName>
        <Affiliation>Department of Gastroenterology, Kitasato University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mariko</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Gastroenterology, Institute of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Eizuka</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunichi</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Gastroenterology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyoshi</FirstName>
        <LastName>Shibuya</LastName>
        <Affiliation>Department of Gastroenterology, Juntendo University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakiko</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minako</FirstName>
        <LastName>Sako</LastName>
        <Affiliation>Center for Inflammatory Bowel Disease, Tokyo Yamate Medical Center, Japan Community Healthcare Organization</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Center for Gastroenterology and Inflammatory Bowel Disease, Ofuna Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kozo</FirstName>
        <LastName>Tsuruta</LastName>
        <Affiliation>Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miki</FirstName>
        <LastName>Koroku</LastName>
        <Affiliation>Institute of Gastroenterology, Tokyo Women’s Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teppei</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Institute of Gastroenterology, Tokyo Women’s Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Saruta</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Iwate Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Tsuchiya</LastName>
        <Affiliation>Department of Gastroenterology, Institute of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshimitsu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Gastroenterology and Hepatology, Institute of Science Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: It remains unclear whether Janus kinase (JAK) inhibitors differ in efficacy and safety between elderly and non-elderly patients with ulcerative colitis. Methods: We retrospectively compared outcomes between patients who started a JAK inhibitor at &#8805;65 years (elderly group) and those &lt;65 years (non-elderly group). Results: Among 228, 215, and 159 patients treated with upadacitinib, filgotinib, and tofacitinib, we identified 14, 36, and 13 elderly patients, respectively. There were no significant differences in efficacy between elderly and non-elderly patients for any of the three JAK inhibitors. The elderly group had a 3-fold higher risk of herpes zoster infection with upadacitinib or tofacitinib compared to the non-elderly group, whereas the risk with filgotinib was less than 3% in both groups. The non-elderly group had a 3-fold higher risk of acne with upadacitinib. Conclusion: Adverse event risks with JAK inhibitors should be considered by age. Given the limitations of this study, including its retrospective design and small sample size, further studies with larger sample sizes are needed to validate our findings.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Elderly</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Janus kinase inhibitors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ulcerative colitis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2452-302X</Issn>
      <Volume>10</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Inhibition of Scarb1 on Endothelial Cells Attenuates Pressure Overload-Induced Heart Failure Progression</ArticleTitle>
    <FirstPage LZero="delete">101308</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshiomi</FirstName>
        <LastName>Katsuki</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dai</FirstName>
        <LastName>Kusumoto</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Akiba</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mai</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jin</FirstName>
        <LastName>Komuro</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisayuki</FirstName>
        <LastName>Hashimoto</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thukaa</FirstName>
        <LastName>Kouka</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhisa</FirstName>
        <LastName>Sugai</LastName>
        <Affiliation>Institute for Integrated Sports Medicine, School of Medicine, Keio University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Katsumata</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Miyasaka</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, the University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Computational Biology and Medical Sciences, the University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Kuramoto</LastName>
        <Affiliation>Department of Pathology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Anatomy, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Fukuda</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Ieda</LastName>
        <Affiliation>Department of Cardiology, Keio University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Inappropriate endothelial cell (EC) interactions contribute to heart failure; however, their precise mechanisms remain poorly understood. This study investigated EC-fibroblast interactions mediated by Scarb1 using single-cell RNA-sequencing analysis in a mouse heart failure model. ECs exhibited inflammatory and fibrotic gene expression, with Scarb1-mediated fibroblast-EC interactions driving disease progression. EC-specific Scarb1 knockout and systemic SCARB1 inhibition attenuated heart failure progression. In vitro and spatial omics analyses confirmed the role of SCARB1 in ECs and cell-cell interaction during heart failure progression. These findings highlight SCARB1 as a promising therapeutic target for EC-focused interventions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">endothelial cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibroblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">heart failure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SCARB1</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1439-7595</Issn>
      <Volume>36</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Vaccination in paediatric, adolescent, and transitional-age rheumatic diseases: a systematic review</ArticleTitle>
    <FirstPage LZero="delete">97</FirstPage>
    <LastPage>112</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuma</FirstName>
        <LastName>Ohnishi</LastName>
        <Affiliation>Department of Pediatrics, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Wakiguchi</LastName>
        <Affiliation>Division of General Pediatrics and Emergency Medicine, Department of Pediatrics, Oita University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Ishimori</LastName>
        <Affiliation>Department of Pediatrics, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Itoh</LastName>
        <Affiliation>Faculty of Medical Sciences, Department of Pediatrics, University of Fukui</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Yashiro</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Yamazaki</LastName>
        <Affiliation>Department of Pediatrics and Adolescent Medicine, Juntendo University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuo</FirstName>
        <LastName>Okafuji</LastName>
        <Affiliation>Department of Pediatrics, Kobe City Medical Center General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Ohtomo</LastName>
        <Affiliation>Department of Pediatrics, Juntendo University Nerima Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: This systematic review evaluated the efficacy and safety of vaccination in patients with paediatric, adolescent, and transitional-age rheumatic diseases as per the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 statement.&lt;br&gt;
Methods: An independent investigator systematically searched PubMed to identify relevant studies published by September 2022. The search results were divided into vaccines or toxoids for diphtheria, pertussis, tetanus, pneumococcus, influenza virus, hepatitis A virus, hepatitis B virus, human papillomavirus, poliovirus, measles virus, mumps virus, rubella virus, varicella zoster virus, and tuberculosis.&lt;br&gt;
Results: A meta-analysis was not feasible due to the lack of randomized controlled trials with standardized patient backgrounds and conditions. Non-live vaccines are generally immunogenic and safe for patients with rheumatic diseases. In contrast, live attenuated vaccines should usually be withheld in patients on immunosuppressants, corticosteroids, biologics, or Janus kinase inhibitors. However, for necessary immunizations against measles, rubella, mumps, or varicella, live attenuated vaccines may be considered for patients receiving low-dose corticosteroids, methotrexate, or tumour necrosis factor inhibitors.&lt;br&gt;
Conclusions
This review highlights the significant gap in evidence for paediatric populations compared with adults, particularly concerning new biological therapies and Janus kinase inhibitors. Further evidence is needed regarding vaccination in paediatric patients with rheumatic diseases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Bacille Calmette&#8211;Gu&#233;rin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diphtheria, pertussis, and tetanus vaccine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatitis A virus vaccine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hepatitis B virus vaccine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">human papillomavirus vaccine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inactivated polio vaccine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">influenza vaccine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">measles, mumps, and rubella vaccine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pneumococcal vaccine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">varicella zoster virus vaccine</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1341-9625</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Workforce and institutional factors associated with comprehensive genomic profiling utilization in gynecologic oncology: a nationwide questionnaire survey in Japan</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tamotsu</FirstName>
        <LastName>Sudo</LastName>
        <Affiliation>Department of Cancer Genetics and Genomics, School of Medicine, Fujita Health University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsutoshi</FirstName>
        <LastName>Oda</LastName>
        <Affiliation>Division of Integrative Genomics, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemichi</FirstName>
        <LastName>Watari</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Graduate School of Medicine and Faculty of Medicine, Hokkaido University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Hirasawa</LastName>
        <Affiliation>Department of Clinical Genomic Medicine, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Tottori University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenichi</FirstName>
        <LastName>Harano</LastName>
        <Affiliation>Department of Medical Oncology, National Cancer Center Hospital East</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Nagase</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Yamagata University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Takehara</LastName>
        <Affiliation>Department of Gynecologic Oncology, NHO Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Mandai</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Kyoto University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Sasajima</LastName>
        <Affiliation>Department of Pathology, Teikyo University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirouki</FirstName>
        <LastName>Yanai</LastName>
        <Affiliation>Department of Pathology, Dentistry, and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Tsuda</LastName>
        <Affiliation>Department of Basic Pathology, National Defense Medical College</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Institute of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Kawana</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Nihon University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikio</FirstName>
        <LastName>Mikami</LastName>
        <Affiliation>Department of Medical Science, Shonan University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoko</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Gynecology and Obstetrics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>International University of Health and Welfare Graduate School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aikou</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, The Jikei University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Comprehensive genomic profiling (CGP) has been widely introduced into precision oncology; however, its real-world implementation in gynecologic oncology remains unclear. This study evaluated nationwide CGP utilization, treatment translation, and management of secondary germline findings in Japanese gynecologic oncology.&lt;br&gt;
Methods A nationwide survey was conducted across 98 institutions participating in gynecologic oncology training and/or Japan’s cancer genomic medicine network. Institutional characteristics, workforce composition, treatment translation, and management of germline findings were assessed. Associations between institutional factors and CGP utilization or trial-related treatment translation were analyzed using incidence rate ratios (IRRs) with 95% confidence intervals.&lt;br&gt;
Results Among 68 institutions with complete CGP volume data, 6,964 CGP tests were performed, including 922 for gynecologic malignancies. The median number of gynecologic CGP tests per institution was 10. In multivariate analysis, the number of board-certified obstetrician&#8211;gynecologists was associated with CGP utilization (IRR, 1.05; 95% CI 1.01&#8211;1.08). CGP-guided therapy was delivered to 80 patients (8.7%). Trial-related treatment translation was associated with the number of board-certified obstetrician&#8211;gynecologists (IRR, 1.09; 95% CI 1.02&#8211;1.16) and the presence of a medical oncology department (IRR, 7.93; 95% CI 1.41&#8211;44.72). Presumed germline pathogenic variants were identified in 100 cases (10.8%); however, confirmatory germline testing was performed in only 38 cases.&lt;br&gt;
Conclusion CGP utilization in Japanese gynecologic oncology was associated with gynecologic workforce capacity and multidisciplinary genomic infrastructure. Collaboration between gynecologic oncology and medical oncology may facilitate treatment translation. CGP may also serve as an entry point for hereditary cancer evaluation despite incomplete downstream germline evaluation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Comprehensive genomic profiling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gynecological oncology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Precision oncology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Cancer genomic medicine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Organ-specialty&#8211;led implementation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Germline findings</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2304-6767</Issn>
      <Volume>14</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oral Supplementation of Bacillus subtilis Attenuated Alveolar Bone Loss in a Mouse Model of Ligature-Induced Periodontitis</ArticleTitle>
    <FirstPage LZero="delete">494</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yixuan</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Preventive Dentistry, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Toyama</LastName>
        <Affiliation>Dental School, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mohammad</FirstName>
        <LastName>Nurhamim</LastName>
        <Affiliation>Department of Preventive Dentistry, Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Momoko</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Preventive Dentistry, Academic Field of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daiki</FirstName>
        <LastName>Fukuhara</LastName>
        <Affiliation>Dental School, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Preventive Dentistry, Academic Field of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ekuni</LastName>
        <Affiliation>Department of Preventive Dentistry, Academic Field of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: This study aimed to investigate the effects of oral Bacillus subtilis (BS) on alveolar bone loss, intestinal morphology, and gut microbiota in a mouse model of ligature-induced periodontitis. Methods: A total of 24 male C57BL/6J mice (6 weeks old) were allocated to control, periodontitis (P), BS, and BS+P groups. Periodontitis was induced by bilateral ligation of maxillary second molars, and BS was orally administered for 18 consecutive days. Gut microbiota composition was analyzed by 16S rDNA sequencing, alveolar bone loss and gut morphology were evaluated using ImageJ version 1.54g, and ELISA-detectable serum vitamin D metabolite concentrations were measured using an enzyme-linked immunosorbent assay. Results: Compared with the P group, the BS+P group showed reduced bone loss. Serum vitamin D metabolite concentrations, small-intestine villus height, and villus height-to-crypt depth ratios were higher in the BS+P group. In gut microbiota, alpha diversity differed significantly among groups based on the Shannon index. Bray&#8211;Curtis-based beta diversity differed significantly among groups. Conclusions: Oral supplementation of BS attenuated the progression of ligature-induced periodontitis in a mouse model, and changes in gut microbiota may be associated with this effect.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Bacillus subtilis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">periodontitis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">alveolar bone loss</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gut microbiota</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intestinal morphology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vitamin D</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mouse model</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Institute of Electrical and Electronics Engineers (IEEE)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0885-8993</Issn>
      <Volume>41</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Structural Design of Litz Wires for Reducing AC Transport Current Loss Using an Equivalent Circuit Model Considering the Path of All Strands</ArticleTitle>
    <FirstPage LZero="delete">19516</FirstPage>
    <LastPage>19529</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Inoue</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SeokBeom</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Litz wires are generally fabricated based on the proprietary know-how of wire manufacturers. Therefore, the design guidelines for the conductor structure of low-loss Litz wires have not been clearly established. In this study, we investigated the effect of differences in the conductor structure on the AC resistance using the equivalent circuit model considering the path of all strands. Moreover, we proposed design guidelines for the conductor structure of Litz wires to reduce AC resistance originating from strand paths. Furthermore, we prototyped Litz wires according to the proposed design guidelines and compared the AC resistance of the proposed Litz wires with that of commercial Litz wires. As a result, the AC resistance of the prototyped Litz wires according to the proposed design guidelines was reduced compared to that of the commercial Litz wires. Moreover, the quality factor of the spiral coil using the proposed Litz wire was higher than that using the commercial Litz wire. From the above results, we experimentally clarified that the proposed design guidelines for the conductor structure of Litz wires are effective in reducing the AC resistance originating from strand paths.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">AC resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">copper loss</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">equivalent circuit</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Litz wire</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spiral coil</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>18</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The New Era of Intraperitoneal Carboplatin in Ovarian Cancer: From Biological Rationale to Clinical Implementation</ArticleTitle>
    <FirstPage LZero="delete">764</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shoji</FirstName>
        <LastName>Nagao</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujikawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yui</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Momoko</FirstName>
        <LastName>Tanioka</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoko</FirstName>
        <LastName>Imatani</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Tani</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanako</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Matsuoka</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoyuki</FirstName>
        <LastName>Ida</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Haraga</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisashi</FirstName>
        <LastName>Masuyama</LastName>
        <Affiliation>Department of Obstetrics and Gynecology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Epithelial ovarian cancer is predominantly characterized by peritoneal dissemination, providing a strong biological rationale for intraperitoneal (IP) chemotherapy. Although IP cisplatin-based regimens have demonstrated substantial survival benefits in pivotal randomized trials, toxicity and catheter-related complications limit their widespread adoption. IP carboplatin has emerged as a pragmatic alternative with improved tolerability while preserving its pharmacokinetic advantages. This review summarizes the biological and pharmacological rationale for IP carboplatin and critically examines the clinical evidence, with a particular emphasis on the Intraperitoneal Carboplatin for Ovarian Cancer (iPocc) trial and its divergence from Gynecologic Oncology Group (GOG)-252. We further discuss the potential applicability of IP carboplatin beyond the traditional setting of minimal residual disease, including patients undergoing neoadjuvant chemotherapy and interval debulking surgery, as well as its possible use in the contemporary era of maintenance therapy. Collectively, the accumulated evidence supports renewed consideration of IP carboplatin as a versatile component in modern ovarian cancer management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ovarian cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">intraperitoneal chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">carboplatin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dose-dense TC therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">homologous recombination deficiency</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PARP inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neoadjuvant chemotherapy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0275-5319</Issn>
      <Volume>91</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Does ESG performance enhance investment efficiency and firm performance? Evidence from Japan</ArticleTitle>
    <FirstPage LZero="delete">103582</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yusra</FirstName>
        <LastName>Nazir</LastName>
        <Affiliation>Graduate School of Humanities and Social Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiaojing</FirstName>
        <LastName>Cai</LastName>
        <Affiliation>Graduate School of Humanities and Social Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsumasa</FirstName>
        <LastName>Tennojiya</LastName>
        <Affiliation>Graduate School of Humanities and Social Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study examines the association between investment sensitivity to growth opportunities, firm performance, and environmental, social, and governance (ESG) performance in Japanese listed firms. To determine whether ESG performance is associated with a firm’s investment sensitivity to growth opportunities rather than directly increasing investment levels, panel data covering the period from 2002 to 2023 and an investment-Q sensitivity framework are employed. To evaluate robustness and reduce endogeneity issues, high-dimensional fixed effects (HDFE), the System Generalized Method of Moments (GMM), and a difference-in-differences (DID) design based on Japan’s post-2015 governance and disclosure environment are added to the baseline fixed-effects estimations. The findings show a positive association between investment-Q sensitivity and ESG performance, indicating a conditional association wherein firms with higher ESG performance are more receptive to expansion prospects. The findings, however, contradict the hypothesis that ESG performance and investment intensity are consistently associated. Stricter identification techniques diminish positive baseline associations, demonstrating sensitivity to model specification and cross-sectional firm variations. As a result, firm performance results are mixed. Governance-related factors are comparatively more consistently associated with investment outcomes across all ESG components. By focusing on ESG performance and capital allocation behavior under various economic scenarios rather than on whether ESG generally enhances firm outcomes, this study expands the ESG literature. The results imply that ESG serves more as a governance and information mechanism associated with investment sensitivity than as a reliable indicator of firm performance or investment efficiency.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">ESG performance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Investment efficiency</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Firm performance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Return on assets</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Asset turnover</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Corporate sustainability</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Japanese firms</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2168-8184</Issn>
      <Volume>17</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Efficacy of Ibuprofen Gargle for Oral Lichen Planus: A Single-Center, Placebo-Controlled, Double-Blind, Randomized Crossover Study Trial</ArticleTitle>
    <FirstPage LZero="delete">e91242</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasumasa</FirstName>
        <LastName>Kakei</LastName>
        <Affiliation>Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Kitahiro</LastName>
        <Affiliation>Pharmacy, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ioroi</LastName>
        <Affiliation>Pharmacy, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiko</FirstName>
        <LastName>Kashin</LastName>
        <Affiliation>Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Oral and Maxillofacial Surgery, Shin-suma General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Morioka</LastName>
        <Affiliation>Pharmacy, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Integrated Clinical and Basic Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Pharmacy, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Akashi</LastName>
        <Affiliation>Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: Oral lichen planus (OLP) is a chronic, refractory type of stomatitis characterized by abnormal keratinization and often accompanied by pain. The best treatment for OLP, particularly for pain management, remains unclear. This study focuses on the short-term efficacy of ibuprofen gargle for pain relief in patients with OLP.&lt;br&gt;
Methods: In this crossover study, 24 patients with painful OLP were enrolled. One group received an ibuprofen gargle (0.6%) on days one and three to five and a placebo on day two. The other group received a placebo on day one and ibuprofen on days two to five. The primary outcome was the change in pain level, measured by a Visual Analogue Scale (VAS) before and after gargling on days one and two. Additionally, changes in each domain of the Patient-Reported Oral Mucositis Symptom (PROMS) scale were evaluated from days one to five.&lt;br&gt;
Results: There was no significant difference in the degree of reduction in pain VAS values between the ibuprofen and placebo groups before and five and 15 minutes after use of the gargle. However, the PROMS scale showed a significant reduction in dietary restrictions (p = 0.032) in favor of the ibuprofen gargle compared to baseline.&lt;br&gt;
Conclusion: Ibuprofen gargle may help alleviate dietary restrictions associated with oral intake in patients with OLP who experience pain.&lt;br&gt;
Trial registration: This study was registered with the Japan Registry of Clinical Trials (jRCT) (jRCTs051220009).</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">crossover study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ibuprofen</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mouthwash</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral lichen planus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pain</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2076-2607</Issn>
      <Volume>14</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Upregulation of the Outer Membrane Protein OmpV and Its Role in Polymyxin B Stress Adaptation in Vibrio mimicus</ArticleTitle>
    <FirstPage LZero="delete">1527</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Onodera</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunki</FirstName>
        <LastName>Annoi</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Basilua Andre</FirstName>
        <LastName>Muzembo</LastName>
        <Affiliation>Research Center for Intestinal Health Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Imamura</LastName>
        <Affiliation>Research Institute of Nursing Care for People and Community, University of Hyogo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>OmpV is an outer membrane protein found in a variety of Gram-negative bacteria. In this study, we demonstrated that V. mimicus strain CS-66, isolated from a patient with diarrhea, was resistant to polymyxin B (PL-B) and colistin (CL) but susceptible to chloramphenicol and ciprofloxacin. When strain CS-66 was cultured in Luria&#8211;Bertani broth containing a sub-minimal inhibitory concentration of each antibiotic used for the susceptibility tests, ompV expression as assayed by reverse transcription-qPCR, significantly increased regardless of the antibiotic tested. In contrast, cell aggregation during the early log phase was observed only when the strain was grown in the broth supplemented with PL-B or CL. A space-filling model of V. mimicus OmpV was generated. The model showed that, although OmpV adopted a β-barrel conformation, it had closed top and bottom ends and possessed a lateral cavity. Structural analysis further indicated that the interior of this lateral cavity was negatively charged and sufficiently large to accommodate PL-B. These results suggest that V. mimicus may adapt to PL-B stress through physical sequestration within the negatively charged cavity of OmpV.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Vibrio mimicus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">polymyxin B</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">OmpV</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">β-barrel protein</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antibiotic sequestration</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1746-8094</Issn>
      <Volume>127</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Outcome-aware and interpretable subtyping of chronic kidney disease: an analysis of the FROM-J study</ArticleTitle>
    <FirstPage LZero="delete">111090</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tianyi</FirstName>
        <LastName>Shi</LastName>
        <Affiliation>Department of Computer Science, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xiucai</FirstName>
        <LastName>Ye</LastName>
        <Affiliation>Department of Computer Science, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wenyu</FirstName>
        <LastName>Xi</LastName>
        <Affiliation>Department of Computer Science, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Imakura</LastName>
        <Affiliation>Department of Computer Science, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Mase</LastName>
        <Affiliation>Department of Nephrology, Faculty of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoya</FirstName>
        <LastName>Tsunoda</LastName>
        <Affiliation>Department of Nephrology, Faculty of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Nephrology, Faculty of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Blood Purification Unit, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichi</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Department of Nephrology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Wada</LastName>
        <Affiliation>Department of Nephrology and Rheumatology, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiei</FirstName>
        <LastName>Narita</LastName>
        <Affiliation>Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Yamagata</LastName>
        <Affiliation>Department of Nephrology, Faculty of Medicine, University of Tsukuba</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Department of Computer Science, University of Tsukuba</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Chronic kidney disease (CKD) affects approximately 10% of the global population and exhibits substantial heterogeneity in disease progression and clinical outcomes. Despite ongoing efforts to develop new therapeutic strategies, the number of patients progressing to end-stage kidney disease (ESKD) and the incidence of cardiovascular disease (CVD) continue to rise. Although severity classification systems for CKD are well established and refined, they remain insufficient to capture prognostically relevant patient subtypes. In this study, we developed an outcome-aware and interpretable clustering framework for CKD subtyping using data from the FROM-J cohort with prognostic follow-up. A supervised XGBoost model was first trained to predict a &#8805; 30% decline in estimated glomerular filtration rate (eGFR), a surrogate marker of CKD progression. SHAP (SHapley Additive exPlanations) values derived from this model were then used to quantify outcome-relevant feature contributions. Based on these feature attributions, a similarity graph was constructed, and spectral clustering was performed to identify patient subtypes driven by prognostic relevance. The proposed framework identified four CKD subtypes with distinct baseline clinical characteristics and significantly different risks of renal replacement therapy (RRT) and cardiovascular disease (CVD) events. Serum albumin, blood urea nitrogen (BUN), and smoking status consistently emerged as key features defining subtype structure and prognosis. Robust risk stratification was preserved even when clustering was restricted to these three routinely measured variables. Overall, our findings demonstrate that integrating outcome-driven feature attribution into clustering enables interpretable and clinically relevant CKD subtyping, providing a practical approach for characterizing disease heterogeneity and supporting risk stratification and personalized management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Chronic kidney disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Outcome-aware clustering</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interpretable machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Risk stratification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Disease progression</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2296-4185</Issn>
      <Volume>14</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>High horizontal force and lateral force transmission induced by the twist of the Achilles tendon</ArticleTitle>
    <FirstPage LZero="delete">1874501</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Enomoto</LastName>
        <Affiliation>Graduate School of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohta</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Artificial Intelligence Research Center, National Institute of Advanced Industrial Science and Technology (AIST)</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The Achilles tendon―the largest and strongest of the many tendons in the human body―consists of subtendons arising from each head of the triceps surae. These subtendons run helically and intertwine to form a twisted three-dimensional structure. More than a century has passed since the twisted structure of the Achilles tendon was first described, and numerous studies have investigated its functional morphology. However, it remains unclear how the presence or degree of twist affects the mechanical function of the lower limbs. Here, using finite element models of the Achilles tendon with and without twist, we show that the presence and degree of twist can modulate the forces transmitted from muscle to skeleton in a complex manner. In contrast to the model without twist, the twisted models clearly exhibit anterolaterally directed horizontal forces at the distal end under a simple proximal tensile load. The lateral and anterior components reach approximately 101 N and 63 N, respectively. Furthermore, the twisted structure induces inter-subtendon force transmission, and the magnitude of the transmitted force increases with increasing degree of twist. These results indicate that the uniaxial contractile force generated by the triceps surae is transformed into triaxial forces by the twisted Achilles tendon and is redistributed in a complex three-dimensional manner through inter-subtendon interactions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">computer aided engineering</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">finite element analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">modeling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">morphology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">subtendons</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0140-7791</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tripartite Interaction Between Penicillium pinophilum-Host Plants and CMV-Y: A Model for Endophyte-Mediated Viral Biocontrol</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sarah R.</FirstName>
        <LastName>Ibiang</LastName>
        <Affiliation>Group of Plant-Microbe Interactions, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ivan</FirstName>
        <LastName>Galis</LastName>
        <Affiliation>Group of Plant-Insect Interactions, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Group of Plant-Microbe Interactions, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Group of Plant-Microbe Interactions, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Plant-fungus-virus tripartite interactions represent complex ecological systems in which mutualistic endophytes can influence host physiology, yet the molecular basis of endophyte-mediated defence remains poorly understood. Here, we demonstrate that the endophytic fungus Penicillium pinophilum EU0013 suppresses the yellow strain of cucumber mosaic virus (CMV-Y) in Solanum lycopersicum and Nicotiana benthamiana. CMV-Y infection induced pronounced oxidative and hormonal perturbations, which were mitigated by P. pinophilum colonisation. Endophyte-associated plants exhibited early accumulation of jasmonate intermediates, consistent with the activation of jasmonate signalling. This response promoted the degradation of jasmonate-ZIM-domain proteins and release of core JA-responsive transcription factors. Virus-induced gene silencing identified MYC2 as a key regulator required for endophyte-mediated antiviral protection, with WRKY17 contributing to defence modulation. In parallel, transcriptome analysis revealed the upregulation of a Dicer-like gene, indicating enhanced engagement of RNA silencing, a primary antiviral mechanism targeting viral RNA. This coordinated activation occurred alongside significant induction of pathogenesis-related proteins, particularly PR9, and improved control of reactive oxygen species. Salicylic acid-responsive defences showed a host-modulated pattern, with PR1 induced by CMV and PR2/PR5 preferentially enhanced in endophyte-associated plants. Collectively, these findings demonstrate that P. pinophilum enhances antiviral immunity through coordinated defence integration pathways, providing a framework for endophyte-based viral disease management.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">cucumber mosaic virus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">endophyte‐mediated resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">jasmonate signalling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pathogenesis‐related proteins</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">solanaceae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tripartite interaction</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0016-2361</Issn>
      <Volume>429</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2027</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Mechanism of Enhanced Heat Release in Spray Combustion of a Methanol&#8211;DME Blended Fuel</ArticleTitle>
    <FirstPage LZero="delete">140693</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshimitsu</FirstName>
        <LastName>Kobashi</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shodai</FirstName>
        <LastName>Makino</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakuni</FirstName>
        <LastName>Namba</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyuki</FirstName>
        <LastName>Kawahara</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyoshi</FirstName>
        <LastName>Asaka</LastName>
        <Affiliation>Technical Management Division, Carbon Neutral Technology Department, DAIHATSU INFINEARTH MFG. CO., LTD.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Technical Management Division, Carbon Neutral Technology Department, DAIHATSU INFINEARTH MFG. CO., LTD.</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This paper investigates the spray combustion characteristics of a methanol&#8211;DME blended fuel with a DME mole fraction of 0.57 in a constant volume vessel. The rate of heat release (ROHR) was evaluated using pressure-based heat release analysis. The results show that the methanol&#8211;DME blended fuel requires a longer injection duration due to the lower LHV (lower heating value), but it exhibits a shorter combustion duration than conventional diesel fuel, together with a higher ROHR normalized by the injection LHV rate and a shorter afterburning duration. To elucidate the relationship between the spray combustion processes and the ROHR characteristics, the spray flame was visualized using schlieren and OH chemiluminescence imaging techniques. In addition, a one-dimensional simulation based on a diesel jet model was conducted to evaluate the distributions of the equivalence ratio. These analyses reveal that the lower theoretical air&#8211;fuel ratio, attributed to the oxygenated nature of the methanol&#8211;DME blended fuel, reduces the equivalence ratio within the spray, promoting earlier formation of near-stoichiometric mixtures. As a result, the ROHR reaches and sustains its maximum earlier during mixing-controlled combustion, and fuel consumption is enhanced during afterburning.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Diesel Engine</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Methanol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DME</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mixing-controlled combustion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oxygenated fuel</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ceramic Society of Japan</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1348-6535</Issn>
      <Volume>134</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dielectric response modulation in relaxor (Sr,Ba)Nb2O6 via engineered defect</ArticleTitle>
    <FirstPage LZero="delete">455</FirstPage>
    <LastPage>460</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryusei</FirstName>
        <LastName>Shiota</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Teranishi</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Department of Energy Engineering, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Kishimoto</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Defect engineering provides an effective pathway to tune the dielectric response of relaxor ferroelectrics, yet the roles of individual defect species in tungsten bronze (TTB) systems remain unclear. Here, we investigated how engineered Ti&#8211;VO&#8226;&#8226; defect dipoles and native oxygen vacancies introduced through reduction annealing modify the dielectric properties of relaxor (Sr0.5,Ba0.5)Nb2O6 (0.5-SBN). Ti loading forms stable defect dipoles that generate smaller polar nanoregions (PNRs), suppress their overgrowth, and increase the number of dynamically active PNRs at room temperature, leading to enhanced permittivity ε′ while preserving DC-bias stability and breakdown strength (EB). Reduction annealing generates Nb4+-related local polarizations aligned with the external electric field, which strengthen dipole fluctuations and slightly increase ε′. Electron localization further relaxes the TTB-A2 site disorder&#8211;induced random fields, yielding a sharper dielectric peak and promoting more uniform PNR growth. Microwave dielectric spectroscopy combined with electromagnetic simulations revealed that the increases in ε′ for both Ti-loaded and reduced samples (0.5-SBNT and Reduced 0.5-SBN, respectively) originate predominantly from enhanced dipole polarization. Despite grain coarsening in 0.5-SBNT, the EB remained unchanged, indicating that defect dipoles act as pinning centers that inhibit field-induced PNR aggregation. In reduced 0.5-SBN, EB increased up to pO0 = 4.3 × 10−3 atm owing to relaxed random fields, whereas excessive reduction reduced EB through carrier-driven space-charge effects. These results demonstrate that precise control of defect species enables simultaneous optimization of ε′, DC-bias stability, and EB in TTB-type relaxor ferroelectrics.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Relaxor ferroelectrics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">(Sr,Ba)Nb2O6</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Polar nanoregions</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Dipole polarization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">DC bias response</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1664-462X</Issn>
      <Volume>17</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Quantitative resistance to Rhizoctonia solani AG-4 develops independently in leaves and roots of Brachypodium distachyon</ArticleTitle>
    <FirstPage LZero="delete">1875734</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Rozi</FirstName>
        <LastName>Fernanda</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Niranjan</FirstName>
        <LastName>Mahadevan</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuka</FirstName>
        <LastName>Kohno</LastName>
        <Affiliation>School of Agriculture, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reiko</FirstName>
        <LastName>Nagao</LastName>
        <Affiliation>School of Agriculture, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Megumi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanami</FirstName>
        <LastName>Sakata</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidenori</FirstName>
        <LastName>Matsui</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Ichinose</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Kouzai</LastName>
        <Affiliation>Crop Stress Management Group, Division of Plant Molecular Regulation Research, Institute of Agrobiological Sciences, National Agriculture and Food Research Organization (NARO)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichi</FirstName>
        <LastName>Mochida</LastName>
        <Affiliation>RIKEN Center for Sustainable Resource Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiteru</FirstName>
        <LastName>Noutoshi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Rhizoctonia solani is a soil-borne phytopathogen with a broad host range, classified into multiple anastomosis groups (AGs). While the rice sheath blight pathogen AG-1 IA is well-studied, defense mechanisms against AG-4, which infects diverse monocots and dicots, remain unclear. Here, we screened 153 Brachypodium distachyon accessions for resistance to AG-4 HG-I+II using both leaf and soil inoculation assays. The accessions exhibited a quantitative resistance spectrum in both assays. Some accessions were resistant to both methods, while others showed resistance in only one, indicating that leaf and root defenses operate independently. Unlike the salicylic acid (SA)-dependent resistance observed in several accessions against AG-1 IA, AG-4 leaf resistance appears to be largely SA-independent. Among 22 resistant accessions, only eight induced the SA marker BdWRKY38, whereas twelve induced the jasmonic acid (JA) marker BdAOS. Additionally, resistance in Bd3&#8211;1 was unaffected by expression of the SA hydroxylase NahG. These results are consistent with previous findings that exogenous application of SA, JA, or ethylene fails to confer AG-4 resistance. Instead, most AG-4-resistant accessions showed common upregulation of cell wall biosynthesis-related genes following leaf infection, suggesting that cell wall fortification may contribute to defense against AG-4. These findings establish B. distachyon as a valuable model for dissecting resistance mechanisms against R. solani AG-4.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Brachypodium distachyon</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell wall fortification</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">phytohormone</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">quantitative resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rhizoctonia solani</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">root infection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1323-8930</Issn>
      <Volume>75</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Outcomes following the discontinuation of biologic therapy in patients with severe asthma</ArticleTitle>
    <FirstPage LZero="delete">400</FirstPage>
    <LastPage>408</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadao</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisako</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Iwanaga</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuto</FirstName>
        <LastName>Matsunaga</LastName>
        <Affiliation>Department of Respiratory Medicine and Infectious Disease, Graduate School of Medicine, Yamaguchi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Sekiya</LastName>
        <Affiliation>Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Department of Multidisciplinary Internal Medicine, Division of Respiratory Medicine and Rheumatology, Faculty of Medicine, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Department of Respiratory Medicine, Shizuoka General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norihiro</FirstName>
        <LastName>Harada</LastName>
        <Affiliation>Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Koya</LastName>
        <Affiliation>Department of Respiratory Medicine and Infectious Diseases, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Fukunaga</LastName>
        <Affiliation>Division of Pulmonary Medicine, Department of Medicine, Keio University, School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Department of Pulmonology, Yokohama City University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhisa</FirstName>
        <LastName>Asai</LastName>
        <Affiliation>Department of Respiratory Medicine, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuko</FirstName>
        <LastName>Komase</LastName>
        <Affiliation>Department of Respiratory Medicine, St.Marianna University School of Medicine, Yokohama Seibu Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Gon</LastName>
        <Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Medicine, Division of Respiratory Medicine and Allergology, Showa Medical University, School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironori</FirstName>
        <LastName>Sagara</LastName>
        <Affiliation>Department of Medicine, Division of Respiratory Medicine and Allergology, Showa Medical University, School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hironobu</FirstName>
        <LastName>Sunadome</LastName>
        <Affiliation>Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Nagano</LastName>
        <Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoichi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Medical Center for Allergic and Immune Diseases, Yokohama City Minato Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akio</FirstName>
        <LastName>Niimi</LastName>
        <Affiliation>Department of Respiratory Medicine, Allergy, and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Hattori</LastName>
        <Affiliation>Department of Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hajiro</LastName>
        <Affiliation>Department of Respiratory Medicine, Tenri Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hajime</FirstName>
        <LastName>Fujimoto</LastName>
        <Affiliation>Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Hojo</LastName>
        <Affiliation>Division of Respiratory Medicine, National Center for Global Health and Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Miyahara</LastName>
        <Affiliation>Department of Medical Technology, Okayama University Graduate School of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Division of Respiratory Medicine, Department of Internal Medicine, Shiga University of Medical Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimiko</FirstName>
        <LastName>Tsuji</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kochi Medical School, Kochi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Haraguchi</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Muraki</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kindai University Nara Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuji</FirstName>
        <LastName>Tohda</LastName>
        <Affiliation>Department of Respiratory Medicine and Allergology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Biologic therapies are pivotal in managing severe asthma. Despite their efficacy, some patients discontinue biologics, with varying outcomes. Predictors of successful versus unsuccessful discontinuation remain poorly defined. This study aimed to identify clinical factors associated with post-discontinuation outcomes in a real-world practice.&lt;br&gt;
Methods: This retrospective cohort included adults with severe asthma who had received biologics for at least 12 months and subsequently discontinued therapy for a minimum of three consecutive months. We assessed the effects of baseline blood eosinophilia (&#8805;300 cells/μL), residual sputum symptoms during biologic therapy, treatment responsiveness, biologic class, and discontinuation reasons on post-discontinuation asthma exacerbation rates using multivariable Cox models.&lt;br&gt;
Results: A total of 118 patients were analyzed. The Kaplan&#8211;Meier analysis estimated a 65 % exacerbation-free probability at 12 months after discontinuation. Factors associated with successful discontinuation included a robust clinical response and absence of exacerbations before cessation. Conversely, baseline eosinophilia, residual sputum symptoms during biologics, and discontinuation due to inadequate therapeutic response or financial burden were associated with post-discontinuation exacerbations. In class-stratified restricted models, persistent sputum remained significantly associated with post-discontinuation exacerbations after stopping anti-IL-5 therapies, while baseline eosinophilia was associated with post-discontinuation exacerbations after stopping anti-IgE or anti-IL-4Rα. Among patients with sputum symptoms or poor-response discontinuation, the overall frequency of exacerbations declined after discontinuation.&lt;br&gt;
Conclusions: Baseline eosinophilia, persistent sputum during therapy, and discontinuation prompted by poor response or cost may serve as risk factors for post-discontinuation exacerbations; however, risk is phenotype- and class-dependent. Careful patient selection and monitoring are essential when considering the discontinuation of biologic treatment.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Adult asthma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Biologics</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Discontinuation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exacerbation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Severe asthma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1745-6215</Issn>
      <Volume>27</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oral health care during pregnancy to prevent preterm birth and low birth weight: study protocol for a randomized controlled trial</ArticleTitle>
    <FirstPage LZero="delete">35</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Yasuoka</LastName>
        <Affiliation>Division of Global Health Sciences, Graduate School of Public Health, St. Luke’s International University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Takeshita</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Oral and Maxillofacial Radiology, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Prodhan MD Rubayet</FirstName>
        <LastName>Alam</LastName>
        <Affiliation>Department of Orthodontics, Dental Unit, TMSS Medical College &amp; Rafatullah Community Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Shibanuma</LastName>
        <Affiliation>Department of Community and Global Health, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiko</FirstName>
        <LastName>Nanishi</LastName>
        <Affiliation>Office of International Academic Affairs, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoko</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Health Sciences, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Md. Zahid</FirstName>
        <LastName>Hossain</LastName>
        <Affiliation>Department of Periodontology and Oral Pathology, Holy Family Red Crescent Medical College Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Musfiqa</FirstName>
        <LastName>Aman</LastName>
        <Affiliation>Department of Periodontology, Dental Unit, TMSS Medical College &amp; Rafatullah Community Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fahmida</FirstName>
        <LastName>Karim</LastName>
        <Affiliation>Department of Obstetrics &amp; Gynecology, Holy Family Red Crescent Medical College Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sultana</FirstName>
        <LastName>Razia</LastName>
        <Affiliation>Department of Obstetrics &amp; Gynecology, TMSS Medical College &amp; Rafatullah Community Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rifat</FirstName>
        <LastName>Rezwana</LastName>
        <Affiliation>Department of Molecular and Cellular Biochemistry, Division of Oral Health, Brain Health and Total Health, Faculty of Dental Science, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Md Mahmudur</FirstName>
        <LastName>Rahman</LastName>
        <Affiliation>Global Communication Center, Grameen Communications</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nusrat</FirstName>
        <LastName>Jahan Khan</LastName>
        <Affiliation>Global Communication Center, Grameen Communications</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Medical Informatics, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rafiqul</FirstName>
        <LastName>Islam</LastName>
        <Affiliation>Division of Healthcare Digital Transformation, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimiyo</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Department of Research Promotion, Institute for Asian and Oceanian Studies, Kyushu University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Periodontal disease during pregnancy has been associated with an increased risk of preterm birth (PTB) and low birth weight (LBW). However, most previous interventional studies have reported that scaling and root planing (SRP), a form of basic periodontal treatment, is insufficient to effectively prevent PTB and LBW. Recent systematic reviews and meta-analyses suggest that combining SRP with routine use of chlorhexidine gluconate (CHG) mouthwash may reduce the risk of these adverse birth outcomes by approximately half. This study will be among the first randomized controlled trials (RCTs) to evaluate the potential synergistic effects of this combined approach on improving birth outcomes.&lt;br&gt;
Methods This multi-center, three-arm RCT will be conducted at two hospitals in Dhaka and Bogura, Bangladesh, between April 2025 and September 2026. A total of 480 pregnant women less than 20 weeks’ gestation attending antenatal checkups will be recruited. Participants diagnosed with periodontal disease will be randomly assigned to either an intervention group or a positive control group. Participants without periodontal disease will be assigned to a negative control group. The intervention consists of SRP combined with continued use of CHG mouthwash throughout pregnancy. The primary outcome will be the rate of PTB. Secondary outcomes include the birth weight of the newborn baby, maternal periodontal status, and oral health-related quality of life (OHRQoL). Effectiveness will be assessed by comparing outcomes across the study groups.&lt;br&gt;
Discussion The oral health intervention is expected to improve both birth outcomes and maternal oral health. Demonstrating its effectiveness in a real-world setting may support the integration of oral health care into broader maternal, neonatal, and child health strategies, particularly in resource-limited settings.&lt;br&gt;
Trial registration UMIN Clinical Trials Registry. UMIN000057519. Registered on April 4, 2025. https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000065719.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Preterm birth</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Low birth weight</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oral health</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Periodontal treatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chlorhexidine gluconate mouthwash</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Randomized controlled trial</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bangladesh</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0914-5087</Issn>
      <Volume>87</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cardio-ankle vascular index as a screening tool for coronary artery disease in patients with metabolic dysfunction-associated steatotic liver disease</ArticleTitle>
    <FirstPage LZero="delete">429</FirstPage>
    <LastPage>433</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mitsutaka</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Ueki</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Nishihara</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Miki</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shohei</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keishi</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Osawa</LastName>
        <Affiliation>Department of General Internal Medicine 3, Kawasaki Medical School General Medicine Centre</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a common hepatic disorder that significantly increases cardiovascular risk. However, no established screening method exists for detecting subclinical coronary artery disease (CAD) in this high-risk population. The cardio-ankle vascular index (CAVI), a blood pressure&#8211;independent measure of arterial stiffness, may offer a non-invasive tool for early detection of coronary atherosclerosis.&lt;br&gt;
Methods: We retrospectively analyzed 295 patients with MASLD who underwent both CAVI measurement and coronary computed tomography angiography at a single center. Significant CAD was defined as &#8805;50&#8239;% luminal stenosis. Receiver operating characteristic (ROC) analysis was used to evaluate diagnostic performance. Multivariable logistic regression was performed to identify independent associations between elevated CAVI and CAD. The incremental predictive value of CAVI was assessed using net reclassification improvement (NRI).&lt;br&gt;
Results: Of the 295 patients, 110 (37.3&#8239;%) had significant CAD. Patients with CAD had significantly higher CAVI values (9.0 vs. 8.7, p&#8239;=&#8239;0.007). The area under the ROC curve for CAVI predicting CAD was 0.614. A CAVI cut-off of 8.6 provided a sensitivity of 66.4&#8239;% and a specificity of 56.8&#8239;%. CAVI &#8805;8.0 was independently associated with CAD (OR 3.44, 95&#8239;% CI: 1.06&#8211;11.2, p&#8239;=&#8239;0.040). Adding CAVI to a conventional risk model improved risk reclassification (NRI 0.4236, p&#8239;&lt;&#8239;0.001), although the C-statistic change was not significant (from 0.724 to 0.725, p&#8239;=&#8239;0.835).&lt;br&gt;
Conclusions: CAVI is independently associated with significant coronary stenosis in MASLD patients and may serve as a non-invasive screening tool to enhance cardiovascular risk stratification. Its moderate diagnostic accuracy suggests utility as a component of a multifactorial risk assessment strategy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cardio-ankle vascular index</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Steatotic liver</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Coronary artery disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Arterial stiffness</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Screening</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0094-8276</Issn>
      <Volume>53</Volume>
      <Issue>14</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Calcium Solubility of Bridgmanite in Subducted Basalt in Earth's Lower Mantle</ArticleTitle>
    <FirstPage LZero="delete">e2026GL121981</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Chengwei</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Department of Earth and Planetary Sciences, Jackson School of Geosciences The University of Texas at Austin</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elias</FirstName>
        <LastName>El Ghazaoui</LastName>
        <Affiliation>School of Earth and Environmental Sciences, Seoul National University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stella</FirstName>
        <LastName>Chariton</LastName>
        <Affiliation>Center for Advanced Radiation Sources, The University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vitali B.</FirstName>
        <LastName>Prakapenka</LastName>
        <Affiliation>Center for Advanced Radiation Sources, The University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Luo</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Earth and Planetary Sciences, Jackson School of Geosciences The University of Texas at Austin</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yanyao</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Earth and Planetary Sciences, Stanford University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jung‐Fu</FirstName>
        <LastName>Lin</LastName>
        <Affiliation>Department of Earth and Planetary Sciences, Jackson School of Geosciences The University of Texas at Austin</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The calcium solubility in bridgmanite and the resulting abundance of davemaoite under lower-mantle pressure-temperature conditions have been under debate following a recent report of extensive calcium dissolution in bridgmanite. We experimentally investigated the calcium solubility in bridgmanite in a basaltic composition at pressures up to 125 GPa and temperatures up to 3,520 K. Our experimental data are modeled thermodynamically along the bridgmanite-davemaoite solvus to quantify the calcium solubility in bridgmanite and the davemaoite proportion in basaltic and pyrolitic assemblages along lower mantle geotherms. Our results indicate that bridgmanite hosts only 0.001&#8211;0.03 Ca cations per formula unit in the lower mantle, while davemaoite remains as an abundant mineral, accounting for 8 and 25 vol% of pyrolitic and basaltic mineralogical models, respectively, along representative lower-mantle geotherms. Our thermoelastic modeling further indicates that the effect of calcium dissolution on the density and bulk sound velocity of lower-mantle assemblages is negligible.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Fuji Technology Press Ltd.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1883-8030</Issn>
      <Volume>21</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Developing and Implementing a Disaster Prevention Game to Enhance Local Understanding</ArticleTitle>
    <FirstPage LZero="delete">128</FirstPage>
    <LastPage>135</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Miri</FirstName>
        <LastName>Shirokane</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Airi</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Misawa</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhisa</FirstName>
        <LastName>Matta</LastName>
        <Affiliation>Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study developed and implemented a local disaster prevention sugoroku-style game to address challenges in preserving and transmitting regional knowledge in areas with high population mobility. Many Japanese communities face both natural and social vulnerabilities, and effective disaster education requires linking hazard knowledge with local characteristics. Conducted at Sonan Junior High School in Okayama, the project combined lectures, workshops, and a community engagement event. Students learned about regional topography, land use, and disaster history and used this knowledge to design quizzes, rules, and disaster scenarios for the game. The final sugoroku set included a map-based board, thematic quiz areas, and preparedness item cards, enabling players to predict damage and consider appropriate actions. After creating the game, students shifted from identifying familiar landmarks to describing concrete disaster impacts such as liquefaction or infrastructure collapse. Interaction with local residents further enriched learning through shared experiences. The model proved feasible in terms of time and cost, and its structure is easily adaptable to other regions by incorporating local information. The findings suggest that this participatory, place-based approach enhances imagination, self-efficacy, and intergenerational knowledge transfer, contributing to community-wide disaster preparedness. Future studies will examine long-term educational impacts and broader regional applications.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">disaster education</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">local disaster knowledge</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">disaster literacy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">damage estimation abilities</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">community resilience</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0168-9525</Issn>
      <Volume>42</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Medaka: a novel model for analyzing genome&#8211;environment interactions</ArticleTitle>
    <FirstPage LZero="delete">350</FirstPage>
    <LastPage>361</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Naruse</LastName>
        <Affiliation>Laboratory of Bioresources, National Institute for Basic Biology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Felix</FirstName>
        <LastName>Loosli</LastName>
        <Affiliation>Institute of Biological and Chemical Systems, Biological Information Processing (IBCS-BIP), Karlsruhe Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Ansai</LastName>
        <Affiliation>Ushimado Marine Institute, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ewan</FirstName>
        <LastName>Birney</LastName>
        <Affiliation>European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joachim</FirstName>
        <LastName>Wittbrodt</LastName>
        <Affiliation>Centre for Organismal Studies (COS), Heidelberg University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Medaka is an established vertebrate model system for biological and biomedical research. It possesses unique features that make it particularly suitable for studying genome&#8211;environment interactions. Endemic to habitats spanning from 4 to 40°C and varying salinities, it combines broad ecological adaptability with experimental tractability. Its exceptional tolerance to inbreeding enabled the creation of the Medaka Inbred Kiyosu-Karlsruhe panel―80 near-isogenic, fully sequenced lines derived from a single wild population. More than 100 wild-derived, fully sequenced strains, collected throughout East Asia for more than 40 years, show relatively low intra-strain variation (inbreeding coefficient of &gt;0.75) but high inter-strain variability (SNP rates &gt;4%). Advanced quantification methods facilitate genome-wide association studies and quantitative trait locus mapping. The system’s amenability to clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 editing and emerging epigenomic profiling enables causal validation and regulatory-mechanism discovery. Collectively, medaka offers an unparalleled vertebrate framework for integrating genetics, environment, and epigenetics―bridging evolutionary, biomedical, and population-level perspectives.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">medaka</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">population genetics resource</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">wild-derived strains</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">GWAS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">QTL mapping</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genome&#8211;environment interactions</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ovid Technologies (Wolters Kluwer Health)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2047-9980</Issn>
      <Volume>15</Volume>
      <Issue>9</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Insomnia and the Risk of Atrial Fibrillation: A Nationwide, Real‐World Cohort Study</ArticleTitle>
    <FirstPage LZero="delete">e045149</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takuro</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kentaro</FirstName>
        <LastName>Ejiri</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidehiro</FirstName>
        <LastName>Kaneko</LastName>
        <Affiliation>Department of Cardiovascular Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Advanced Cardiology, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Taya</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Iwasaki</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Nishii</LastName>
        <Affiliation>Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Cardiovascular Therapeutics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuhito</FirstName>
        <LastName>Fujiu</LastName>
        <Affiliation>Department of Cardiovascular Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norifumi</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Cardiovascular Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Cardiovascular Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideo</FirstName>
        <LastName>Yasunaga</LastName>
        <Affiliation>Department of Clinical Epidemiology and Health Economics, School of Public Health, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norihiko</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Cardiovascular Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinsuke</FirstName>
        <LastName>Yuasa</LastName>
        <Affiliation>Department of Cardiovascular Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Insomnia is one of the most prevalent diseases observed in clinical practice, contributing to increased death and a range of chronic diseases. While numerous studies have explored the relationship between insomnia and cardiovascular disease, research on its association with atrial fibrillation (AF) remains limited. This study aimed to investigate the association between insomnia and incident AF in the general population by comprehensive, nationwide, real‐world data in Japan.&lt;br&gt;
Methods: A total of 1&#8201;780&#8201;764 individuals without prior cardiovascular disease including AF from the DeSC database were included between April 2014 and August 2023. Insomnia was defined by International Classification of Diseases, Tenth Revision (ICD‐10) codes (F510, G470) before the baseline health checkup. The primary outcome was incident AF (I480&#8211;I482 and I489). Cox proportional hazards models were used to estimate hazard ratios of AF according to present insomnia (versus absent).&lt;br&gt;
Results: Insomnia was observed in 216&#8201;919 individuals (12.2%), showing a significant association with incident AF after adjusting for potential confounding factors (adjusted hazard ratio, 1.14 [95% CI, 1.10&#8211;1.18]). Among subgroups, a similar pattern in the association between insomnia and incident AF was seen, while the association was stronger in younger individuals aged &lt;65&#8201;years (versus &#8805;65&#8201;years) and women (versus men) (P for interaction=0.01 and 0.03, respectively).&lt;br&gt;
Conclusions: Insomnia was significantly associated with the risk of AF. It highlighted the importance of recognizing insomnia as a risk factor for AF, given its high prevalence in the general population and the substantial impact of AF on quality of life and prognosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">atrial fibrillation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">insomnia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">risk factors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sleep apnea syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sleep disorder</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society of Hematology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2473-9529</Issn>
      <Volume>10</Volume>
      <Issue>13</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Drivers of temporal improvement in CAR T-cell therapy for large B-cell lymphoma: a Japanese nationwide registry analysis</ArticleTitle>
    <FirstPage LZero="delete">4427</FirstPage>
    <LastPage>4438</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Yagi</LastName>
        <Affiliation>Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Kanemasa</LastName>
        <Affiliation>Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiki</FirstName>
        <LastName>Terao</LastName>
        <Affiliation>2Department of Hematology, Okayama University Hospital, Okayama, Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyasu</FirstName>
        <LastName>Jo</LastName>
        <Affiliation>Department of Hematology, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsu</FirstName>
        <LastName>Shimoyama</LastName>
        <Affiliation>Department of Medical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kitawaki</LastName>
        <Affiliation>Department of Hematology, Kyoto University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Hanajiri</LastName>
        <Affiliation>Department of Hematology and Oncology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Doki</LastName>
        <Affiliation>Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>Department of Hematology, Hyogo Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriko</FirstName>
        <LastName>Iwaki</LastName>
        <Affiliation>Department of Hematology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Matsukawa</LastName>
        <Affiliation>Department of Hematology, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emiko</FirstName>
        <LastName>Sakaida</LastName>
        <Affiliation>Department of Hematology, Chiba University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Hematology and Hematopoietic Cell Transplantation, Osaka Metropolitan University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiyo</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Division of Transfusion Medicine, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Umezawa</LastName>
        <Affiliation>Department of Hematology, Institute of Science Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haryoon</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>11Department of Hematology, Hokkaido University Hospital, Sapporo, Japan</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Atsuta</LastName>
        <Affiliation>Japanese Data Center for Hematopoietic Cell Transplantation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Hematology, Oncology, and Cardiovascular Medicine, Kyushu University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Real-world CD19 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma (LBCL) is characterized by expanded eligibility and evolving management practices. However, the prognostic impact of these changes remains inconsistent, and the specific drivers of outcomes remain unclear. This study analyzed 913 patients with relapsed/refractory (R/R) LBCL from a Japanese registry and compared the outcomes between 2 calendar periods (2019-2021 vs 2022-2024). The 2022-2024 cohort was older, had more adverse baseline features, and was less pretreated. Treatment patterns have shifted toward higher utilization of second-line therapy, a growing preference for axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel), and improved disease control before infusion. Accordingly, the 2022-2024 cohort achieved a longer progression-free survival (PFS; 6-month PFS, 63.2% vs 55.2%; P = .005), which persisted after adjusting for baseline characteristics using propensity score matching. Multivariable analysis identified second-line therapy, improved preinfusion disease control, and a shift in product selection from tisagenlecleucel to axi-cel or liso-cel as the primary drivers of this improvement. This benefit was pronounced in high-risk populations, including patients with stable or progressive disease at infusion (6-month PFS, 54.6% vs 43.8%; P = .012) and those who were refractory to first-line therapy (6-month PFS, 51.7% vs 40.3%; P = .013). Despite broader use in higher-risk populations and greater axi-cel exposure, 6-month nonrelapse mortality remained low (2.1% vs 1.5%). Real-world outcomes of CD19 CAR T-cell therapy for R/R LBCL have improved, predominantly driven by second-line therapy, enhanced preinfusion disease control, and increased use of more potent CAR T products.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0278-0372</Issn>
      <Volume>46</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Estimating the distributional expansion of the invasive crayfish Procambarus clarkii (Girard, 1852) (Decapoda: Astacidea: Cambaridae) in South Korea using environmental DNA analysis</ArticleTitle>
    <FirstPage LZero="delete">ruag033</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Seong-Nam</FirstName>
        <LastName>Ham</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaito</FirstName>
        <LastName>Moriuchi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mayuko</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyoshi</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The red swamp crayfish Procambarus clarkii (Girard, 1852) is a globally invasive species that poses serious threats to native biodiversity and ecosystem functioning. In South Korea, established populations of P. clarkii have been documented from the Jiseokcheon River in the Yeongsangang River basin since 2018; however, information on its current nationwide distribution remains limited. We conducted environmental DNA (eDNA) surveys at 19 sites across 11 river systems in South Korea, including sites with no prior distributional records, to evaluate the current distribution and potential range expansion of P. clarkii. Water samples collected during July-August 2024 were analyzed using quantitative real-time PCR (qPCR) with two species-specific primer-probe sets targeting the mitochondrial COI gene. Procambarus clarkii eDNA was detected at three sites in the Yeongsangang River basin, whereas no eDNA was detected in the other surveyed river systems. Notably, P. clarkii eDNA was not detected at a site in the Mangyeonggang River system despite previous reports of individuals and eDNA data sampled there, indicating a possible local population decline or very low abundance. By contrast, detections within the Yeongsangang River basin, together with elevated eDNA concentrations at some sites, are consistent with localized upstream expansion and increased local abundance. The concordant results from the two primer-probe sets, together with Sterivex-based on-site filtration, support the reliability of the applied eDNA framework. These findings identify the Yeongsangang River basin as the current primary focus of the P. clarkii invasion in South Korea, with evidence consistent with localized upstream expansion and increasing abundance, and provide baseline data for early detection and long-term monitoring, as well as for developing management strategies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Crustacea</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">early detection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">eDNA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">freshwater ecosystems</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">red swamp crayfish</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1465-3621</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of pre-existing schizophrenia spectrum disorder on the receipt of invasive and systemic therapy for gastric cancer: a multicenter nationwide cohort study in Japan</ArticleTitle>
    <FirstPage LZero="delete">hyag102</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Myo Min</FirstName>
        <LastName>Khant</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Neuropsychiatry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Division of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomone</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Division of Health Services Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Fukao</LastName>
        <Affiliation>Department of Neuropsychiatry, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Maiko</FirstName>
        <LastName>Fujimori</LastName>
        <Affiliation>Division of Survivorship Research, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakaya</LastName>
        <Affiliation>Tohoku Medical Megabank Organization, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiko</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Department of Medical Informatics, Shimane University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Otsuki</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiko</FirstName>
        <LastName>Kakiuchi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Dentistry and Pharmaceutical Sciences, Okayama University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Shimazu</LastName>
        <Affiliation>Division of Behavioral Sciences, National Cancer Center Institute for Cancer Control, National Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shiro</FirstName>
        <LastName>Hinotsu</LastName>
        <Affiliation>Department of Biostatistics and Data Management, Sapporo Medical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Uchitomi</LastName>
        <Affiliation>Department of Cancer Survivorship and Digital Medicine, The Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Psychiatry, Faculty of Medicine, Shimane University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Patients with schizophrenia spectrum disorders (SSD) experience higher cancer mortality, partly because of later-stage diagnosis and lower rates of recommended treatments. While treatment disparities have been reported across several cancer types, no study has specifically examined stage-appropriate treatment for gastric cancer among patients with SSD.&lt;br&gt;
Methods: We conducted a retrospective cohort study using a nationwide Hospital-Based Cancer Registry linked to administrative data in Japan. Patients who received initial treatment for gastric cancer between 2018 and 2021 were included. Multivariable logistic regression models examined the association between SSD and the receipt of stage-appropriate cancer treatments, adjusting for age, sex, clinical stage, Charlson Comorbidity Index, and Barthel Index.&lt;br&gt;
Results: Among 189&#8201;447 patients from 709 hospitals, 1312 had SSD. Patients with SSD were more likely to be diagnosed at advanced stages. In crude analysis, SSD was associated with lower rates of surgical or endoscopic treatment; however, this association was not statistically significant after adjustment (adjusted odds ratio [aOR], 0.90; 95% confidence interval [CI], 0.75&#8211;1.08). In contrast, SSD was independently associated with lower rates of postoperative adjuvant chemotherapy for pathological stage II/III disease (aOR, 0.64; 95% CI, 0.45&#8211;0.91) and systemic therapy for stage IV disease (aOR, 0.36; 95% CI, 0.28&#8211;0.47).&lt;br&gt;
Conclusions: Among patients with gastric cancer, SSD was associated with reduced receipt of systemic therapy but not surgical or endoscopic treatment. Efforts to improve early detection among patients with SSD may be important for reducing treatment disparities, alongside strengthened support for systemic therapy to ensure equitable access to guideline-recommended gastric cancer care.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">healthcare disparities</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">schizophrenia Spectrum and other psychotic disorders</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stomach neoplasms</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Dual-calibration RT-qPCR reveals distinct dnaK1/2/3 and groEL1/2 expression dynamics under heat and acid stress in the sinefungin producer Streptomyces incarnatus</ArticleTitle>
    <FirstPage LZero="delete">19282</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zhao</FirstName>
        <LastName>Xiao-Hui</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mao</FirstName>
        <LastName>Kubo</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruka</FirstName>
        <LastName>Yamagata</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuriko</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohisa</FirstName>
        <LastName>Hasunuma</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadayoshi</FirstName>
        <LastName>Kanao</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Streptomyces incarnatus NRRL8089 produces sinefungin, a nucleoside antibiotic whose yield is enhanced under defined environmental stresses. Here, dual-calibration RT-qPCR was used to resolve paralogue-specific expression dynamics of the dnaK and groE chaperone systems under heat and acid stress conditions that increase sinefungin titres. The canonical dnaK1&#8211;dnaJ1 and groES&#8211;groEL1 operons exhibited moderate induction, whereas monocistronic paralogues (dnaK2, dnaK3 and groEL2) showed markedly higher inducibility, with up to ~&#8201;125-fold increases relative to baseline expression. Promoter analyses revealed conserved inverted repeats and differences in predicted secondary-structure stability, suggesting that promoter architecture contributes to paralogue-specific responsiveness. Structural modelling indicated divergence among DnaK paralogues in regions associated with substrate interaction, whereas GroEL paralogues retained a conserved overall scaffold, consistent with kinetic rather than structural differentiation. Together, these findings indicate that duplicated paralogues are not functionally redundant but are differentially regulated to partition proteostasis capacity under stress. This paralogue-specific regulation may provide a framework linking environmental perturbation to secondary-metabolite production in actinomycetes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Heat shock</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Acid stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dnaK</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hspR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">groES</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">groEL</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sinefungin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Streptomyces incarnatus</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Metastatic promoting role of mesenchymal stem cells in oral squamous cell carcinoma revealed by an improved bone marrow chimeric model</ArticleTitle>
    <FirstPage LZero="delete">20445</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Htoo Shwe</FirstName>
        <LastName>Eain</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hotaka</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Sanou</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yamin</FirstName>
        <LastName>Soe</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">May Wathone</FirstName>
        <LastName>Oo</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tianyan</FirstName>
        <LastName>Piao</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zin Zin</FirstName>
        <LastName>Min</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry, and Pharmaceutical Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Mesenchymal stem cells (MSCs) are essential stromal regulators that coordinate tissue repair, angiogenesis, and immune balance. Within tumours, MSCs remodel the microenvironment and influence disease progression, yet their systemic contribution remains unclear due to the limited recovery of functional MSCs in conventional bone marrow transplantation models. Here, we developed an improved bone marrow collection (iBMC) method using enzymatic digestion, which markedly increases MSC yield while preserving their native phenotype. GFP bone marrow chimeric mice generated by iBMC and conventional transplantation displayed comparable hematopoietic reconstitution but differed in MSC abundance, enabling direct analysis of MSC-specific effects under physiological conditions. In mouse models of oral squamous cell carcinoma (OSCC), MSCs profoundly affected tumour development. MSC-deficient tumours exhibited necrosis and infiltration of immature myeloid-derived suppressor cells (MDSCs), whereas MSC-rich tumours showed enhanced vascularisation, adaptive immune infiltration, and stromal remodelling. Notably, lung metastasis occurred only in MSC-rich mice, accompanied by bone marrow&#8211;derived endothelial activation and TNF-α&#8211;driven inflammation. Pharmacological inhibition of LepR signalling using SHU9119 unexpectedly increased metastasis, underscoring the dual, context-dependent functions of MSCs. These findings establish iBMC as a reproducible and physiologically relevant model to study MSC-mediated regulation of tumour immunity, angiogenesis, and metastasis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Mesenchymal stem cells (MSCs)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oral squamous cell carcinoma (OSCC)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Bone marrow transplantation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Chimeric mouse models</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tumour microenvironment (TME)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0019-9567</Issn>
      <Volume>93</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A newly developed oral infection mouse model of shigellosis for immunogenicity and protective efficacy studies of a candidate vaccine</ArticleTitle>
    <FirstPage LZero="delete">e00346-2</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Risha</FirstName>
        <LastName>Haldar</LastName>
        <Affiliation>Division of Clinical Medicine, ICMR-National Institute of Cholera and Enteric Diseases</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Prolay</FirstName>
        <LastName>Halder</LastName>
        <Affiliation>Division of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hemanta</FirstName>
        <LastName>Koley</LastName>
        <Affiliation>Division of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Division of Medicine, Dentistry and Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Santasabuj</FirstName>
        <LastName>Das</LastName>
        <Affiliation>Division of Clinical Medicine, ICMR-National Institute of Cholera and Enteric Diseases</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Shigella infection poses a significant public health challenge in the developing world. However, lack of a widely available mouse model that replicates human shigellosis creates a major bottleneck to better understanding of disease pathogenesis and development of newer drugs and vaccines. BALB/c mice pre-treated with streptomycin and iron (FeCl3) plus desferrioxamine intraperitoneally followed by oral infection with virulent Shigella flexneri 2a resulted in diarrhea, loss of body weight, bacterial colonization and progressive colitis characterized by disruption of epithelial lining, loss of crypt architecture with goblet cell depletion, increased polymorphonuclear infiltration into the mucosa, submucosal swelling (edema), and raised proinflammatory cytokines and chemokines in the large intestine. To evaluate the usefulness of the model for vaccine efficacy studies, mice were immunized intranasally with a recombinant protein vaccine containing Shigella invasion protein invasion plasmid antigen B (IpaB). Vaccinated mice conferred protection against Shigella, indicating that the model is suitable for testing of vaccine candidates. To protect both Shigella and Salmonella, a chimeric recombinant vaccine (rIpaB&#8211;T2544) was developed by fusing IpaB with Salmonella outer membrane protein T2544. Vaccinated mice developed antigen-specific serum IgG and IgA antibodies and a balanced Th1/Th2 response and were protected against oral challenge with Shigella (S. flexneri 2a, Shigella dysenteriae, and Shigella sonnei) using our present mouse model and Salmonella (Salmonella Typhi and Paratyphi) using an iron overload mouse model. We describe here the development of an oral Shigella infection model in wild-type mouse. This model was successfully used to demonstrate the immunogenicity and protective efficacy of a candidate protein subunit vaccine against Shigella.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oral route</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">S. flexneri</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">shigellosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bivalent subunit vaccine (IpaB&#8211;T2544)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mouse model</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0385-5600</Issn>
      <Volume>69</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>RpoB H481Y Rifampicin Resistance Mutation-Associated Oxidative Stress Sensitivity Reduces the Virulence of Staphylococcus aureus</ArticleTitle>
    <FirstPage LZero="delete">128</FirstPage>
    <LastPage>131</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lina</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Furuta</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikara</FirstName>
        <LastName>Kaito</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In this study, we have established a Staphylococcus aureus RpoB H481Y mutant strain and demonstrated that it is sensitive to menadione or hydrogen peroxide-induced oxidative stress and exhibits reduced virulence against a silkworm infection model. Furthermore, the reduced virulence of the RpoB H481Y mutant was abrogated in the presence of N-acetylcysteine, a reactive oxygen species scavenger. These results suggest that oxidative stress sensitivity caused by the RpoB H481Y rifampicin resistance mutation attenuates the virulence of S. aureus.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">oxidative stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">RNA polymerase beta subunit</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Staphylococcus aureus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">virulence</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-9193</Issn>
      <Volume>206</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Overexpression of diglucosyldiacylglycerol synthase leads to daptomycin resistance in Bacillus subtilis</ArticleTitle>
    <FirstPage LZero="delete">e00307-24</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryogo</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Furuta</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-Ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikara</FirstName>
        <LastName>Kaito</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The lipopeptide antibiotic daptomycin exhibits bactericidal activity against Gram-positive bacteria by forming a complex with phosphatidylglycerol (PG) and lipid II in the cell membrane, causing membrane perforation. With the emergence of daptomycin-resistant bacteria, understanding the mechanisms of bacterial resistance to daptomycin has gained great importance. In this study, we aimed to identify the genetic factors contributing to daptomycin resistance in Bacillus subtilis, a model Gram-positive bacterium. Our findings demonstrated that overexpression of ugtP, which encodes diglucosyldiacylglycerol synthase, induces daptomycin resistance in B. subtilis. Specifically, overexpression of ugtP resulted in increased levels of diglucosyldiacylglycerol (Glc2DAG) and decreased levels of acidic phospholipids cardiolipin and PG, as well as the basic phospholipid lysylphosphatidylglycerol. However, ugtP overexpression did not alter the cell surface charge and the susceptibility to the cationic antimicrobial peptide nisin or the cationic surfactant hexadecyltrimethylammonium bromide. Furthermore, by serial passaging in the presence of daptomycin, we obtained daptomycin-resistant mutants carrying ugtP mutations. These mutants showed increased levels of Glc2DAG and a &gt;4-fold increase in the minimum inhibitory concentration of daptomycin. These results suggest that increased Glc2DAG levels, driven by ugtP overexpression, modify the phospholipid composition and confer daptomycin resistance in B. subtilis without altering the cell surface charge of the bacteria.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">diglucosyldiacylglycerol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">daptomycin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">phospholipid</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-6947</Issn>
      <Volume>88</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Evaluation of quercetin as a potential cytoprotector against acetaldehyde using the cultured hepatocyte model with aldehyde dehydrogenase isozyme deficiency</ArticleTitle>
    <FirstPage LZero="delete">1199</FirstPage>
    <LastPage>1202</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuhang</FirstName>
        <LastName>Xu</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Sawamoto</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ruitong</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Aki</FirstName>
        <LastName>Ishikura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shintaro</FirstName>
        <LastName>Munemasa</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiyuki</FirstName>
        <LastName>Murata</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayano</FirstName>
        <LastName>Satoh</LastName>
        <Affiliation>Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Social and Environmental Medicine, Saga University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimasa</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Graduate School of Environmental and Life Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Protective effect of quercetin against acetaldehyde was evaluated using the cultured hepatocyte models with aldehyde dehydrogenase (ALDH) isozyme deficiency (aldh2-kd and aldh1a1-kd). The quercetin-induced cytoprotection against acetaldehyde in the ALDH1A1-deficient mutant (aldh1a1-kd) was weaker than that in the wild type. Furthermore, quercetin did not enhance the ALDH activity in aldh1a1-kd cells, suggesting that ALDH1A1 is involved in quercetin-induced cytoprotection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">quercetin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">acetaldehyde</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aldehyde dehydrogenase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cytoprotection</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0803-5253</Issn>
      <Volume>114</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Outdoor playing during preschool was associated with a reduced risk of school-age obesity in Japan</ArticleTitle>
    <FirstPage LZero="delete">303</FirstPage>
    <LastPage>309</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Tsuge</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soshi</FirstName>
        <LastName>Takao</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aim: This study investigated the association between outdoor play habits during preschool and school-age obesity.&lt;br&gt;
Methods: We conducted a longitudinal cohort study of all children born in Japan during 2&#8201;weeks in January and July 2001. We defined outdoor play habits at age 2.5&#8201;years (third survey) as exposure, while parent-reported height and weight at age 7&#8201;years (seventh survey) were defined as overweight and obesity status using the WHO reference. Logistic regression models were used to estimate odds ratios (ORs) for associations between preschool outdoor play habits and school-age obesity, adjusting for parental and child factors.&lt;br&gt;
Results: Of 53&#8201;575 children born, 42&#8201;812 had data on outdoor play habits at age 2.5&#8201;years, with 91% (38&#8201;970) having such habits. At age 7&#8201;years, 31&#8201;743/42&#8201;812 (74%) children had height and weight data, with 3249/31&#8201;743 (10%) classified as overweight or obesity (BMI SD score&#8201;&#8805;1.0). Outdoor play habits were negatively associated with obesity (adjusted OR 0.85, 95% confidence interval (CI): 0.74&#8211;0.97).&lt;br&gt;
Conclusion: Outdoor play habits in early preschool years are associated with a reduced risk of school-age obesity. Parents and caregivers may consider encouraging their children to outdoor play habits at an early age to help prevent obesity later in life.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">outdoor play habits</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">physical activity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">preschool</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">school-aged obesity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">socioeconomic status</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society of Clinical Oncology (ASCO)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0732-183X</Issn>
      <Volume>43</Volume>
      <Issue>16</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High-Grade Osteosarcoma (JCOG0905): A Multicenter, Open-Label, Randomized Trial</ArticleTitle>
    <FirstPage LZero="delete">1886</FirstPage>
    <LastPage>1897</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Hiraga</LastName>
        <Affiliation>Musculoskeletal Oncology, NHO Hokkaido Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryunosuke</FirstName>
        <LastName>Machida</LastName>
        <Affiliation>Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Musculoskeletal Oncology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Orthopaedic Surgery, Faculty of Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Yonemoto</LastName>
        <Affiliation>Orthopaedic Surgery, Chiba Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Endo</LastName>
        <Affiliation>Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Department of Rehabilitation Medicine, Nagoya University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihito</FirstName>
        <LastName>Nagano</LastName>
        <Affiliation>Orthopaedic Surgery, Gifu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Ae</LastName>
        <Affiliation>Orthopaedic Surgery, Cancer Institute Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichirou</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Orthopaedic Surgery, Tohoku University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kunihiro</FirstName>
        <LastName>Asanuma</LastName>
        <Affiliation>Orthopaedic Surgery, Mie University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junya</FirstName>
        <LastName>Toguchida</LastName>
        <Affiliation>Department of Tissue Regeneration, Center for Induced Pluripotent Stem Cell Research and Application, Institute for Frontier Medical Sciences, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taisuke</FirstName>
        <LastName>Furuta</LastName>
        <Affiliation>Orthopaedic Surgery, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Robert</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Akisue</LastName>
        <Affiliation>Orthopaedic Surgery, Kobe University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Hiruma</LastName>
        <Affiliation>Bone and Soft Tissue Tumour Surgery, Kanagawa Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Morii</LastName>
        <Affiliation>Orthopaedic Surgery, Kyorin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Orthopaedic Surgery, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Orthopaedic Surgery, Kurume University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanobu</FirstName>
        <LastName>Takeyama</LastName>
        <Affiliation>Orthopaedic Surgery, Yokohama City University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makoto</FirstName>
        <LastName>Emori</LastName>
        <Affiliation>Orthopaedic Surgery, Sapporo Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Tsukushi</LastName>
        <Affiliation>Orthopaedic Surgery, Aichi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Hatano</LastName>
        <Affiliation>Musculoskeletal Oncology, Niigata Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Orthopaedic Surgery, Niigata University Medical &amp; Dental Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuo</FirstName>
        <LastName>Isu</LastName>
        <Affiliation>Orthopaedic Surgery, Higashi Sapporo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Advanced Medical Sciences, Oita University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhiko</FirstName>
        <LastName>Fukuda</LastName>
        <Affiliation>Japan Clinical Oncology Group Data Center/Operations Office, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukihide</FirstName>
        <LastName>Iwamoto</LastName>
        <Affiliation>Orthopaedic Surgery, Kyushu Rosai Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Orthopaedic Surgery, Faculty of Medicine, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Our previous NECO phase II studies on high-grade osteosarcoma suggested that administering ifosfamide (IF; 16 g/m2 [4g/m2 once on day 1, then 2g/m2 once on days 2-7] × six) to patients showing a poor response (PrRsp) to preoperative chemotherapy with methotrexate, doxorubicin, and cisplatin (MAP) improves their prognoses. In this Japan Clinical Oncology Group (JCOG) study, JCOG0905, we aimed to investigate the efficacy and safety of IF in patients with PrRsp.&lt;br&gt;
Methods JCOG0905 is a multicenter, open-label, multi-institutional, randomized trial. Eligible patients (50 years and younger) had resectable, high-grade osteosarcoma (stage II or III, Union for International Cancer Control TNM) of the extremities, limb girdles, and thoracic wall. After two MAP cycles and tumor resection, patients with PrRsp were randomly assigned to either the MAP or MAP plus 15 g/m2 (3g/m2 once daily on days 1-5) × six IF (MAP + IF [MAPIF]) group. The primary end point was disease-free survival (DFS); secondary end points were overall survival (OS) and safety. The planned sample size was 100 patients with a one-sided α of .1 and a power of 0.7, assuming a 3-year DFS of 50% and 65% for MAP and MAPIF, respectively. This trial is registered with the Japan Registry of Clinical Trials (jRCT; jRCTs031180126).&lt;br&gt;
Results Of the 287 patients registered between February 2010 and August 2020, 51 and 52 patients with PrRsp were assigned to the MAP and MAPIF groups, respectively. As of March 2022, DFS did not differ between groups (hazard ratio [HR], 1.05 [95% CI, 0.55 to 1.98]) and OS was numerically inferior in the MAPIF group (HR, 1.48 [95% CI, 0.68 to 3.22]). Nine and zero patients in the MAPIF and MAP groups discontinued treatment because of adverse events, respectively.&lt;br&gt;
Conclusion Evidence from JCOG0905 does not support the addition of IF for patients with PrRsp.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-0531</Issn>
      <Volume>226</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Costly subjective learning</ArticleTitle>
    <FirstPage LZero="delete">105997</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Youichiro</FirstName>
        <LastName>Higashi</LastName>
        <Affiliation>Faculty of Economics, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Hyogo</LastName>
        <Affiliation>Faculty of Economics, Ryukoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Takeoka</LastName>
        <Affiliation>Department of Economics, Hitotsubashi University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We examine the behavioral foundation of rational inattention within a menu-choice framework. Unlike previous studies, our approach enables the unique identification of nonadditive information costs. The nonadditivity of information costs makes the effective cost inherently dependent on benefits of information. In contrast to additive cost models, this feature may lead to a violation of the preference for early resolution of menu uncertainty. Early resolution is typically preferable as it allows the agent to fine-tune information for relevant menus. However, if the effective cost function is convex in benefits of information, late resolution may reduce the effective information costs. The violation occurs when this cost-reduction effect outweighs the benefits of early resolution.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Information acquisition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Rational inattention</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Preference for the timing of the resolution of uncertainty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Preference over menus</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0031-9201</Issn>
      <Volume>361</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effect of chemistry on the compressibility and high-pressure structural evolution of the CaFe2O4-type aluminous silicate phase</ArticleTitle>
    <FirstPage LZero="delete">107331</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Giacomo</FirstName>
        <LastName>Criniti</LastName>
        <Affiliation>Bayerisches Geoinstitut, University of Bayreuth</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tiziana</FirstName>
        <LastName>Boffa Ballaran</LastName>
        <Affiliation>Bayerisches Geoinstitut, University of Bayreuth</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Alexander</FirstName>
        <LastName>Kurnosov</LastName>
        <Affiliation>Bayerisches Geoinstitut, University of Bayreuth</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Elena-Marie</FirstName>
        <LastName>Rogmann</LastName>
        <Affiliation>Bayerisches Geoinstitut, University of Bayreuth</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Konstantin</FirstName>
        <LastName>Glazyrin</LastName>
        <Affiliation>Deutsches Elektronen-Synchrotron DESY</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Timofey</FirstName>
        <LastName>Fedotenko</LastName>
        <Affiliation>Deutsches Elektronen-Synchrotron DESY</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daniel J.</FirstName>
        <LastName>Frost</LastName>
        <Affiliation>Bayerisches Geoinstitut, University of Bayreuth</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Approximately 22&#8211;26 vol% of a basaltic phase assemblage at lower mantle conditions is comprised of a (Na,Mg,Fe2+)(Al,Si,Fe3+)2O4 phase with CaFe2O4-type (CF-type) structure. Previous experimental studies attempted to determine the equation of state of the CF-type phase but reported contrasting compressibility values, even for samples with the same composition. Therefore, the elastic properties of the CF-type phase remain, to date, largely unconstrained. Here, we conducted single-crystal X-ray diffraction (SCXRD) measurements in the diamond anvil cell (DAC) at high pressure and room temperature on three samples of CF-type phase with compositions Na0.90(1)Al1.03(2)Si1.00(2)O4 (NaCF), Na0.66(4)Mg0.28(4)Al1.22(3)Si0.78(3)O4 (MgCF) and Na0.62(2)Mg0.19(1)Fe2+0.17(1)Fe3+0.080(4)Al1.20(3)Si0.70(1)O4 (FeCF). A multi-sample loading approach was employed for most DAC runs, where two samples were loaded in the same sample chamber to reduce possible systematic deviations between datasets, thus enhancing internal consistency and corroborating data reproducibility. Experiments on the NaCF and MgCF samples were conducted up to &#8764;50 GPa, while the FeCF sample was compressed to &#8764;72 GPa to better characterize the effect of the spin crossover of octahedrally coordinated Fe3+. We found the isothermal bulk modulus (KT0) to increase with decreasing NaAlSiO4 content, accompanied by only a slight decrease in its pressure derivative (K'T0). Analysis of the crystal structures of the three samples at high pressure allowed compositional trends to be determined also for the interatomic bonds and polyhedral compressibility, as well as the distortion indices. These suggest an overall stiffening of the A site with increasing Mg2+ and Fe2+ content, as well of the two B sites with increasing Al3+ and Fe3+ content. Enhanced compressibility of the unit cell and octahedral B sites was observed between &#8764;26&#8211;42 GPa in the FeCF sample, suggesting a pressure-induced spin crossover of Fe3+, in agreement with some previous observations. Finally, trends in the elastic properties from experimental studies conducted along the NaAlSiO4-MgAl2O4 join are discussed and used as a proxy to evaluate the reliability of end-member properties for the CF-type phase employed in most recent mineral physical and thermodynamic databases. Our analysis suggests current mineral physical models might underestimate densities and overestimate bulk sound velocities of NaAlSiO4-rich CF-type phases with basaltic composition.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">CaFe2O4-type phase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Lower mantle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Equations of state</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Structural refinements</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Crystal chemistry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fe3+ spin-crossover</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Geological Society of America</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0091-7613</Issn>
      <Volume>53</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Long-term and multi-stage ice accumulation in the martian mid-latitudes during the Amazonian</ArticleTitle>
    <FirstPage LZero="delete">945</FirstPage>
    <LastPage>950</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Trishit</FirstName>
        <LastName>Ruj</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hanaya</FirstName>
        <LastName>Okuda</LastName>
        <Affiliation>Kochi Institute for Core Sample Research (X-star), JAMSTEC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Goro</FirstName>
        <LastName>Komatsu</LastName>
        <Affiliation>International Research School of Planetary Sciences, Universit&#224; d’Annunzio</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Global Environment and Disaster Prevention, Faculty of Science and Technology, Kochi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">James W.</FirstName>
        <LastName>Head</LastName>
        <Affiliation>Department of Earth, Environmental and Planetary Sciences, Brown University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Usui</LastName>
        <Affiliation>Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Mihira</LastName>
        <Affiliation>Institute of Space and Astronautical Science, Japan Aerospace Exploration Agency</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makito</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Systems Innovation, School of Engineering, University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Subsurface ice in the mid-latitudes of Mars represents one of the largest present-day water ice reservoirs. While atmospheric models predict Late Amazonian (during the past hundreds of millions of years) obliquity-driven ice accumulation, its long-term variations, and the factors influencing accumulation remain unclear. Using geomorphological evidence and numerical modeling, we reveal a southwestern depositional trend within northern mid-latitudinal crater walls and floors. Detailed crater-fill deposit analyses indicate multiple glaciation stages, including an earlier, high-intensity stage followed by a later, lower-intensity stage, both exhibiting this southwestern trend (ca. 640&#8211;98 Ma). We conclude that persistent multiple-stage Amazonian glaciations were governed by atmospheric water availability and obliquity-driven climate cycles.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Department of Mathematics, Faculty of Science, Okayama University</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1566</Issn>
      <Volume>68</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>On the stratification of combinatorial spectra</ArticleTitle>
    <FirstPage LZero="delete">183</FirstPage>
    <LastPage>204</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Horiuchi</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>In this note, we investigate a mixture of combinatorial spectra and stratified simplicial sets, which would be thought of as a model of the spectrum objects of (∞,∞)-categories.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Department of Mathematics, Faculty of Science, Okayama University</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0030-1566</Issn>
      <Volume>68</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Natural homotopy of multipointed d-spaces</ArticleTitle>
    <FirstPage LZero="delete">13</FirstPage>
    <LastPage>62</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Philippe</FirstName>
        <LastName>Gaucher</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, CNRS, IRIF</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We identify Grandis’ directed spaces as a full reflective subcategory of the category of multipointed d-spaces. When the multipointed d-space realizes a precubical set, its reflection coincides with the standard realization of the precubical set as a directed space. The reflection enables us to extend the construction of the natural system of topological spaces in Baues-Wirsching’s sense from directed spaces to multipointed d-spaces. In the case of a cellular multipointed d-space, there is a discrete version of this natural system which is proved to be bisimilar up to homotopy. We also prove that these constructions are invariant up to homotopy under globular subdivision. These results are the globular analogue of Dubut’s results. Finally, we point the apparent incompatibility between the notion of bisimilar natural systems and the q-model structure of multipointed d-spaces and we give some suggestions for future works.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">multipointed d-space</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">globular subdivision</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">directed path</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">natural system</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bisimulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">open map</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Chemical Society (ACS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2637-6105</Issn>
      <Volume>8</Volume>
      <Issue>11</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Solution Structure and Counterion Condensation of Carboxymethyl Cellulose in Organic Solvents</ArticleTitle>
    <FirstPage LZero="delete">8183</FirstPage>
    <LastPage>8197</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Anish</FirstName>
        <LastName>Gulati</LastName>
        <Affiliation>Institute of Physical Chemistry, RWTH Aachen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lingzi</FirstName>
        <LastName>Meng</LastName>
        <Affiliation>Materials Science and Engineering Department, The Pennsylvania State University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Can</FirstName>
        <LastName>Hou</LastName>
        <Affiliation>Institute of Physical Chemistry, RWTH Aachen University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaichi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Applied Chemistry, Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Carlos G.</FirstName>
        <LastName>Lopez</LastName>
        <Affiliation>Materials Science and Engineering Department, The Pennsylvania State University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We report scattering (SANS and SAXS) and electrical conductivity data for aqueous and organic solutions of carboxymethyl cellulose with tetrabutylammonium counterions. For SANS in deuterated solvents, the contrast is heavily dominated by the hydrogen-rich counterions, while for SAXS the polymer backbone has a more significant contribution to the scattering signal. The correlation length calculated from the SAXS measurements follows a scaling law of ξ ∝ c&#8211;1/2, while that measured by SANS displays a weaker exponent at higher concentrations for solvents of high dielectric constants. These results indicate a decoupling in the characteristic length scales of fluctuations of the polymer backbone and counterions at high polyelectrolyte concentrations. The stretching parameter calculated from the correlation length indicates a highly stretched local conformation for TBACMC in water and several high dielectric constant solvents, consistent with the semiflexible nature of the cellulose backbone. In solvents of lower dielectric permittivity, the chains display a higher degree of local coiling. Combining electrical conductivity and scattering data, we find that the fraction of monomers bearing a dissociated charge is nearly independent of concentration and approximately proportional to the reciprocal of the Bjerrum length of the solvent, as expected by the Oosawa-Manning model.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">polyelectrolyte</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">scattering</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">conductivity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cellulose</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">condensation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2056-3426</Issn>
      <Volume>12</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Optimizing β-TCP with E-rhBMP-2-infused fibrin for vertical bone regeneration in a mouse calvarium model</ArticleTitle>
    <FirstPage LZero="delete">rbae144</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kun</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuaki</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xindi</FirstName>
        <LastName>Mu</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shichao</FirstName>
        <LastName>Xie</LastName>
        <Affiliation>Department of Biomaterials, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Yonezawa</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Division of Dental Biomaterials, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Biomaterials, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuo</FirstName>
        <LastName>Kuboki</LastName>
        <Affiliation>Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshitaka</FirstName>
        <LastName>Oohashi</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Effective reconstruction of large bone defects, particularly in thickness, remains one of the major challenges in orthopedic and dental fields. We previously produced an Escherichia coli-based industrial-scale GMP-grade recombinant human bone morphogenetic protein-2 (E-rhBMP-2) and showed that the combination of E-rhBMP-2 with beta-tricalcium phosphate (β-TCP/E-rhBMP-2) can effectively promote bone reconstruction. However, the limited mechanical strength and poor morphology retention of β-TCP granules are key points that need optimization to obtain more effective grafts and further expand its clinical applications. Therefore, we combined β-TCP/E-rhBMP-2 with fibrin gel to enhance its mechanical properties and usability for vertical bone regeneration. We investigated the mechanical properties and vertical bone regeneration effects of the materials applied, with or without fibrin containing E-rhBMP-2, in a calvarial defect model in mice. Compression tests were conducted to assess the initial stability of the materials. Scanning electron microscopy and Fourier transform infrared spectroscopy were conducted to characterize the presence of fibrin on the scaffold. After 4 and 12&#8201;weeks of implantation, micro-computed tomography and histological and immunofluorescent analyses were performed to assess the morphology and volume of the newly formed bone. The fibrin-containing groups had significantly higher initial mechanical strength and higher ability to maintain their morphology in vivo compared to the counterparts without fibrin. However, fibrin gel alone suppressed the bone formation ability of β-TCP/E-rhBMP-2 whereas the presence of high doses of E-rhBMP-2 in fibrin gel resulted in material resorption and enhanced new bone formation. In conclusion, fibrin gel significantly improved the mechanical strength and surgical manageability of the β-TCP/E-rhBMP-2 scaffold, and the addition of E-rhBMP-2 to the fibrin gel further enhanced the vertical bone regeneration and initial structural integrity of the scaffold.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">BMP-2</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">fibrin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">vertical bone regeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">biocompatible materials</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2673-8937</Issn>
      <Volume>5</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The Early Response After Radiation Therapy on Three-Dimensional Oral Cancer Model Using Patient-Derived Cancer-Associated Fibroblasts</ArticleTitle>
    <FirstPage LZero="delete">12</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Izumi</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyo</FirstName>
        <LastName>Igawa</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsuko</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Particle Radiation Oncology Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Particle Radiation Oncology Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Peng</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Michiue</LastName>
        <Affiliation>Neutron Therapy Research Center, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Izumi</LastName>
        <Affiliation>Division of Biomimetics, Faculty of Dentistry &amp; Graduate School of Medical and Dental Sciences, Niigata University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Cancer-associated fibroblasts (CAFs), which are an important component of the tumor microenvironment, have been reported to have an adverse effect on conventional radiotherapy. This study aims to elucidate the effects of CAFs in boron neutron capture therapy (BNCT) using a three-dimensional (3D) oral cancer model. Methods: Three-dimensional cancer models were fabricated using patient-derived CAFs or patient-derived normal oral fibroblasts (NOFs) and a human oral squamous cell carcinoma cell line. Each 3D cancer model was performed with either a conventional X-ray treatment or BNCT and additionally analyzed histomorphologically. Results: The 3D oral cancer-CAFs model demonstrated a greater depth of cancer cell invasion than the 3D oral cancer-NOFs model. Radiation therapy for the 3D oral cancer models indicated a trend for decreasing cancer cell invasion and cell number with dose dependence in both X-ray and BNCT. In comparison with X-rays, BNCT showed a consistent increase in the number of NOFs and a significant reduction in the number of CAFs. Conclusions: BNCT for the 3D oral cancer model was shown to be effective against cancer cells and CAFs but not against NOFs, indicating its usefulness as a minimally invasive treatment for advanced cancer. Furthermore, it is indicated that the 3D oral cancer-CAFs model is a valuable tool to evaluate cancer treatment and research, particularly in high-grade malignant tumors with invasion.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">3D model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">patient-derived cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer-associated fibroblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radiation treatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">boron neutron capture therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">malignant tumors</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1718-7729</Issn>
      <Volume>32</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Global Incidence Trend of Early-Onset Obesity-Related and Non-Obesity-Related Cancers</ArticleTitle>
    <FirstPage LZero="delete">324</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Miyu</FirstName>
        <LastName>Terashima</LastName>
        <Affiliation>Okayama University Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kota</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Okayama University Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoko</FirstName>
        <LastName>Ugai</LastName>
        <Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02215, USA</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hwa-Young</FirstName>
        <LastName>Lee</LastName>
        <Affiliation>Graduate School of Public Health and Healthcare Management, The Catholic University of Korea</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Tsukumo</LastName>
        <Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Etsuji</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Epidemiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroki</FirstName>
        <LastName>Mizuno</LastName>
        <Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minkyo</FirstName>
        <LastName>Song</LastName>
        <Affiliation>Laboratory of Epidemiology and Population Sciences, National Institute on Aging, National Institutes of Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoko</FirstName>
        <LastName>Sasamoto</LastName>
        <Affiliation>Public Health Sciences Division, Fred Hutchinson Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ichiro</FirstName>
        <LastName>Kawachi</LastName>
        <Affiliation>Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomotaka</FirstName>
        <LastName>Ugai</LastName>
        <Affiliation>Department of Epidemiology, Harvard T.H. Chan School of Public Health</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The global rise in obesity prevalence and the incidence of early-onset cancer (diagnosed between 20 and 49 years of age) is a serious public health concern. We, therefore, evaluated the recent global trends in the incidence of early-onset obesity-related cancers and compared them to those of non-obesity-related cancers. We obtained age-standardized incidence rates of early-onset cancers diagnosed between 2000 and 2012 in 44 countries from the Cancer Incidence in Five Continents database. Using joinpoint regression models, we calculated the average annual percentage changes (AAPCs) and their corresponding 95% confidence intervals (95% CIs) for combined and individual categories of obesity-related cancers (11 and 9 cancer types in females and males, respectively) and non-obesity-related cancers (12 cancer types in both females and males). Differences in the AAPC were assessed by comparing 95% CIs, where nonoverlapping 95% CIs were considered statistically significantly different. We observed statistically significant positive AAPCs for early-onset obesity-related cancers in all available countries combined among females (global AAPC, 4.3%; 95% CI, 4.1&#8211;4.6%) and males (global AAPC, 1.4%; 95% CI, 1.2&#8211;1.7%). When analyzed by countries, we observed statistically significant positive AAPCs in 26 countries among females and 11 countries among males. AAPCs for early-onset obesity-related cancers were statistically significantly higher than those of non-obesity-related cancers in several regions, especially North America and Oceania. In conclusion, this study indicates that the incidence of early-onset obesity-related cancers exhibited a more pronounced increasing trend than non-obesity-related cancers among both sexes in many countries and regions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">neoplasms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">etiology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">risk factors</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">global health</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">young adults</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-9258</Issn>
      <Volume>301</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Taste receptor type 1 member 3 in osteoclasts regulates osteoclastogenesis via detection of glucose</ArticleTitle>
    <FirstPage LZero="delete">108273</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Anna</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Division of Molecular Signaling and Biochemistry, Kyushu Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuma</FirstName>
        <LastName>Matsubara</LastName>
        <Affiliation>Division of Molecular Signaling and Biochemistry, Kyushu Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Kodama</LastName>
        <Affiliation>Division of Molecular Signaling and Biochemistry, Kyushu Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshimitsu</FirstName>
        <LastName>Kakuta</LastName>
        <Affiliation>Laboratory of Structural Biology, Graduate School of Systems Life Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuma</FirstName>
        <LastName>Yasuda</LastName>
        <Affiliation>Division of Molecular Signaling and Biochemistry, Kyushu Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Oral Physiology, Graduate School of Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Kaminuma</LastName>
        <Affiliation>Department of Disease Model, Research Institute of Radiation Biology and Medicine, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuhei</FirstName>
        <LastName>Hosomi</LastName>
        <Affiliation>Department of Gastroenterology, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroji</FirstName>
        <LastName>Shinkawa</LastName>
        <Affiliation>Department of Hepatobiliary-Pancreatic Surgery, Graduate School of Medicine, Osaka Metropolitan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Quan</FirstName>
        <LastName>Yuan</LastName>
        <Affiliation>State Key Laboratory of Oral Diseases &amp; National Center for Stomatology &amp; National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Kawamoto</LastName>
        <Affiliation>Division of Orofacial Functions and Orthodontics, Kyushu Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Kokabu</LastName>
        <Affiliation>Division of Molecular Signaling and Biochemistry, Kyushu Dental University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The taste system extends beyond the oral cavity, with various taste receptors found in extraoral organs. Mice deficient in the taste receptor type 1 (TAS1R) family member, TAS1R3, and fed a high-fat, high-sugar diet showed high bone mass without altering food consumption. However, the underlying mechanisms, including the cell types responsible for TAS1R3 expression, remain unclear. Here, we demonstrate the expression and function of TAS1R3 in osteoclasts, which are responsible for bone resorption. The expression of Tas1r3, but not Tas1r1 or Tas1r2, is evoked during osteoclast differentiation. Osteoclastogenesis-related genes were downregulated in TAS1R3-deficient mice, whereas the opposite phenotypes were elicited by TAS1R3 overexpression. Contrary to the common heterodimerization with TAS1R1 or TAS1R2, TAS1R3 formed a homodimer that functioned to detect glucose, enhance p38 phosphorylation, and induce osteoclastogenesis. These results provide novel insights into the role of TAS1R3 in bone metabolism and suggest that TAS1R3 may be a viable target for therapeutic agents in bone metabolic diseases.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">glucose</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osteoclasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p38</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TAS1R3</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">taste receptor</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1931-5244</Issn>
      <Volume>295</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A novel spontaneous rat model of chronic kidney disease with mitochondrial dysfunction driven by thioredoxin insufficiency</ArticleTitle>
    <FirstPage LZero="delete">51</FirstPage>
    <LastPage>64</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Iori K.</FirstName>
        <LastName>Ohmori</LastName>
        <Affiliation>Section of Developmental Physiology and Pathology, Faculty of Education, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mamoru</FirstName>
        <LastName>Ouchida</LastName>
        <Affiliation>Department of Molecular Oncology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Hada</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito A.</FirstName>
        <LastName>Uchida</LastName>
        <Affiliation>Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinya</FirstName>
        <LastName>Toyokuni</LastName>
        <Affiliation>Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoji</FirstName>
        <LastName>Mashimo</LastName>
        <Affiliation>Division of Animal Genetics, Laboratory Animal Research Center, Institute of Medical Science, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Chronic kidney disease (CKD) is a global health burden with high prevalence and poor prognosis. Although oxidative stress and mitochondrial dysfunction have been implicated in its pathogenesis, in vivo causal evidence remains limited. Thioredoxin (Trx), encoded by Txn1, is a redox-active protein that plays a central role in controlling oxidative stress and maintaining intracellular redox homeostasis.&lt;br&gt;
Methods: To address this gap, we investigated the lifelong phenotypes of Txn1-F54L mutant rats harboring approximately one-third of the normal Trx activity. These rats were generated via N-ethyl-N-nitrosourea mutagenesis and validated by clustered regularly interspaced palindromic repeat (CRISPR)/CRISPR-associated protein 9 genome editing. Comprehensive analyses included biochemical testing, histopathology, immunohistochemistry, transmission electron microscopy, RNA-sequencing, western blotting, and cytokine profiling.&lt;br&gt;
Results: Txn1-F54L mutant rats spontaneously developed progressive CKD, with median survival times of 110&#8211;119 days for homozygotes and 303&#8211;346 days for heterozygotes. Their clinical features―elevated blood urea nitrogen, hypoalbuminemia, hypercholesterolemia, hypertension, and arterial medial sclerosis―closely resembled those of human CKD. Histopathological evaluation revealed extensive tubular injury, interstitial fibrosis, and glomerulosclerosis. Transcriptomic profiling identified 3,418 differentially expressed genes significantly enriched in immune activation and fibrosis pathways. Mitochondrial dysfunction was prominent in proximal tubules, accompanied by oxidative stress accumulation and concurrent activation of regulated cell death pathways (apoptosis, necroptosis, and pyroptosis). Elevated serum levels of interleukin-1β, interleukin-6, and interferon-γ indicated systemic inflammation.&lt;br&gt;
Conclusions: Our findings demonstrate that lifelong Trx deficiency induces oxidative stress&#8211;mediated mitochondrial dysfunction and regulated cell death, leading to inflammation and progressive CKD. This study establishes the Txn1 mutant rat as a valuable spontaneous CKD model, providing translational insights and a platform for developing therapeutic strategies targeting oxidative stress&#8211;induced pathways.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Chronic kidney disease</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mitochondria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thioredoxin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Trx</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Txn1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Regulated cell death</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1999-5903</Issn>
      <Volume>18</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Batch-Based VNF Deployment Mechanism for Privacy-Preserving Multi-Domain SFC Deployment Using Deep Reinforcement Learning</ArticleTitle>
    <FirstPage LZero="delete">312</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Arif Indra</FirstName>
        <LastName>Irawan</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yukinobu</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Future 6G networks require higher performance and wider service coverage. Multi-domain Service Function Chain (SFC) deployment enables service provisioning across multiple network domains to meet these demands. However, when collaboration occurs among different network operators, privacy-preserving mechanisms are required to protect sensitive information such as internal topology and resource availability. Existing SIRM-based mechanisms, such as the Privacy-Preserving Deployment Mechanism (PPDM), address this challenge but suffer from structural limitations: PPDM performs whole-chain feasibility evaluation with extensive virtual occupation. This paper proposes a &#8492;-Batch Sequential Deployment mechanism for privacy-preserving multi-domain SFC deployment. Instead of evaluating whole-chain feasibility at once, the proposed &#8492;-Batch mechanism partitions each incoming SFC into fixed-size VNF batches and constructs a batch-level SIRM. This design confines virtual occupation to the current batch and reduces both its magnitude and duration while remaining fully compatible with the SIRM privacy model and the hierarchical multi-domain control architecture. A Deep Q-Network (DQN) is employed to learn substrate node selection policies based solely on SIRM-based state information, without exposing domain-internal topology or resource details. Simulation results on a three-domain AARNET substrate topology demonstrate that the proposed mechanism consistently improves deployment robustness under varying traffic intensities and SFC lengths, including short (3&#8211;6 VNFs), medium (6&#8211;9 VNFs), and long (9&#8211;12 VNFs) service chains. Compared with PPDM, the proposed &#8492;-Batch mechanism achieves higher acceptance ratios under moderate-to-heavy traffic while reducing end-to-end delay and improving average substrate resource utilization. Node selection analysis further shows that smaller batch sizes preserve feasibility through compact node reuse, whereas larger batch sizes encourage broader substrate exploration. Overall, the proposed &#8492;-Batch mechanism enhances feasibility preservation and deployment robustness in privacy-preserving multi-domain SFC orchestration.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Service Function Chain (SFC)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Virtual Network Embedding (VNE)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">privacy preservation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">SIRM</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Virtual Network Function (VNF)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Deep Q-network (DQN)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>HIP COMPASS&#174;: A Mechanical Intraoperative Navigation Guide Associated with Improved Revision-Free Implant Survivorship after Ceramic-on-Ceramic Total Hip Arthroplasty at Minimum 10-Year Follow-up</ArticleTitle>
    <FirstPage LZero="delete">195</FirstPage>
    <LastPage>202</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Tei</LastName>
        <Affiliation>Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norio</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Division of Comprehensive Musculoskeletal Medicine, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keishi</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Hirano</LastName>
        <Affiliation>Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoji</FirstName>
        <LastName>Horigome</LastName>
        <Affiliation>Division of Comprehensive Musculoskeletal Medicine, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Suda</LastName>
        <Affiliation>Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Kawashima</LastName>
        <Affiliation>Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">/10.18926/AMO/70855</ArticleId>
    </ArticleIdList>
    <Abstract>HIP COMPASS&#174; has demonstrated improved accuracy in intraoperative support for the acetabular component insertion angle. We assessed long-term revision-free implant survivorship following total hip arthroplasty (THA) using HIP COMPASS, with &#8805;10 years of follow-up. We retrospectively analyzed 210 hips of 186 patients who underwent cementless THA with ceramic-on-ceramic bearing couples, with or without HIP COMPASS. The mean follow-up duration was 10.8 years in the HIp COMPASS group and 12.7 years in the control group. Overall, 86.0% and 78.2% of cups were placed within Lewinnek’s safe zone with and without HIP COMPASS, respectively. Variability in radiographic inclination and anteversion was greater in the control group than in the HIP COMPASS group. Dislocation rates were 3.2% in the control group and 1.2% in the HIP COMPASS group, with no significant difference between groups. The control group had a significantly higher revision rate than the HIP COMPASS group (7.3% vs. 1.2%). Use of HIP COMPASS was associated with improved long-term revision-free implant survivorship over &#8805; 10 years and more consistent acetabular component positioning at an appropriate insertion angle, which may contribute to stable initial fixation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">HIP COMPASS&#174;</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">survivorship</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">total hip arthroplasty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ceramic-on-ceramic</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Oral Eicosapentaenoic Acid and Paclitaxel-Associated Peripheral Neuropathy: A Retrospective Study at Okayama University Hospital</ArticleTitle>
    <FirstPage LZero="delete">179</FirstPage>
    <LastPage>184</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">/10.18926/AMO/70853</ArticleId>
    </ArticleIdList>
    <Abstract>This retrospective study investigated whether eicosapentaenoic acid (EPA) reduces paclitaxel-associated chemotherapy-induced peripheral neuropathy (CIPN) and acute neuropathic pain in dyslipidemic cancer patients. The medical records of cancer patients treated with paclitaxel or nab-paclitaxel at Okayama University Hospital between January 2018 and December 2022 were reviewed. Patients receiving concomitant therapy for dyslipidemia were categorized as EPA users or non-EPA users. Numbness and pain severity were extracted from medical records. The primary endpoint was the change from baseline in Common Terminology Criteria for Adverse Events (CTCAE) grade for peripheral neuropathy and pain; groups were analyzed using the Mann&#8211;Whitney U test. Of 184 eligible patients, 18 received EPA. Bleeding events were more frequent in the EPA group; however, changes in numbness and pain did not differ significantly between groups at any time point. Overall, EPA did not show a preventive effect on paclitaxel-associated CIPN or acute neuropathic pain. Future studies should evaluate EPA in combination with other neuroprotective agents to better define its potential role in CIPN prevention.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">eicosapentaenoic acid</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer patients</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chemotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">peripheral neuropathy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cancer pain</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Self-Reported Adolescent Menstrual Symptoms and Delayed Gynecologic Consultation among Japanese Women with Endometriosis</ArticleTitle>
    <FirstPage LZero="delete">159</FirstPage>
    <LastPage>168</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomoko</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mikiya</FirstName>
        <LastName>Nakatsuka</LastName>
        <Affiliation>Faculty of Health Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">/10.18926/AMO/70851</ArticleId>
    </ArticleIdList>
    <Abstract>Endometriosis symptoms often first appear during adolescence, yet delays in seeking gynecologic consultation remain a persistent challenge worldwide. Despite growing international evidence, the specific patterns of symptom recognition and consultation delay among Japanese women ― particularly in relation to self-monitoring behaviors and cultural barriers ― remain poorly understood. This study aimed to provide foundational data to guide menstrual education and preconception care strategies by conducting a cross-sectional online survey with retrospective recall among women with endometriosis to assess menstrual characteristics and symptom patterns from adolescence to initial care seeking. The survey was conducted in Japan in January 2024 and enrolled 166 women with endometriosis and 200 controls. Participants reported current and adolescent menstrual characteristics, symptom recognition, analgesic and low-dose estrogen&#8211;progestin use, school/work impact, and age at first gynecologic consultation for menstrual problems. Women with endometriosis reported heavier bleeding, stronger pain, and greater school/work absence than controls, both currently and retrospectively. The median age at first recognition of heavy bleeding or school/work absence was 16 years, whereas consultation occurred at approximately 21-23 years, indicating a consultation delay of 5-6 years. Notably, while self-monitoring of symptoms was more frequent among women with endometriosis, it only modestly shortened consultation delays. This study provides evidence from Japan that consultation delay persists despite active self-monitoring of symptoms, highlighting the influence of educational and cultural barriers on health-seeking behavior. These findings underscore the importance of integrating menstrual education with clinical guidance to promote timely gynecologic consultation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">endometriosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adolescence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">menstrual disorders</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">consultation delay</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">health-seeking behavior</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Physiological Society</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1040-0605</Issn>
      <Volume>330</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The role of S100A8/A9 in the pathogenesis of acute exacerbations of pulmonary fibrosis</ArticleTitle>
    <FirstPage LZero="delete">L593</FirstPage>
    <LastPage>L609</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naoki</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisao</FirstName>
        <LastName>Higo</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Senoo</LastName>
        <Affiliation>Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Taniguchi</LastName>
        <Affiliation>Department of Respiratory Medicine, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Ozeki</LastName>
        <Affiliation>Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryota</FirstName>
        <LastName>Sunami</LastName>
        <Affiliation>Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Inukai</LastName>
        <Affiliation>Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shusei</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Medical Laboratory Science, Okayama University Faculty of Health Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Itano</LastName>
        <Affiliation>Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayaka</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Respiratory Medicine, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nahoko</FirstName>
        <LastName>Tomonobu</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Rie</FirstName>
        <LastName>Kinoshita</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masakiyo</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology, Allergy and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Miyahara</LastName>
        <Affiliation>Department of Allergy and Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Acute exacerbation of idiopathic pulmonary fibrosis is a life-threatening condition characterized by neutrophilic inflammation. S100A8/A9, an alarmin released by activated neutrophils and monocytes/macrophages, plays a pivotal role in regulating inflammatory responses. However, its specific involvement in acute exacerbations of pulmonary fibrosis remains unclear. This study evaluated the role of S100A8/A9 in the pathogenesis of acute exacerbations of pulmonary fibrosis. S100A8/A9 levels were measured in bronchoalveolar lavage fluid and serum from patients with idiopathic interstitial pneumonia, with and without acute exacerbations. To model acute exacerbations of pulmonary fibrosis, mice were intratracheally administered bleomycin followed by lipopolysaccharide. Subsequently, inflammatory cell infiltration, cytokine levels, morphological changes, and fibrosis marker levels in lung tissue and airways were analyzed. S100A8/A9 levels were significantly higher in the bronchoalveolar lavage fluid and serum of patients with idiopathic interstitial pneumonia experiencing acute exacerbations relative to those without; these levels were correlated with patient prognosis. In an experimental mouse model, intratracheal administration of bleomycin followed by lipopolysaccharide resulted in a significant increase in airway S100A8/A9 levels compared with bleomycin alone and control mice. Anti-S100A8/A9 neutralizing antibody Ab45 mitigated airway inflammation and lung fibrosis in mice with acute exacerbations of pulmonary fibrosis, reducing S100A8/A9 levels and neutrophil extracellular traps. In vitro, recombinant S100A8/A9 or lipopolysaccharide and neutrophils activated and differentiated fibroblasts; these effects were inhibited by anti-S100A8/A9 neutralizing antibody Ab45 and the humanized form of Ab45 (HuAb45). These findings highlight S100A8/A9 as a potential prognostic biomarker and therapeutic target for acute exacerbations of pulmonary fibrosis.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anti-S100A8/A9 neutralizing antibody</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">calprotectin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">idiopathic pulmonary fibrosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lipopolysaccharide</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">neutrophil extracellular traps</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1574-7891</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in                    &lt;i&gt;Egfr&lt;/i&gt;                    ‐mutated lung&#160;cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiro</FirstName>
        <LastName>Kuribayashi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Johannes</FirstName>
        <LastName>Br&#228;gelmann</LastName>
        <Affiliation>Department of Translational Genomics Faculty of Medicine and University Hospital Cologne, University of Cologne  Germany</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachi</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Taoka</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunta</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kammei</FirstName>
        <LastName>Rai</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Division of Experimental Chemotherapy, Cancer Chemotherapy Centre, Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Tabata</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Martin L.</FirstName>
        <LastName>Sos</LastName>
        <Affiliation>Department of Translational Genomics Faculty of Medicine and University Hospital Cologne, University of Cologne  Germany</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Kiura</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancers (NSCLCs) lack effective immunotherapy due to a noninflamed tumor microenvironment (TME). We previously reported that EGFR tyrosine-kinase-inhibitor (TKI) induced CD8+ T-cell immunity, which was insufficient for tumor eradication. We evaluated the potential of combining EGFR-TKI with stimulator of interferon genes (STING) agonists in activating a systemic antitumor response. Using a syngeneic mouse model of genetically engineered Egfr-mutant NSCLC, we evaluated the antitumor effects of STING agonist ADU-S100, alone and combined with osimertinib. Immunohistochemistry and flow cytometry were used to assess the TME. Osimertinib alone enhanced CD8+ T-cell infiltration but not Natural Killer (NK) cell infiltration. ADU-S100 injection alone modestly suppressed tumor growth with increasing CD8+/NK cell infiltration in the TME, but lacked an abscopal effect. Combining ADU-S100 with osimertinib significantly enhanced the antitumor effects and CD8+/NK cell infiltration. Depletion of either CD8+ or NK cells reduced the combination effect. Crucially, the combination induced an abscopal effect accompanied by PD-1+/CD8+ cell infiltration. Combining osimertinib with a STING agonist augmented innate and adaptive immunity, inducing systemic antitumor responses in EGFR-mutant NSCLC.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">abscopal effect</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CD8+ T cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EGFR mutation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EGFR tyrosine kinase inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">NK cells</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">stimulator of interferon genes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0950-9232</Issn>
      <Volume>45</Volume>
      <Issue>18</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Trisomy 8 alters chromatin conformations and activates Y chromosome genes in stem cells to drive a pre-leukemic state</ArticleTitle>
    <FirstPage LZero="delete">1675</FirstPage>
    <LastPage>1687</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Jie</FirstName>
        <LastName>Bai</LastName>
        <Affiliation>Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimi</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Institute of Resource Development and Analysis, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Kurotaki</LastName>
        <Affiliation>Laboratory of Chromatin Organization in Immune Cell Development, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Eerdunduleng</LastName>
        <Affiliation>Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Supannika</FirstName>
        <LastName>Sorin</LastName>
        <Affiliation>Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Department of Chromosome Biomedical Engineering, Integrated Medical Sciences, Graduate School of Medical Sciences, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Narumi</FirstName>
        <LastName>Uno</LastName>
        <Affiliation>Laboratory of Bioengineering, School of Life Sciences, Tokyo University of Pharmacy and Life Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ai</FirstName>
        <LastName>Hamashima</LastName>
        <Affiliation>Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mihoko</FirstName>
        <LastName>Iimori</LastName>
        <Affiliation>Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Kikuchi</LastName>
        <Affiliation>Laboratory of Chromatin Organization in Immune Cell Development, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Terashima</LastName>
        <Affiliation>Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sho</FirstName>
        <LastName>Kubota</LastName>
        <Affiliation>Department of Medicinal Pharmacology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensaku</FirstName>
        <LastName>Kohrogi</LastName>
        <Affiliation>Department of Pediatrics, Graduate School of Medical Sciences, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Gang</FirstName>
        <LastName>Huang</LastName>
        <Affiliation>Department of Cell Systems &amp; Anatomy, Department of Pathology &amp; Laboratory Medicine, UT Health San Antonio, Joe R. and Teresa Lozano Long School of Medicine, Mays Cancer Center at UT Health San Antonio</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minetaro</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Department of Cell Differentiation, Institute of Molecular Embryology and Genetics, Kumamoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuo</FirstName>
        <LastName>Oshimura</LastName>
        <Affiliation>Chromosome Engineering Research Center, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Kazuki</LastName>
        <Affiliation>Department of Chromosome Biomedical Engineering, Integrated Medical Sciences, Graduate School of Medical Sciences, Tottori University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Goro</FirstName>
        <LastName>Sashida</LastName>
        <Affiliation>Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The mechanistic role of trisomy 8 in the development of myelodysplastic syndrome (MDS) remains poorly defined. Here, we generated a trisomy 8 mouse model by transferring a human chromosome 8 into murine embryonic stem cells and prospectively examined the effects on hematopoietic stem cells (HSC) by trisomy 8. The expression of inflammatory genes was enhanced, and hematopoietic programs mediated by transcription factors and polycomb repressive complex 2 (PRC2) were dysregulated in trisomy 8 HSC, which impaired their self-renewal and balanced differentiation. Trisomy 8 HSC altered the chromatin accessibility and conformations and activated Y chromosome genes, such as Uty/Kdm6c epigenetic modifier, which is known to demethylate histone H3K27me3 modification. The Uty gene facilitated the activation of PRC2-target and Runx1-target genes in leukemogenesis and drove the proliferation of human trisomy 8 leukemic cells. Since the RUNX1 gene is frequently mutated in patients with trisomy 8 MDS, its deletion attenuated the enhanced expression of inflammatory genes and mitigated the impaired self-renewal of trisomy 8 HSC in mice. Our findings reveal that trisomy 8 altered the transcriptional programs and chromatin conformations in HSC and drove a pre-malignant state through activating the expression of Uty, suggesting a route for the development of trisomy 8 MDS.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2041-1723</Issn>
      <Volume>17</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Structural insights into YheS-mediated release of SecM-arrested ribosome</ArticleTitle>
    <FirstPage LZero="delete">4963</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kaishi</FirstName>
        <LastName>Iso</LastName>
        <Affiliation>Department of Biological Sciences, Graduate School of Science, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toma</FirstName>
        <LastName>Ikeda</LastName>
        <Affiliation>School of Life Science and Technology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Yamasaki</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yushin</FirstName>
        <LastName>Ando</LastName>
        <Affiliation>Department of Biological Sciences, Graduate School of Science, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiya K.</FirstName>
        <LastName>Sano</LastName>
        <Affiliation>Department of Biological Sciences, Graduate School of Science, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadaomi</FirstName>
        <LastName>Furuta</LastName>
        <Affiliation>School of Life Science and Technology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Taguchi</LastName>
        <Affiliation>School of Life Science and Technology, Institute of Science Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Nureki</LastName>
        <Affiliation>Department of Biological Sciences, Graduate School of Science, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuhei</FirstName>
        <LastName>Chadani</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuzuru</FirstName>
        <LastName>Itoh</LastName>
        <Affiliation>Department of Biological Sciences, Graduate School of Science, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>ATP-binding cassette subfamily F (ABCF) proteins interact with the ribosome to resolve translation defects near the peptidyl transferase center (PTC). In Escherichia coli, four ABCF proteins (EttA, Uup, YbiT, and YheS) selectively promote translation of distinct problematic nascent peptide sequences, but their molecular mechanisms remain unclear. Here, we present a 2.8&#8201;&#197; cryo-EM structure of the ribosome in complex with an ATPase-deficient mutant of YheS and investigate how it releases ribosomes arrested by the SecM nascent chain. YheS binds to the ribosomal E-site via the L1 stalk, and its P-site tRNA-interaction motif (PtIM) extends toward the PTC, displacing the CCA end of the P-site tRNA. Notably, the cryo-EM density corresponding to the SecM nascent chain within the exit tunnel is largely lost upon YheS binding. These observations suggest that YheS relieves peptide sequence-dependent stalling by perturbing nascent chain-tunnel interactions through P-site tRNA relocation. Steered molecular dynamics simulations provide qualitative support for this model. Together, our findings provide mechanistic insight into a mode of arrest release distinct from the translocon-mediated release mechanism.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2732-7787</Issn>
      <Volume>6</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Predictors for Recurrences Within One Year Following Radical Nephrectomy for Non-metastatic Renal Cell Carcinomas</ArticleTitle>
    <FirstPage LZero="delete">419</FirstPage>
    <LastPage>427</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">KENSUKE</FirstName>
        <LastName>BEKKU</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOMOAKI</FirstName>
        <LastName>YAMANOI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TATSUSHI</FirstName>
        <LastName>KAWADA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YUSUKE</FirstName>
        <LastName>TOMINAGA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKUYA</FirstName>
        <LastName>SADAHIRA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SATOSHI</FirstName>
        <LastName>KATAYAMA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKEHIRO</FirstName>
        <LastName>IWATA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHINGO</FirstName>
        <LastName>NISHIMURA</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MOTOO</FirstName>
        <LastName>ARAKI</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: This study aimed to identify predictors of rapid recurrence following radical nephrectomy for non-metastatic renal cell carcinomas.&lt;br&gt;
Patients and Methods: Patients with non-metastatic renal cell carcinoma who underwent radical nephrectomy between 2014 and 2024 at Okayama University Hospital were included. Rapid recurrence was defined as local or distant metastasis occurring within one year after radical nephrectomy, whereas recurrences occurring beyond one year were classified as non-rapid.&lt;br&gt;
Results: Among a total of 194 patients, 37 (19%) experienced recurrence during a median follow-up of 37 months, with 16 (43%) being classified as experiencing rapid recurrence. The multivariate Cox hazard model revealed that microscopic venous invasion and a size of 60 mm or larger were predictors of rapid recurrence (hazard ratio=4.1, 95% confidence interval=1.5-11.4, p=0.006, and hazard ratio=8.0, 95% confidence interval=2.6-25.0, p&lt;0.001, respectively). Dividing the entire cohort into four groups based on the presence of the two risk factors (0, 1: venous invasion, 1: tumor size, and 2), the median PFS was not estimable, 87, 67, and 7 months, respectively (p&lt;0.001).&lt;br&gt;
Conclusion: Microscopic venous invasion and tumor size of 60 mm or larger were identified as independent predictors of rapid recurrence following radical nephrectomy for non-metastatic renal cell carcinoma.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Renal cell carcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">adjuvant therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">radical nephrectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">early recurrence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">metastases</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model</ArticleTitle>
    <FirstPage LZero="delete">1</FirstPage>
    <LastPage>17</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Fujitani</LastName>
        <Affiliation>Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Taoka</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Iwao</FirstName>
        <LastName>Shimomura</LastName>
        <Affiliation>Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachi</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunta</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiro</FirstName>
        <LastName>Kuribayashi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naofumi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisao</FirstName>
        <LastName>Higo</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kammei</FirstName>
        <LastName>Rai</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Kiura</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryohei</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Division of Experimental Chemotherapy, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Osimertinib is the standard first-line treatment for advanced EGFR-mutant non-small cell lung cancer. However, acquired resistance invariably develops, and identifying novel resistance pathways is clinically important as a substantial portion remains undefined. We used an immunocompetent syngeneic lung cancer mouse model harboring an Egfr exon 19 deletion (mDEL tumors) to establish acquired resistance. Osimertinib-resistant tumors were generated in vivo using a drug-holiday/re-challenge protocol. The resistance mechanism was identified using Sanger sequencing, receptor tyrosine kinase arrays, and western blotting. Egfr V804F knock-in cells were generated using CRISPR/Cas9, and their sensitivity to osimertinib and afatinib was assessed in vitro and in vivo. We established two distinct osimertinib-resistant tumor lines in a syngeneic lung cancer mouse model (mDEL OsiR #1/#3). The analysis revealed an on-target secondary Egfr V804F mutation (corresponding to human EGFR V802F) in both tumor lines. Importantly, Egfr V804F knock-in cells demonstrated significant osimertinib resistance, with a 5.7&#8211;10.5-fold increase in in vitro IC50 (mean, 8.2-fold), but remained highly sensitive to afatinib. Furthermore, afatinib effectively overcame osimertinib resistance in the V804F knock-in cell-derived mouse model. Consistently, afatinib treatment resulted in marked tumor shrinkage and suppression of EGFR signaling in the established mDEL OsiR #1/#3 in vivo. These findings establish secondary Egfr V804F/EGFR V802F as an on-target osimertinib resistance mechanism, providing a preclinical rationale for evaluating afatinib in biomarker-selected patients harboring this alteration.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">afatinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">EGFR-mutant NSCLC</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">exon 19 deletion</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osimertinib resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">V802F (human EGFR)/V804F (murine Egfr)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1664-2392</Issn>
      <Volume>17</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Behavior of serum thyroglobulin in relation to thyroid function under low-thyrotropin conditions in general practice</ArticleTitle>
    <FirstPage LZero="delete">1756863</FirstPage>
    <LastPage>1756863</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Sazumi</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Soejima</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhito</FirstName>
        <LastName>Suyama</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Takase</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Miho</FirstName>
        <LastName>Yasuda</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Furukawa</LastName>
        <Affiliation>Department of Laboratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Serum thyroglobulin (Tg) and thyroid hormones are essential biomarkers in the diagnosis and management of thyroid diseases. Although Tg is routinely measured as a marker for thyroid neoplasia and an adjunct in the diagnosis of thyrotoxicosis due to destructive thyroiditis, its clinical significance under conditions of abnormal thyroid function remains unclear.&lt;br&gt;Methods: We investigated the association between serum Tg levels and thyroid function in 292 patients who underwent simultaneous evaluation of serum Tg, free thyroxine (FT4), and free triiodothyronine (FT3) levels in routine clinical practice. Based on thyroid-stimulating hormone (TSH) levels, participants were classified into three groups: high-TSH (&gt; 4.23 μIU/mL; n = 38), normal-TSH (0.61&#8211;4.23 μIU/mL; n = 191), and low-TSH (&lt; 0.61 μIU/mL; n = 63).&lt;br&gt;Results: The low-TSH group exhibited significantly higher serum Tg levels (118.66 ± 32.13 ng/mL) than the normal-TSH (70.20 ± 23.48 ng/mL) and high-TSH (34.70 ± 13.62 ng/mL) groups. Among patients positive for TSH-receptor antibodies (TRAb) or thyroid-stimulating antibodies (TSAb), elevated Tg levels were observed exclusively in the low-TSH group. Correlation analyses revealed that Tg levels were positively correlated with the FT3/FT4 ratio in the low-TSH group (rho = 0.62, p &lt; 0.01), and this association was more evident in patients positive for both TRAb and TSAb (rho = 0.71, p &lt; 0.01). These associations remained significant after multivariable adjustment and were supported by correlations between Tg and SPINA-GD, a model-based index of thyroid function reflecting deiodinase activity, with similar findings observed in patients with autoimmune hyperthyroidism.&lt;br&gt;Conclusion: These findings suggest that serum Tg levels may reflect biochemical features consistent with T3 predominance in autoimmune hyperthyroidism and have potential clinical utility in characterizing disease pathophysiology.
</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">FT3/FT4 ratio</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hyperthyroidism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">iodothyronine deiodinase</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">thyroglobulin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TSH- receptor antibody</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>18</Volume>
      <Issue>7</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)</ArticleTitle>
    <FirstPage LZero="delete">1181</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Hioki</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Surgery, Okayama Saiseikai General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshikatsu</FirstName>
        <LastName>Endo</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Nobuoka</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Sui</LastName>
        <Affiliation>Department of Surgery, Kagawa Prefectural Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Shinoura</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Surgery, Matsuyama Shimin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Tenwakai Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Postoperative recurrence is a critical issue in the treatment of resectable pancreatic ductal adenocarcinoma (rPDAC). Moreover, the prognosis after early recurrence is extremely poor. This study aimed to develop a recurrence prediction model and to define early recurrence after upfront surgery (UFS) for rPDAC. Methods: This multicenter retrospective study included patients who underwent UFS for anatomically rPDAC between January 2013 and December 2017. Multivariate analyses were conducted to identify the risk factors for recurrence-free survival and to construct a recurrence prediction model. Subsequently, a minimum p value approach was used to determine the optimal cutoff values for early and late recurrence. Results: The cohort included 603 patients (325 men and 278 women). During the median follow-up period of 25 months (interquartile range, 15&#8211;38 months), 381 patients (63.2%) experienced a recurrence. Multivariate analyses revealed carbohydrate antigen 19-9 &#8805;37 U/mL (hazard ratio [HR], 1.58; p &lt; 0.001), tumor size &#8805; 2.2 cm (HR, 1.59; p &lt; 0.001), lymph node metastasis (HR, 1.86; p &lt; 0.001), R1 resection (HR, 1.56; p = 0.002), and no adjuvant chemotherapy (HR, 1.54; p &lt; 0.001) as independent predictors. The recurrence prediction model demonstrated an area under the curve of 0.72&#8211;0.75. The optimal threshold for early and late recurrences was a recurrence-free interval of five months. Carbohydrate antigen 19-9 &#8805; 156 U/mL was a significant predictor of early recurrence (OR, 3.28; p &lt; 0.001). Conclusions: This study identified the prognostic risk factors for recurrence and developed a recurrence prediction model for patients undergoing UFS for rPDAC. Moreover, a recurrence-free interval of five months was identified as the optimal threshold for distinguishing between early and late recurrences.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">resectable</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">upfront surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">recurrence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nomogram</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>17</Volume>
      <Issue>22</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2)</ArticleTitle>
    <FirstPage LZero="delete">3694</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kosei</FirstName>
        <LastName>Takagi</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuya</FirstName>
        <LastName>Yasui</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayoshi</FirstName>
        <LastName>Hioki</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takehiro</FirstName>
        <LastName>Okabayashi</LastName>
        <Affiliation>Department of Surgery, Kochi Health Sciences Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Surgery, Okayama Saiseikai General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshikatsu</FirstName>
        <LastName>Endo</LastName>
        <Affiliation>Department of Surgery, Himeji Red Cross Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Nobuoka</LastName>
        <Affiliation>Department of Surgery, Fukuyama City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Sui</LastName>
        <Affiliation>Department of Surgery, Kagawa Prefectural Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaru</FirstName>
        <LastName>Inagaki</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Fukuyama Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Susumu</FirstName>
        <LastName>Shinoura</LastName>
        <Affiliation>Department of Surgery, Tsuyama Chuo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masashi</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Surgery, Matsuyama Shimin Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuo</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of Surgery, Tenwakai Matsuda Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Aoki</LastName>
        <Affiliation>Department of Surgery, National Hospital Organization Iwakuni Clinical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyoshi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Objectives: Upfront surgery (UFS) remains the standard treatment for patients with resectable pancreatic ductal adenocarcinoma (PDAC). We aimed to investigate the prognostic factors for survival after UFS in patients with resectable PDAC and to develop a prognostic prediction model. Methods: This multicenter, retrospective study included 603 patients who underwent UFS for resectable PDAC between January 2013 and December 2017. Univariate and multivariate analyses were performed to identify prognostic factors for overall survival (OS). We constructed a prognostic prediction model for OS after UFS. An internal validation was performed to evaluate the discriminative performance of the model. Results: The 1-, 3-, and 5-year OS rates were 83.7%, 48.2%, and 37.5%, respectively. The Cox proportional hazards model showed that tumor size &gt; 2 cm (hazard ratio [HR] 1.50, p = 0.001); tumor contact with the portal and superior mesenteric veins of &#8804;180° (HR 1.47, p = 0.003); carbohydrate antigen 19-9 levels of 40 to 500 U/mL (HR 1.59, p = 0.002) and &#8805;500 U/mL (HR 2.16, p &lt; 0.001); and a modified Glasgow Prognostic Score of two (HR 1.56, p = 0.038) were predictors associated with OS. The prognostic prediction model for 5-year OS demonstrated an area under the curve of 0.68. The calibration plots indicate a concordance index of 0.63. Conclusions: We identified the preoperative prognostic factors for OS and developed a prognostic prediction model to estimate OS in patients undergoing UFS for resectable PDAC. Our model may be useful and internally validated for predicting OS.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">pancreatic cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">resectable</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">upfront Surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">outcomes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0039-6060</Issn>
      <Volume>195</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Biliverdin supplementation in perfusate and preservation solution attenuates ischemia-reperfusion injury in a rat donation-after-circulatory-death heart transplantation model</ArticleTitle>
    <FirstPage LZero="delete">110231</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Tokioka</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Nojima</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Hirayama</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Ageta</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuro</FirstName>
        <LastName>Igawa</LastName>
        <Affiliation>Department of Pathology and Oncology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Aokage</LastName>
        <Affiliation>Biological Process of Aging, Tokyo Metropolitan Institute for Geriatrics and Gerontology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tetsuya</FirstName>
        <LastName>Yumoto</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsunori</FirstName>
        <LastName>Nakao</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Heart transplantation faces a persistent donor shortage; therefore, hearts from donation after circulatory death have become a feasible option despite unavoidable warm ischemia and subsequent ischemia-reperfusion injury. Biliverdin, an endogenous bile pigment with strong antioxidant and anti-inflammatory properties, has shown protective effects against ischemia-reperfusion injury in several organ transplantation models. Whether biliverdin attenuates warm ischemic injury in donation after circulatory death heart transplantation remains unclear. This study evaluated biliverdin supplementation in the perfusate and preservation solution in a rat donation after circulatory death model.&lt;br&gt;
Methods: Circulatory death was induced under deep anesthesia, and warm ischemia was maintained for 18 minutes, including the mandatory 5-minute stand-off period. Donor hearts were then flushed and subsequently cold-stored in the same biliverdin-supplemented extracellular-type trehalose&#8211;containing Kyoto solution, whereas control grafts received extracellular-type trehalose&#8211;containing Kyoto without biliverdin at both stages before heterotopic transplantation. Grafts were assessed at 3 and 24 hours after reperfusion (n = 6 per group). Evaluations included early graft recovery, myocardial injury markers, histological and ultrastructural changes, and inflammatory and stress-response gene expression.&lt;br&gt;
Results: Biliverdin significantly improved early graft recovery, shortening reanimation time and increasing left ventricular fractional shortening at 24 hours. Serum troponin I levels were lower in biliverdin-treated grafts. Biliverdin also reduced histological injury and inflammatory cell infiltration. Ultrastructural analysis showed preserved mitochondrial architecture and ultrastructural integrity. Early proinflammatory gene expression was suppressed.&lt;br&gt;
Conclusion: Biliverdin supplementation in the perfusate and preservation solution attenuates ischemia-reperfusion injury in the experimental rat donation after circulatory death heart transplantation model. These findings provide proof of concept for further mechanistic and translational evaluation of biliverdin for myocardial protection in donation after circulatory death.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0919-8172</Issn>
      <Volume>33</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort Study</ArticleTitle>
    <FirstPage LZero="delete">e70494</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Tamura</LastName>
        <Affiliation>Department of Urology, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuto</FirstName>
        <LastName>Matsushita</LastName>
        <Affiliation>Department of Urology, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromitsu</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Urology, Hamamatsu University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Yanagisawa</LastName>
        <Affiliation>Department of Urology, Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Urology, Jikei University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Morinaka</LastName>
        <Affiliation>Department of Urology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Bekku</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shingo</FirstName>
        <LastName>Toyoda</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuhisa</FirstName>
        <LastName>Nukaya</LastName>
        <Affiliation>Department of Urology, Fujita-Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryoichi</FirstName>
        <LastName>Maenosono</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazumasa</FirstName>
        <LastName>Komura</LastName>
        <Affiliation>Department of Urology, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoo</FirstName>
        <LastName>Araki</LastName>
        <Affiliation>Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazutoshi</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Urology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyoshi</FirstName>
        <LastName>Takahara</LastName>
        <Affiliation>Department of Urology, Fujita-Health University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haruhito</FirstName>
        <LastName>Azuma</LastName>
        <Affiliation>Department of Urology, Osaka Medical and Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruo</FirstName>
        <LastName>Inamoto</LastName>
        <Affiliation>Department of Urology, Hamamatsu University School of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: Sarcomatoid renal cell carcinoma (sRCC) is an aggressive histological variant associated with a poor prognosis. While immune checkpoint inhibitor (ICI)-based combinations have become the standard of care, the optimal first-line regimen, specifically dual immunotherapy (IO-IO) vs. IO plus tyrosine kinase inhibitor (IO-TKI), remains controversial. We herein examined the real-world clinical outcomes of Japanese patients with sRCC.&lt;br&gt;
Methods: We conducted a retrospective multicenter study on 46 patients with advanced or metastatic sRCC receiving first-line ICI-based combination therapy between January 2018 and December 2024 (IO-IO: n =&#8201;18; IO-TKI: n =&#8201;28). In a comparative survival analysis, three favorable-risk patients in the IO-TKI group were excluded to align risk profiles, focusing on intermediate/poor-risk groups (n =&#8201;43). The primary endpoint was overall survival (OS).&lt;br&gt;
Results: In the entire cohort (n =&#8201;46), the objective response rate was numerically higher in the IO-TKI group (64.3%) than in the IO-IO group (50.0%) (p =&#8201;0.37). In the comparative analysis of intermediate/poor-risk patients (n =&#8201;43), progression-free survival (PFS) was slightly longer (p =&#8201;0.071), and OS was significantly longer (p =&#8201;0.016) in the IO-TKI group than in the IO-IO group. A multivariable analysis adjusted for IMDC risk categories showed favorable survival with the IO-TKI regimen (HR 0.37, p =&#8201;0.061).&lt;br&gt;
Conclusions: The present study indicates that first-line IO-TKI combination therapy represents a promising treatment option with a potential survival advantage over IO-IO therapy for Japanese patients with sRCC. However, due to the retrospective design and small sample size, reliably determining the comparative efficacy of these regimens remains challenging, and further validation is warranted.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">dual immunotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immune checkpoint inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunotherapy plus tyrosine kinase inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sarcomatoid renal cell carcinoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Institute of Electrical and Electronics Engineers (IEEE)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2169-3536</Issn>
      <Volume>14</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Construction of a Lightweight Simulation Environment Based on Topological Mapping</ArticleTitle>
    <FirstPage LZero="delete">73466 	</FirstPage>
    <LastPage>73478</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yukinaga</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Matsuno</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Autonomous mobile robots require safe and efficient environmental representations for traversability-aware navigation and learning. In particular, self-learning of traversability from real-world driving experience can require robots to operate near the limits of their mobility, which introduces physical risks such as falls, malfunctions, or hardware damage. To provide a safer complementary environment for such validation and future learning, this paper proposes ATC-Mesh. This framework constructs a lightweight, simulation-ready mesh environment from the topological map produced by Adaptive Resonance Theory-based Topological Clustering with Different Topologies (ATC-DT) using high-density LiDAR point clouds. Unlike standard mesh reconstruction methods that directly process dense point clouds, ATC-Mesh generates a compact mesh from the node&#8211;edge structure of the topological map while preserving traversability attributes associated with the topological map. Experiments using two real-world LiDAR datasets show that ATC-Mesh achieves competitive mesh-construction quality compared with standard baseline methods while reducing construction time and mesh size. Gazebo experiments further show that the generated meshes can support waypoint-based navigation with a low simulation load.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Autonomous mobile robot </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">topological map</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">digital twin</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0753-3322</Issn>
      <Volume>194</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Elucidation of mechanisms underlying the therapeutic effects of cordycepin on pulmonary hypertension, with a focus on cell senescence and gut microbiota</ArticleTitle>
    <FirstPage LZero="delete">118923</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Gaopeng</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhixin</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Machitani</LastName>
        <Affiliation>Division of Cancer Stem Cell, National Cancer Center Research Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryou</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kaori</FirstName>
        <LastName>Ishikawa</LastName>
        <Affiliation>Department of General Medicine, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naoya</FirstName>
        <LastName>Yokota</LastName>
        <Affiliation>Department of General Thoracic Surgery, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Reiji</FirstName>
        <LastName>Haba</LastName>
        <Affiliation>Department of Diagnostic Pathology, Kagawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazufumi</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>Center for Advanced Heart Failure, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhihong</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>Inner Mongolia Key Laboratory of Dairy Biotechnology and Engineering, Key Laboratory of Dairy Products Processing, Ministry of Agriculture and Rural Affairs, Key Laboratory of Dairy Biotechnology and Engineering, Ministry of Education, Inner Mongolia Agricultural University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Lin-Hai</FirstName>
        <LastName>Kurahara</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuya</FirstName>
        <LastName>Hirano</LastName>
        <Affiliation>Department of Cardiovascular Physiology, Faculty of Medicine, Kagawa University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Pulmonary hypertension (PH) is a progressive cardiopulmonary disorder characterized by excessive pulmonary vascular remodeling and aberrant proliferation of pulmonary artery smooth muscle cells (PASMCs). Emerging evidence suggests that gut microbiota dysbiosis contributes to PH development. Cordycepin, a natural adenosine analogue derived from Cordyceps militaris, has demonstrated antiproliferative and microbiota-modulating properties; however, its mechanism of action in PH remains unclear.&lt;br&gt;
Objective: Elucidate the mechanisms underlying the therapeutic effects of cordycepin on PH, focusing on cellular senescence and gut microbiota.&lt;br&gt;
Methods: The effects of cordycepin on PH pathology were investigated by transcriptome analysis of PASMCs from patients, and metagenomic analysis of rodent PH models. Cellular senescence was analyzed in lung tissue from p16Ink4a-CreERT2 reporter mice and in rat bone marrow-derived macrophages (BMDMs).&lt;br&gt;
Results: RNA sequencing analysis revealed activation of p53 signaling by cordycepin in PASMCs. Cordycepin suppressed CDK1 expression and TERT phosphorylation at threonine 249. It ameliorated vascular and cardiac remodeling in PH rat and mouse models. Cordycepin induced M1-like macrophage senescence in p16 Ink4a reporter mice lungs and rat BMDMs. Cordycepin significantly reshaped the gut microbiota, increasing beneficial genera (e.g. Alistipes and Acetatifactor) and reducing proinflammatory taxa (e.g., Ruminococcus), with modulating key metabolic pathways, including short-chain fatty acid, tryptophan, and vitamin K2 metabolism.&lt;br&gt;
Conclusion: Cordycepin exerts multi-target therapeutic effects in PH by inhibiting PASMC proliferation via the p53&#8211;CDK1/pTERT axis, modulating gut microbiota-linked immunometabolism and induces proinflammatory macrophage senescence. These findings support cordycepin as a promising candidate for PH therapies targeting the vascular, immune, and gut&#8211;lung axes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Pulmonary hypertension</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p53</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CDK1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TERT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p16</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Microbiota</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0007-1048</Issn>
      <Volume>208</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Decreased renal function predicts severe cytokine release syndrome after CAR-T-cell therapy for large B-cell lymphoma</ArticleTitle>
    <FirstPage LZero="delete">2124</FirstPage>
    <LastPage>2133</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yasuyuki</FirstName>
        <LastName>Arai</LastName>
        <Affiliation>Department of Hematology, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyasu</FirstName>
        <LastName>Jo</LastName>
        <Affiliation>Department of Hematology, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Department of Hematology and Oncology, Kurashiki Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Kaji</LastName>
        <Affiliation>Department of Hematology, Toranomon Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kitawaki</LastName>
        <Affiliation>Department of Hematology, Graduate School of Medicine, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Shimada</LastName>
        <Affiliation>Department of Hematology and Oncology, Nagoya University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsu</FirstName>
        <LastName>Shimoyama</LastName>
        <Affiliation>Division of Clinical Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Yoshihara</LastName>
        <Affiliation>Department of Hematology, Hyogo Medical University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichi</FirstName>
        <LastName>Makita</LastName>
        <Affiliation>Department of Hematology, National Cancer Center Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuharu</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Hematology and Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Hematology, Toranomon Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Kataoka</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emiko</FirstName>
        <LastName>Sakaida</LastName>
        <Affiliation>Department of Hematology, Chiba University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Goto</LastName>
        <Affiliation>Department of Hematology, Hokkaido University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Department of Hematology, Osaka Metropolitan University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiyo</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Hematology, Kanazawa University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Umezawa</LastName>
        <Affiliation>Department of Hematology, Institute of Science Tokyo Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Haryoon</FirstName>
        <LastName>Kim</LastName>
        <Affiliation>Division of Hematology, Department of Medicine, Keio University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiro</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Department of Pediatrics, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiko</FirstName>
        <LastName>Atsuta</LastName>
        <Affiliation>Japanese Data Center for Hematopoietic Cell Transplantation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kato</LastName>
        <Affiliation>Hematology, Oncology and Cardiovascular Medicine, Kyushu University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cytokine release syndrome (CRS) remains a major toxicity of chimeric antigen receptor (CAR) T-cell therapy in large B-cell lymphoma (LBCL), and robust pre-infusion predictors are needed for risk-adapted management. We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR-T-cell therapy between 2019 and 2024. Among 900 patients (median age 62&#8201;years), cumulative incidences of CRS within 30&#8201;days after infusion were 75.0% for any grade, 20.8% for grade&#8201;&#8805;&#8201;2 and 14.0% for grade&#8201;&#8805;&#8201;3. In multivariable analysis, lower estimated glomerular filtration rate (eGFR) (adjusted hazard ratio [aHR] 1.108 per 10&#8201;mL/min per 1.73&#8201;m2 decrease; 95% confidence interval [CI] 1.015&#8211;1.209; p&#8201;=&#8201;0.022), higher ferritin (aHR 1.006 per 100&#8201;ng/mL; 95% CI 1.001&#8211;1.010; p&#8201;=&#8201;0.016), C-reactive protein (CRP) (aHR 1.142 per mg/dL; 95% CI 1.091&#8211;1.195; p&#8201;&lt;&#8201;0.001) and lactate dehydrogenase (LDH) (aHR 1.073 per 100&#8201;U/L; 95% CI 1.008&#8211;1.142; p&#8201;=&#8201;0.028) independently predicted grade&#8201;&#8805;&#8201;2 CRS. We then built a four-factor CRS pre-infusion risk evaluation model, cytokine release syndrome-pre-infusion risk evaluation (CRS-PRE), that stratified grade&#8201;&#8805;&#8201;2 CRS risk into low, intermediate and high groups with incidences of 2.8%, 26.0% and 50.0% respectively. Decreased eGFR, a surrogate of host renal reserve, with elevated ferritin, CRP and LDH emerged as predictors of high-grade CRS. The CRS-PRE may facilitate risk-adapted monitoring and intervention in clinical practice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">chimeric antigen receptor T-cell therapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cytokine release syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">estimated glomerular filtration rate</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">large B-cell lymphoma</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2667-2421</Issn>
      <Volume>20</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Behavioral effects of a chronic envy-like stress paradigm in mice using an adjacent cage model</ArticleTitle>
    <FirstPage LZero="delete">148</FirstPage>
    <LastPage>159</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Department of Medical Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Kitano</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachiko</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Wani</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoi</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ishihara</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Social comparison and envy are significant psychosocial stressors in humans and are known to be involved in the onset and persistence of psychiatric disorders. However, animal models capable of experimentally reproducing the effects of indirect social comparison without physical contact are limited. In this study, we used a newly developed "adjacent-cage paradigm" to investigate whether chronic vicarious exposure to conspecifics in different environments induces envy-like stress in mice.&lt;br&gt;
Methods: Male C57BL/6&#8239;N mice served as observers, while demonstrator mice were assigned to one of four conditions: (1) an environment enriched with objects, (2) an igloo, (3) a tube, or (4) social isolation. Observers were continuously exposed to these adjacent cages for 21 days. Subsequently, a comprehensive battery of behavioral tests was conducted to assess general health, anxiety-like behavior, spatial memory, social behavior, and depression-like behavior.&lt;br&gt;
Results: In the objects condition, a decrease in time spent in the light compartment of the light/dark box indicated an increase in anxiety-like behavior. In the isolation condition, the mean duration per social interaction was shortened, suggesting a qualitative change in social behavior. The igloo condition resulted in reduced immobility time in the forced swim test, suggesting a possible alteration in stress coping behavior. Furthermore, increased nociceptive sensitivity was observed in the hot plate test under both the objects and isolation conditions.&lt;br&gt;
Conclusion: Although the envy-like stress paradigm did not affect many behavioral indices, it did cause condition-dependent and limited behavioral changes. This suggests that the paradigm may serve as a novel model for capturing psychological and context-dependent social stress, which differs from conventional physical stress models. Elucidating the neural basis of this paradigm is expected to contribute to the understanding of how social comparison affects mental health in modern society.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">envy-like stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">social comparison</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">psychosocial stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mouse model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anxiety-like behavior</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Adolescent envy-like social comparison stress induces HPA axis hypoactivity and anxiety in female mice: implications for somatic symptom disorder</ArticleTitle>
    <FirstPage LZero="delete">15771</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Department of Medical Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Kitano</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachiko</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Wani</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoi</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ishihara</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Adolescence is a critical developmental window marked by heightened neuroplasticity and maturation of the stress response system, conferring vulnerability to psychosocial stress. Chronic stress during this period increases the risk of anxiety and depressive disorders and may contribute to somatic symptom disorder (SSD), which is characterized by medically unexplained physical complaints and shows a striking female predominance. The impact of envy-like stress arising from social comparison, a pervasive psychosocial factor in modern society, remains poorly understood. Male and female C57BL/6N mice were exposed to chronic envy-like stress from postnatal day (P)21 to P52 by housing them adjacent to enriched cages, while control mice were housed without such exposure. From P52 onward, mice underwent behavioral testing of anxiety-like behavior, exploratory activity, social interaction, spatial working memory, motor coordination, nociception, and depression-like behavior. Serum corticosterone and adrenocorticotropic hormone (ACTH) concentrations were measured to assess hypothalamic&#8211;pituitary&#8211;adrenal (HPA) axis function. Envy-like stress induced sex-specific phenotypes. Male mice exhibited hyperactivity, reduced social interaction, and impaired spatial working memory. In contrast, female mice displayed robust increases in anxiety-like behavior, impaired motor coordination, and significant reductions in basal corticosterone and ACTH levels. Chronic envy-like stress during adolescence elicits distinct, sex-dependent behavioral and endocrine alterations. The phenotype observed in female mice―characterized by heightened anxiety and lower basal HPA axis hormone levels―shares some biological features with clinical observations in SSD. This model may serve as a starting point for elucidating the mechanisms linking psychosocial stress and somatic symptoms in a sex-dependent manner.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Envy-like stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Social comparison</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Adolescence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">HPA axis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Somatic symptom disorder (SSD)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sex differences</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Psychosocial stress</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>15</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Post-weaning maternal presence exerts a protective effect against social isolation-induced behavioural alterations in mice</ArticleTitle>
    <FirstPage LZero="delete">44248</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Ueno</LastName>
        <Affiliation>Department of Medical Technology, Kawasaki University of Medical Welfare</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eriko</FirstName>
        <LastName>Kitano</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachiko</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Murakami</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Wani</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Neuropsychiatry, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motoi</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ishihara</LastName>
        <Affiliation>Department of Psychiatry, Kawasaki Medical School</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Parental “watchful presence” is considered an important factor influencing behavioural and emotional development in offspring across mammalian species, including humans. However, the effects of such parental presence remain insufficiently understood, even in human studies. In laboratory mice, offspring are typically weaned at approximately three weeks of age, leaving the impact of post-weaning maternal presence on behavioural development largely unexplored. This study aimed to investigate whether maternal presence in an adjacent cage after weaning can attenuate behavioural effects of social isolation stress in mice. Furthermore, we sought to assess whether this experimental paradigm could serve as a novel animal model for studying the effects of parental watchful presence, with potential relevance to human parent&#8211;child relationship research. Mouse pups were weaned at postnatal day 21 and housed either adjacent to their mother (maternal presence group) or without maternal presence (control group). The pups were subsequently housed either in groups with littermates or individually until eight weeks of age. After maturation, behavioural tests were conducted to assess locomotor activity, anxiety-like behaviour, social behaviour, and depression-like behaviour. In group-housed mice, maternal presence did not influence behavioural outcomes. However, in individually housed mice, maternal presence partially attenuated social isolation-induced behavioural alterations, suggesting a subtle protective effect, including hyperlocomotion, reduced anxiety-like behaviour, and abnormal social interactions. Our findings demonstrate that maternal presence during the post-weaning period can offer a protective effect against certain behavioural abnormalities induced by social isolation stress in mice.　This simple adjacent-cage paradigm provides a novel and practical model for elucidating the impact of parental watchful presence on behavioural and emotional development, offering insights relevant to the understanding of parent&#8211;child relationships in humans.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Maternal presence</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Social isolation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Post-weaning period</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Resilience</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mice</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0916-7005</Issn>
      <Volume>43</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Machine learning prediction of the Madden&#8211;Julian oscillation using reservoir computing</ArticleTitle>
    <FirstPage LZero="delete">25</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tamaki</FirstName>
        <LastName>Suematsu</LastName>
        <Affiliation>RIKEN Center for Computational Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kengo</FirstName>
        <LastName>Nakai</LastName>
        <Affiliation>Graduate School of Environmental Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Yoneda</LastName>
        <Affiliation>Graduate School of Economics, Hitotsubashi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Takasuka</LastName>
        <Affiliation>Department of Geophysics, Tohoku University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takuya</FirstName>
        <LastName>Jinno</LastName>
        <Affiliation>Graduate School of Science, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshitaka</FirstName>
        <LastName>Saiki</LastName>
        <Affiliation>Graduate School of Business Administration, Hitotsubashi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>Graduate School of Science, The University of Tokyo</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The prediction of the Madden&#8211;Julian Oscillation (MJO), a massive tropical weather event with global socio-economic impacts, has been infamously difficult with physics-based weather prediction models. We employ the reservoir computing, a brain-inspired machine-learning technique, to construct a machine learning model that forecasts the real-time multivariate MJO index (RMM), a macroscopic variable that represents the state of the MJO. The training data was refined by development of a novel real-time band-pass filter that extracts the recurrency of MJO signals only from the past raw atmospheric data, and by selection of a suitable time-delay coordinate of the RMM that enhances the recurrency of the input data. The constructed model demonstrated the skill to forecast the time sequence of the RMM for a month from pre-developmental stages of the MJO. Examination of best-performing cases suggested that RMM sequences may be predicted for over two months in some cases. These results imply that inherent predictability limit of the MJO is longer than that has been estimated from physics-based weather prediction models.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Reservoir computing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Machine learning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Madden&#8211;Julian Oscillation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sub-seasonal forecast</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2072-6694</Issn>
      <Volume>18</Volume>
      <Issue>10</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Activation of TAS2R Signaling by Diphenidol Suppresses Tumor Growth and Remodels the Tumor Immune Microenvironment in Oral Squamous Cell Carcinoma</ArticleTitle>
    <FirstPage LZero="delete">1527</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nisrina Ekayani</FirstName>
        <LastName>Nasrun</LastName>
        <Affiliation>Division of Reconstructive Surgery for Oral and Maxillofacial Region, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiko</FirstName>
        <LastName>Tanimura</LastName>
        <Affiliation>Division of Pharmacology, Department of Oral Biology, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Division of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Uehara</LastName>
        <Affiliation>Division of Disease Control and Molecular Epidemiology, Department of Oral Growth and Development, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiyofumi</FirstName>
        <LastName>Takabatake</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Hosoya</LastName>
        <Affiliation>Division of Craniofacial Development and Tissue Biology, Tohoku University Graduate School of Dentistry</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Takebe</LastName>
        <Affiliation>Division of Histology, Department of Oral Biology, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hitoshi</FirstName>
        <LastName>Nagatsuka</LastName>
        <Affiliation>Department of Oral Pathology and Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Abiko</LastName>
        <Affiliation>Division of Oral Medicine and Pathology, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Muhammad</FirstName>
        <LastName>Ruslin</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Hasanuddin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>Shimo</LastName>
        <Affiliation>Division of Reconstructive Surgery for Oral and Maxillofacial Region, Department of Human Biology and Pathophysiology, School of Dentistry, Health Sciences University of Hokkaido</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Oral squamous cell carcinoma (OSCC) remains a clinically challenging malignancy characterized by aggressive behavior and limited therapeutic options. Bitter taste receptors (TAS2Rs), expressed across multiple tissues and cancer types, have recently emerged as regulators of tumor biology and immune responses; however, their functional significance in OSCC remains poorly understood. Methods: Immunohistochemical analysis was performed using surgically resected human tongue OSCC specimens and a tissue microarray (TMA) cohort. In parallel, four TAS2R agonists were evaluated in SCC7 cells to assess intracellular calcium responses. RNA sequencing was conducted to analyze transcriptional changes following diphenidol treatment, and functional assays, including proliferation, migration, and apoptosis analyses, were performed in vitro. Antitumor effects were further evaluated in a syngeneic SCC7 mouse model, followed by TUNEL staining and flow cytometry to assess apoptosis and immune cell infiltration. Results: TAS2R38 expression was markedly upregulated in dysplastic and invasive OSCC lesions with predominant nuclear localization and was associated with histological grade and clinical stage, indicating an early and sustained alteration during tumor progression. Among the agonists tested, diphenidol most strongly induced IP3-dependent intracellular Ca2+ elevation. RNA sequencing revealed upregulation of Il1rl1 and Lzts2. Functionally, diphenidol significantly suppressed SCC7 cell proliferation and migration and induced apoptosis in vitro. In vivo, diphenidol reduced tumor volume and weight and increased apoptotic activity. Flow cytometry demonstrated a marked reduction in tumor-infiltrating CD4+CD25+Foxp3+ regulatory T cells, indicating modulation of the tumor immune microenvironment. Conclusions: TAS2R activation by diphenidol suppresses tumor growth through both tumor-intrinsic mechanisms and modulation of the tumor immune microenvironment in OSCC. These findings define TAS2R-mediated calcium signaling as a novel axis linking tumor progression and immunoregulation. Given that diphenidol is a clinically approved drug with an established safety profile, our results provide a strong rationale for TAS2R-targeted drug repurposing strategies in cancer therapy.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">bitter taste receptor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">diphenidol</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunometabolism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oral squamous cellcarcinoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TAS2R signaling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tumor immune microenvironment</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2730-7182</Issn>
      <Volume>26</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Revised taxonomy reveals sustained introgression and secondary contact in ancient lake ricefishes</ArticleTitle>
    <FirstPage LZero="delete">46</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Yashima</LastName>
        <Affiliation>Tropical Biosphere Research Center, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Andy B.</FirstName>
        <LastName>Nofrianto</LastName>
        <Affiliation>Tropical Biosphere Research Center, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Handung</FirstName>
        <LastName>Nuryadi</LastName>
        <Affiliation>Tropical Biosphere Research Center, University of the Ryukyus</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Kakioka</LastName>
        <Affiliation>Department of Applied Aquabiology, National Fisheries University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirozumi</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>The Natural History Museum and Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoshi</FirstName>
        <LastName>Ansai</LastName>
        <Affiliation>Ushimado Marine Institute, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ixchel F.</FirstName>
        <LastName>Mandagi</LastName>
        <Affiliation>Faculty of Fisheries and Marine Science, Sam Ratulangi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kawilarang W. A.</FirstName>
        <LastName>Masengi</LastName>
        <Affiliation>Faculty of Fisheries and Marine Science, Sam Ratulangi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sjamsu A.</FirstName>
        <LastName>Lawelle</LastName>
        <Affiliation>Faculty of Fisheries and Marine Science, Halu Oleo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi J.</FirstName>
        <LastName>Nagano</LastName>
        <Affiliation>Bioscience and Biotechnology Center, Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junko</FirstName>
        <LastName>Kusumi</LastName>
        <Affiliation>Faculty of Social and Cultural Studies, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazunori</FirstName>
        <LastName>Yamahira</LastName>
        <Affiliation>Tropical Biosphere Research Center, University of the Ryukyus</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Biotic diversification in ancient lakes is shaped by complex geological histories and genetic exchange among populations. The Malili Lake system on Sulawesi Island represents a classic natural laboratory for studying freshwater fish evolution and harbors multiple endemic Oryzias species that diversified under repeated hydrological reorganizations. Previous genomic analyses inferred that two sympatric species in Lake Towuti (O. profundicola and O. loxolepis) experienced a single ancient introgression event from a “ghost lineage” derived from O. marmoratus inhabiting another lake. However, recent taxonomic re-evaluation has revealed the presence of an extant O. marmoratus population within Lake Towuti itself. This finding suggests that the putative ghost lineage may in fact represent a living population co-occurring in the lake, calling for a re-examination of the introgression history and speciation mode in Lake Towuti.&lt;br&gt;
Results By incorporating newly generated ddRAD-seq data from the true O. marmoratus in Lake Towuti, we reanalyzed phylogenetic relationships and population genetic structure among Malili Lake Oryzias. Previously reported major phylogenetic relationships and inter-lake introgression patterns were largely reproduced. In contrast, TreeMix and f4-statistic analyses revealed that introgression signals previously attributed to a “ghost lineage” into O. profundicola and O. loxolepis instead originated from the extant O. marmoratus population coexisting within Lake Towuti. Demographic model comparisons explicitly incorporating within-lake gene flow further supported a scenario in which O. profundicola and O. loxolepis diverged in allopatry, subsequently came into secondary contact within Lake Towuti, and later experienced additional gene flow following secondary contact with O. marmoratus that entered the lake.&lt;br&gt;
Conclusion Our results demonstrate that introgression from the O. marmoratus lineage into O. profundicola and O. loxolepis was not a single ancient event, but rather a more sustained process. This finding highlights the critical importance of taxonomic resolution for accurately inferring introgression and divergence history. Comparative studies across other ancient lakes on Sulawesi will be valuable for understanding how the timing and nature of gene flow from third lineages influence patterns of population divergence and the strength of reproductive isolation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Demography</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Hybridization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Malili Lakes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oryzias</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Speciation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sulawesi</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0250-7005</Issn>
      <Volume>46</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of Polymeric Formula on Outcomes in Robotic Pancreatectomy: A Randomized Controlled Trial</ArticleTitle>
    <FirstPage LZero="delete">407</FirstPage>
    <LastPage>414</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">KOSEI</FirstName>
        <LastName>TAKAGI</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOMOKAZU</FirstName>
        <LastName>FUJI</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">KAZUYA</FirstName>
        <LastName>YASUI</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MOTOHIKO</FirstName>
        <LastName>YAMADA</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKEYOSHI</FirstName>
        <LastName>NISHIYAMA</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YASUO</FirstName>
        <LastName>NAGAI</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">MASASHI</FirstName>
        <LastName>HASHIMOTO</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOSHIHARU</FirstName>
        <LastName>MITSUHASHI</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOSHIYOSHI</FirstName>
        <LastName>FUJIWARA</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: Evidence regarding the benefits of nutritional therapy after robotic pancreatectomy is limited. This randomized controlled trial aimed to investigate the effects of a polymeric formula (PF) on preventing body weight loss (BWL) following robotic pancreatectomy.&lt;br&gt;
Patients and Methods: This single-center, open-label, randomized trial was conducted to assign 46 patients undergoing robotic pancreatectomy in a 1:1 ratio to either the PF (ISOCAL Clear) or control group. The primary endpoint was the percentage of BWL on postoperative days 14 and 28. The secondary endpoints were postoperative outcomes.&lt;br&gt;
Results: Of the 52 eligible patients between December 2023 and November 2024, 46 were analyzed using intention-to-treat principles: 23 in the ISOCAL group and 23 in the control group. The %BWL was significantly lower in the ISOCAL group compared with that in the control group on postoperative days 14 (4.8±3.5% vs. 6.6±3.2%, p=0.02) and 28 (6.4±3.0% vs. 8.4±3.5%, p=0.047). Postoperative outcomes, including major complications (p=0.55) and hospital stay (p=0.83), did not differ significantly between the groups.&lt;br&gt;
Conclusion: This study demonstrates the safety and feasibility of administering PF to patients undergoing robotic pancreatectomy. The results showed the beneficial effects of PF on mitigating BWL without compromising short-term outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Robotic pancreatectomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nutrition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">polymeric formula</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">outcomes</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Japan Medical Association</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2433-3298</Issn>
      <Volume>9</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Post Hoc Analysis of Frailty and Tracheostomy Risk in Older Patients Intubated and in an Intensive Care Unit in Japan: An Inverse Association in Older Patients with Advanced Age</ArticleTitle>
    <FirstPage LZero="delete">643</FirstPage>
    <LastPage>650</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takehide</FirstName>
        <LastName>Umeda</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hongo</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mototaka</FirstName>
        <LastName>Inaba</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Ariyasu</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation/>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: This post hoc analysis of a prospectively collected intensive care unit (ICU) cohort examined the association between frailty and the likelihood of tracheostomy in older Japanese patients (aged &#8805;65 years). Frailty, a condition of increased vulnerability to stressors, is common among older patients in the ICU and may influence clinical decision-making and outcomes. We aimed to explore whether baseline frailty is associated with the likelihood of receiving tracheostomy in older patients in the ICUs.&lt;br&gt;
Methods: We analyzed data from a multicenter prospective study conducted from November 2019 to April 2020 at 17 hospitals in Japan. Patients aged &#8805;65 years, admitted directly from the emergency department, and requiring mechanical ventilation, were included. After excluding early deaths (&#8804;5 days) or treatment-limit cases, 363 patients with intubation remained. Frailty was assessed using the Clinical Frailty Scale (CFS), with primary cutoff CFS &#8805;4. The primary outcome was the occurrence of tracheostomy during ICU stay. Risk ratios (RRs) and 95% confidence intervals (CIs) were estimated using generalized linear models with a Poisson distribution, adjusted for age, sex, Charlson Comorbidity Index, and Acute Physiology and Chronic Health Evaluation II score.&lt;br&gt;
Results: Among 363 patients, patients with frailty (CFS &#8805;4) had a significantly lower adjusted risk of having tracheostomy than did those with less frailty (CFS &lt;4) (adjusted RR: 0.40; 95% CI: 0.27-0.61). In patients aged &#8805;75 years, the adjusted RR for CFS &#8805;4 was 0.32 (95% CI: 0.20-0.50), indicating a pronounced reduction in tracheostomy use among patients with frailty.&lt;br&gt;
Conclusions: Frailty (CFS &#8805;4) was independently associated with a lower likelihood of tracheostomy, particularly in patients aged &#8805;75 years.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">frailty</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">respiration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tracheostomy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">critical care outcomes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">aged</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1201-9712</Issn>
      <Volume>166</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>eConsult in infectious diseases: A narrative review</ArticleTitle>
    <FirstPage LZero="delete">108524</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hideharu</FirstName>
        <LastName>Hagiya</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinnosuke</FirstName>
        <LastName>Fukushima</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidemasa</FirstName>
        <LastName>Akazawa</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenta</FirstName>
        <LastName>Nakamoto</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of Infectious Diseases, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Objectives: Asynchronous electronic consultation, eConsult, is increasingly applied in infectious diseases (ID) management to improve access to specialty care and reduce unnecessary referrals. We aimed to integrate published studies to provide a comparative perspective and propose future directions for ID eConsult.&lt;br&gt;
Methods: To synthesize relevant findings and present a comprehensive overview of ID eConsult, we searched in MEDLINE database and identified 11 studies between 2017 and 2025 on ID eConsult programs. Structured data were extracted on study characteristics, mode of consultation, and outcomes.&lt;br&gt;
Results: Nine studies on outpatient ID eConsult demonstrated faster turnaround times, high rates of avoidance of in-person referrals (24-87%), improved antimicrobial optimization, and high provider satisfaction. Two studies on inpatient ID eConsult reported reductions in mortality, readmission rates, and broad-spectrum antibiotic use.&lt;br&gt;
Conclusions: Given its affordability and scalability, the ID eConsult model is particularly advantageous in resource-limited environments. Collectively, ID eConsult may replace traditional telephone or face-to-face consultations, reducing the need for informal curbside discussions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Electronic consultation (eConsult)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Telehealth</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infectious diseases</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Antimicrobial stewardship</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Primary care</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Remote consultation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Wiley</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1347-9032</Issn>
      <Volume>117</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer</ArticleTitle>
    <FirstPage LZero="delete">1260</FirstPage>
    <LastPage>1272</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tadahiro</FirstName>
        <LastName>Kuribayashi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sachi</FirstName>
        <LastName>Okawa</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masataka</FirstName>
        <LastName>Taoka</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shunta</FirstName>
        <LastName>Mori</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaaki</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Nishimura</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayako</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naofumi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiichiro</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Go</FirstName>
        <LastName>Makimoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kammei</FirstName>
        <LastName>Rai</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eiki</FirstName>
        <LastName>Ichihara</LastName>
        <Affiliation>Center for Clinical Oncology, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Kiura</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Immunotherapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) remains challenging. We previously found that EGFR-tyrosine kinase inhibitors induced antitumor immunity but also triggered immunosuppressive cytokines, including transforming growth factor-β (TGF-β), in Egfr-mutant lung cancer. Here, we investigate whether TGF-β inhibition potentiates osimertinib-induced antitumor immunity using a syngeneic mouse model of Egfr-mutated lung cancer, with cancer cells subcutaneously transplanted into wild-type C57BL/6J mice. We evaluated the antitumor effect of the combination therapy with osimertinib and either nintedanib (an indirect TGF-β inhibitor) or vactosertib (a specific TGF-β type I receptor kinase inhibitor). Changes in the tumor microenvironment during treatment were assessed using immunohistochemical staining, western blot analysis, and flow cytometry. We found that TGF-β expression was upregulated in the tumor treated with osimertinib. Nintedanib monotherapy showed no significant antitumor effect, whereas osimertinib combined with nintedanib significantly potentiates the antitumor effect compared with osimertinib monotherapy in vivo. Crucially, no additive effect of nintedanib on osimertinib monotherapy was observed in vitro. Combination therapy with osimertinib and nintedanib significantly increased effector T cells (CD8+CD44+CD62L−) and Granzyme B+ areas and decreased CD206+ cells, while significantly decreasing TGF-β and SMAD2/3 expression. Similar effects were observed with vactosertib but not with a vascular endothelial growth factor receptor 2 inhibitor. In conclusion, combination therapy with osimertinib and TGF-β inhibitors potentiates osimertinib-induced antitumor immunity. These findings highlight a novel therapeutic strategy for EGFR-mutated NSCLC and warrant further clinical investigation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">EGFR</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lung cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">nintedanib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">osimertinib</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TGF-β</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1471-2407</Issn>
      <Volume>26</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>High-risk soft-tissue sarcomas in elderly patients: does perioperative radiotherapy improve local control and prognosis?</ArticleTitle>
    <FirstPage LZero="delete">329</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiharu</FirstName>
        <LastName>Mitsuhashi</LastName>
        <Affiliation>Centre for Innovative Clinical Medicine, Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yutaka</FirstName>
        <LastName>Nezu</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Yokohama City University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Tajima</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kyorin University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Miwa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kanazawa University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshio</FirstName>
        <LastName>Kojima</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Nihon University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Fujiwara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akira</FirstName>
        <LastName>Kawai</LastName>
        <Affiliation>Department of Musculoskeletal Oncology, National Cancer Centre Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Advanced Medical Sciences, Oita University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Aims Accumulating evidence suggests that advanced age is associated with poor local control and prognosis in patients with soft-tissue sarcomas (STSs), highlighting the need to optimise treatment for this age group. However, real-world data on treatment details and outcomes in elderly patients are limited. This study aimed to clarify the role of perioperative radiotherapy (RT) for treating high-risk STSs in elderly patients.&lt;br&gt;
Methods Patients aged&#8201;&#8805;&#8201;70 years who underwent surgery for localised, high-grade, deep-seated non-small round cell STSs measuring&#8201;&#8805;&#8201;5 cm were included in the Bone and Soft Tissue Tumour Registry in Japan. Patients with small-round cell STSs or myxoid liposarcomas, or those who received perioperative chemotherapy or intraoperative RT, were excluded.&lt;br&gt;
Results Among the 1,214 patients who met the criteria, 47 (4%), 219 (18%), and 2 (0.2%) received neoadjuvant, adjuvant, and both neoadjuvant and adjuvant RT, respectively. The 5- and 10-year disease-specific survival (DSS) rates were 72.7% and 64.7%, respectively. Tumour size&#8201;&#8805;&#8201;10 cm, intralesional margin, and local recurrence were associated with poorer DSS; however, perioperative RT did not affect DSS. The 5- and 10-year cumulative probabilities of local recurrence (LR) were 14.6% and 19.5%, respectively. Trunk wall tumours, dedifferentiated liposarcomas, marginal margins, and intralesional margins were associated with a higher probability of LR. Adjuvant RT was associated with a reduced LR probability in patients with intralesional (p = 0.005) or marginal margins (p&#8201;=&#8201;0.044); however, no such benefit was observed in patients with wide margins, who constituted the majority of the cohort, resulting in no significant association between perioperative RT and LR in overall analyses. In the propensity score-matched cohort, no significant differences in DSS or cumulative probability of LR were observed between patients with and without perioperative RT.&lt;br&gt;
Conclusion Adjuvant RT was associated with reduced LR rates in elderly patients with high-risk STSs who had intralesional or marginal margins. However, because most patients achieved wide margins and no benefit of perioperative RT was observed in this group, RT was not associated with reduced LR or improved survival in the overall or propensity score&#8211;matched analyses. Prospective trials are warranted to define the role of perioperative RT in elderly patients with high-risk STSs.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Soft-tissue sarcoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">High-risk</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Perioperative radiotherapy</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Elderly patients</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>MDPI AG</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1422-0067</Issn>
      <Volume>27</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Possible Involvement of Hypothalamic Dysfunction in Long COVID Patients Characterized by Delayed Response to Gonadotropin-Releasing Hormone</ArticleTitle>
    <FirstPage LZero="delete">832</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshiaki</FirstName>
        <LastName>Soejima</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Nakano</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsuhito</FirstName>
        <LastName>Suyama</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryosuke</FirstName>
        <LastName>Takase</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Oguni</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Masuda</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Omura</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasue</FirstName>
        <LastName>Sakurada</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yui</FirstName>
        <LastName>Matsuda</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Honda</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuki</FirstName>
        <LastName>Tokumasu</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keigo</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumio</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of General Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Long COVID (LC) may involve endocrine dysfunction; however, the underlying mechanism remains unclear. To examine hypothalamic&#8211;pituitary responses in patients with LC, we conducted a single-center retrospective study of patients with refractory LC referred to our University Hospital who underwent anterior pituitary stimulation tests. Between February 2021 and November 2025, 1251 patients with long COVID were evaluated, of whom 207 (19%) had relatively low random ACTH or cortisol levels. Ultimately, 16 underwent anterior pituitary stimulation tests and were included. All tests were performed in an inpatient setting without exogenous steroids. Fifteen patients (six women, mean age 35.6 years) underwent corticotropin-releasing hormone (CRH), thyrotropin-releasing hormone (TRH), and gonadotropin-releasing hormone (GnRH) tests. All patients had mild acute COVID-19, eight had &#8805;2 vaccinations, and the mean interval from infection was 343 days. Frequent symptoms included fatigue (100%), insomnia (66.7%), headache (60.0%), anorexia/nausea (40.0%), and brain fog (40.0%). Mean early-morning cortisol and 24 h urinary free cortisol were 7.5 μg/dL and 41.0 μg/day, respectively. MRI showed an empty sella in one case. Peak hormonal responses were preserved (ΔACTH 247%, ΔTSH 918%, ΔPRL 820%, ΔFSH 187%, ΔLH 1150%); however, peaks were delayed beyond 60 min in ACTH (13%), LH (33%), and FSH (87%). Notably, significantly delayed elevations remained at 120 min in the responses of TSH (4.1-fold), PRL (1.8-fold), LH (9.3-fold), and FSH (2.8-fold), suggesting possible hypothalamic involvement, particularly in the gonadotropin responses. Additionally, serum IGF-I was lowered (−0.70 SD), while GH response (mean peak 35.5 ng/mL) was preserved by growth hormone-releasing peptide (GHRP)-2 stimulation. Low-dose hydrocortisone and testosterone were initiated for three patients. Although direct viral effects and secondary suppression have been proposed, our findings may suggest that, at least in part, the observed response characteristics are consistent with functional secondary hypothalamic dysfunction rather than irreversible primary injury. These findings highlight the need for objective endocrine evaluation before initiating hormone replacements.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">COVID-19</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gonadotropin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">gonadotropin-releasing hormone (GnRH)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">hypothalamus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">long COVID</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Association for Cancer Research (AACR)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2767-9764</Issn>
      <Volume>6</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Constitutive EGFR Activation Induced by PTPRR Downregulation Confers Resistance to KRAS Inhibitors</ArticleTitle>
    <FirstPage LZero="delete">728 	</FirstPage>
    <LastPage>741</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Kanemura</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshiyuki</FirstName>
        <LastName>Takehara</LastName>
        <Affiliation>Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Osamu</FirstName>
        <LastName>Maenishi</LastName>
        <Affiliation>Department of Pathology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuta</FirstName>
        <LastName>Tomida</LastName>
        <Affiliation>Center for Comprehensive Genomic Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Natsumi</FirstName>
        <LastName>Iwawaki</LastName>
        <Affiliation>Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kei</FirstName>
        <LastName>Kunimasa</LastName>
        <Affiliation>Department of Thoracic Oncology, Osaka International Cancer Institute</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomohiro</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Medical Oncology, Kishiwada City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satomi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Medical Oncology, Kishiwada City Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinichiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuko</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Genome Biology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Azuma</LastName>
        <Affiliation>Division of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keita</FirstName>
        <LastName>Kudo</LastName>
        <Affiliation>Department of Medical Oncology, National Hospital Organization Osaka Minami Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuto</FirstName>
        <LastName>Nishio</LastName>
        <Affiliation>Department of Genome Biology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiko</FirstName>
        <LastName>Nakagawa</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hidetoshi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Teramura</LastName>
        <Affiliation>Division of Cell Biology for Regenerative Medicine, Institute of Advanced Clinical Medicine, Kindai University Faculty of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kimio</FirstName>
        <LastName>Yonesaka</LastName>
        <Affiliation>Department of Medical Oncology, Kindai University Faculty of Medicine</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>KRASG12C inhibitors, such as sotorasib, show clinical efficacy for non&#8211;small cell lung cancer (NSCLC) positive for the G12C mutations of KRAS, but primary and acquired resistance to these drugs remains a clinical problem. In this study, we show that the development of resistance to sotorasib in KRASG12C-positive NSCLC cells was mediated by constitutive activation of EGFR resulting from downregulation of the protein tyrosine phosphatase receptor type R (PTPRR). PTPRR has been identified as a physiologic regulator of ERK signaling in several cancer types. In our study, PTPRR was demonstrated to bind directly to EGFR, facilitating its dephosphorylation on tyrosine residues. Resumption of PTPRR expression in the resistant cells attenuated EGFR phosphorylation and restored sotorasib sensitivity. PTPRR downregulation was associated with gene promoter hypermethylation in the sotorasib-resistant cells and NSCLC tissue samples. Furthermore, low PTPRR expression in tumor specimens was associated with shorter progression-free and overall survival for patients with NSCLC treated with sotorasib. In contrast to sotorasib, high PTPRR expression was associated with a poor response to EGFR tyrosine kinase inhibitors in EGFR-mutated NSCLC, suggesting that PTPRR may broadly regulate EGFR dependence in NSCLC. Finally, dual blockade of KRASG12C and EGFR showed a substantial antitumor effect in a xenograft model of sotorasib-resistant NSCLC. This approach is therefore a rational therapeutic strategy for KRASG12C-positive NSCLC, especially for tumors showing PTPRR downregulation.&lt;br&gt;
Significance: The current study shows that downregulation of PTPRR induces EGFR activation and resistance to KRASG12C inhibitors in NSCLC, suggesting dual KRAS-EGFR blockade as a rational therapy. PTPRR may help identify patient subgroups that would benefit from the addition of EGFR inhibitors to KRASG12C-targeted therapies.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2673-253X</Issn>
      <Volume>8</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of a generative AI agent for family support in implementing family-based treatment for children and adolescents with anorexia nervosa</ArticleTitle>
    <FirstPage LZero="delete">1759690</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mana</FirstName>
        <LastName>Hanzawa</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital Medical Center for Children</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joe</FirstName>
        <LastName>Hasei</LastName>
        <Affiliation>Department of Medical Informatics and Clinical Support Technology Development, Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ayumi</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital Medical Center for Children</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital Medical Center for Children</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshie</FirstName>
        <LastName>Shigeyasu</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital Medical Center for Children</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chikako</FirstName>
        <LastName>Fujii</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital Medical Center for Children</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Makiko</FirstName>
        <LastName>Horiuchi</LastName>
        <Affiliation>Clinical Psychology Section, Department of Medical Support, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiko</FirstName>
        <LastName>Sugihara</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital Medical Center for Children</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Takeuchi</LastName>
        <Affiliation>Life Natural Science and Technology, Graduate School of Environmental, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuichi</FirstName>
        <LastName>Nakahara</LastName>
        <Affiliation>Department of Musculoskeletal Health Promotion, Faculty of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Katayama</LastName>
        <Affiliation>Department of Palliative and Supportive Care, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Takahashi</LastName>
        <Affiliation>NEC Corporation</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirokazu</FirstName>
        <LastName>Tsukahara</LastName>
        <Affiliation>Department of Pediatrics, Okayama University Hospital Medical Center for Children</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Family-based treatment (FBT) is a first-line psychotherapy for children and adolescents with anorexia nervosa (AN). However, families must understand the principles of FBT, provide meal support, and manage their children's pathological behaviors. Difficulties occur outside clinic hours when it is impossible to consult professionals. This “support gap” increases caregivers’ psychological distress and threatens their treatment continuity. To the best of our knowledge, this is the first domain-specific generative artificial intelligence (AI) agent designed to provide situation-specific, FBT-concordant advice and psychological support.&lt;br&gt;
Methods: The system integrates three components: (1) an FBT-specific knowledge base constructed from treatment manuals, family guides, guideline-compliant resources, and a clinical Q&amp;A corpus; (2) a multistage natural language processing pipeline using Retrieval-Augmented Generation (RAG), with intent and sentiment analyses; and (3) safety guardrails that prohibit unsolicited numerical goals or direct hospitalization recommendations and standardized escalation to clinicians. When strong negative emotions are detected, empowerment messages are dynamically incorporated to maintain caregivers’ confidence. Six clinicians with expertise with pediatric mental health authored queries that simulated common FBT-related concerns and evaluated each response for clinical appropriateness and safety, and classified problems as information insufficiency, not FBT concordant, or escalation insufficiency.&lt;br&gt;
Results: Of the 477 queries, 57.0% were FBT-related, 24.5% were general AN, 16.5% were parental psychological distress, and 1.8% were related to other topics. The clinically appropriate response rate was 91.6% (437/477), including 92.3% for FBT-related questions, 88.0% for general knowledge, 93.7% for psychological distress, and 100.0% for other questions. Clinically inappropriate responses (8.4%) were mainly attributable to information insufficiency; not FBT concordant (1.8% of FBT-related responses) and escalation insufficiency (0.6% of all dialogs) rarely occurred.&lt;br&gt;
Discussion: In this expert review, the safety-gated RAG system predominantly generated FBT-concordant responses that provided meal-level guidance and empathic empowerment-oriented support to families. By proceduralizing complex FBT concepts and presenting multiple response options for pathological behaviors, the system translates FBT principles into practical guidance supporting refeeding adherence, preserving family self-efficacy, and suggesting that domain-specific AI may help bridge structural limitations in FBT. Usability studies and randomized controlled trials are warranted to determine their impact on caregiver burden, self-efficacy, treatment adherence, and clinical outcomes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anorexia nervosa</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">caregiver burden</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">family support</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">family-based treatment</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">generative AI agent</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">large language model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">retrieval-augmented generation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Royal Society of Chemistry (RSC)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1477-9226</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Unraveling the structural features of Dion&#8211;Jacobson-type layered perovskite-related material HCa2Nb3O10&#183;1.5H2O</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Zihao</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Kano</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shu</FirstName>
        <LastName>Morita</LastName>
        <Affiliation>Institute of Materials and Systems for Sustainability (IMaSS), Nagoya University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromu</FirstName>
        <LastName>Shimokawa</LastName>
        <Affiliation>Graduate School of Interdisciplinary Science and Engineering in Health Systems, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Osada</LastName>
        <Affiliation>Department of Materials Chemistry and Institute of Materials and Systems for Sustainability (IMaSS), Nagoya University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Hydrated layered oxides are widely encountered, yet the presence of disordered interlayer water often complicates crystal structure determination from laboratory X-ray diffraction. Here, we report the crystal structure of the Dion&#8211;Jacobson-type layered perovskite-related material HCa2Nb3O10&#183;1.5H2O, solved from synchrotron X-ray diffraction data by combining direct methods in reciprocal space, Le Bail whole-pattern fitting, and Rietveld refinement. The hydrate crystallizes in a tetragonal structure with space group P42212 (a = 7.7070(5) &#197;, c = 32.4870(3) &#197;). Incorporation of partially occupied interlayer water-oxygen sites on the (110) plane at z = 0 and 1/2 successfully reproduces the low-angle 00l reflections while preserving the Ca2Nb3O10 framework. The resulting crystallographic model explicitly resolves the arrangement of interlayer water molecules and provides a robust structural foundation for band-structure calculations as well as for the rational design of hydration-controlled intercalation, exfoliation, and composite materials based on layered perovskite-related materials.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0168-1702</Issn>
      <Volume>370</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Toward in planta studies of persistent fungal viruses in a model plant</ArticleTitle>
    <FirstPage LZero="delete">199761</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Paul</FirstName>
        <LastName>Telengech</LastName>
        <Affiliation>Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakae</FirstName>
        <LastName>Hisano</LastName>
        <Affiliation>Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Francesco</FirstName>
        <LastName>Favaretto</LastName>
        <Affiliation>Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuyuki</FirstName>
        <LastName>Maruyama</LastName>
        <Affiliation>Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kiwamu</FirstName>
        <LastName>Hyodo</LastName>
        <Affiliation>Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hideki</FirstName>
        <LastName>Kondo</LastName>
        <Affiliation>Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuhiro</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Agrivirology Laboratory, Institute of Plant Science and Resources, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A model plant, Nicotiana benthamiana, was examined as a host for persistent fungal viruses capable of crossing organismal kingdoms. Protoplasts of N. benthamiana were transfected with a mixture of virions of a betapartitivirus, Rosellinia necatrix partitivirus 18 (RnPV18), and an alphapartitivirus, RnPV19, and were then subjected to plantlet regeneration. Primary RT-PCR-based screening showed that nearly 100% of the resulting calli tested positive for RnPV18, whereas approximately 90% were positive for RnPV19. However, secondary screening performed at a later stage of tissue culture revealed that only 6% of the calli retained RnPV19, whereas approximately 33% retained RnPV18. These results suggest that the calli were chimeric, consisting of virus-infected and virus-free sectors, and that the partitiviruses were progressively lost during callus maintenance. It is also possible that these fungal partitiviruses were unable to fully adapt to, or counteract, host defense responses sufficiently to establish stable infection. We succeeded in obtaining RnPV18-positive calli and suspension cultures that maintained the virus at detectable levels, as shown by northern blotting, after prolonged subculture for at least 9 months. High-throughput small RNA analyses revealed both similarities and differences in virus-derived small RNA profiles among protoplasts, calli, and suspension cultures. Viral genome analyses further revealed developmental stage-specific and stage-independent substitutions compared with the RnPV18 genomic sequence maintained in the original fungal host. Interestingly, a C-to-U mutation in the RNA-dependent RNA polymerase-encoding region of RnPV18 was detected much more frequently in a particular line, designated B21, than in another stably RnPV18-infected line, P8, irrespective of whether the virus was maintained in suspension cultures or calli. This may explain why virus accumulation in B21 calli and suspension cultures was much lower than that in P8 cell cultures, as RNA-seq analyses showed 159 K counts per million for P8 versus 44 K counts per million for B21. Taken together, this study provides a platform for investigating partitiviruses and other ubiquitous persistent viruses, which are generally difficult to inoculate experimentally.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cross-kingdom infection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tissue culture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Partitivirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">dsRNA virus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Nicotiana, benthamiana</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Callus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Suspension culture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Model plant</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0924-4247</Issn>
      <Volume>408</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A flexible PVDF-based galloping flow sensor</ArticleTitle>
    <FirstPage LZero="delete">117978</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mitsuki</FirstName>
        <LastName>Kurose</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takefumi</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Wakimoto</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Hiejima</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeji</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Hydro-VENUS Co., Ltd., Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Effective monitoring of low flow velocities in small rivers and irrigation channels is hindered by the power requirements and maintenance costs of existing technologies. This study proposes a novel flexible piezoelectric polymer flow sensor utilizing galloping vibration to detect flow velocity in the low range (&#8804;  0.1&#8201;m/s). The sensor features a flexible cantilever structure composed of a silicone rubber beam embedded with a polyvinylidene fluoride (PVDF) film and a tip pillar. Unlike conventional devices based on flow-induced vibration, the use of low-stiffness materials enables the induction of self-excited vibration even under weak fluid forces. Computational fluid dynamics (CFD) analysis has been conducted to optimize the tip shape; a D-shaped semicylinder is selected over a cylinder and a square prism because the geometry maximizes the lift force per unit mass, ensuring efficient energy conversion. To predict sensor behavior, a coupled mechanical-fluid-electrical model was developed. Specifically, the model accounts for the static deflection angle caused by fluid drag. Water channel experiments demonstrated that sensors with beam thicknesses under 4&#8201;mm successfully generated stable periodic outputs at 0.1&#8201;m/s, a regime previously difficult for galloping-based devices. Conversely, thicker beam which has a thickness of 8&#8201;mm achieved higher outputs at higher velocities but failed to actuate at low speeds. Furthermore, the study showed a vibration suppression phenomenon in flexible beams at high flow velocities due to excessive static deflection, which was accurately reproduced by the analytical model. These findings establish structural stiffness as the critical design parameter for optimizing the operable velocity range of flow sensors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Flow velocity sensor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Piezoelectric polymer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Flow induced vibration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Galloping vibration</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0924-4247</Issn>
      <Volume>408</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Tip position estimation of a 3-DOF soft mechanism using artificial muscles with optical fibers</ArticleTitle>
    <FirstPage LZero="delete">117938</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Rikimaru</FirstName>
        <LastName>Okada</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Wakimoto</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichiro</FirstName>
        <LastName>Toda</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shun</FirstName>
        <LastName>Miura</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Yamaguchi</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takefumi</FirstName>
        <LastName>Kanda</LastName>
        <Affiliation>Graduate School of Environment, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>McKibben-type pneumatic artificial muscles (PAMs) are lightweight and flexible soft actuators with a high power-to-weight ratio, and have been widely applied to rehabilitation devices, power-assist systems, and soft robotic mechanisms. By integrating sensing functions into PAMs, their usability and controllability can be enhanced, enabling the development of more practical and advanced soft mechanisms. We previously proposed a smart artificial muscle (SAM) by integrating an optical fiber into the braided sleeve of a McKibben-type PAM, which enables displacement estimation by measuring optical bending loss. The SAM is compatible with conventional PAM fabrication processes; however, the sensor output exhibits strong nonlinearity and time dependency. In this study, an LSTM-based state estimation framework is extended from a single SAM to a three-degree-of-freedom soft mechanism composed of multiple SAMs, where strong nonlinear coupling and mutual interference arise among actuators. In the proposed framework, the LSTM model jointly processes time-series data of multi-channel optical sensor outputs and applied pressures of the three SAMs, along with past estimated states as inputs. This structure enables the model to capture nonlinear coupling, hysteresis, and time-dependent behavior, allowing estimation of the tip position of the soft mechanism. Experimental results demonstrate that the proposed method accurately captures complex nonlinear dynamics and mutual mechanical interference among multiple SAMs, achieving accurate tip position estimation. These results indicate that SAMs with integrated sensing and actuation capabilities, combined with machine-learning-based estimation, provide an effective approach for state estimation of multi-DOF soft robotic mechanisms.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Pneumatic artificial muscle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Smart artificial muscle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Soft mechanism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">State estimation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Long short-term memory</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0178-8051</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Uniqueness of Dirichlet forms for random point fields in the absence of tail triviality</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Kawamoto</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama university</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We consider an infinite system of interacting Brownian motions that preserves a given random point field invariant. Such dynamics are constructed using Dirichlet form theory, which naturally leads to two Dirichlet forms for the random point field: the upper and the lower Dirichlet forms. A fundamental question is the uniqueness of the Dirichlet form: that is, whether these two forms coincide. This uniqueness has often been imposed as a key assumption in the Dirichlet form approach to the stochastic analysis for infinite particle systems. A sufficient condition for the uniqueness of the Dirichlet forms is known when the random point field is tail trivial. However, tail triviality has been established for only a limited class of random point fields. In this paper, we prove the uniqueness of the Dirichlet form without assuming tail triviality. The main contribution of this work is to establish the tail preserving property, which asserts that global properties of the system, such as particle density, are preserved under time evolution. As a consequence, our results also imply the strong uniqueness of solutions to the associated infinite-dimensional stochastic differential equations.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Infinite particle systems</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Interacting Brownian motions</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Uniqueness of Dirichlet forms</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Random matrices</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1865-1569</Issn>
      <Volume>30</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Three-dimensional virtual planning reduces operative time in orthognathic surgery: a procedure-specific retrospective study incorporating additive manufacturing</ArticleTitle>
    <FirstPage LZero="delete">94</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kunisada</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Norie</FirstName>
        <LastName>Yoshioka</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akiyoshi</FirstName>
        <LastName>Nishiyama</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masanori</FirstName>
        <LastName>Masui</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Kadoya</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroaki</FirstName>
        <LastName>Takakura</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kyoichi</FirstName>
        <LastName>Obata</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kisho</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koki</FirstName>
        <LastName>Umemori</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose Three-dimensional virtual surgical planning (3D-VSP) is increasingly used in orthognathic surgery; however, procedure-specific evidence regarding its real-world impact on operative efficiency and intraoperative blood loss remains limited. This study evaluated the association between 3D-VSP implementation and operative time, and intraoperative blood loss across different orthognathic procedures.&lt;br&gt;
Methods This retrospective cohort study included consecutive patients who underwent orthognathic surgery at a single academic institution before (2019&#8211;2020) and after (2023&#8211;2024) the full implementation of 3D-VSP integrated with in-house additive manufacturing (n&#8201;=&#8201;344). Procedure-specific multivariable linear regression analyses were performed, adjusting for age, sex, and surgeon experience.&lt;br&gt;
Results After 3D-VSP implementation, operative time was reduced by approximately 36 min in sagittal split ramus osteotomy (SSRO), 50 min in Le Fort I (LF1) combined with SSRO, and 42 min in segmental LF1 combined with SSRO, representing a 15&#8211;20% reduction in total operative time. No meaningful reduction was observed in intraoral vertical ramus osteotomy (IVRO)-based procedures. A statistically significant, but modest, reduction in intraoperative blood loss was observed only in SSRO. The time-saving effect was independent of surgeon experience.&lt;br&gt;
Conclusion The clinical benefit of 3D-VSP in orthognathic surgery is procedure-dependent and most evident in geometrically complex SSRO-based operations. These findings support the targeted implementation of digital planning and additive manufacturing workflows to improve operative efficiency in routine practice.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Orthognathic surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surgical planning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Three-dimensional virtual surgical planning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Operative time</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Intraoperative blood loss</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Additive manufacturing</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Sagittal split ramus osteotomy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Public Library of Science (PLoS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1932-6203</Issn>
      <Volume>21</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A multicenter, randomized, parallel-group confirmatory study protocol to evaluate the efficacy of Soft Protector CPC, a novel oral mucosal protectant, in preventing oral mucositis and alleviating pain in patients with breast cancer</ArticleTitle>
    <FirstPage LZero="delete">e0350803</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Omori</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kohei</FirstName>
        <LastName>Furukawa</LastName>
        <Affiliation>Department of Dentistry and Oral Surgery, Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masatoshi</FirstName>
        <LastName>Usubuchi</LastName>
        <Affiliation>Department of Dentistry, Miyagi Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomofumi</FirstName>
        <LastName>Hamada</LastName>
        <Affiliation>Department of Dentistry and Oral Surgery, Sagara Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tadahiko</FirstName>
        <LastName>Shien</LastName>
        <Affiliation>Department of Breast and Endocrine Surgery, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Michihiro</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Nakatsuka</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsuyuki</FirstName>
        <LastName>Hotta</LastName>
        <Affiliation>Center for Innovative Clinical Medicine, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Soichiro</FirstName>
        <LastName>Ibaragi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shogo</FirstName>
        <LastName>Takashiba</LastName>
        <Affiliation>Department of Pathophysiology-Periodontal Science, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Oral mucositis is a frequent and debilitating adverse event observed in patients undergoing chemotherapy or radiotherapy. Current management strategies are limited in duration, require frequent application, and fail to address the mechanical irritation from teeth. A novel device, Soft Protector CPC, was developed to overcome these limitations. This multicenter, randomized, two-arm, open-label, confirmatory trial aims to evaluate the efficacy and safety of Soft Protector CPC in patients with breast cancer undergoing chemotherapy. A total of 154 participants will be randomly assigned in a 1:1 ratio to receive either oral care with Soft Protector CPC or oral care alone. The primary endpoint will be oral mucositis as assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v3.0 during the comparative treatment period. The secondary endpoints will include CTCAE v3.0 during the continuous treatment period, oral mucositis, pain (CTCAE v5.0), quality of life (Patient Reported Outcomes-CTCAE version 1.0 [PRO-CTCAE v1.0], the 15-item oral health questionnaire of the European Organization For Research And Treatment Of Cancer [EORTC QLQ-OH15], and the pain Numeric Rating Scale), onset and site of mucositis, completion of chemotherapy, use of rescue medications, technical feasibility, and patient preference. The safety endpoints will include adverse events, device malfunction, and laboratory tests. This trial is expected to establish the clinical utility of the Soft Protector CPC for the prevention and management of oral mucositis, with the potential to improve the patients’ quality of life and adherence to cancer therapy. This study was approved by the Clinical Research Review Board and registered with the Japan Registry of Clinical Trials, jRCTs062250005, on April 18, 2025.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0094-8276</Issn>
      <Volume>53</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sound Velocities of FeO‐Bearing Ringwoodite and Majorite: Implication for Martian Mantle Seismic Profiles</ArticleTitle>
    <FirstPage LZero="delete">e2025GL118991</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Luo</FirstName>
        <LastName>Li</LastName>
        <Affiliation>Department of Earth and Planetary Sciences, Jackson School of Geosciences, The University of Texas at Austin</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Young Jay</FirstName>
        <LastName>Ryu</LastName>
        <Affiliation>GeoSoilEnviroCARS, University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dongzhou</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>GeoSoilEnviroCARS, University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stella</FirstName>
        <LastName>Chariton</LastName>
        <Affiliation>GeoSoilEnviroCARS, University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vitali B.</FirstName>
        <LastName>Prakapenka</LastName>
        <Affiliation>GeoSoilEnviroCARS, University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jung‐Fu</FirstName>
        <LastName>Lin</LastName>
        <Affiliation>Department of Earth and Planetary Sciences, Jackson School of Geosciences, The University of Texas at Austin</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Compressional and shear wave velocities (Vp, Vs) of candidate Martian deep-mantle minerals, FeO-rich ringwoodite ((Mg0.66Fe0.34)2SiO4) and majorite (Mg0.75Fe0.10Al0.26Ca0.07Si0.84O3), were measured up to 25 GPa and 700 K using Brillouin light scattering coupled with externally-heated diamond anvil cells. Thermoelastic modeling of our results and literature data along a representative areotherm showed that Vp and Vs of FeO-bearing ringwoodite are approximately 7.5% and 11.0% higher than that of the majorite. Our results reveal that velocity profiles of these Martian deep-mantle minerals are more sensitive to variations in the ringwoodite/majorite (Mg/Si) ratio than to thermal and FeO chemical perturbations. Our best-fit velocity model to a recent seismic model by Samuel et al. (2023, https://doi.org/10.1038/s41586-023-06601-8) indicates the Martian mantle contains approximately 67 vol.% ringwoodite and 33 vol.% majorite, suggesting a ringwoodite-rich aggregate in the Martian lowermost solid mantle. The ringwoodite-majorite mantle likely co-evolved with the FeO and other incompatible elements in the molten silicate layer above the Martian core-mantle boundary.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">sound velocity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ringwoodite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">majorite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Martian mantle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">FeO-rich</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0094-8276</Issn>
      <Volume>53</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Davemaoite Elasticity Reveals Slab‐Induced Heterogeneity in the Mantle Transition Zone</ArticleTitle>
    <FirstPage LZero="delete">e2025GL118147</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yingxin</FirstName>
        <LastName>Yu</LastName>
        <Affiliation>State Key Laboratory of Precision Geodesy, School of Earth and Space Sciences, University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xinyue</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>State Key Laboratory of Precision Geodesy, School of Earth and Space Sciences, University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Dongzhou</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>GeoSoilEnviroCARS, University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Luo</FirstName>
        <LastName>Li</LastName>
        <Affiliation>State Key Laboratory of Precision Geodesy, School of Earth and Space Sciences, University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zhu</FirstName>
        <LastName>Mao</LastName>
        <Affiliation>State Key Laboratory of Precision Geodesy, School of Earth and Space Sciences, University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ningyu</FirstName>
        <LastName>Sun</LastName>
        <Affiliation>State Key Laboratory of Precision Geodesy, School of Earth and Space Sciences, University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Denglei</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>State Key Laboratory of Precision Geodesy, School of Earth and Space Sciences, University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jing</FirstName>
        <LastName>Li</LastName>
        <Affiliation>State Key Laboratory of Precision Geodesy, School of Earth and Space Sciences, University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chaoshuai</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>State Key Laboratory of Precision Geodesy, School of Earth and Space Sciences, University of Science and Technology of China</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Cheng</FirstName>
        <LastName>Qian</LastName>
        <Affiliation>State Key Laboratory of Geological Processes and Mineral Resources, China University of Geosciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yingzhan</FirstName>
        <LastName>Wei</LastName>
        <Affiliation>State Key Laboratory of High Pressure and Superhard Materials, College of Physics, Jilin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Xinyang</FirstName>
        <LastName>Li</LastName>
        <Affiliation>State Key Laboratory of High Pressure and Superhard Materials, College of Physics, Jilin University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuzhu</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Shanghai Advanced Research Institute, Chinese Academy of Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The observed 2%&#8211;7% low-shear velocity (VS) anomalies near the subducted slab at the bottom mantle transition zone (MTZ) indicate strong lateral heterogeneity, which is commonly attributed to subducted oceanic crust. However, davemaoite, a major constituent of the subducted oceanic crust, has been poorly constrained in its elasticity, hindering accurate velocity modeling and obscuring the origin of these low-velocity features. Here we report single-crystal elasticity of Ti-bearing davemaoite with the composition of Ca(Si0.57Ti0.43)O3 under high pressure-temperature and found that Ti incorporation significantly reduces velocities and alters the pressure dependence of the shear modulus. Further velocity modeling demonstrated that subducted crusts with varying Ti content have seismic signatures of 1.7(2)&#8211;6.8(5)% low-VS at the bottom MTZ, consistent with the observed low-VS structure in the region. These findings highlight the role of slab-derived chemical heterogeneity in generating mantle seismic anomalies and provide new experimental constraints on the structure and dynamics of the deep Earth.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Ti-bearing davemaoite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">single-crystal elasticity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">slab-induced heterogeneity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mantle transition zone</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Frontiers Media SA</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1664-042X</Issn>
      <Volume>17</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Bee larvae ameliorate andropause-like symptoms via a hormone-independent, antioxidant mechanism</ArticleTitle>
    <FirstPage LZero="delete">1850114</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ito</LastName>
        <Affiliation>Department of Biology, Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuaki</FirstName>
        <LastName>Okumura</LastName>
        <Affiliation>Institute for Bee Products &amp; Health Science, Yamada Bee Company, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Oti</LastName>
        <Affiliation>Department of Biology, Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirotaka</FirstName>
        <LastName>Sakamoto</LastName>
        <Affiliation>Department of Biology, Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Late-onset hypogonadism (LOH), also known as the male menopause, is characterized by a decline in sexual function as well as various physical and psychological symptoms, including anxiety. Although bee larvae have historically been utilized as a traditional food and medicine, their efficacy and physiological mechanisms of action against male menopausal symptoms remain unclear. In this study, we investigated the effects of bee larvae (BL) on sexual and anxiety-like behaviors using two rodent models of the male menopause: aged rats and castrated mice. In the aged rat model (64 weeks old), dietary BL supplementation for 4 weeks significantly attenuated the age-associated decline in ejaculation frequency compared to controls, while no significant effects were observed on mount or intromission frequencies. Notably, plasma analysis revealed no significant differences in testosterone or dihydrotestosterone levels between the BL and control groups. To elucidate the underlying mechanism, we evaluated sexual function using a castrated mouse model. While BL supplementation did not affect sexual behavior in intact mice, post-castration BL treatment significantly shortened intromission latency without altering mount frequency. In the elevated plus maze test, BL significantly alleviated castration-induced anxiety-like behaviors and improved exploratory activity. Furthermore, in vitro assays demonstrated that the BL extract exerts potent protective effects against oxidative stress, a pathological factor contributing to both erectile dysfunction and anxiety. These results suggest that BL improves erectile function and anxiety via hormone-independent mechanisms, potentially by mitigating oxidative stress in vascular and neural tissues. Thus, bee larvae represent a promising functional food for ameliorating the multi-faceted physical and psychological symptoms associated with male menopause.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">anxiety</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">bee larvae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">late-onset hypogonadism</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oxidative stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sexual behavior</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2169-9313</Issn>
      <Volume>130</Volume>
      <Issue>8</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Linking the Spin Transition of Ferric Iron in δ‐(Al,Fe)OOH to Water Storage in the Lower Mantle</ArticleTitle>
    <FirstPage LZero="delete">e2025JB031715</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Johannes</FirstName>
        <LastName>Buchen</LastName>
        <Affiliation>Bayerisches Geoinstitut, Universit&#228;t Bayreuth</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Olivia S.</FirstName>
        <LastName>Pardo</LastName>
        <Affiliation>Seismological Laboratory, California Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Vasilije V.</FirstName>
        <LastName>Dobrosavljevic</LastName>
        <Affiliation>Seismological Laboratory, California Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wolfgang</FirstName>
        <LastName>Sturhahn</LastName>
        <Affiliation>Seismological Laboratory, California Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takayuki</FirstName>
        <LastName>Ishii</LastName>
        <Affiliation>Now at Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Stella</FirstName>
        <LastName>Chariton</LastName>
        <Affiliation>GSECARS, The University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eran</FirstName>
        <LastName>Greenberg</LastName>
        <Affiliation>GSECARS, The University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thomas S.</FirstName>
        <LastName>Toellner</LastName>
        <Affiliation>Advanced Photon Source, Argonne National Laboratory</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jennifer M.</FirstName>
        <LastName>Jackson</LastName>
        <Affiliation>Seismological Laboratory, California Institute of Technology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>As the most massive geochemical reservoir, the lower mantle affects the Earth's budget of volatile elements, including hydrogen or H2O. The properties of minerals in the lower mantle are further affected by changes in the electronic configurations of iron cations, that is, by spin transitions. The feedback between spin transitions and potential storage of H2O in solid hydrous phases in the lower mantle, however, remains unexplored. By combining high-pressure nuclear resonant inelastic X-ray scattering and high-pressure high-temperature X-ray diffraction experiments, we constrained the thermal equation of state of δ-(Al,Fe)OOH, a member of the phase H solid solution. Based on the derived thermal equation of state of δ-(Al,Fe)OOH and the underlying thermodynamic model, we calculate the excess Gibbs free energy that arises from the spin transition of ferric iron in this compound and evaluate the effect on phase equilibria. The results of our analysis show that the spin transition of ferric iron in phase H may significantly reduce the thermodynamic activity and hence the concentration of H2O in a coexisting hydrous melt. As a consequence, nominally anhydrous minerals of the lower mantle may become dehydrated in the presence of phase H. Our analysis further suggests that, under certain conditions, the spin transition may expand the thermal stability of Fe3+-bearing phase H and create a geochemical link between the storage of H2O in phase H and ferric iron in the lower mantle.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">spin transition</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">phase H</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">lower mantle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">high pressure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">equation of state</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">phonon density of states</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0020-7128</Issn>
      <Volume>70</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Immediate and delayed effects of thermal stress on fever-associated seizures in children: A time-stratified case-crossover study in Japan</ArticleTitle>
    <FirstPage LZero="delete">86</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naomi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuka</FirstName>
        <LastName>Yamamura</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kensuke</FirstName>
        <LastName>Uraguchi</LastName>
        <Affiliation>Department of Epidemiology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Obara</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiromichi</FirstName>
        <LastName>Naito</LastName>
        <Affiliation>Department of Emergency, Critical Care, and Disaster Medicine, Okayama University Faculty of Medicine, Dentistry, and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yorifuji</LastName>
        <Affiliation>Department of Epidemiology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study aimed to examine the non-linear and delayed effects of thermal stress, measured by the hourly Universal Thermal Climate Index (UTCI), on the risk of pediatric fever-associated seizures (FAS). We conducted a time-stratified case-crossover study in Okayama, Japan (May 2015&#8211;March 2023), analyzing 3,201 ambulance-attended FAS cases in children younger than 7 years. Using a distributed lag non-linear model (DLNM) with a 144-h lag, we estimated the association between UTCI and FAS. The analysis revealed a bimodal exposure&#8211;response relationship. Moderate Cold Stress (10th percentile, &#8211;1.6 °C) was associated with a significant cumulative odds ratio (OR) of 2.22 (95% CI: 1.22&#8211;4.06). Risk also increased at the upper range of No Thermal Stress (24.2 °C; cumulative OR 2.74, 95% CI: 1.63&#8211;4.63), extending into Moderate Heat Stress (28.7 °C; cumulative OR 2.26, 95% CI: 1.33&#8211;3.84). These effects were primarily delayed to 72&#8211;96 h for Moderate Cold and reached a peak around 100 h for Moderate Heat. Strong Heat Stress showed immediate but non-significant risk patterns. These findings suggest that infection-mediated pathways likely drive the observed bimodal risk pattern, demonstrate the utility of high-resolution bioclimatic indices, and can inform the development of temperature-specific public health alerts.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Time-stratified Case-crossover study</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Thermal stress</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Fever-associated seizures</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Universal Thermal Climate Index (UTCI)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Climate change</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pediatric emergency</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Total Thymectomy Is Oncologically Superior to Partial Thymectomy in Patients with Thymic Carcinoma: Insights from a Multicenter Real World Data Analysis</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>HAYASHI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Comparable Clinical Outcomes Between Segmentectomy and Lobectomy for NSCLC With Unsuspected N1/N2: A Multicenter Real-World Data Study</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tsuyoshi</FirstName>
        <LastName>RYUKO</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Enhancement of drug delivery through fibroblast activation protein-targeted near-infrared photoimmunotherapy</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Seitaro</FirstName>
        <LastName>NISHIMURA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Adenosine-mediated Neutrophil Regulation by Dapagliflozin Attenuates Renal Ischemia/Reperfusion Injury: Real-time Imaging and Metabolic Insights</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Tomoaki</FirstName>
        <LastName>YAMANOI</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The potential mechanism maintaining transactive response DNA binding protein 43 kDa in the mouse stroke model</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">YUTING</FirstName>
        <LastName>BIAN</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Bioresorbable Membrane Composed of Sodium Hyaluronate and Carboxymethylcellulose (Seprafilm) Prevents Cancer Implantation at Peritoneal Defects in 3D‐Peritoneum and Murine Models</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>UNE</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of a Hydrodynamic-Simulation-Informed Random Forest Method for Efficient Spatiotemporal Flood Prediction</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">KEXIN</FirstName>
        <LastName>LIU</LastName>
        <Affiliation>Graduate School of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of Bacillus subtilis on Periodontitis in a Mouse Model</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">YIXUAN</FirstName>
        <LastName>ZHANG</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Effects of miR-128-3p on Renal Inflammation in a Rat Periodontitis Model</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>MOHAMMAD NURHAMIM</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName/>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn/>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Assessment of Boron Neutron Capture Therapy on Three Dimensional Model of Patient-Derived Cancer-Associated Fibroblasts and Oral Cancer</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Izumi</FirstName>
        <LastName>HARA</LastName>
        <Affiliation>Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2055-0294</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Ibuprofen gargle for quality of life and pain improvement in oral lichen planus: randomized crossover and long-term extension phase II study</ArticleTitle>
    <FirstPage LZero="delete">14</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yumi</FirstName>
        <LastName>Kitahiro</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasumasa</FirstName>
        <LastName>Kakei</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ioroi</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nanae</FirstName>
        <LastName>Yatagai</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiko</FirstName>
        <LastName>Kashin</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaki</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asami</FirstName>
        <LastName>Morioka</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kazuhiro</FirstName>
        <LastName>Yamamoto</LastName>
        <Affiliation>Department of Integrated Clinical and Basic Pharmaceutical Sciences, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takumi</FirstName>
        <LastName>Hasegawa</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masaya</FirstName>
        <LastName>Akashi</LastName>
        <Affiliation>Department of Oral and Maxillofacial Surgery, Kobe University Graduate School of Medicine</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ikuko</FirstName>
        <LastName>Yano</LastName>
        <Affiliation>Department of Pharmacy, Kobe University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract/>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Oral lichen planus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Ibuprofen gargle</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PROMS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Oral pain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Long-term extension study</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0021-9258</Issn>
      <Volume>302</Volume>
      <Issue>6</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A photoactivatable Cre-loxP system for spatiotemporal genetic manipulation in mouse taste buds</ArticleTitle>
    <FirstPage LZero="delete">113085</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Yu</FirstName>
        <LastName>Zuo</LastName>
        <Affiliation>Department of Oral Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kengo</FirstName>
        <LastName>Horie</LastName>
        <Affiliation>Department of Oral Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Mitoh</LastName>
        <Affiliation>Department of Oral Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasuhiro</FirstName>
        <LastName>Yamada</LastName>
        <Affiliation>Department of Molecular Pathology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Takao</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Takarada</LastName>
        <Affiliation>Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shoichiro</FirstName>
        <LastName>Kokabu</LastName>
        <Affiliation>Division of Biochemistry, Kyushu Dental University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryusuke</FirstName>
        <LastName>Yoshida</LastName>
        <Affiliation>Department of Oral Physiology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Conventional genetic approaches, including global gene KO and conditional KO strategies such as the Cre-loxP system, have some limitations arising from systemic effects or insufficient temporal resolution. The recently developed photoactivatable Cre (PA-Cre) system may have a potential to improve spatiotemporal control of gene manipulation. In this study, we established and validated the feasibility of the PA-Cre system using taste buds as a model. We generated TRE-PA-Cre:R26-rtTA/tdTomato mice to evaluate blue-light-induced Cre recombinase activity. Through systematic optimization of illumination parameters, we found that a single session of blue-light-illumination resulted in limited recombination efficiency, whereas a multisession illumination strategy markedly increased recombination efficiency. To further assess the utility of the PA-Cre system for gene KO, we generated TRE-PA-Cre:R26-rtTA:Tas1r3-flox mice and targeted a taste-related gene Tas1r3. Genomic DNA quantitative PCR and reverse transcription-quantitative PCR both showed partial reductions in Tas1r3 at the DNA and mRNA levels, respectively. Behavioral assays further revealed a selective decrease in sensitivity to sweet and umami stimuli. Together, these findings demonstrate PA-Cre-mediated gene manipulation in taste buds and establish a practical optical activation paradigm, providing a high-spatiotemporal-resolution tool for investigating gene function in optically targeted regions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Cre-loxP</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">genetic manipulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">mouse</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">photoactivatable Cre</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">spatiotemporal</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">taste</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Fuji Technology Press Ltd.</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1883-8014</Issn>
      <Volume>30</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>A Verification of Relationship Between Multiplicatively Weighted Voronoi Diagram and Huff Model: A Case Study on Order Assignment in E-Commerce</ArticleTitle>
    <FirstPage LZero="delete">921</FirstPage>
    <LastPage>930</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takaki</FirstName>
        <LastName>Kawamoto</LastName>
        <Affiliation>Faculty of Environmental, Life, Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Hasuike</LastName>
        <Affiliation>Department of Industrial and Management Systems Engineering, School of Creative Science and Engineering, Waseda University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study examines the relationship between a multiplicatively weighted (MW-) Voronoi diagram and the Huff model. A mathematical comparison demonstrates that the models are structurally equivalent when the Huff model is deterministic and the distance decay parameter λ takes a specific value. This theoretical finding was empirically validated using real-world e-commerce order assignment data. The experiments demonstrate the distinct strengths of each model. The Huff model enables the flexible balancing of competing objectives through parameter adjustment, whereas the MW-Voronoi diagram provides geometric clarity in the interpretation of territories. We conclude that the selection of the two models should be guided by the problem objectives, depending on whether probabilistic flexibility or deterministic spatial partitioning is required.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">multiplicatively weighted Voronoi diagram</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Huff model</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">order assignment algorithm</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>The Japanese Society for Neuroendovascular Therapy</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1882-4072</Issn>
      <Volume>20</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Current Status of Middle Meningeal Artery Embolization for Chronic Subdural Hematoma: An International Perspective Including Japan</ArticleTitle>
    <FirstPage LZero="delete">ra.2025-0153</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Masato</FirstName>
        <LastName>Kawakami</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kenji</FirstName>
        <LastName>Sugiu</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masafumi</FirstName>
        <LastName>Hiramatsu</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Haruma</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryu</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuta</FirstName>
        <LastName>Soutome</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Juntaro</FirstName>
        <LastName>Fujita</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuichi</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fukiko</FirstName>
        <LastName>Baba</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shota</FirstName>
        <LastName>Tanaka</LastName>
        <Affiliation>Department of Neurological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Middle meningeal artery embolization (MMAE) for chronic subdural hematoma (CSDH) is gaining global prevalence as a minimally invasive treatment aimed at serving as an adjunct to or method of avoiding surgery; however, its optimal positioning remains unclear. This study outlines the current status of MMAE in Japan, Germany, and the United States based on nationwide survey reports, recently published consensus guidelines, and meta-analyses including randomized controlled trials (RCTs) reported in the New England Journal of Medicine (NEJM; EMBOLISE, STEM, and MAGIC-MT) and examines its efficacy and limitations. Real-world clinical data from Japan, Germany, and the United States indicate that MMAE is primarily used as an adjunctive therapy following surgery for older and high-risk or recurrent cases, or as a stand-alone therapy in selected cases to safely reduce the risk of recurrence and reoperation. While a multidisciplinary consensus statement takes a cautious stance that limits MMAE to recurrent or inoperable cases such as those at high risk associated with interrupting antithrombotic medication, the Society of Vascular and Interventional Neurology guidelines published after the RCTs strongly recommend the concurrent use of MMAE with standard therapy in de novo cases. Meta-analyses integrating the 3 NEJM trials and other RCTs showed that MMAE suppressed recurrence and reoperation versus standard treatment, with particularly pronounced effects in the nonsurgical (conservative treatment) group; however, the additive effect was limited in the surgical adjunct group. No improvement in functional outcomes (modified Rankin Scale score) was observed. Cost-effectiveness analyses suggest that, while MMAE reduces reoperations, routine implementation for all cases is difficult to justify economically because of high procedural costs, indicating the need to narrow the indication to populations at high risk of recurrence. In conclusion, although MMAE is an effective treatment option, the current evidence does not support its uniform introduction in all patients with CSDH. Thus, it is necessary to individualize and adapt the indications for specific patient subgroups, such as those at high risk of recurrence or those for whom surgery is difficult. Finally, we propose a pragmatic treatment strategy for MMAE stratified by disease stage (de novo vs. recurrent) and clinical severity to guide the individualized selection of adjunctive and stand-alone embolization.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">middle meningeal artery embolization</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">chronic subdural hematoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">current status</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Association for Cancer Research (AACR)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1078-0432</Issn>
      <Volume/>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Incidence of B-cell Malignancies in Patients with Lung Cancer Receiving PD-1 Blockade Therapy</ArticleTitle>
    <FirstPage LZero="delete"/>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ninomiya</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Caiyang</FirstName>
        <LastName>Fang</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruya</FirstName>
        <LastName>Morinaga</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Wenhao</FirstName>
        <LastName>Zhou</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshihiro</FirstName>
        <LastName>Koyama</LastName>
        <Affiliation>Department of Pharmaceutical Data Science, Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sakura</FirstName>
        <LastName>Miki</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Li</FirstName>
        <LastName>Zhu</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yusuke</FirstName>
        <LastName>Naoi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daisuke</FirstName>
        <LastName>Ennishi</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoya</FirstName>
        <LastName>Katsuta</LastName>
        <Affiliation>Department of Respiratory Medicine, Ehime Prefectural Central Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Kadoaki</FirstName>
        <LastName>Ohashi</LastName>
        <Affiliation>Department of Respiratory Medicine, Okayama University Hospital, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin</FirstName>
        <LastName>Morizane</LastName>
        <Affiliation>Department of Dermatology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoka</FirstName>
        <LastName>Ohki-Ikeda</LastName>
        <Affiliation>Department of Pathology, Okayama University Hospital, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuya</FirstName>
        <LastName>Nishi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Youki</FirstName>
        <LastName>Ueda</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takamasa</FirstName>
        <LastName>Ishino</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinobu</FirstName>
        <LastName>Maeda</LastName>
        <Affiliation>Department of Hematology, Oncology and Respiratory Medicine, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Isamu</FirstName>
        <LastName>Okamoto</LastName>
        <Affiliation>Department of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joji</FirstName>
        <LastName>Nagasaki</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Togashi</LastName>
        <Affiliation>Department of Tumor Microenvironment, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Purpose: Many patients with various cancer types have received immune checkpoint inhibitors (ICI) worldwide since their approval, and novel unexpected complications from their long-term use are apparent. We identified some cases of B-cell lymphoma occurring during PD-1 blockade therapy as such unexpected complications. In this study, we aimed to evaluate the incidence of hematologic malignancies in patients with lung cancer receiving PD-1 blockade therapy and to elucidate the mechanisms underlying the progression of these malignancies.&lt;br&gt;
Experimental Design: We performed IHC staining on the clinical samples from patients with B-cell lymphoma that developed during PD-1 blockade therapy and analyzed large-scale real-world datasets. We further investigated the underlying mechanisms through in vitro and in vivo experiments.&lt;br&gt;
Results: A higher incidence of B-cell malignancies has been observed in patients with lung cancer treated with PD-1 blockade therapies based on large-scale real-world data analyses (n = 15,670). The identified lymphomas had a large amount of CD4+ T follicular helper (TFH) cell infiltration. In addition, PD-1 blockade activated PD-1+ TFH cells, which promoted lymphoma proliferation via the IL4/IL4R, IL21/IL21R, and CD40L/CD40 axes. Notably, the lymphomas exhibited high expression of IL4R, IL21R, and CD40.&lt;br&gt;
Conclusions: Our findings highlight the need for careful monitoring and consideration of the potential B-cell malignancy complications in clinical settings in which ICIs are used.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2211-0348</Issn>
      <Volume>109</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Bile acids as candidate therapies for multiple sclerosis: inverse signal analysis using the FDA adverse event reporting system and preclinical validation</ArticleTitle>
    <FirstPage LZero="delete">107113</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Mizuho</FirstName>
        <LastName>Asada</LastName>
        <Affiliation>Department of Medical Molecular Informatics, Meiji Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fuka</FirstName>
        <LastName>Aizawa</LastName>
        <Affiliation>Department of Pharmacy, Tokushima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahisa</FirstName>
        <LastName>Mikami</LastName>
        <Affiliation>Department of Neurology, Massachusetts General Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mitsuhiro</FirstName>
        <LastName>Goda</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Graduate School of Biomedical and Health Sciences, Hiroshima University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuhei</FirstName>
        <LastName>Sonoda</LastName>
        <Affiliation>Department of Pharmacy, Tokushima University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takahiro</FirstName>
        <LastName>Niimura</LastName>
        <Affiliation>Department of Clinical Pharmacology and Therapeutics, Tokushima University Graduate School of Biomedical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masayuki</FirstName>
        <LastName>Chuma</LastName>
        <Affiliation>Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University and University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Uesawa</LastName>
        <Affiliation>Department of Medical Molecular Informatics, Meiji Pharmaceutical University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Ishizawa</LastName>
        <Affiliation>Department of Pharmacy, Tokushima University Hospital</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Alterations in bile acid metabolism have been observed in individuals with multiple sclerosis (MS), yet the therapeutic implications of bile acid supplementation remain uncertain.&lt;br&gt;
Methods: We conducted a two-stage study integrating pharmacovigilance analysis with preclinical validation to evaluate bile acid derivatives as candidate therapies for MS. A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS; Q4/2003&#8211;Q2/2025) was performed to identify inverse associations between MS and bile acid preparations. The effects of ursodeoxycholic acid (UDCA) and obeticholic acid (6-ECDCA) were evaluated in a therapeutic experimental autoimmune encephalomyelitis (EAE) model, with treatment initiated after disease onset.&lt;br&gt;
Results: Among 13,734,539 FAERS reports, 75,659 involved MS. Inverse associations were identified for UDCA (odds ratio [OR]: 0.197, 95% confidence interval [CI]: 0.117&#8211;0.333) and 6-ECDCA (OR: 0.128, 95% CI: 0.041&#8211;0.396). In the EAE model, UDCA was associated with lower clinical scores at the peak (day 18) and late phases (days 26&#8211;28), whereas 6-ECDCA showed only a non-significant trend toward improvement at day 28.&lt;br&gt;
Conclusion: This two-stage investigation highlights the potential utility of pharmacovigilance-guided approaches for identifying therapeutic candidates. Bile acid derivatives, particularly UDCA, are biologically plausible candidates meriting further investigation in the context of MS.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Bile acids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Multiple sclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Database analysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Drug repositioning</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Experimental autoimmune encephalomyelitis</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2055-0294</Issn>
      <Volume>12</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Adverse events of romidepsin versus tucidinostat for peripheral T-cell lymphoma: a pharmacovigilance study using the Japanese adverse drug event report database</ArticleTitle>
    <FirstPage LZero="delete">48</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nao</FirstName>
        <LastName>Takatsu</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jun</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yurie</FirstName>
        <LastName>Oka</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomonori</FirstName>
        <LastName>Sakai</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Naohiro</FirstName>
        <LastName>Iwata</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsukasa</FirstName>
        <LastName>Higashionna</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuaki</FirstName>
        <LastName>Takeda</LastName>
        <Affiliation>Department of Pharmacy, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hirofumi</FirstName>
        <LastName>Hamano</LastName>
        <Affiliation>Department of Clinical Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshito</FirstName>
        <LastName>Zamami</LastName>
        <Affiliation>Department of Clinical Pharmacology, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of lymphomas with poor prognosis, particularly in patients with relapsed or refractory (R/R) disease. Romidepsin and tucidinostat are histone deacetylase inhibitors used to treat R/R PTCL. No head-to-head post-marketing surveillance studies have compared adverse events (AEs) between the two agents. In this brief report, the AE profiles of romidepsin and tucidinostat were compared using the Japanese Adverse Drug Event Report (JADER) database to facilitate their differentiation and promote the management of AEs.&lt;br&gt;
Methods We conducted a descriptive analysis using data from the JADER database from April 2018 to July 2025. The reported AEs for romidepsin and tucidinostat were extracted and classified according to preferred terms (PTs) and system organ classes (SOCs). Reporting odds ratios with 95% confidence intervals were calculated to compare the AE profiles between the groups.&lt;br&gt;
Results In total, 998,397 reports were analysed for all drugs, including 323 for romidepsin and 753 for tucidinostat. Compared with all drugs, both agents showed significant disproportionality signals in four SOCs: Blood and lymphatic system disorders; General disorders and administration site conditions; Investigations; and Neoplasms benign, malignant and unspecified. Romidepsin exhibited additional significant signals in six SOCs: Cardiac disorders, Eye disorders, Gastrointestinal disorders, Immune system disorders, Infections and infestations, and Metabolism and nutrition disorders. Direct comparison between the two agents revealed broader AE profiles for romidepsin, with AEs more frequently reported in eight SOCs, whereas tucidinostat showed AEs in only two SOCs. Romidepsin was associated with AEs more frequently reported in several PTs, including atrial fibrillation and gastrointestinal toxicities, such as constipation, tumour lysis syndrome, hepatotoxicity, and peripheral neuropathy, which was consistent with the results at the SOC level. In contrast, several significant PTs for tucidinostat were observed in General disorders and administration site conditions and Investigations.&lt;br&gt;
Conclusions The Japanese real-world pharmacovigilance analysis showed differences in the AE profiles between romidepsin and tucidinostat. These differences in safety profiles may be useful for treatment selection and AE management in routine clinical practice among patients with R/R PTCL. Further studies are warranted to confirm these findings and better characterise the safety profiles of these agents.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Romidepsin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Tucidinostat</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Adverse event</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">JADER</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pharmacovigilance</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1557-1963</Issn>
      <Volume>21</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Surface Plasmon Resonances in Silver Nanodendrites : Trunk Length and Branch Connectivity Dependence</ArticleTitle>
    <FirstPage LZero="delete">2247</FirstPage>
    <LastPage>2258</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Qingyuan</FirstName>
        <LastName>Ma</LastName>
        <Affiliation>Graduate School of Informatics and Engineering, The University of Electro-communications</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Kishida</LastName>
        <Affiliation>Graduate School of Informatics and Engineering, The University of Electro-communications</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nobuyuki</FirstName>
        <LastName>Takeyasu</LastName>
        <Affiliation>Graduate School of Natural Science and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Shoji</LastName>
        <Affiliation>Graduate School of Informatics and Engineering, The University of Electro-communications</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>This study systematically investigates how trunk length and branch connectivity govern surface plasmon resonances in silver nanodendrites in the infrared (IR) region using a computational modeling strategy. We show that a continuous conductive trunk is essential for exciting long-wavelength collective plasmon modes. In a simulated bottom-up construction scheme, the trunk length is gradually increased to conductively connect additional branches to the backbone. Our results reveal that the fundamental δ mode resonance can be deterministically tuned across the mid-infrared spectrum (from 3840 nm to 4360 nm) primarily by controlling the trunk connectivity. As the number of connected branches grows, the lowest-order collective resonance peak exhibits a systematic redshift, and its resonance wavelength scales linearly with the effective dipole length Leff of the electron oscillation path. Concurrently, new higher-order modes emerge as local resonances of the connected substructures. These observations indicate that interrupting the conductive pathway causes a global collective mode to decompose into multiple resonances associated with more weakly coupled subsystems. The established linear scaling relationship provides a highly predictable design rule for this “programmable” connectivity, offering a robust platform for advanced applications such as multi-spectral infrared imaging, selective chemical sensing, and surface-enhanced infrared absorption (SEIRA) spectroscopy, where precise, a priori control over narrow-band infrared resonances is essential.
</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Silver nanodendrites                                  </Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Surface plasmon resonances</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Conductive coupling</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Topological connectivity</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Infrared nanoantennas</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Plasmonic metamaterials</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>8756-3282</Issn>
      <Volume>209</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>PPy-coated wire actuators for micromechanostimulation of cells &#8211; identification of immediate-early responsive mechanoregulatory genes in osteoblasts</ArticleTitle>
    <FirstPage LZero="delete">117914</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Jiamin</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Amaia B.</FirstName>
        <LastName>Ortega-Santos</LastName>
        <Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#246;ping University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Satoru</FirstName>
        <LastName>Hayano</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ziyi</FirstName>
        <LastName>Wang</LastName>
        <Affiliation>Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jose G.</FirstName>
        <LastName>Martinez</LastName>
        <Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#246;ping University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emilio Satoshi</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Department of Advanced International and Information Dentistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Edwin W.H.</FirstName>
        <LastName>Jager</LastName>
        <Affiliation>Department of Physics, Chemistry and Biology (IFM), Link&#246;ping University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kamioka</LastName>
        <Affiliation>Department of Orthodontics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Mechanotransduction, i.e., the conversion of mechanical cues into biochemical signals, is essential for bone development, remodeling, and adaptation. Although mechanical loading is known to regulate osteoblast function and bone homeostasis, dissecting the early and sustained mechanotransductive responses at the microscale remains challenging due to limitations of existing in vitro models. Here, we report the development and application of a mechanostimulation system comprising a polypyrrole (PPy)-based wire actuator that expands and contracts (4 μm in radius) upon electrical actuation and enables precise, localized micromechanical stimulation of a small number of cells within standard culture formats. Using this system, we applied short-term (30 min) cyclic (Cyc30) or static (Stat30), as well as prolonged (120 min) cyclic (Cyc120) stimulations to two osteoblast-like cells (MC3T3-E1 or KUSA-A1). Subsequent transcriptomic profiling and computational network analyses revealed that Cyc30 was not capable of inducing significant changes in mRNA expression, suggesting cellular adaptation to short-term cyclic loading. In contrast, Stat30 induced the upregulation of Fos, Btg2, Egr1, and Fosl1, all known genes associated with mechanotransduction, supporting the validity and reproducibility of our experimental mechanostimulation system. Notably, two long non-coding RNAs (B930036N10Rik and 5430431A17Rik) were identified for the first time as being upregulated in response to Stat30 stimuli. Among the differentially expressed genes (DEGs) upregulated by Cyc120 stimuli, Hmox1, a stress-inducible enzyme known for its roles in maintaining cellular homeostasis and promoting survival, was the only DEG repeatedly observed across the Cyc30/Cyc120 and Stat30/Cyc120 comparisons in both cell types, potentially emerging as a key stress-response gene under prolonged mechanical loading. Collectively, these results establish the PPy-based microactuator as a powerful tool for microscale mechanobiology, and provide molecular insight into immediate-early responsive transcriptional programs underlying osteoblastic mechanoadaptation conserved across different cell types.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Mechanotransduction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Mechanostimulation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Osteoblasts</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Polypyrrole</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0012-821X</Issn>
      <Volume>687</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Phase diagram of Fe-C-S ternary system under planetary core conditions</ArticleTitle>
    <FirstPage LZero="delete">120087</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Bin</FirstName>
        <LastName>Zhao</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Jintao</FirstName>
        <LastName>Zhu</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Daniele</FirstName>
        <LastName>Antonangeli</LastName>
        <Affiliation>Mus&#233;um National d’Histoire Naturelle, Sorbonne Universit&#233;, UMR CNRS 7590, Institut de Min&#233;ralogie, de Physique des Mat&#233;riaux et de Cosmochimie, IMPMC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Guillaume</FirstName>
        <LastName>Morard</LastName>
        <Affiliation>Mus&#233;um National d’Histoire Naturelle, Sorbonne Universit&#233;, UMR CNRS 7590, Institut de Min&#233;ralogie, de Physique des Mat&#233;riaux et de Cosmochimie, IMPMC</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Qi</FirstName>
        <LastName>Chen</LastName>
        <Affiliation>Center for Advanced Radiation Sources, University of Chicago</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Yoshino</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>High-pressure, high-temperature experiments were conducted to investigate melting relations and phase assemblages in the Fe-C-S ternary system at 5 and 15 GPa, covering a temperature range of 1300&#8211;1900 K, conditions directly relevant to the Moon’s and Mercury’s cores. At 1300 K, the system is primarily governed by Fe-S eutectic melting, exhibiting notable complexity in the carbon-rich and sulfur-poor regions. With increasing temperature, the phase diagram simplifies: at 5 GPa and 1700 K, the Fe-Fe&#8323;C-FeS system features three regions (Fe+L, C + L, and L). Similar phase assemblages are observed at 15 GPa, with Fe7C3 and diamond replacing Fe3C and graphite, respectively. Extensive Fe+L, C + L, and L regions are observed at 1900 K.&lt;br&gt;
For a Moon’s core composed of a Fe-C-S alloy, nearly pure Fe is the only viable inner core phase above 1700 K. Below this temperature, both Fe and Fe&#8323;C are potential solid inner core phases, depending on carbon content; a two-phase solid inner core is also theoretically possible. The inferred compositions of the outer core suggest densities of 6200&#8211;7300 kg/m&#179;, with tighter constraints for models featuring an Fe&#8323;C core.&lt;br&gt;
At Mercury-relevant pressures, either Fe or Fe&#8327;C&#8323; may form the solid inner core, again depending on carbon content. If the inner core is nearly pure Fe, the liquid outer core density ranges from 7300 to 7900 kg/m&#179;. In both scenarios, a “snow” regime is plausible, though with distinct settling times. The ternary phase diagram indicates that Mercury is likely to develop a structurally layered inner core during secular cooling.&lt;br&gt;</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">planetary core</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">phase diagram</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">multi-anvil experiments</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">iron alloy</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Chemical Society (ACS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2574-0970</Issn>
      <Volume>9</Volume>
      <Issue>14</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Reversible Droplet Bridging and Tunable Viscoelasticity in Emulsions Using Biocompatible PLA-b-PEO-b-PLA Telechelic Block Copolymers: Implications for Injectable Emulsion Gels</ArticleTitle>
    <FirstPage LZero="delete">6176</FirstPage>
    <LastPage>6185</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hinako</FirstName>
        <LastName>Nakayama</LastName>
        <Affiliation>Department of Applied Chemistry, Graduate School of Environmental, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Matsumoto</LastName>
        <Affiliation>Department of Applied Chemistry and Biotechnology, Graduate School of Engineering, University of Fukui</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuya</FirstName>
        <LastName>Iida</LastName>
        <Affiliation>Department of Applied Chemistry, Graduate School of Environmental, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsutomu</FirstName>
        <LastName>Ono</LastName>
        <Affiliation>Department of Applied Chemistry, Graduate School of Environmental, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaichi</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Applied Chemistry, Graduate School of Environmental, Life, Natural Science, and Technology, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Telechelic polymers are known to form reversible networks through end-group association; however, their application as structuring agents in emulsion-based soft materials remains underexplored. Herein, we systematically investigate the biocompatible amphiphilic triblock copolymer poly(d,l-lactic acid)-block-poly(ethylene oxide)-block-poly(d,l-lactic acid)(PLA-b-PEO-b-PLA) as a rheology modifier in toluene-in-water model emulsions. Owing to the selective adsorption of PLA end blocks at the oil&#8211;water interface and the solvation of the PEO midblock in the aqueous phase, this polymer is expected to form reversible droplet-bridging networks. During the process, the polymer concentration, molecular weight of the mid and end blocks, and the dispersed phase volume fraction were adjusted, and the factors governing network formation were elucidated using oscillatory rheology and stress-relaxation measurements. The results show that anchoring of the PLA end blocks and PEO-mediated bridging predominantly control the strength and dynamic reversibility of the network. Step-strain experiments further reveal that the droplet-bridging interactions can be disrupted under large deformation and partially recover when small-strain conditions are restored, confirming the presence of reversible physical associations. These findings establish a molecular design strategy for biodegradable telechelic copolymers as effective and reprocessable structuring agents in emulsion gels. The shear-responsive, tunable, and reversible nature of the droplet-bridging network makes this material platform particularly suitable for injectable emulsion gels for advanced soft matter and biomedical engineering applications.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">PLA-b-PEO-b-PLA</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">telechelic polymer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">rheology</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">emulsion gel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">viscoelasticity</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1525-2027</Issn>
      <Volume>27</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Chemical Geodynamics of Granitoid Magmatism During a Pacific‐Philippine Sea Plate Transition in Southwest Japan</ArticleTitle>
    <FirstPage LZero="delete">e2026GC012945</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Nghiem V.</FirstName>
        <LastName>Dao</LastName>
        <Affiliation>The Pheasant Memorial Laboratory for Geochemistry and Cosmochemistry, Institute for Planetary Materials, Okayama University at Misasa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tsegereda A.</FirstName>
        <LastName>Yemer</LastName>
        <Affiliation>The Pheasant Memorial Laboratory for Geochemistry and Cosmochemistry, Institute for Planetary Materials, Okayama University at Misasa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tulibako T.</FirstName>
        <LastName>Mwaisuba</LastName>
        <Affiliation>The Pheasant Memorial Laboratory for Geochemistry and Cosmochemistry, Institute for Planetary Materials, Okayama University at Misasa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chie</FirstName>
        <LastName>Sakaguchi</LastName>
        <Affiliation>The Pheasant Memorial Laboratory for Geochemistry and Cosmochemistry, Institute for Planetary Materials, Okayama University at Misasa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kitagawa</LastName>
        <Affiliation>The Pheasant Memorial Laboratory for Geochemistry and Cosmochemistry, Institute for Planetary Materials, Okayama University at Misasa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Katsura</FirstName>
        <LastName>Kobayashi</LastName>
        <Affiliation>The Pheasant Memorial Laboratory for Geochemistry and Cosmochemistry, Institute for Planetary Materials, Okayama University at Misasa</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Teruyoshi</FirstName>
        <LastName>Imaoka</LastName>
        <Affiliation>Division of Earth Science, Graduate School of Sciences and Technology for Innovation, Yamaguchi University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Eizo</FirstName>
        <LastName>Nakamura</LastName>
        <Affiliation>The Pheasant Memorial Laboratory for Geochemistry and Cosmochemistry, Institute for Planetary Materials, Okayama University at Misasa</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Granitoid magmatism along the western Pacific margin records interactions between subduction dynamics and crust&#8211;mantle processes; however, the links between plate reorganization and magma-source evolution remain debated. Here we integrate U&#8211;Pb zircon geochronology with Pb&#8211;Sr&#8211;Nd&#8211;Hf isotope systematics to investigate Cretaceous&#8211;Paleogene granitoids in Southwest Japan. Zircon U&#8211;Pb ages define two discrete magmatic episodes at 110&#8211;60 Ma and 45&#8211;30 Ma, separated by a magmatic hiatus of &#8764;10&#8211;15 Myr. These granitoid groups exhibit distinct isotopic signatures, indicating derivation from isotopically distinct magma sources linked to the paleo-Pacific (Izanagi) plate and the Philippine Sea plate, respectively. Isotope-based mass-balance modeling indicates higher sediment contributions to the older granitoids, with decreasing sediment input both landward and through time. The magmatic lull at ca. 52&#8211;40 Ma coincides with an abrupt isotopic shift and is interpreted to reflect plate reorganization, during which subduction of the paleo-Pacific plate was replaced by a transform or highly oblique plate boundary associated with the northward migration of the proto&#8211;Philippine Sea plate. Independent constraints from convergence rates, sediment flux, and accretionary complex development support this interpretation. These results demonstrate that granitoid magmatism in Southwest Japan was fundamentally controlled by temporal changes in subducted lithosphere and sediment flux driven by plate reorganization, highlighting the sensitivity of arc magmatism to transient tectonic regimes.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">granitoids</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pb&#8211;Sr&#8211;Nd&#8211;Hf isotopes</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Pacific-Philippine Sea plates</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">sub-crustal origin</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">tectonic transition</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Geophysical Union (AGU)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2169-9097</Issn>
      <Volume>131</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Lateral Variations in Lunar Crustal Thickness Inferred From Apollo Seismic and GRAIL Gravity Data</ArticleTitle>
    <FirstPage LZero="delete">e2025JE009453</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Xiang</FirstName>
        <LastName>Zhang</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de physique du globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Kawamura</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de physique du globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M&#233;lanie</FirstName>
        <LastName>Drilleau</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de physique du globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Philippe</FirstName>
        <LastName>Lognonn&#233;</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de physique du globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Samuel</FirstName>
        <LastName>Henri</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de physique du globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Zongbo</FirstName>
        <LastName>Xu</LastName>
        <Affiliation>Universit&#233; Paris Cit&#233;, Institut de physique du globe de Paris, CNRS</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keisuke</FirstName>
        <LastName>Onodera</LastName>
        <Affiliation>Institute for Planetary Materials, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Thomas</FirstName>
        <LastName>Bodin</LastName>
        <Affiliation>Instituto de Ciencias del Mar (ICM)&#8211;CSIC</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>The internal structure of the Moon is key to understanding its formation, evolution, and bulk composition. In particular, determining the structure of the crust&#8211;mantle interface (Moho), including its lateral variations, is of significant importance, but current knowledge is still insufficient to fully constrain it. To address this, we used seismic wave arrivals from impact events, which yield constraints on the crust at both the impact sites and the Apollo stations, to invert for local crustal thickness. Based on a series of assumed crust and mantle density models, we compared Moho depths inferred from global gravity recovery and interior laboratory gravity data with those from seismic observations. Although the gravity‐derived results broadly capture the overall Moho relief, local discrepancies remain, with differences reaching up to 10 km in the vicinity of the Apollo 17 Saturn IVB impact site. These results may reflect regional geological anomalies and highlight the importance of incorporating multiple seismically constrained crustal thickness estimates as anchors in gravity inversions. Using seven seismic anchor points and assuming an upper mantle velocity of Vp = 7.68 km/ s, an upper mantle density of 3,280 kg/m3, and a crustal density of 2,693 kg/m3, we obtain an average lunar crustal thickness of 43.6 ± 1.9 km. The findings also provide valuable guidance for future global 3D modeling of the Moon.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Oxford University Press (OUP)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0449-3060</Issn>
      <Volume>67</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Development of Linear Interpolation System for SMK Model Parameters Evaluated from Cellular-Scale Simulation (LISMEC) and its application to BNCT dosimetry</ArticleTitle>
    <FirstPage LZero="delete">170</FirstPage>
    <LastPage>181</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Takafumi</FirstName>
        <LastName>Shigehira</LastName>
        <Affiliation>Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tubasa</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Minoru</FirstName>
        <LastName>Suzuki</LastName>
        <Affiliation>Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuho</FirstName>
        <LastName>Hirata</LastName>
        <Affiliation>Research Group for Radiation Transport Analysis, Nuclear Science and Engineering Center , Japan Atomic Energy Agency (JAEA)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuhiko</FirstName>
        <LastName>Ogawa</LastName>
        <Affiliation>Research Group for Radiation Transport Analysis, Nuclear Science and Engineering Center , Japan Atomic Energy Agency (JAEA)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Atsushi</FirstName>
        <LastName>Fujimura</LastName>
        <Affiliation>Department of Cellular Physiology, Neutron Therapy Research Center, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshinori</FirstName>
        <LastName>Sakurai</LastName>
        <Affiliation>Particle Radiation Oncology Research Center, Institute for Integrated Radiation and Nuclear Science, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tatsuhiko</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Research Group for Radiation Transport Analysis, Nuclear Science and Engineering Center , Japan Atomic Energy Agency (JAEA)</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Boron neutron capture therapy (BNCT) utilizes high linear energy transfer (LET) α-particles and 7Li ions generated through the 10B(n, α)7Li reaction. Precise dosimetry is essential for maximizing therapeutic efficacy while minimizing normal tissue adverse events, considering the microscopic distribution of 10B and cellular structures. Recently, the photon isoeffective dose (DisoE) has been proposed as a more appropriate metric for BNCT treatment planning and can be evaluated using the stochastic microdosimetric kinetic (SMK) model. However, clinical implementation of the SMK model remains challenging due to the difficulty of evaluating its input parameters, which requires computationally intensive radiation transport simulations at the cellular scale. To address this issue, we developed LISMEC (Linear Interpolation System for Stochastic Microdosimetric Kinetic model parameters Evaluated from Cellular-scale simulation), a rapid estimation framework based on precomputed cellular-scale PHITS (Particle and Heavy Ion Transport code System) simulations covering various cell geometries and boron distributions. By applying a linear interpolation algorithm, LISMEC enables the retrieval of SMK model parameters without the need for computationally intensive cellular-scale simulations. The utility of LISMEC, in conjunction with PHITS, was demonstrated through simulations of various irradiation scenarios in reactor-based BNCT. The results showed that DisoE values ranged from 7.4 to 32.7 Gy, even under a fixed macroscopic 10B concentration of 60 ppm. These findings emphasize the importance of incorporating a microscopic distribution of 10B and cellular structures into BNCT treatment planning.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">BNCT</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">microdosimetry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">borondistribution</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cellmorphology</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0039-9140</Issn>
      <Volume>306</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Instrument-free quantitative colorimetric analysis using adsorption-band length in a packed silica gel column</ArticleTitle>
    <FirstPage LZero="delete">129728</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sychanh</FirstName>
        <LastName>Phonxayxiong</LastName>
        <Affiliation/>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Kaneta</LastName>
        <Affiliation>Department of Chemistry, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>A simple and instrument-free colorimetric method for quantitative analysis is reported, in which analyte concentration is determined by measuring the length of a colored adsorption band formed in a packed silica gel column. The proposed method employs a miniature silica gel column that acts as a signal transducer after it adsorbs the colored compound from a solution during its flow in the column. The length of this band increases proportionally with analyte concentration, which enables quantitative detection via simple distance measurement. A theoretical model was developed to describe the relationship between solute concentration, adsorption behavior, and band propagation along the column. The principle was validated via the detection of both iron ions and enzyme-mediated glutamic acid. For Fe2+ analysis, the o-phenanthroline complexation method shows a level of sensitivity comparable to that of conventional spectrophotometry, which enables an almost quantitative recovery of trace iron in tap water. The limit of detection (LOD) and the limit of quantification (LOQ) were estimated to be 0.20 μM and 0.60 μM for the proposed method and 0.23 μM and 0.70 μM for spectrophotometry, respectively. The approach was further extended to glutamate detection using a cascade reaction involving glutamate oxidase and horseradish peroxidase with N-benzoyl leucomethylene blue as the chromogenic substrate. The LOD and the LOQ of the proposed method were 0.08 and 0.25 μM, and both values are superior to the 0.24 μM and 0.73 μM obtained using a microplate reader. By integrating preconcentration with a distance-based readout, this method provides a simple yet highly sensitive analytical platform and establishes distance as a quantitative signal for colorimetric detection.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Colorimetry</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Distance-based detection</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Silica gel</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Adsorption</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Ceramic Society of Japan</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1348-6535</Issn>
      <Volume>134</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Cation distribution and diffusion-path topologies of A-site-deficient perovskite LixLa(1−x)/3NbO3</ArticleTitle>
    <FirstPage LZero="delete">225</FirstPage>
    <LastPage>231</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Naoto</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Department of Pure and Applied Chemistry, Faculty of Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yizhong</FirstName>
        <LastName>Tang</LastName>
        <Affiliation>Department of Pure and Applied Chemistry, Faculty of Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Kimura</LastName>
        <Affiliation>Department of Physical Science and Engineering, Nagoya Institute of Technology</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ippei</FirstName>
        <LastName>Obayashi</LastName>
        <Affiliation>Center for Artificial Intelligence and Mathematical Data Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yohei</FirstName>
        <LastName>Onodera</LastName>
        <Affiliation>Center for Basic Research on Materials, National Institute for Materials Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ken</FirstName>
        <LastName>Nakashima</LastName>
        <Affiliation>Faculty of Materials for Energy, Shimane University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chiaki</FirstName>
        <LastName>Ishibashi</LastName>
        <Affiliation>Department of Pure and Applied Chemistry, Faculty of Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasushi</FirstName>
        <LastName>Idemoto</LastName>
        <Affiliation>Department of Pure and Applied Chemistry, Faculty of Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koichi</FirstName>
        <LastName>Hayashi</LastName>
        <Affiliation>Department of Physical Science and Engineering, Nagoya Institute of Technology</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>LixLa(1−x)/3NbO3 with an A-site-deficient perovskite structure was investigated with a focus on the relationship between its atomic configuration and Li+ diffusion properties. To this end, total scattering (diffraction) measurements were performed, and then reverse Monte Carlo modeling using the data was employed to construct the atomic configuration. The results suggest that the partial occupancy of La in the La-poor layer facilitate Li+ diffusion across the layer owing to the volume contraction. Furthermore, topological analyses conducted via persistent homology using the constructed atomic configuration indicate that a large fourfold ring formed by Nb and O is one of the reasons for superior Li+ diffusion in LixLa(1−x)/3NbO3.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">A-site-deficient perovskite</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Li+ conduction</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Total scattering</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Local structure</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Persistent homology</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Springer Science and Business Media LLC</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2045-2322</Issn>
      <Volume>16</Volume>
      <Issue>1</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Explainable analysis of the complex maze magnetic domain structure through extension of the Landau free energy model by adding an entropy feature</ArticleTitle>
    <FirstPage LZero="delete">12889</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">K.</FirstName>
        <LastName>Masuzawa</LastName>
        <Affiliation>Department of Material Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">A. L.</FirstName>
        <LastName>Foggiatto</LastName>
        <Affiliation>Department of Material Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">S.</FirstName>
        <LastName>Kunii</LastName>
        <Affiliation>Department of Material Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">R.</FirstName>
        <LastName>Nagaoka</LastName>
        <Affiliation>Department of Material Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M.</FirstName>
        <LastName>Taniwaki</LastName>
        <Affiliation>Department of Material Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">T.</FirstName>
        <LastName>Yamazaki</LastName>
        <Affiliation>Department of Material Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">C.</FirstName>
        <LastName>Mitsumata</LastName>
        <Affiliation>Department of Material Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">I.</FirstName>
        <LastName>Obayashi</LastName>
        <Affiliation>Interdisciplinary Education and Research Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Y.</FirstName>
        <LastName>Hiraoka</LastName>
        <Affiliation>Kyoto University Institute for Advanced Study, Kyoto University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">M.</FirstName>
        <LastName>Kotsugi</LastName>
        <Affiliation>Department of Material Science and Technology, Tokyo University of Science</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Maze magnetic domains exhibit complex, temperature-dependent behavior that impacts energy loss in soft magnets, yet their magnetization reversal mechanisms remain poorly understood due to current model limitations. To address this gap, we develop an entropy-extended Landau free energy model that incorporates thermal effects into the analysis of magnetic domain. We employ a data-driven pipeline combining persistent homology, energy decomposition, and principal component analysis to construct an interpretable model that quantifies structure&#8211;property relationships and enables causal analysis of magnetic pattern formation. Using this approach, we trace entropy increases to their origins in initial domain configurations and quantify energy transfer among entropic, demagnetization, and exchange contributions. We also find that domain wall lengthening tracks increasing structural complexity, yielding previously inaccessible insights into magnetization reversal mechanism and enabling automated visualization. Our entropy-augmented model provides an explainable framework to decipher magnetization processes and guide the design of magnetic materials to reduce energy loss.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Society for Microbiology</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2379-5042</Issn>
      <Volume>10</Volume>
      <Issue>5</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Sodium butyrate inhibits the expression of virulence factors in Vibrio cholerae by targeting ToxT protein</ArticleTitle>
    <FirstPage LZero="delete">e00824-24</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Sushmita</FirstName>
        <LastName>Kundu</LastName>
        <Affiliation>Division of Biochemistry, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Suman</FirstName>
        <LastName>Das</LastName>
        <Affiliation>Division of Biochemistry, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Priyanka</FirstName>
        <LastName>Maitra</LastName>
        <Affiliation>Division of Biochemistry, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Prolay</FirstName>
        <LastName>Halder</LastName>
        <Affiliation>Division of Bacteriology, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hemanta</FirstName>
        <LastName>Koley</LastName>
        <Affiliation>Division of Bacteriology, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Asish K.</FirstName>
        <LastName>Mukhopadhyay</LastName>
        <Affiliation>Division of Bacteriology, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shin-ichi</FirstName>
        <LastName>Miyoshi</LastName>
        <Affiliation>Division of Pharmaceutical Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shanta</FirstName>
        <LastName>Dutta</LastName>
        <Affiliation>Division of Bacteriology, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Nabendu Sekhar</FirstName>
        <LastName>Chatterjee</LastName>
        <Affiliation>Division of Biochemistry, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Sushmita</FirstName>
        <LastName>Bhattacharya</LastName>
        <Affiliation>Division of Biochemistry, ICMR-National Institute for Research in Bacterial Infections (Formerly ICMR-National Institute of Cholera and Enteric Diseases)</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Cholera, a diarrheal disease caused by the gram-negative bacterium Vibrio cholerae, remains a global health threat in developing countries due to its high transmissibility and increased antibiotic resistance. There is a pressing need for alternative strategies, with an emphasis on anti-virulent approaches to alter the outcome of bacterial infections, given the increase in antimicrobial-resistant strains. V. cholerae causes cholera by secreting virulence factors in the intestinal epithelial cells. These virulence factors facilitate bacterial colonization and cholera toxin production during infection. Here, we demonstrate that sodium butyrate (SB), a small molecule, had no effect on bacterial viability but was effective in suppressing the virulence attributes of V. cholerae. The production of cholera toxin (CT) was significantly reduced in a standard V. cholerae El Tor strain and two clinical isolates when grown in the presence of SB. Analysis of mRNA and protein levels further revealed that SB reduced the expression of the ToxT-dependent virulence genes like tcpA and ctxAB. DNA-protein interaction assays, conducted at cellular (ChIP) and in vitro conditions (EMSA), indicated that SB weakens the binding between ToxT and its downstream promoter DNA, likely by blocking DNA binding. Furthermore, the anti-virulence efficacy of SB was confirmed in animal models. These findings suggest that SB could be developed as an anti-virulence agent against V. cholerae, serving as a potential alternative to conventional antibiotics or as an adjunctive therapy to combat cholera.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">sodium butyrate (SB)</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">inhibitor</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">pathogenesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Vibrio cholerae</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ctxAB</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">antimicrobial resistance</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">toxin-coregulated pilus (TcpA)</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1353-8020</Issn>
      <Volume>145</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Real-world evaluation of Armstrong's criteria in corticobasal degeneration: Phenotypic overlap and diagnostic challenges</ArticleTitle>
    <FirstPage LZero="delete">108229</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Emi</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Osakada</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taijun</FirstName>
        <LastName>Yunoki</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mami</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background: Corticobasal degeneration (CBD) is a four-repeat tauopathy with heterogeneous clinical manifestations. Armstrong's criteria involve a two-step diagnostic approach: first, classifying patients into five clinical phenotypes―probable/possible corticobasal syndrome (CBS), frontal behavioral-spatial syndrome (FBS), non-fluent/agrammatic variant primary progressive aphasia (naPPA), and progressive supranuclear palsy syndrome (PSPS); second, determining whether they meet the clinical research criteria for probable CBD (cr-CBD) or the clinical criteria for possible CBD (p-CBD), which are distinct from the initial CBS classifications.&lt;br&gt;
Objective: To investigate how real-world patients with suspected CBD fulfill Armstrong's clinical phenotypes and diagnostic criteria, and to compare clinical and imaging features between the Alzheimer's disease (AD) group and the non-AD group defined by CSF amyloid biomarkers.&lt;br&gt;
Methods: We retrospectively reviewed 137 patients undergoing differential diagnosis for CBS, frontotemporal dementia, primary progressive aphasia, or PSPS. Of these, 78 met the criteria for cr-CBD (n = 36) or p-CBD (n = 42). CSF was examined in 32 patients, and based on the CSF Aβ42/40 ratio, patients were classified into an AD-group (AD-CBS; n = 6) and a non-AD group (n = 26).&lt;br&gt;
Results: Among patients classified as cr-CBD or p-CBD, 79% fulfilled two or more clinical phenotypes, with FBS and PSPS most commonly. Compared with the AD group, the non-AD group showed more parkinsonian features and frontal hypoperfusion on [123I]-IMP SPECT.&lt;br&gt;
Conclusion: Armstrong's criteria captured a spectrum of overlapping clinical features. While helpful in clinical phenotyping, further validation with biomarkers is essential to distinguish CBD from AD and related disorders. Prospective studies with pathological confirmation are warranted.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Corticobasal degeneration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CBD</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Corticobasal syndrome</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">CBS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Armstrong's criteria</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0022-510X</Issn>
      <Volume>481</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>The utility of Gold Coast criteria for amyotrophic lateral sclerosis</ArticleTitle>
    <FirstPage LZero="delete">125733</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Emi</FirstName>
        <LastName>Nomura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryuta</FirstName>
        <LastName>Morihara</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yosuke</FirstName>
        <LastName>Osakada</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taijun</FirstName>
        <LastName>Yunoki</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Mami</FirstName>
        <LastName>Takemoto</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toru</FirstName>
        <LastName>Yamashita</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hiroyuki</FirstName>
        <LastName>Ishiura</LastName>
        <Affiliation>Department of Neurology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Introduction: Amyotrophic lateral sclerosis (ALS) is a rapidly progressive neurodegenerative disease. Current diagnostic criteria, including the revised El Escorial (rEE) and Awaji (AW) criteria, have limitations in sensitivity. The Gold Coast (GC) criteria were proposed to simplify diagnosis and improve early detection, but their real-world performance remains unclear.&lt;br&gt;
Methods: We retrospectively analyzed 260 patients suspected of ALS who were admitted to our department between 2013 and 2022. The GC, AW, and rEE criteria were applied to data from initial hospitalization. Final diagnoses were based on follow-up data, and sensitivity/specificity were compared using McNemar's test.&lt;br&gt;
Results: The GC criteria showed equivalent sensitivity (91.6 %), but higher specificity (75.9 %) compared to all combined AW and rEE categories. GC sensitivity was significantly higher than that of AW/rEE definite/probable categories. False negatives of GC criteria were often due to insufficient LMN signs, particularly in bulbar-onset cases. Subgroup analysis showed consistent trends.&lt;br&gt;
Conclusion: The GC criteria demonstrated high sensitivity and moderate specificity, supporting their clinical utility in early ALS diagnosis. However, variability in clinical presentation and retrospective limitations suggest the need for further prospective validation.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Amyotrophic lateral sclerosis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ALS</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Gold Coast criteria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Revised El Escorial criteria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Awaji criteria</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Elsevier BV</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>1366-5545</Issn>
      <Volume>211</Volume>
      <Issue/>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Lease or sale: When a durable goods monopolist can choose supply chain openness</ArticleTitle>
    <FirstPage LZero="delete">104882</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hiroshi</FirstName>
        <LastName>Kitamura</LastName>
        <Affiliation>Faculty of Economics, Kyoto Sangyo University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriaki</FirstName>
        <LastName>Matsushima</LastName>
        <Affiliation>Osaka School of International Public Policy, University of Osaka</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Misato</FirstName>
        <LastName>Sato</LastName>
        <Affiliation>Faculty of Humanities and Social Sciences, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We construct a two-period model of supply chain openness in a durable goods market with two marketing modes: leasing and selling. For a given marketing mode, at the beginning of the first period, an incumbent supplier and the downstream monopolist choose one of two trading modes: (i) a two-period exclusive supply chain, or (ii) an open supply chain, allowing the downstream monopolist to trade with an efficient supplier in the second period. We show that in the selling mode, the exclusive supply chain can arise if the incumbent supplier is highly efficient. In contrast, under the leasing mode, the exclusive supply chain never arises; instead, the open supply chain is always selected. Furthermore, when the downstream monopolist is allowed to endogenously choose the marketing mode before the first period, it opts for the selling mode if the incumbent supplier is relatively inefficient; otherwise, it selects the leasing mode. Regardless of the chosen marketing mode, the open supply chain always arises on the equilibrium path, implying that the recent advancement of ICT to enhance leasing may discourage the adoption of exclusive supply chains.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Durable goods</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Exclusive supply chain</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Vertical relation</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Selling versus leasing</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Impact of Proteinuria on Postoperative Complications Following Colorectal Cancer Surgery</ArticleTitle>
    <FirstPage LZero="delete">131</FirstPage>
    <LastPage>139</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Shunsuke</FirstName>
        <LastName>Nakata</LastName>
        <Affiliation>Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Fumiaki</FirstName>
        <LastName>Takatsu</LastName>
        <Affiliation>Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yoshihiro</FirstName>
        <LastName>Mikuriya</LastName>
        <Affiliation>Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomokazu</FirstName>
        <LastName>Kakishita</LastName>
        <Affiliation>Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shinji</FirstName>
        <LastName>Hato</LastName>
        <Affiliation>Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Ohta</LastName>
        <Affiliation>Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takaya</FirstName>
        <LastName>Kobatake</LastName>
        <Affiliation>Department of Gastroenterological Surgery, National Hospital Organization Shikoku Cancer Center</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">/10.18926/AMO/70455</ArticleId>
    </ArticleIdList>
    <Abstract>Colorectal surgery is associated with a high incidence of postoperative complications regardless of the advances in surgical techniques and multidisciplinary treatment. Proteinuria is common in patients with malignancies, but few studies have investigated the association between preoperative proteinuria and patient prognoses, especially postoperative complications. We investigated the impact of proteinuria on patients undergoing colorectal surgery in a single-center, retrospective cohort study of 767 patients who underwent surgical resection for colorectal cancer between January 2016 and December 2022 at the National Hospital Organization Shikoku Cancer Center. Among them, 81 patients with preoperative proteinuria were compared with the control group of 686 patients without proteinuria. Our analyses revealed that the patients with proteinuria had malnutrition with a significantly lower prognostic nutritional index compared to the no-proteinuria control group (p&lt;0.001). The proteinuria group had a significantly advanced tumor stage (p=0.005), experienced more bleeding during the surgery (p=0.002), and required more transfusions (p&lt;0.001). Postoperative complications were significantly more frequent in the proteinuria group (p=0.03), thus demonstrating that proteinuria was independently associated with postoperative complications (p=0.045). Proteinuria in patients undergoing colorectal cancer surgery can therefore be considered a risk factor for postoperative complications.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">colorectal cancer</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">surgery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">proteinuria</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">complication</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">malnutrition</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Consistent Clinical Outcomes of Anteroinferior Minimally Invasive Plate Osteosynthesis for Midshaft Clavicle Fractures Across AO/OTA Fracture Types</ArticleTitle>
    <FirstPage LZero="delete">99</FirstPage>
    <LastPage>107</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N"/>
        <LastName>Nguyen Trung Thanh</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Ryo</FirstName>
        <LastName>Nakamichi</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasunori</FirstName>
        <LastName>Shimamura</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kousei Hospital</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Taichi</FirstName>
        <LastName>Saito</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takeshi</FirstName>
        <LastName>Ishihara</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoki</FirstName>
        <LastName>Furutani</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Hisakazu</FirstName>
        <LastName>Shitozawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Tomoyuki</FirstName>
        <LastName>Noda</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Kawasaki Medical School General Medical Center</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70452</ArticleId>
    </ArticleIdList>
    <Abstract>Although the performance of minimally invasive plate osteosynthesis (MIPO) via the anteroinferior approach is increasingly adopted for midshaft clavicle fractures, the influence of fracture morphology on clinical outcomes under a standardized protocol is unclear. We retrospectively analyzed the cases of 54 patients who underwent anteroinferior MIPO for an acute midshaft clavicle fracture (AO/OTA types B1, B2, B3) performed by a single surgeon across three affiliated institutions (2009-2022). We evaluated the clinical outcomes, i.e., the surgical time, incision length, radiographic union, reduction accuracy, range of motion, pain (visual analog scale [VAS]), and complications and compared them among the three AO/OTA subtypes. The mean incision length (3.4 cm) and surgical time (71-79 min) were similar among the groups (both p&gt;0.2). All fractures achieved radiographic union at a mean of 3.5 months. Postoperative alignment and clavicular length were maintained (length reduction −1.0±2.2 mm [B1], −0.5±2.0 mm [B2], −0.6±1.8 mm [B3]; p=0.825; angulation −0.8±3.4°, −1.1±3.1°, −0.3±3.3°; p=0.888). At 3 months, shoulder elevation and abduction were 169°-175° (p=0.079) and 164°-175° (p=0.324). Pain was minimal (100-mm VAS: &#8804;1 mm; p=0.782). One plate-fatigue failure occurred; no supraclavicular-nerve symptoms were recorded. Anteroinferior MIPO yielded consistent outcomes across AO/OTA types, with excellent union rates, functional recovery, and few complications, indicating that this technique is safe and reproducible for the surgical management of midshaft clavicle fractures.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">clavicle fracture</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">minimally invasive plate osteosynthesis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">anteroinferior plating</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">AO/OTA classification</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>Okayama University Medical School</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0386-300X</Issn>
      <Volume>80</Volume>
      <Issue>2</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Involvement of ADAM12 in TGF-β1-Induced Proliferation of Rheumatoid Arthritis Synovial Fibroblasts</ArticleTitle>
    <FirstPage LZero="delete">75</FirstPage>
    <LastPage>83</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Deting</FirstName>
        <LastName>Lin</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahiro</FirstName>
        <LastName>Horita</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Masahito</FirstName>
        <LastName>Watanabe</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Muscat Orthopaedic Clinic</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Joe</FirstName>
        <LastName>Hasei</LastName>
        <Affiliation>Medical Information and Assistive Technology Development, Faculty of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Takashi</FirstName>
        <LastName>Ohtsuki</LastName>
        <Affiliation>Medical Technology, Graduate School of Health Sciences, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriaki</FirstName>
        <LastName>Otsuka</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Chinatsu</FirstName>
        <LastName>Ichikawa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noriyuki</FirstName>
        <LastName>Shimizu</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Shuichi</FirstName>
        <LastName>Naniwa</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Toshifumi</FirstName>
        <LastName>Ozaki</LastName>
        <Affiliation>Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Keiichiro</FirstName>
        <LastName>Nishida</LastName>
        <Affiliation>Division of Chronic Pain Medicine and Division of Comprehensive Rheumatology, Locomotive Pain Center, Faculty of Medical Development Field, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType>Original Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.18926/AMO/70450</ArticleId>
    </ArticleIdList>
    <Abstract>A disintegrin and metalloproteinase 12 (ADAM12) is known to be involved in chondrocyte proliferation and is upregulated in the synovial tissue of osteoarthritis (OA). However, the underlying mechanisms of ADAM12 on rheumatoid arthritis (RA) synovial cell proliferation remain unknown. Here, we investigated the role of ADAM12 in the proliferation of RA synovial fibroblasts (RASFs). The expression and localization of ADAM12 in RA synovial tissues were examined by immunohistochemistry and compared with OA and healthy control (HC) synovial tissues. The effect of inflammatory cytokines (TNF-α, TGF-β1, and PDGF-BB) on ADAM12 expression in RASFs from RA patients was examined by real-time RT-PCR. The effect of ADAM12 knock-down by ADAM12 siRNA and ADAM12 overexpression on cell proliferation of RASFs were examined by WST-1 assay. ADAM12 was identified predominantly in RA synovial tissue rather than OA and HC synovial tissues. Stimulation with TGF-β1 upregulated the expression of ADAM12 and cell proliferation of RASFs. ADAM12 siRNA suppressed TGF-β1-induced cell proliferation of RASFs, while ADAM12 overexpression promoted the cell proliferation of RASFs. These findings demonstrate that ADAM12 may have a key role in TGF-β1-induced cell proliferation of synovial fibroblasts in patients with RA.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">rheumatoid arthritis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">synovial tissue</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">TGF-β1</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">ADAM12</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">cell proliferation</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>American Physical Society (APS)</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>2469-9926</Issn>
      <Volume>113</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>Analytical and numerical studies of periodic superradiance</ArticleTitle>
    <FirstPage LZero="delete">043713</FirstPage>
    <LastPage/>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">Hideaki</FirstName>
        <LastName>Hara</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yuki</FirstName>
        <LastName>Miyamoto</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Junseok</FirstName>
        <LastName>Han</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Riku</FirstName>
        <LastName>Omoto</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Yasutaka</FirstName>
        <LastName>Imai</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Akihiro</FirstName>
        <LastName>Yoshimi</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Koji</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Motohiko</FirstName>
        <LastName>Yoshimura</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">Noboru</FirstName>
        <LastName>Sasao</LastName>
        <Affiliation>Research Institute for Interdisciplinary Science, Okayama University</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>We conduct a theoretical study to understand the periodic superradiance observed in an Er:YSO crystal. First, we construct a model based on the Maxwell-Bloch equations for a reduced level system, a pair of superradiance states, and a population reservoir state. Analysis of the eigenvalues of the linearized differential equations shows that periodic superradiance can be realized only for certain parameters. We also derive two-variable equations consisting of the coherence and population difference between the two superradiance states, which contain the essential feature of the periodic superradiance. The two-variable equations clarify the mathematical structure of this periodic phenomenon and give analytical forms of the period, pulse duration, and number of emitted photons. Our model successfully reproduces the periodic behavior, but the actual experimental parameters are found to be outside the parameter region for the periodic superradiance. This result implies that some other mechanism(s) is (are) required. As one example, assuming that the field decay rate varies with the electric field, the periodic superradiance can be reproduced even under the actual experimental conditions.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList/>
    <ReferenceList/>
  </Article>
  <Article>
    <Journal>
      <PublisherName>International Institute of Anticancer Research</PublisherName>
      <JournalTitle>Acta Medica Okayama</JournalTitle>
      <Issn>0250-7005</Issn>
      <Volume>46</Volume>
      <Issue>4</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2026</Year>
        <Month/>
      </PubDate>
    </Journal>
    <ArticleTitle>P53-armed Oncolytic Adenovirus Enhances the Efficacy of PD-1 Blockade in Neuroblastoma by Inducing Immunogenic Cell Death</ArticleTitle>
    <FirstPage LZero="delete">1769</FirstPage>
    <LastPage>1784</LastPage>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName EmptyYN="N">MORIMICHI</FirstName>
        <LastName>TANI</LastName>
        <Affiliation>Department of Pediatric Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">HIROSHI</FirstName>
        <LastName>TAZAWA</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TERUTAKA</FirstName>
        <LastName>TANIMOTO</LastName>
        <Affiliation>Department of Pediatric Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">HIROSHI</FirstName>
        <LastName>NOUSO</LastName>
        <Affiliation>Department of Pediatric Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">HINAKO</FirstName>
        <LastName>WATANABE</LastName>
        <Affiliation>Department of Pediatric Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKANORI</FirstName>
        <LastName>OYAMA</LastName>
        <Affiliation>Department of Pediatric Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">YASUO</FirstName>
        <LastName>URATA</LastName>
        <Affiliation>Oncolys BioPharma, Inc.</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHUNSUKE</FirstName>
        <LastName>KAGAWA</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TAKUO</FirstName>
        <LastName>NODA</LastName>
        <Affiliation>Department of Pediatric Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">SHINJI</FirstName>
        <LastName>KURODA</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
      <Author>
        <FirstName EmptyYN="N">TOSHIYOSHI</FirstName>
        <LastName>FUJIWARA</LastName>
        <Affiliation>Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences</Affiliation>
      </Author>
    </AuthorList>
    <PublicationType/>
    <ArticleIdList>
      <ArticleId IdType="doi"/>
    </ArticleIdList>
    <Abstract>Background/Aim: Neuroblastoma (NB) is a primary malignant tumor of the peripheral sympathetic nervous system. Although immunotherapy with immune checkpoint inhibitors (ICIs) targeting programmed cell death 1 (PD-1)/PD ligand 1 (PD-L1) has emerged as novel antitumor therapy, high-risk NB tumors are refractory to ICI therapy. Oncolytic virotherapy is expected to potentiate the antitumor immune response by inducing immunogenic cell death (ICD). In the present study, we assessed the therapeutic potential of OBP-301 and OBP-702, telomerase-specific oncolytic adenoviruses, for the induction of ICD and combined effect with PD-1 blockade against NB cells.&lt;br&gt;
Materials and Methods: The cytopathic activity of OBP-301 and OBP-702 was assessed using three human MYCN-amplified NB cell lines (IMR-32, LA-N-5, and NB-1) and a murine non-MYCN-amplified NB cell line (Neuro-2a). Virus-mediated antitumor effect was assessed by analyzing cell viability, secretion of extracellular adenosine triphosphate (ATP) and high-mobility group box protein B1 (HMGB1), apoptosis, autophagy, and PD-L1 levels. A subcutaneous Neuro-2a tumor model was used to evaluate the in vivo antitumor effect of combination therapy with OBP-702 and anti-PD-1 antibody.&lt;br&gt;
Results: OBP-702 exhibited stronger cytopathic activity, inducing ICD with secretion of ATP and HMGB1, compared to OBP-301 in human and murine NB cells. OBP-301 and OBP-702 increased apoptosis, autophagy, and PD-L1 expression in murine NB cells. Moreover, OBP-702 significantly prolonged the survival of tumor-bearing mice compared to monotherapy with PD-1 blockade.&lt;br&gt;
Conclusion: OBP-702 is a promising antitumor strategy to promote the antitumor effect of ICIs by inducing ICD against NB tumors.</Abstract>
    <CoiStatement>No potential conflict of interest relevant to this article was reported.</CoiStatement>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Neuroblastoma</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">oncolytic adenovirus</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">p53</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">immunogenic cell death</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">PD-1</Param>
      </Object>
    </ObjectList>
    <ReferenceList/>
  </Article>
</ArticleSet>
